{"PMC7277828": [], "PMC7115376": [["IntroductionL\u2019analyse ultrastructurale des l\u00e9sions tissulaires et cellulaires observ\u00e9es chez l\u2019homme a permis au fil des ann\u00e9es de distinguer diff\u00e9rentes entit\u00e9s anatomocliniques et aussi d\u2019am\u00e9liorer la connaissance physiopathologique des maladies.", [["IntroductionL\u2019analyse ultrastructurale des", "TREATMENT", 0, 42]]], ["Ainsi, les premi\u00e8res caract\u00e9risations et distinctions de diff\u00e9rentes tumeurs humaines peu diff\u00e9renci\u00e9es ont pu se faire gr\u00e2ce \u00e0 la microscopie \u00e9lectronique (ME).", [["humaines", "TEST", 77, 85], ["peu", "TEST", 86, 89], ["ont pu", "TEST", 104, 110]]], ["De la m\u00eame fa\u00e7on, de nombreuses maladies d\u00e9g\u00e9n\u00e9ratives (\u00e9lastopathies, connectivites, certaines neuropathies), de surcharge (amylose), ou m\u00e9taboliques (glycog\u00e9noses, dyslipo\u00efdoses) ont \u00e9t\u00e9 initialement identifi\u00e9es par des observations ultrastructurales [1].", [["neuropathies", "DISEASE", 96, 108], ["neuropathies", "PROBLEM", 96, 108], ["ou m\u00e9taboliques", "PROBLEM", 135, 150]]], ["Enfin, des agents pathog\u00e8nes, en particulier viraux, mais aussi bact\u00e9riens, parasitaires ou mycotiques, ainsi que les cons\u00e9quences cellulaires de leurs infections ont \u00e9t\u00e9 identifi\u00e9s et caract\u00e9ris\u00e9s gr\u00e2ce \u00e0 la ME [2], [3].", [["infections", "DISEASE", 152, 162], ["Enfin", "TREATMENT", 0, 5], ["de leurs infections", "PROBLEM", 143, 162]]], ["L\u2019arriv\u00e9e des techniques d\u2019immuno-histochimie (IHC) et de biologie mol\u00e9culaire (BM) a r\u00e9volutionn\u00e9 l\u2019approche diagnostique en pathologie depuis un peu plus d\u2019une vingtaine d\u2019ann\u00e9es.", [["L\u2019arriv\u00e9e des techniques", "TREATMENT", 0, 24], ["et de biologie mol\u00e9culaire (BM", "TREATMENT", 52, 82], ["a r\u00e9volutionn\u00e9 l\u2019approche diagnostique", "TREATMENT", 84, 122]]], ["Ces techniques ont aussi permis progressivement de d\u00e9terminer le pronostic tumoral et, plus r\u00e9cemment, de pouvoir pr\u00e9dire la r\u00e9ponse tumorale \u00e0 des th\u00e9rapeutiques cibl\u00e9es.", [["Ces techniques", "TEST", 0, 14]]], ["Ainsi, l\u2019approche ultrastructurale des l\u00e9sions a \u00e9t\u00e9 brutalement supplant\u00e9e par l\u2019IHC et la BM.", [["BM", "ANATOMY", 92, 94], ["Ainsi", "TREATMENT", 0, 5], ["l\u2019approche ultrastructurale des", "TREATMENT", 7, 38], ["la BM", "OBSERVATION", 89, 94]]], ["Cette approche est en effet consid\u00e9r\u00e9e comme fastidieuse, on\u00e9reuse et difficile.", [["et difficile", "PROBLEM", 67, 79]]], ["Ainsi, les microscopes \u00e9lectroniques ont d\u00e9sert\u00e9 les laboratoires hospitaliers d\u2019anatomopathologie et se trouvent le plus souvent implant\u00e9s dans des centres de recherche universitaire dans lesquels, au mieux, les pathologistes disposent d\u2019un acc\u00e8s limit\u00e9.", [["Ainsi", "TEST", 0, 5], ["les microscopes", "TEST", 7, 22], ["\u00e9lectroniques", "TEST", 23, 36], ["et se trouvent le", "TREATMENT", 99, 116]]], ["L\u2019analyse en ME devient alors essentiellement utilis\u00e9e pour des approches exp\u00e9rimentales animales et surtout in vitro (cultures cellulaires).", [["pour des", "TREATMENT", 55, 63], ["vitro (cultures cellulaires", "TEST", 112, 139]]], ["Enfin, nous insisterons sur le r\u00f4le que la ME peut continuer \u00e0 jouer pour am\u00e9liorer la connaissance physiopathologique des maladies humaines.Apport de la microscopie \u00e9lectronique en pathologie infectieuseC\u2019est certainement dans le domaine de la pathologie infectieuse que la ME a permis chez l\u2019homme une identification plus pr\u00e9cise de nombreuses maladies.", [["maladies humaines", "DISEASE", 123, 140], ["nombreuses maladies", "DISEASE", 335, 354], ["pour am\u00e9liorer la connaissance physiopathologique des maladies humaines", "TREATMENT", 69, 140], ["C\u2019est certainement", "TEST", 204, 222]]], ["Ainsi, la ME a apport\u00e9 et apporte encore une contribution importante dans le diagnostic de certaines infections virales, mais aussi bact\u00e9riennes, mycotiques et parasitaires [5], [6].", [["infections virales", "DISEASE", 101, 119], ["infections virales", "PROBLEM", 101, 119]]], ["La morphologie des virus est r\u00e9sistante \u00e0 la fixation formol\u00e9e.", [["La morphologie des virus", "TREATMENT", 0, 24], ["la fixation formol\u00e9e", "TREATMENT", 42, 62], ["la fixation", "OBSERVATION", 42, 53]]], ["Ils peuvent ainsi \u00eatre observ\u00e9s dans des tissus inclus en paraffine.", [["en paraffine", "TREATMENT", 55, 67]]], ["De nombreux virus comme celui de la rage, le cytom\u00e9galovirus mais aussi diff\u00e9rents virus \u00e9mergents ont \u00e9t\u00e9 analys\u00e9s en ultrastructure (Fig. 1) [7], [8].", [["le cytom\u00e9galovirus mais aussi", "TEST", 42, 71]]], ["Les deux exemples les plus spectaculaires sont ceux du virus de l\u2019immunod\u00e9ficience humaine (VIH) et du virus du coronavirus [9], [10].", [["Les deux exemples les plus spectaculaires sont ceux du virus de l\u2019immunod\u00e9ficience humaine (VIH) et du virus du coronavirus", "SPECIES", 0, 123], ["Les deux", "TEST", 0, 8], ["les", "TEST", 18, 21], ["spectaculaires", "TEST", 27, 41], ["ceux", "TEST", 47, 51], ["du virus", "PROBLEM", 52, 60], ["et du virus du coronavirus", "PROBLEM", 97, 123]]], ["Actuellement, l\u2019optimisation des m\u00e9thodes (en utilisant notamment une coloration n\u00e9gative) peut permettre un diagnostic ultrastructural d\u2019infection virale dans un d\u00e9lai tr\u00e8s rapide (moins de 30 minutes !) [11].", [["l\u2019optimisation des m\u00e9thodes", "CHEMICAL", 14, 41]]], ["Ainsi, les microsporidies (en particulier, Enterocytozoon bieneusii, Nosema spp., Encephalitozoon hellem, Vittaforma cornea, Trachipleistophora hominis, Septata intestinalis), Isospora belli, Cyclospora cayatenesis, Cryptosporidium parvum, sont bien identifi\u00e9s en ultrastructure (Fig. 2A\u2013D) [12], [13].", [["Isospora belli", "DISEASE", 176, 190], ["Cryptosporidium parvum", "DISEASE", 216, 238], ["Enterocytozoon bieneusii", "ORGANISM", 43, 67], ["Nosema spp.", "ORGANISM", 69, 80], ["Encephalitozoon hellem", "ORGANISM", 82, 104], ["Vittaforma cornea", "ORGANISM", 106, 123], ["Trachipleistophora hominis", "ORGANISM", 125, 151], ["Septata intestinalis", "ORGANISM", 153, 173], ["Isospora belli", "ORGANISM", 176, 190], ["Cyclospora cayatenesis", "ORGANISM", 192, 214], ["Cryptosporidium parvum", "ORGANISM", 216, 238], ["Enterocytozoon bieneusii", "SPECIES", 43, 67], ["Nosema spp.", "SPECIES", 69, 80], ["Encephalitozoon hellem", "SPECIES", 82, 104], ["Vittaforma cornea", "SPECIES", 106, 123], ["Trachipleistophora hominis", "SPECIES", 125, 151], ["Septata intestinalis", "SPECIES", 153, 173], ["Isospora belli", "SPECIES", 176, 190], ["Cyclospora cayatenesis", "SPECIES", 192, 214], ["Cryptosporidium parvum", "SPECIES", 216, 238], ["Enterocytozoon bieneusii", "SPECIES", 43, 67], ["Nosema spp.", "SPECIES", 69, 80], ["Encephalitozoon hellem", "SPECIES", 82, 104], ["Vittaforma cornea", "SPECIES", 106, 123], ["Trachipleistophora hominis", "SPECIES", 125, 151], ["Septata intestinalis", "SPECIES", 153, 173], ["Isospora belli", "SPECIES", 176, 190], ["Cyclospora cayatenesis", "SPECIES", 192, 214], ["Cryptosporidium parvum", "SPECIES", 216, 238], ["Ainsi", "TEST", 0, 5], ["les microsporidies", "PROBLEM", 7, 25], ["Enterocytozoon bieneusii", "PROBLEM", 43, 67], ["Nosema spp.", "PROBLEM", 69, 80], ["Encephalitozoon hellem", "PROBLEM", 82, 104], ["Vittaforma cornea", "PROBLEM", 106, 123], ["Trachipleistophora hominis", "PROBLEM", 125, 151], ["Septata intestinalis", "PROBLEM", 153, 173], ["Isospora belli", "PROBLEM", 176, 190], ["Cyclospora cayatenesis", "PROBLEM", 192, 214], ["Cryptosporidium parvum", "PROBLEM", 216, 238], ["les", "ANATOMY_MODIFIER", 7, 10], ["cornea", "ANATOMY", 117, 123], ["Isospora belli", "OBSERVATION", 176, 190]]], ["Bien d\u2019autres parasites, en particulier chez le patient VIH positif, ont \u00e9t\u00e9 \u00e9galement analys\u00e9s en ME (Fig. 2E et F) [14], [15], [16], [17], [18], [19].", [["patient", "ORGANISM", 48, 55], ["[15], [16], [17], [18], [19]", "SIMPLE_CHEMICAL", 123, 151], ["patient", "SPECIES", 48, 55], ["Bien d\u2019autres parasites", "PROBLEM", 0, 23], ["positif", "TEST", 60, 67], ["ont \u00e9t\u00e9 \u00e9galement analys\u00e9s", "TEST", 69, 95]]], ["Ainsi, au cours de la malacoplaquie, maladie initialement \u00e9tiquet\u00e9e comme \u00e9tant d\u2019origine tumorale, des structures bact\u00e9riennes plus ou moins d\u00e9grad\u00e9es sont observ\u00e9es dans les macrophages (Fig. 3A).", [["macrophages", "CELL", 176, 187], ["macrophages", "CELL_TYPE", 176, 187], ["maladie", "TREATMENT", 37, 44]]], ["Bartonella sp., responsable notamment des l\u00e9sions d\u2019angiomatose bacillaire chez le patient VIH positif, est bien caract\u00e9ris\u00e9 par la pr\u00e9sence d\u2019une membrane plasmique trilamellaire (Fig. 3B) [21].", [["patient", "ORGANISM", 83, 90], ["patient", "SPECIES", 83, 90], ["Bartonella sp.", "TEST", 0, 14], ["est bien caract\u00e9ris\u00e9", "TREATMENT", 104, 124]]], ["Des bact\u00e9ries digestives, comme celles responsables de la maladie de Whipple, ont \u00e9t\u00e9 initialement identifi\u00e9es en ME (Fig. 3C) [20], [22].", [["Whipple", "TREATMENT", 69, 76], ["ont \u00e9t\u00e9 initialement", "TREATMENT", 78, 98], ["Whipple", "OBSERVATION", 69, 76]]], ["Des bact\u00e9ries sont \u00e9galement mise en \u00e9vidence dans des biopsies effectu\u00e9es pour une analyse ultrastructurale en l\u2019absence d\u2019\u00e9l\u00e9ments cliniques d\u2019orientation \u00e9tiologique (Fig. 3D).", [["Des bact\u00e9ries", "TREATMENT", 0, 13], ["dans des biopsies", "TEST", 46, 63], ["pour une analyse", "TEST", 75, 91]]], ["Parmi les diff\u00e9rents agents mycotiques, Penicillium marneffei peut \u00eatre bien reconnu gr\u00e2ce \u00e0 une \u00e9tude ultrastructurale [23].", [["Parmi les diff\u00e9rents agents", "TREATMENT", 0, 27]]], ["D\u2019une fa\u00e7on plus g\u00e9n\u00e9rale, la ME peut aussi permettre de d\u00e9tecter et de caract\u00e9riser des agents pathog\u00e8nes dans des sites tissulaires et cellulaires tr\u00e8s inhabituelles ou bien de d\u00e9couvrir parfois des co-infections, notamment chez le patient immunod\u00e9prim\u00e9 (Fig. 3E) [21].Apport de la microscopie \u00e9lectronique en pathologie tumoraleL\u2019IHC a r\u00e9volutionn\u00e9 le diagnostic des tumeurs en anatomopathologie et a fait ainsi dispara\u00eetre la quasi-totalit\u00e9 des indications de la ME en pathologie tumorale [24], [25].", [["patient", "SPECIES", 234, 241], ["la ME peut aussi permettre de d\u00e9tecter et de caract\u00e9riser des agents", "TREATMENT", 27, 95], ["dans des sites", "TREATMENT", 107, 121], ["et cellulaires", "PROBLEM", 134, 148], ["a r\u00e9volutionn\u00e9 le diagnostic des tumeurs", "TREATMENT", 337, 377], ["a fait ainsi dispara\u00eetre la quasi", "TREATMENT", 402, 435]]], ["La plupart des structures caract\u00e9ristiques r\u00e9v\u00e9l\u00e9es par la ME et utilis\u00e9es comme marqueurs diagnostiques peuvent aujourd\u2019hui \u00eatre mises en \u00e9vidence de mani\u00e8re beaucoup plus rapide, simple, \u00e9conomique et reproductible par les techniques immuno-histochimiques qui identifient la pr\u00e9sence des prot\u00e9ines sp\u00e9cifiques associ\u00e9es \u00e0 ces structures.", [["La plupart des", "TREATMENT", 0, 14], ["immuno-histochimiques", "TEST", 236, 257]]], ["La mise en \u00e9vidence de filaments interm\u00e9diaires et des desmosomes a \u00e9t\u00e9 pendant longtemps un bon moyen pour identifier les carcinomes peu diff\u00e9renci\u00e9s et les distinguer des autres tumeurs, en particulier des sarcomes (Fig. 4A).", [["La mise en \u00e9vidence de filaments", "TREATMENT", 0, 32]]], ["Aujourd\u2019hui, les m\u00eames informations peuvent \u00eatre obtenues par la mise en \u00e9vidence des prot\u00e9ines constitutives de ces structures caract\u00e9ristiques des cellules \u00e9pith\u00e9liales, comme les cytok\u00e9ratines, constituants mol\u00e9culaires des tonofilaments et les prot\u00e9ines comme les desmoplakines et la desmogl\u00e9ine, constituants des desmosomes.", [["desmosomes", "ANATOMY", 318, 328], ["desmosomes", "ORGANISM_SUBSTANCE", 318, 328], ["\u00e9pith\u00e9liales", "TEST", 158, 170], ["comme les cytok\u00e9ratines", "PROBLEM", 172, 195], ["constituants mol\u00e9culaires", "PROBLEM", 197, 222], ["et la desmogl\u00e9ine", "TREATMENT", 282, 299]]], ["L\u2019IHC puis la BM ont \u00e9galement \u00ab balay\u00e9 \u00bb les indications de la ME pour identifier les diff\u00e9rents types de sarcomes ou certains types d\u2019h\u00e9mopathies, comme les leuc\u00e9mies \u00e0 tricholeucocytes et les h\u00e9mopathies \u00e0 lymphocytes villeux [26], [27].", [["types d\u2019h\u00e9mopathies", "PROBLEM", 128, 147], ["comme les leuc\u00e9mies", "TEST", 149, 168], ["et les h\u00e9mopathies", "TEST", 188, 206], ["lymphocytes villeux", "TEST", 209, 228]]], ["Ainsi, l\u2019observation de structures plus ou moins matures correspondant \u00e0 des grains neuros\u00e9cr\u00e9toires peut permettre d\u2019identifier des tumeurs neuroendocrines peu diff\u00e9renci\u00e9es pour lesquelles l\u2019IHC peut \u00eatre moins contributive (Fig. 4B).", [["neuroendocrines", "TEST", 141, 156]]], ["La pr\u00e9sence de m\u00e9lanosomes peut aussi exceptionnellement permettre aujourd\u2019hui l\u2019identification d\u2019un m\u00e9lanome, en particulier pour certaines tumeurs muqueuses achromiques (Fig. 4C et D).", [["La pr\u00e9sence", "TEST", 0, 11]]], ["La ME peut encore aider au diagnostic diff\u00e9rentiel entre un m\u00e9soth\u00e9liome malin et un ad\u00e9nocarcinome, au diagnostic de certaines tumeurs rhabdo\u00efdes, de rares tumeurs \u00e0 cellules rondes de l\u2019enfant et d\u2019histiocytose langheransienne (Fig. 4E et F) [30], [31], [32], [33].Apport de la microscopie \u00e9lectronique en pathologie non infectieuse et non tumoraleCe domaine regroupe des maladies humaines tr\u00e8s h\u00e9t\u00e9rog\u00e8nes, en particulier, les pathologies de surcharge, d\u00e9g\u00e9n\u00e9ratives et iatrog\u00e8nes.", [["rhabdo\u00efdes", "PROBLEM", 136, 146], ["les pathologies", "PROBLEM", 426, 441]]], ["Certains grands m\u00e9canismes de mort cellulaire, comme l\u2019apoptose ou l\u2019autophagie, ont \u00e9t\u00e9 d\u2019abord analys\u00e9s par la ME (Fig. 5A et B) qui reste la technique de r\u00e9f\u00e9rence pour d\u00e9montrer leur implication en pathologie [34], [35].", [["A et B) qui reste la technique", "TREATMENT", 123, 153]]], ["Un certain nombre de myopathies et de neuropathies p\u00e9riph\u00e9riques b\u00e9n\u00e9ficient encore \u00e0 ce jour de l\u2019apport de la ME pour \u00eatre mieux caract\u00e9ris\u00e9es et la ME reste \u00e9galement un outil privil\u00e9gi\u00e9 pour analyser les anomalies de la jonction neuromusculaire (Fig. 5C) [36], [37], [38], [39].", [["myopathies et de neuropathies", "DISEASE", 21, 50], ["myopathies et de neuropathies", "PROBLEM", 21, 50], ["p\u00e9riph\u00e9riques", "TEST", 51, 64], ["b\u00e9n\u00e9ficient", "TEST", 65, 76], ["pour analyser les anomalies", "PROBLEM", 190, 217]]], ["La ME a permis de mieux identifier les d\u00e9p\u00f4ts d\u2019amylose et des plaques amylo\u00efdes dans des maladies neurod\u00e9g\u00e9n\u00e9ratives, comme celles observ\u00e9es dans la maladie d\u2019Alzheimer (Fig. 5C et D).", [["Alzheimer", "DISEASE", 160, 169], ["Alzheimer", "PROBLEM", 160, 169]]], ["De la m\u00eame fa\u00e7on, avant le d\u00e9veloppement des analyses mol\u00e9culaires et g\u00e9n\u00e9tiques, les glycog\u00e9noses et les dyslipo\u00efdoses \u00e9taient identifi\u00e9es, diagnostiqu\u00e9es et class\u00e9es essentiellement gr\u00e2ce aux images observ\u00e9es en ME.Apport de la microscopie \u00e9lectronique en pathologie non infectieuse et non tumoraleLa ME reste le seul outil efficace pour analyser des structures dont l\u2019\u00e9tude n\u00e9cessite un niveau de r\u00e9solution tr\u00e8s pouss\u00e9 et/ou dont la composition est trop complexe pour se pr\u00eater facilement \u00e0 une \u00e9tude immuno-histochimique.", [["et non tumoraleLa", "PROBLEM", 285, 302], ["efficace pour analyser des structures", "TREATMENT", 326, 363], ["nt la composition", "TEST", 431, 448]]], ["C\u2019est \u00e9videmment le cas des organites intracellulaires et des sp\u00e9cialisations de la membrane plasmique, que la ME a contribu\u00e9 \u00e0 identifier et \u00e0 d\u00e9crire, mais aussi de certaines diff\u00e9renciations tissulaires complexes, comme les lames basales, voire de certaines structures histologiques, comme le glom\u00e9rule r\u00e9nal ou la paroi du sinuso\u00efde h\u00e9patique, dont l\u2019\u00e9tude de la pathologie et de la physiopathologie continue encore \u00e0 n\u00e9cessiter une approche ultrastructurale [40], [41], [42] (Fig. 6).", [["C\u2019est \u00e9videmment le cas des", "TREATMENT", 0, 27], ["tissulaires complexes", "PROBLEM", 194, 215], ["histologiques", "TEST", 272, 285]]], ["En cons\u00e9quence, la ME peut \u00eatre tr\u00e8s utile pour le diagnostic de certaines maladies r\u00e9nales, en particulier les glom\u00e9rulopathies h\u00e9r\u00e9ditaires ou associ\u00e9es \u00e0 des d\u00e9p\u00f4ts d\u2019immunoglobulines mono- ou polyclonales, pour celui des dyskin\u00e9sies ciliaires et dans certains cas d\u2019infertilit\u00e9 masculine (centriolopathie et anomalies des spermatozo\u00efdes) [43], [44], [45].Apport de la microscopie \u00e9lectronique en pathologie non infectieuse et non tumoraleCertaines alt\u00e9rations cellulaires li\u00e9es \u00e0 des toxiques et \u00e0 des m\u00e9dicaments sont d\u00e9tectables de fa\u00e7on tr\u00e8s caract\u00e9ristiques en ME.", [["maladies r\u00e9nales", "PROBLEM", 75, 91], ["mono", "TEST", 187, 191], ["ou polyclonales", "PROBLEM", 193, 208], ["pour celui des dyskin\u00e9sies", "TREATMENT", 210, 236], ["ciliaires et dans certains cas d\u2019infertilit\u00e9 masculine (centriolopathie et anomalies des spermatozo\u00efdes", "TREATMENT", 237, 340]]], ["Aujourd\u2019hui, l\u2019effet iatrog\u00e8ne de la cordarone dans les cellules isol\u00e9es des liquides de lavage bronchoalv\u00e9olaires ou l\u2019atteinte mitochondriale li\u00e9es \u00e0 certains antir\u00e9troviraux comme l\u2019azidothymidine donnent des images ultrastructurales tr\u00e8s caract\u00e9ristiques [47].", [["lavage bronchoalv\u00e9olaires", "TREATMENT", 89, 114]]], ["Enfin, certaines anomalies de la k\u00e9ratinisation de l\u2019\u00e9piderme ou de la jonction dermo\u00e9pidermique, souvent associ\u00e9es \u00e0 des maladies cong\u00e9nitales, sont caract\u00e9ris\u00e9es par la ME, qui reste pour certains la technique de r\u00e9f\u00e9rence pour faire leur diagnostic [48], [49], [50], [51].Perspectives\u00c0 travers les quelque exemples cit\u00e9s plus haut, il est donc certain que l\u2019analyse ultrastructurale en pathologie humaine reste un domaine d\u2019expertise indispensable \u00e0 conserver dans notre discipline (Tableau 1).", [["certaines anomalies", "PROBLEM", 7, 26], ["des maladies cong\u00e9nitales", "PROBLEM", 118, 143]]], ["Les nouvelles orientations \u00e9conomiques du secteur public ne favorisent gu\u00e8re le maintien d\u2019un \u00e9quipement de ce type dans le cadre de l\u2019offre de soins aux patients, ainsi que celui d\u2019un personnel technique hautement qualifi\u00e9 uniquement d\u00e9di\u00e9 \u00e0 cette activit\u00e9.", [["patients", "ORGANISM", 154, 162], ["patients", "SPECIES", 154, 162]]], ["En effet, la confrontation des images observ\u00e9es en ME, avec celles observ\u00e9es en microscopie optique, les r\u00e9sultats des analyses immuno-histochimiques et/ou mol\u00e9culaires et les donn\u00e9es cliniques, est parfois d\u2019un apport diagnostique important et doit \u00eatre du domaine de l\u2019expertise m\u00e9dicale [53].", [["la confrontation des images", "TEST", 10, 37], ["celles", "TEST", 60, 66], ["les r\u00e9sultats des analyses", "TEST", 101, 127], ["immuno", "TEST", 128, 134]]]], "b1b261a266ebfd1cb931dc80e15f8e47139111cd": [["IntroductionRecent research on nursing education has revealed a massive wave of interest in the use of simulation practices to promote undergraduate nurses' learning experiences.", [["nursing education", "TREATMENT", 31, 48], ["simulation practices", "TREATMENT", 103, 123], ["massive", "OBSERVATION_MODIFIER", 64, 71], ["wave", "OBSERVATION_MODIFIER", 72, 76]]], ["[1] [2] [3] Simulation practices, in this context, refer to a teaching technique that creates a rich teaching environment that mimics real hospital scenarios.", [["Simulation practices", "TEST", 12, 32], ["a teaching technique", "TREATMENT", 60, 80]]], ["2, 5 This clinical training mostly happens within a supervised context, which not only promotes students' learning but also provides a space for making errors that do not jeopardize real patient safety.", [["patient", "ORGANISM", 187, 194], ["patient", "SPECIES", 187, 194]]], ["2 This widespread use of simulations in nursing programs has led to opportunities to research this topic from many angles, including its impact on students' skill performance, 6, 7 self-efficacy, [8] [9] [10] self-confidence and satisfaction, [11] [12] [13] and, most importantly, clinical knowledge acquisition.", [["simulations in nursing programs", "TREATMENT", 25, 56]]], ["13 Collectively, the major findings of this research indicate the positive impact of simulation practices regarding reinforcement of students' learning and professional skills (including providing valuable opportunities for students to spot areas where they need to improve) and improvement of students' self-esteem.", [["simulation practices", "TREATMENT", 85, 105]]], ["Based on an investigation involving a similar context in Saudi Arabia as that involved in the current study, Omer surveyed Saudi nursing students' satisfaction and self-confidence after clinical simulation sessions and reported students' overall satisfaction with simulation-based training as well as the simulations' positive impact on their acquisition and retention of clinical knowledge.", [["an investigation", "TEST", 9, 25], ["simulation-based training", "TREATMENT", 264, 289]]], ["3 Most students reported having confidence in their clinical skills and they demonstrated that they were able to recognize signs and symptoms of diseases and perform appropriate clinical practices to assess patients' needs.", [["patients", "ORGANISM", 207, 215], ["patients", "SPECIES", 207, 215], ["signs and symptoms of diseases", "PROBLEM", 123, 153], ["appropriate clinical practices", "TREATMENT", 166, 196]]], ["3 Clear evidence in the literature strongly supports the use of simulations, and there is now a need for further studies on the best ways to improve these simulations.", [["further studies", "TEST", 105, 120]]], ["However, it is worth noting that despite the abundance of research on simulation practices, few actual examples of authentic simulation interactions are available in the literature.", [["simulation practices", "TREATMENT", 70, 90]]], ["Additionally, analysis of authentic data can provide deep insights and opportunities to improve communication in simulation practices in order to improve actual patient care in hospital settings.", [["patient", "ORGANISM", 161, 168], ["patient", "SPECIES", 161, 168], ["authentic data", "TEST", 26, 40], ["simulation practices", "TREATMENT", 113, 133]]], ["Furthermore, the study aimed to examine the way students linguistically managed this critical communication, exhibiting their logical, reflective, decision-making, problem-solving, and collaborative work skills.", [["the study", "TEST", 13, 22]]], ["2 Additionally, the analyses shed light on the students' use of effective and/or less effective communicative strategies, 15 which could help to further improve the quality of simulation training in this context.", [["simulation training", "TREATMENT", 176, 195]]], ["Effectiveness in this paper was operationalized as \"the recommended best practices,\" meaning the extent to which students put in effort to obtain, understand, and negotiate patient-related information and to make appropriate clinical decisions (as expected in the ideal model training scenario).", [["patient", "ORGANISM", 173, 180], ["patient", "SPECIES", 173, 180]]], ["15, 19 Design and MethodsParticipantsA convenience sample of 54 senior female undergraduate nursing students enrolled in a critical care nursing course participated in this study.", [["this study", "TEST", 168, 178]]], ["The participants also included a faculty member who spoke English as her first language, and two simulation lab assistants who were from the Philippines and spoke Tagalog as their first language.", [["participants", "SPECIES", 4, 16]]], ["English is the official means of communication among the participants during the simulation sessions.", [["participants", "SPECIES", 57, 69]]], ["The collected data for this setting included audio recordings of six authentic, acute care simulation sessions along with observations and detailed field notes.", [["The collected data", "TEST", 0, 18], ["audio recordings", "TEST", 45, 61], ["acute", "OBSERVATION_MODIFIER", 80, 85]]], ["Ethical approval was obtained in April 2019 from King Abdullah International Medical Research Center (KAIMRC) for collecting data in clinical simulation laboratories at a nursing college in Saudi Arabia.", [["collecting data", "TEST", 114, 129]]], ["All participants were provided with informed consent forms, which thoroughly explained the purpose of the study as well as the confidential and anonymous nature of the collected data, and they all provided signed informed consent.ResultsIn this section, a single extended simulation session, which was the most representative of the six recorded simulation sessions, is presented and discussed.Simulation sessionDuring simulation sessions in this context, nursing students are expected to demonstrate their clinical knowledge in accordance with the cognitive skills acquired in classroom settings via lectures, video tutorials, and/or independent reading assignments.", [["participants", "SPECIES", 4, 16], ["the study", "TEST", 102, 111]]], ["Similar to a model simulation session, the students involved in this study were assigned to act as members in a fast-track team providing healthcare in an emergency room (ER).", [["this study", "TEST", 64, 74]]], ["Following the model, the roles within the team comprise a primary nurse, who lead the team and delegate responsibilities and tasks, assisted by other students who play various roles including a doctor, a pharmacist, a social worker, a patient, a patient relative, and a recorder.", [["patient", "ORGANISM", 235, 242], ["patient", "ORGANISM", 246, 253], ["patient", "SPECIES", 235, 242], ["patient", "SPECIES", 246, 253]]], ["In the following script, while the role of some students was identifiable including the role of the patient and the patient relative, there was little evidence of the roles that other students were taking.", [["patient", "ORGANISM", 100, 107], ["patient", "ORGANISM", 116, 123], ["patient", "SPECIES", 100, 107], ["patient", "SPECIES", 116, 123]]], ["Thus, in the script, I refer to the rest of the participants as student 2 and student 3 due to the uncertainty of the roles they were playing.", [["participants", "SPECIES", 48, 60]]], ["In the simulation scenario in this paper, the team must manage a patient who sustained a severe injury on her right thigh in an auto accident.", [["right thigh", "ANATOMY", 110, 121], ["injury on her right thigh", "DISEASE", 96, 121], ["patient", "ORGANISM", 65, 72], ["thigh", "ORGANISM_SUBDIVISION", 116, 121], ["patient", "SPECIES", 65, 72], ["a severe injury on her right thigh", "PROBLEM", 87, 121], ["severe", "OBSERVATION_MODIFIER", 89, 95], ["injury", "OBSERVATION", 96, 102], ["right", "ANATOMY_MODIFIER", 110, 115], ["thigh", "ANATOMY", 116, 121], ["auto accident", "OBSERVATION", 128, 141]]], ["The management of the patient was expected to involve performing various medical interventions during three major scenarios (1: conducting a primary survey; 2: managing sudden hemodynamic changes; and 3: managing cardiopulmonary arrest).", [["cardiopulmonary arrest", "DISEASE", 213, 235], ["patient", "ORGANISM", 22, 29], ["patient", "SPECIES", 22, 29], ["various medical interventions", "TREATMENT", 65, 94], ["sudden hemodynamic changes", "PROBLEM", 169, 195], ["managing cardiopulmonary arrest", "TREATMENT", 204, 235]]], ["The timeframe assigned for the three scenarios was approximately 25 min: 10, 5, and 10 min for Scenarios 1, 2, and 3, respectively.", [["Scenarios", "TEST", 95, 104]]], ["It should be noted here that only the first two scenarios are discussed in this paper as none of the teams participating in the six recorded simulation sessions completed Scenario 3 (largely due to the teams' failure to perform an expected procedure, i.e., to call a code).Scenario 1: Conducting a primary surveyScenario 1 aimed to assess students' ability to prioritize the procedures needed to assess the patient, including performing the Air, Breathing, Circulation, Disability, and Exposure (ABCDE) primary survey.", [["patient", "ORGANISM", 407, 414], ["patient", "SPECIES", 407, 414], ["an expected procedure", "TREATMENT", 228, 249], ["the procedures", "TEST", 371, 385]]], ["Based on the faculty member's remarks in lines 6-12, it can be noted that she reminded the students of certain critical information concerning the patient.", [["patient", "ORGANISM", 147, 154], ["patient", "SPECIES", 147, 154]]], ["This information set-up the scenario, revealing the primary medical diagnosis of the patient, i.e., trauma in the form of a severe laceration to the right leg.", [["right leg", "ANATOMY", 149, 158], ["trauma", "DISEASE", 100, 106], ["laceration to the right leg", "DISEASE", 131, 158], ["patient", "ORGANISM", 85, 92], ["leg", "ORGANISM_SUBDIVISION", 155, 158], ["patient", "SPECIES", 85, 92], ["trauma", "PROBLEM", 100, 106], ["a severe laceration to the right leg", "PROBLEM", 122, 158], ["severe", "OBSERVATION_MODIFIER", 124, 130], ["laceration", "OBSERVATION", 131, 141], ["right", "ANATOMY_MODIFIER", 149, 154], ["leg", "ANATOMY", 155, 158]]], ["This introductory information, if well responded to by the team, should positively contribute to the commencement and completion of the expected interventions in Scenario 1.", [["the expected interventions", "TREATMENT", 132, 158]]], ["Declaring the beginning of the scenario, with a rising intonation (line 12), the faculty member concluded the set-up phase by delegating responsibility to the primary nurse.Scenario 1: Conducting a primary surveyFollowing the set-up phase, students were expected to commence the simulation scenario and work as a team to perform the required medical interventions.", [["a rising intonation (line", "TREATMENT", 46, 71], ["medical interventions", "TREATMENT", 342, 363]]], ["The scenario began with a dramat- ic entrance by the student who was taking on the role of a severely injured patient laying on a stretcher, escorted by the two lab assistants.", [["patient", "ORGANISM", 110, 117], ["patient", "SPECIES", 110, 117]]], ["Ideally, the team is required to act immediately, receiving the patient and beginning the case management process.", [["patient", "ORGANISM", 64, 71], ["patient", "SPECIES", 64, 71], ["the case management process", "TREATMENT", 86, 113]]], ["As shown in Extract 2, the patient was conscious, breathing, and able to inform the team about the location of her injury (lines [13] [14] .", [["patient", "ORGANISM", 27, 34], ["patient", "SPECIES", 27, 34], ["her injury", "PROBLEM", 111, 121]]], ["However, this valuable information seemed to be overlooked by the team, meaning that the primary nurse could not build on the introductory information by obtaining more information from the patient (e.g., by double-checking the patient's information, the type of incident that happened, the location of the injury, the severity of pain, the level of consciousness, etc.).", [["pain", "DISEASE", 331, 335], ["patient", "ORGANISM", 190, 197], ["patient", "ORGANISM", 228, 235], ["patient", "SPECIES", 190, 197], ["patient", "SPECIES", 228, 235], ["the injury", "PROBLEM", 303, 313], ["pain", "PROBLEM", 331, 335]]], ["In line 15, the primary nurse requested an assessment of the patient's vital signs.", [["patient", "ORGANISM", 61, 68], ["patient", "SPECIES", 61, 68], ["an assessment", "TEST", 40, 53], ["the patient's vital signs", "TEST", 57, 82]]], ["Although the primary nurse attempted to use different request strategies, mostly relying on intonation, both requests seemed to lack not only the necessary paralinguistic features but also the basic syntactic features that are needed for effective speech act performance i.e., a request.", [["different request strategies", "TREATMENT", 44, 72], ["the necessary paralinguistic features", "PROBLEM", 142, 179]]], ["20 Due to the passive behavior of the rest of the team, the patient intervened (line 21) by providing the students with a cue, which most probably was intended to direct the team's attention to the wound, so they could begin the Exposure assessment in the ABCDE primary survey.", [["wound", "ANATOMY", 198, 203], ["patient", "ORGANISM", 60, 67], ["wound", "PATHOLOGICAL_FORMATION", 198, 203], ["patient", "SPECIES", 60, 67], ["the wound", "PROBLEM", 194, 203], ["the Exposure assessment", "TEST", 225, 248], ["wound", "ANATOMY", 198, 203]]], ["Following the model, the team were required to conduct wound management (i.e., undressing and assessing the injury).", [["wound", "ANATOMY", 55, 60], ["wound", "PATHOLOGICAL_FORMATION", 55, 60], ["wound management", "TREATMENT", 55, 71], ["the injury", "PROBLEM", 104, 114], ["injury", "OBSERVATION", 108, 114]]], ["However, due to there being no immediate uptake to the cue, the patient screamed /Please HURRY\u2191/ (line 23), which reflected the slow interactions between the team rather than the expected dynamic, fast-paced environment in the ER.", [["ER", "ANATOMY", 227, 229], ["patient", "ORGANISM", 64, 71], ["ER", "GENE_OR_GENE_PRODUCT", 227, 229], ["ER", "PROTEIN", 227, 229], ["patient", "SPECIES", 64, 71], ["fast-paced environment", "TREATMENT", 197, 219]]], ["21 The details of Scenario 1 (conducting a primary survey) are continued in Extract 3, with the primary nurse attempting to measure the patient's vital signs (line 24), as nobody had started this task.", [["patient", "ORGANISM", 136, 143], ["patient", "SPECIES", 136, 143], ["the patient's vital signs", "TEST", 132, 157]]], ["Next, Student 2, who failed to disclose her role in the team, commented on the patient's behavior (line 25), asking the patient to quit her \"drama.\"", [["patient", "ORGANISM", 79, 86], ["patient", "ORGANISM", 120, 127], ["patient", "SPECIES", 79, 86], ["patient", "SPECIES", 120, 127]]], ["Although the student who took on the role of the patient distinguished herself, creating a realistic ER environment and seeming to be highly engaged in her role in the simulation session, most of the other students, unfortunately, could not react as authentically to the interactions initiated by the patient.", [["patient", "ORGANISM", 49, 56], ["ER", "GENE_OR_GENE_PRODUCT", 101, 103], ["patient", "ORGANISM", 301, 308], ["patient", "SPECIES", 49, 56], ["patient", "SPECIES", 301, 308]]], ["The comment made by Student 2 about \"drama\" (line 25) may also be a reflec-tion of the lack of seriousness among the team during the simulation practice.Scenario 1: Conducting a primary surveyIn response to this comment, the patient wittily redirected the communication to the scenario by declaring that she was in pain (line 27).", [["pain", "DISEASE", 315, 319], ["patient", "ORGANISM", 225, 232], ["patient", "SPECIES", 225, 232], ["the simulation practice", "TREATMENT", 129, 152], ["pain", "PROBLEM", 315, 319]]], ["The primary nurse responded with a lower tone /okay\u2193/ (line 28), and then she stated that she needed to assess the vital signs, a procedure that had been started at the beginning of the scenario.", [["the vital signs", "TEST", 111, 126], ["a procedure", "TREATMENT", 128, 139]]], ["The patient, again, tried to redirect the nurses' attention to the wound in her leg (line 29), this time with explicit cues, i.e., directing the team's attention to her physical problem (the wound) and its location (the right leg).", [["wound", "ANATOMY", 67, 72], ["leg", "ANATOMY", 80, 83], ["wound", "ANATOMY", 191, 196], ["right leg", "ANATOMY", 220, 229], ["patient", "ORGANISM", 4, 11], ["wound", "PATHOLOGICAL_FORMATION", 67, 72], ["leg", "ORGANISM_SUBDIVISION", 80, 83], ["wound", "PATHOLOGICAL_FORMATION", 191, 196], ["leg", "ORGANISM_SUBDIVISION", 226, 229], ["patient", "SPECIES", 4, 11], ["the wound", "PROBLEM", 63, 72], ["her physical problem", "PROBLEM", 165, 185], ["the wound", "PROBLEM", 187, 196], ["wound", "ANATOMY", 67, 72], ["leg", "ANATOMY", 80, 83], ["wound", "ANATOMY", 191, 196], ["right", "ANATOMY_MODIFIER", 220, 225], ["leg", "ANATOMY", 226, 229]]], ["However, once again, the cues were overlooked by the team, and the patient's further contributions were silenced with Student 2's high-pitched comment, /DAGEE-GAH/, i.e., wait a minute (line 30).", [["patient", "ORGANISM", 67, 74], ["patient", "SPECIES", 67, 74]]], ["In another desperate attempt (line 31), the patient intervened, asking the team to administer pain medication.", [["pain", "DISEASE", 94, 98], ["patient", "ORGANISM", 44, 51], ["patient", "SPECIES", 44, 51], ["pain medication", "TREATMENT", 94, 109]]], ["With this interaction, the patient redirected the team to the Circulation assessment in the ABCDE primary survey, meaning that IV insertion should be attempted to allow potential administration of medicine.", [["patient", "ORGANISM", 27, 34], ["patient", "SPECIES", 27, 34], ["the Circulation assessment", "TEST", 58, 84], ["IV insertion", "TREATMENT", 127, 139], ["potential administration of medicine", "TREATMENT", 169, 205]]], ["This sequence of interactions showed that the students seemed slightly impatient, and their communicative style silenced the patient instead of encouraging her to share information in order to allow them to undertake an effective clinical assessment.Scenario 1: Conducting a primary surveyAccording to the US Joint Commission, effective communication and teamwork collaboration are essential to guarantee quality patient care.", [["patient", "ORGANISM", 125, 132], ["patient", "ORGANISM", 413, 420], ["patient", "SPECIES", 125, 132], ["patient", "SPECIES", 413, 420], ["an effective clinical assessment", "TEST", 217, 249], ["Joint", "ANATOMY", 309, 314]]], ["22 Hence, regarding the transcript presented in the extracts, various untoward events should have been addressed with the students to teach them to avoid preventable medical errors.", [["extracts", "ANATOMY", 52, 60], ["extracts", "ORGANISM_SUBSTANCE", 52, 60], ["various untoward events", "PROBLEM", 62, 85], ["preventable medical errors", "PROBLEM", 154, 180]]], ["Secondly, the nurses failed to effectively communicate with the patient, offer her space to tell her story, and build a shared medical knowledge about the case, which is especially important as patients attending an ER usually have no written medical histories with them and there are usually no other patient records accessible in the hospital.", [["patient", "ORGANISM", 64, 71], ["patients", "ORGANISM", 194, 202], ["ER", "GENE_OR_GENE_PRODUCT", 216, 218], ["patient", "ORGANISM", 302, 309], ["patient", "SPECIES", 64, 71], ["patients", "SPECIES", 194, 202], ["patient", "SPECIES", 302, 309]]], ["18 Students need to understand that the patient is a valuable source of vital information that can facilitate the whole healthcare process.", [["patient", "ORGANISM", 40, 47], ["patient", "SPECIES", 40, 47]]], ["Furthermore, it should be noted that, in all six recorded simulation sessions, there was a noticeable lack of use of interactional features (e.g., backchannels, discourse markers, hesitation markers, and yes/no and tag questions), which are considered to be effective tools in spoken discourse as well as being important in effective medical discourse.", [["hesitation markers", "PROTEIN", 180, 198], ["interactional features", "PROBLEM", 117, 139], ["hesitation markers", "TEST", 180, 198]]], ["18, 23, 24 Students need to be trained regarding how to effec-tively elicit patient information as they simultaneously perform the physical assessment (e.g., by using yes/no and tag questions) instead of completely ignoring or silencing the patient.", [["patient", "ORGANISM", 76, 83], ["patient", "ORGANISM", 241, 248], ["patient", "SPECIES", 76, 83], ["patient", "SPECIES", 241, 248], ["the physical assessment", "TEST", 127, 150]]], ["Lastly, as for skill performance, the nurses at this point failed to demonstrate their ability to effectively assess the patient's vital signs, perform IV insertion, and check and manage the patient's wound appropriately.Scenario 1: Conducting a primary surveyAs shown in Extract 4, Student 3, whose role in the team is unidentified, requested that the physician be called and physically waved for the code team to join in (line 35).", [["wound", "ANATOMY", 201, 206], ["patient", "ORGANISM", 121, 128], ["patient", "ORGANISM", 191, 198], ["wound", "PATHOLOGICAL_FORMATION", 201, 206], ["patient", "SPECIES", 121, 128], ["patient", "SPECIES", 191, 198], ["the patient's vital signs", "TEST", 117, 142], ["IV insertion", "TREATMENT", 152, 164], ["the patient's wound", "PROBLEM", 187, 206]]], ["It should be noted here that, according to the model scenario progression, the role of the code team should have begun only in Scenario 3 (managing cardiopulmonary arrest).", [["cardiopulmonary arrest", "DISEASE", 148, 170], ["managing cardiopulmonary arrest", "TREATMENT", 139, 170]]], ["Although Student 3 produced a clear and effective request, she provided no clinical justification for this request, and the patient was still conscious.", [["patient", "ORGANISM", 124, 131], ["patient", "SPECIES", 124, 131]]], ["As can be seen in Extract 4, these interactions between the two teams were ceased by the faculty member (line 42).Scenario 1: Conducting a primary surveyThe faculty member's interjection at this point shifted the interaction back to the first procedure, i.e., measurement of the vital signs by the nurses (line 44).", [["the first procedure", "TREATMENT", 233, 252], ["the vital signs", "TEST", 275, 290]]], ["Thereafter, Student 2 finally reported the readings of the vital signs and she indicated that the patient was hypertensive (line 45); however, it is unclear how she came to this clinical conclusion.Scenario 1: Conducting a primary surveyAs shown in Extract 5, Student 3 re-joined the interaction and seemed to recall the management procedures.", [["hypertensive", "DISEASE", 110, 122], ["patient", "ORGANISM", 98, 105], ["patient", "SPECIES", 98, 105], ["the vital signs", "TEST", 55, 70], ["hypertensive", "PROBLEM", 110, 122], ["the management procedures", "TREATMENT", 317, 342]]], ["In line 46, she interjected with the discourse marker \"Okay,\" followed by \"FIRST\u2191\" with a rising intonation.", [["a rising intonation", "PROBLEM", 88, 107]]], ["This made it seem like she was taking the interaction to the very beginning; thus, she was interrupted by the patient, who asked her to hurry (line 47).", [["patient", "ORGANISM", 110, 117], ["patient", "SPECIES", 110, 117]]], ["Next, the nurse successfully recalled the first step in wound management procedure, i.e., controlling the bleeding (line 48).", [["wound", "ANATOMY", 56, 61], ["bleeding", "DISEASE", 106, 114], ["wound", "PATHOLOGICAL_FORMATION", 56, 61], ["wound management procedure", "TREATMENT", 56, 82], ["the bleeding", "PROBLEM", 102, 114], ["bleeding", "OBSERVATION", 106, 114]]], ["The use of the first-person plural pronoun /we/ (lines 48 and 49) may indicate that the nurse was requesting the team's assistance and that they all should work on this collaboratively.", [["person", "SPECIES", 21, 27]]], ["Though Student 3 started the procedure, she then abruptly delegated the task to the primary nurse (line 50).", [["the procedure", "TREATMENT", 25, 38]]], ["After a short chat between the nurses, the primary nurse seemed to be about to perform the procedure; however, she just re-covered the wound.", [["wound", "ANATOMY", 135, 140], ["wound", "PATHOLOGICAL_FORMATION", 135, 140], ["the procedure", "TREATMENT", 87, 100], ["the wound", "PROBLEM", 131, 140], ["wound", "OBSERVATION", 135, 140]]], ["Shortly after this, the faculty member signaled the end of Scenario 1 to the patient, who was simulating being unconscious.Scenario 1: Conducting a primary surveyExtracts 4 and 5 illustrate other untoward events, including the contentious confusion about the assigned roles, task delegation, and responsibilities among the team.", [["confusion", "DISEASE", 239, 248], ["patient", "ORGANISM", 77, 84], ["patient", "SPECIES", 77, 84], ["the contentious confusion", "PROBLEM", 223, 248]]], ["Again, regarding skill performance, the students failed to demonstrate effective management of the patient's wound or reporting of the patient's vital signs with accurate language and clear justification, which indicate the lack of adequate preparation for this practice.", [["wound", "ANATOMY", 109, 114], ["patient", "ORGANISM", 99, 106], ["wound", "PATHOLOGICAL_FORMATION", 109, 114], ["patient", "ORGANISM", 135, 142], ["patient", "SPECIES", 99, 106], ["patient", "SPECIES", 135, 142], ["effective management", "TREATMENT", 71, 91], ["the patient's wound", "PROBLEM", 95, 114], ["the patient's vital signs", "TEST", 131, 156], ["this practice", "TREATMENT", 257, 270]]], ["In addition, the nurses failed to notice that the once active patient had stopped speaking after line 52; accordingly, they missed identifying the deterioration in the patient's status and therefore missed the opportunity to act appropriately and in a timely manner to save the patient.Scenario 2: Managing sudden hemodynamic changesWith the patient unconscious, Scenario 2 began.", [["patient", "ORGANISM", 62, 69], ["patient", "ORGANISM", 168, 175], ["patient", "ORGANISM", 278, 285], ["patient", "ORGANISM", 342, 349], ["patient", "SPECIES", 62, 69], ["patient", "SPECIES", 168, 175], ["patient", "SPECIES", 278, 285], ["patient", "SPECIES", 342, 349], ["the deterioration", "PROBLEM", 143, 160]]], ["Ideally, students are required to identify and manage sudden hemodynamic changes (i.e., a sudden decrease in heart rate, blood pressure, and response level) in the patient.", [["heart", "ANATOMY", 109, 114], ["blood", "ANATOMY", 121, 126], ["heart", "ORGAN", 109, 114], ["blood", "ORGANISM_SUBSTANCE", 121, 126], ["patient", "ORGANISM", 164, 171], ["patient", "SPECIES", 164, 171], ["sudden hemodynamic changes", "PROBLEM", 54, 80], ["a sudden decrease", "PROBLEM", 88, 105], ["heart rate", "TEST", 109, 119], ["blood pressure", "TEST", 121, 135], ["heart", "ANATOMY", 109, 114]]], ["As can be seen in lines 54-55, with the use of the first-person plural pronoun /we/, Student 2, suddenly, decided that the patient needed an allergy medication; accordingly, she decided to call the pharmacy.", [["allergy", "DISEASE", 141, 148], ["patient", "ORGANISM", 123, 130], ["patient", "SPECIES", 123, 130], ["an allergy medication", "TREATMENT", 138, 159]]], ["Following a brief interjection from the patient's relative, which should have alerted the nurses to the patient's deteriorating status, the primary nurse declared to the team that she would call the pharmacy (line 58).", [["patient", "ORGANISM", 40, 47], ["patient", "ORGANISM", 104, 111], ["patient", "SPECIES", 40, 47], ["patient", "SPECIES", 104, 111]]], ["With a high pitch, the faculty member stated that the nurses cannot call anyone because they were in the ER and, accordingly, the full team (including the doctor and pharmacist) was there.", [["ER", "GENE_OR_GENE_PRODUCT", 105, 107], ["ER", "PROTEIN", 105, 107], ["high pitch", "OBSERVATION_MODIFIER", 7, 17]]], ["The faculty member then addressed the code team, which was physically present in the same simulation room, asking them not to interact with the rest of the team as, ideally, they should not be physically present in the ER area.", [["ER area", "ANATOMY", 219, 226], ["ER", "GENE_OR_GENE_PRODUCT", 219, 221], ["ER", "PROTEIN", 219, 221]]], ["The faculty member's interjection at this moment, again, regressed the whole interaction back to an earlier stage, as evidenced by Student 2's decision to proceed with cannula insertion (line 68).Scenario 2: Managing sudden hemodynamic changesThe interactions in Extract 6 ended with a lengthy pause.", [["cannula insertion (line", "TREATMENT", 168, 191], ["Managing sudden hemodynamic changes", "PROBLEM", 208, 243]]], ["For instance, the students' decision to administer allergy medication in Extract 6 clearly reflects inappropriate critical thinking and/or clinical decision-making ability.", [["allergy", "DISEASE", 51, 58], ["allergy medication", "TREATMENT", 51, 69]]], ["If there was a pause after this incident, the students would have gotten a chance to qualify the rationale behind their decision and decide whether the medication really fit with the patient's needs or situation.", [["patient", "ORGANISM", 183, 190], ["patient", "SPECIES", 183, 190], ["the medication", "TREATMENT", 148, 162]]], ["According to the institute of medicine (IOM) report, hospitalized patients often experience medication errors, which occur during the prescribing and/or administration phases in hospital.", [["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["medication errors", "PROBLEM", 92, 109]]], ["In addition, as observed in Extracts 4 and 6 and in other recorded simulation sessions, the interjections of the faculty member always caused a deterioration in the interactions, with the participants reverting back to earlier in the scenario.", [["participants", "SPECIES", 188, 200], ["a deterioration", "PROBLEM", 142, 157], ["deterioration", "OBSERVATION", 144, 157]]], ["Although the reason behind this deterioration is undetermined, based on the transcripts, the interjections could be modified to better impact the whole interaction.", [["this deterioration", "PROBLEM", 27, 45]]], ["If the faculty member systemized her interjections at critical points, e.g., to clear up confusion, clarify misconceptions, provide suggestions, direct the students' attention to specific training issues, and/or instruct the students on how to perform certain actions (e.g., using the phone to call a code), her interjections would facilitate rather than hinder the practice process.", [["confusion", "DISEASE", 89, 98], ["confusion", "PROBLEM", 89, 98], ["her interjections", "TREATMENT", 308, 325]]], ["The advantages of such facilitation include ensuring the continuity of the simulation sessions (as most of the six recorded simulation sessions did not make it to Scenario 3) and increasing self-confidence (as students had the opportunity to learn via this instructional strategy for the first time, while being observed, and were allowed to play various roles other than the role of a nurse).Scenario 2: Managing sudden hemodynamic changesInterestingly, most of the six recorded simulation sessions ended in the first 5-10 min of the simulation scenario.", [["such facilitation", "TREATMENT", 18, 35], ["the simulation sessions", "TREATMENT", 71, 94], ["Managing sudden hemodynamic changes", "PROBLEM", 405, 440]]], ["As can be seen in Extract 7, the student who took the role of the patient's relative attempted to initiate communication with the patient, who had remained unconscious for several minutes.", [["patient", "ORGANISM", 66, 73], ["patient", "ORGANISM", 130, 137], ["patient", "SPECIES", 66, 73], ["patient", "SPECIES", 130, 137]]], ["In response to this attempt, in the next turn, Student 2 ended the whole session, declaring the death of the patient \"/khalas/ [i.e., That's it].", [["death", "DISEASE", 96, 101], ["patient", "ORGANISM", 109, 116], ["patient", "SPECIES", 109, 116]]], ["In the remainder of the sessions, the faculty member declared the death of the patient.", [["death", "DISEASE", 66, 71], ["patient", "ORGANISM", 79, 86], ["patient", "SPECIES", 79, 86]]], ["This death announcement triggered an abnormal reaction, i.e., group laughter.", [["death", "DISEASE", 5, 10], ["an abnormal reaction", "PROBLEM", 34, 54], ["abnormal", "OBSERVATION_MODIFIER", 37, 45], ["reaction", "OBSERVATION", 46, 54]]], ["Regardless of this declaration, the patient's relative redirected the interactions back to the scenario (line 71).", [["patient", "ORGANISM", 36, 43], ["patient", "SPECIES", 36, 43]]], ["This prompted the primary nurse to continue with the simulation scenario (i.e., the cannula insertion).", [["the simulation scenario", "TREATMENT", 49, 72], ["the cannula insertion", "TREATMENT", 80, 101]]], ["In response, Student 3 interjected, asking the team if they should clean the wound up.", [["wound", "ANATOMY", 77, 82], ["wound", "PATHOLOGICAL_FORMATION", 77, 82], ["the wound", "PROBLEM", 73, 82], ["wound", "OBSERVATION", 77, 82]]], ["With no immediate uptake regarding either the comment about cannula insertion or the one about cleaning the wound, the interactions stopped, with a long pause.", [["wound", "ANATOMY", 108, 113], ["wound", "PATHOLOGICAL_FORMATION", 108, 113], ["cannula insertion", "TREATMENT", 60, 77], ["the wound", "PROBLEM", 104, 113], ["a long pause", "PROBLEM", 146, 158], ["no", "UNCERTAINTY", 5, 7], ["immediate", "OBSERVATION_MODIFIER", 8, 17], ["uptake", "OBSERVATION", 18, 24], ["wound", "OBSERVATION", 108, 113]]], ["This silence was interrupted by Student 2, who re-announced the death of the patient, this time twice (line 74).", [["death", "DISEASE", 64, 69], ["patient", "ORGANISM", 77, 84], ["patient", "SPECIES", 77, 84]]], ["Again, this made the whole team burst out laughing.", [["laughing", "PROBLEM", 42, 50]]], ["The primary nurse stated that she wanted to check the patient's pulse (line 75), rather than performing the action itself.", [["patient", "ORGANISM", 54, 61], ["patient", "SPECIES", 54, 61], ["the patient's pulse", "TEST", 50, 69]]], ["The faculty member then interjected and ended the simulation session by declaring the death of the patient: \"The patient dies <PAUSE:1.0> because you <PAUSE:2.0> OH MY GOD\u2193\" (line 76).", [["death", "DISEASE", 86, 91], ["OH", "CHEMICAL", 162, 164], ["patient", "ORGANISM", 99, 106], ["patient", "ORGANISM", 113, 120], ["patient", "SPECIES", 99, 106], ["patient", "SPECIES", 113, 120]]], ["As can be seen, the faculty member seemed to start to offer an evaluation regarding the patient's cause of death (\"because you\") but she did not complete this utterance, closing with the interjection \"OH MY GOD\u2193,\" which may demonstrate disbelief, shock, or even worry because the simulation session deteriorated to this degree.", [["death", "DISEASE", 107, 112], ["shock", "DISEASE", 247, 252], ["patient", "ORGANISM", 88, 95], ["patient", "SPECIES", 88, 95], ["an evaluation", "TEST", 60, 73], ["death", "PROBLEM", 107, 112], ["shock", "PROBLEM", 247, 252]]], ["24 The final extract ended, as all of the other five recorded simulation sessions, with the simulated death of the patient.", [["death", "DISEASE", 102, 107], ["patient", "ORGANISM", 115, 122], ["patient", "SPECIES", 115, 122]]], ["The lack of effective teamwork and appropriate and timely clinical decisionmaking, along with the teams' inability to perform the expected procedure (i.e., to call a code), contributed to the termination of many of the simulation sessions, including this one.", [["the expected procedure", "TREATMENT", 126, 148]]], ["One of the major advantages of simulation practices is that errors are allowed because there is no potential risk to a real patient.", [["patient", "ORGANISM", 124, 131], ["patient", "SPECIES", 124, 131], ["simulation practices", "TREATMENT", 31, 51], ["no potential", "UNCERTAINTY", 96, 108]]], ["2 Thus, thorough debriefing following simulation sessions might help trainees to analyze their performance and decide how to improve it in future in-hospital situations.DiscussionThis study aimed to contribute to nursing simulation research by highlighting some of the favorable as well as untoward practices that appear as simulation practices unfold.", [["simulation sessions", "TREATMENT", 38, 57], ["This study", "TEST", 179, 189]]], ["Examining authentic data shows that effective communication and collaborative teamwork between the team members are essential for the success of simulation practices.", [["Examining authentic data", "TEST", 0, 24], ["simulation practices", "TREATMENT", 145, 165]]], ["Based on the analyses, faculty members participating in nurse training are highly encouraged to help students to develop and practice strategies to improve team communication, thereby improving the quality of simulation practices.", [["practice strategies", "TREATMENT", 125, 144]]], ["For example, crew resource management (CRM) interventions, which have been adopted by many healthcare organizations, can be used to enhance team training in this context.", [["crew resource management", "TREATMENT", 13, 37], ["CRM) interventions", "TREATMENT", 39, 57], ["team training", "TREATMENT", 140, 153]]], ["Nursing students need to learn how to work in harmony during simulation practices, be active participants, identify critical changes in the patient's status, and rapidly and appropriately intervene to save the patient and limit any possible adverse events.", [["patient", "ORGANISM", 140, 147], ["patient", "ORGANISM", 210, 217], ["participants", "SPECIES", 93, 105], ["patient", "SPECIES", 140, 147], ["patient", "SPECIES", 210, 217], ["adverse events", "PROBLEM", 241, 255]]], ["28, 29 The analyses also revealed the role of the faculty member during the simulation practices.", [["The analyses", "TEST", 7, 19]]], ["It is recommended that faculty members take an active role and be vigilant during training sessions to identify and assess critical communication and/or practice issues.", [["training sessions", "TREATMENT", 82, 99]]], ["However, faculty members' interjections need to be wellplanned to avoid communication deterioration as shown in this data.", [["communication deterioration", "PROBLEM", 72, 99]]], ["Although all of the recorded simulation sessions ended with the simulated death of the patient, they still possess an educational value that can be shared and discussed with future students either via debriefings or in classroom settings, especially that students are rarely exposed to such authentic simulation scripts prior to practice.", [["death", "DISEASE", 74, 79], ["patient", "ORGANISM", 87, 94], ["patient", "SPECIES", 87, 94]]], ["Thus, the authentic transcribed sessions in this study can be used to supplement course materials and be used prior to similar simulation sessions to improve students' understanding of this type of instructional procedure and optimize simulation practice outcomes.", [["this study", "TEST", 44, 54], ["course materials", "TREATMENT", 81, 97], ["instructional procedure", "TREATMENT", 198, 221], ["simulation practice outcomes", "TREATMENT", 235, 263]]], ["21 Lastly, as shown in the extracts, although both the faculty member and lab assistants were English language speakers, the students used Arabic to communicate, which may jeopardize the effectiveness of the simulation interactions and limit the faculty member's ability to address communication and clinical errors during debriefing sessions.", [["extracts", "ANATOMY", 27, 35], ["extracts", "ORGANISM_SUBSTANCE", 27, 35], ["debriefing sessions", "TREATMENT", 323, 342]]], ["19 Simulation sessions have been shown to be a promising instructional tool to support nursing education, allowing students to practice in a safe and controlled environment.", [["nursing education", "TREATMENT", 87, 104]]]], "PMC7223322": [["To the Editor:With interest, we read the study by Oh et al. [1], which retrospectively analyzed a large cohort of patients admitted to the surgical intensive care unit.", [["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["the study", "TEST", 37, 46], ["large", "OBSERVATION_MODIFIER", 98, 103]]], ["Although results are encouraging in the quest to find evidence that supports the relevance of intensivist in the management of post-surgical patients, two questions have come up in the interpretations of the results.To the Editor:Firstly, parameters of intraoperative management which may affect the postoperative incidence of acute kidney injury (AKI) were not sufficiently included in the contributors of propensity score.", [["kidney", "ANATOMY", 333, 339], ["acute kidney injury", "DISEASE", 327, 346], ["AKI", "DISEASE", 348, 351], ["patients", "ORGANISM", 141, 149], ["kidney", "ORGAN", 333, 339], ["patients", "SPECIES", 141, 149], ["intraoperative management", "TREATMENT", 253, 278], ["acute kidney injury", "PROBLEM", 327, 346], ["AKI", "PROBLEM", 348, 351], ["acute", "OBSERVATION_MODIFIER", 327, 332], ["kidney", "ANATOMY", 333, 339], ["injury", "OBSERVATION", 340, 346]]], ["Just like the patient management variables during postoperative days, intraoperative parameters including hemodynamics, vasopressor infusion, hydroxyethyl starch use, nephrotoxic agent use such as diuretics, and transfusion are equally or more important for the development of AKI especially during immediate postoperative period [2].", [["hydroxyethyl starch", "CHEMICAL", 142, 161], ["nephrotoxic", "DISEASE", 167, 178], ["AKI", "DISEASE", 277, 280], ["hydroxyethyl", "CHEMICAL", 142, 154], ["patient", "ORGANISM", 14, 21], ["hydroxyethyl starch", "SIMPLE_CHEMICAL", 142, 161], ["patient", "SPECIES", 14, 21], ["intraoperative parameters", "TEST", 70, 95], ["hemodynamics", "TEST", 106, 118], ["vasopressor infusion", "TREATMENT", 120, 140], ["hydroxyethyl starch", "TREATMENT", 142, 161], ["nephrotoxic agent", "TREATMENT", 167, 184], ["diuretics", "TREATMENT", 197, 206], ["transfusion", "TREATMENT", 212, 223], ["AKI", "PROBLEM", 277, 280], ["AKI", "OBSERVATION", 277, 280]]], ["Secondly, in the sensitivity analysis of AKI according to admission time, there were only two time-points where the associations were significant and there seems no dose\u2013response relationship between the duration of non-intensivist coverage and the incidence of AKI.", [["AKI", "DISEASE", 41, 44], ["AKI", "DISEASE", 262, 265], ["AKI", "PROBLEM", 41, 44], ["non-intensivist coverage", "TREATMENT", 216, 240], ["AKI", "PROBLEM", 262, 265], ["AKI", "OBSERVATION", 41, 44], ["AKI", "OBSERVATION", 262, 265]]], ["To suggest causality in the retrospective analysis, dose\u2013response relationship should be demonstrated in addition to consistency, biological plausibility and temporal relationship [3].", [["the retrospective analysis", "TEST", 24, 50]]], ["Further evidence are required to substantiate their hypothesis.", [["their hypothesis", "PROBLEM", 46, 62]]]], "PMC7508200": [["In December 2019, China released the first report of coronavirus disease (COVID-19)1.", [["coronavirus disease", "DISEASE", 53, 72], ["COVID-19)1", "CHEMICAL", 74, 84], ["coronavirus", "ORGANISM", 53, 64], ["coronavirus disease", "PROBLEM", 53, 72], ["COVID", "TEST", 74, 79], ["coronavirus disease", "OBSERVATION", 53, 72]]], ["At the end of June 2020, data showed that more than 10 million people wereinfected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide andmore than 500,000 deaths3.", [["acute respiratory syndrome coronavirus", "DISEASE", 93, 131], ["deaths", "DISEASE", 178, 184], ["people", "ORGANISM", 63, 69], ["people", "SPECIES", 63, 69], ["severe acute respiratory syndrome coronavirus", "SPECIES", 86, 131], ["SARS-CoV-2", "SPECIES", 135, 145], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 86, 131], ["severe", "OBSERVATION_MODIFIER", 86, 92], ["acute", "OBSERVATION_MODIFIER", 93, 98], ["respiratory syndrome", "OBSERVATION", 99, 119]]]], "PMC7224457": [["IntroductionIn December 2019, there was an outbreak of pneumonia with an unknown cause in Wuhan, Hubei province, China, with an epidemiological link to the Huanan Seafood Wholesale Market, a local live animal and seafood market.", [["pneumonia", "DISEASE", 55, 64], ["pneumonia", "PROBLEM", 55, 64], ["pneumonia", "OBSERVATION", 55, 64]]], ["Clinical presentations of this disease greatly resembled viral pneumonia.", [["viral pneumonia", "DISEASE", 57, 72], ["this disease", "PROBLEM", 26, 38], ["viral pneumonia", "PROBLEM", 57, 72], ["viral", "OBSERVATION_MODIFIER", 57, 62], ["pneumonia", "OBSERVATION", 63, 72]]], ["Through deep sequencing on the lower respiratory tract samples of patients, a novel coronavirus named the 2019 novel coronavirus was identified [1], the name of which was then determined as SARS-CoV-2.", [["lower respiratory tract samples", "ANATOMY", 31, 62], ["patients", "ORGANISM", 66, 74], ["coronavirus", "ORGANISM", 84, 95], ["coronavirus", "ORGANISM", 117, 128], ["SARS-CoV-2", "ORGANISM", 190, 200], ["patients", "SPECIES", 66, 74], ["coronavirus", "SPECIES", 84, 95], ["coronavirus", "SPECIES", 117, 128], ["SARS-CoV", "SPECIES", 190, 198], ["a novel coronavirus", "PROBLEM", 76, 95], ["deep", "ANATOMY_MODIFIER", 8, 12], ["lower", "ANATOMY_MODIFIER", 31, 36], ["respiratory tract", "ANATOMY", 37, 54]]], ["This virus has spread to all provinces across China and more than 200 additional countries.", [["This virus", "PROBLEM", 0, 10], ["virus", "OBSERVATION", 5, 10]]], ["As of April 11, 2020, the epidemic has resulted in 83,400 laboratory confirmed cases, 3,349 of which were fatal in China, while there were 1,643,047 laboratory confirmed cases and 101,507 deaths in other countries.", [["deaths", "DISEASE", 188, 194]]], ["The global toll of new cases and deaths is still increasing sharply.IntroductionTo effectively control the disease and prevent new spillovers, it is critical to identify the animal origin of this newly emerging coronavirus.", [["deaths", "DISEASE", 33, 39], ["coronavirus", "DISEASE", 211, 222], ["coronavirus", "ORGANISM", 211, 222], ["IntroductionTo", "TREATMENT", 68, 82], ["the disease", "PROBLEM", 103, 114], ["new spillovers", "PROBLEM", 127, 141], ["this newly emerging coronavirus", "PROBLEM", 191, 222], ["global", "OBSERVATION_MODIFIER", 4, 10], ["new", "OBSERVATION_MODIFIER", 19, 22], ["increasing", "OBSERVATION_MODIFIER", 49, 59], ["sharply", "OBSERVATION_MODIFIER", 60, 67], ["disease", "OBSERVATION", 107, 114], ["new", "OBSERVATION_MODIFIER", 127, 130], ["spillovers", "OBSERVATION", 131, 141], ["coronavirus", "OBSERVATION", 211, 222]]], ["In the Wuhan wet market, high viral loads were reported in environmental samples.", [["samples", "ANATOMY", 73, 80], ["high viral loads", "PROBLEM", 25, 41], ["viral loads", "OBSERVATION", 30, 41]]], ["Therefore, it remains unclear which animals initiated the first infections.IntroductionCoronaviruses usually cause respiratory and gastrointestinal tract infections and are genetically classified into four major genera: Alphacoronavirus, Betacoronavirus, Gammacoronavirus, and Deltacoronavirus.", [["respiratory", "ANATOMY", 115, 126], ["gastrointestinal tract", "ANATOMY", 131, 153], ["infections", "DISEASE", 64, 74], ["respiratory and gastrointestinal tract infections", "DISEASE", 115, 164], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 87, 100], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 131, 153], ["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 220, 236], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 238, 253], ["Gammacoronavirus", "GENE_OR_GENE_PRODUCT", 255, 271], ["the first infections", "PROBLEM", 54, 74], ["IntroductionCoronaviruses", "PROBLEM", 75, 100], ["respiratory and gastrointestinal tract infections", "PROBLEM", 115, 164], ["Alphacoronavirus", "PROBLEM", 220, 236], ["Betacoronavirus", "TREATMENT", 238, 253], ["Gammacoronavirus", "TREATMENT", 255, 271], ["Deltacoronavirus", "TREATMENT", 277, 293], ["infections", "OBSERVATION", 64, 74], ["gastrointestinal tract", "ANATOMY", 131, 153]]], ["The former two genera primarily infect mammals, whereas the latter two predominantly infect birds [2].", [["genera primarily", "OBSERVATION_MODIFIER", 15, 31], ["infect mammals", "OBSERVATION", 32, 46]]], ["In addition to SARS-CoV-2, other members of the Betacoronavirus genus caused the 2003 SARS (severe acute respiratory syndrome) outbreaks and the 2012 MERS (Middle East respiratory syndrome) outbreaks in humans [3, 4].", [["SARS", "DISEASE", 86, 90], ["acute respiratory syndrome", "DISEASE", 99, 125], ["Middle East respiratory syndrome", "DISEASE", 156, 188], ["SARS-CoV-2", "ORGANISM", 15, 25], ["Betacoronavirus genus", "ORGANISM", 48, 69], ["humans", "ORGANISM", 203, 209], ["humans", "SPECIES", 203, 209], ["SARS-CoV", "SPECIES", 15, 23], ["humans", "SPECIES", 203, 209], ["SARS", "TEST", 15, 19], ["severe acute respiratory syndrome)", "PROBLEM", 92, 126], ["Middle East respiratory syndrome", "PROBLEM", 156, 188], ["severe", "OBSERVATION_MODIFIER", 92, 98], ["acute", "OBSERVATION_MODIFIER", 99, 104], ["respiratory syndrome", "OBSERVATION", 105, 125], ["respiratory syndrome", "OBSERVATION", 168, 188]]], ["SARS-CoV and MERS-CoV are of bat origin, but both coronaviruses had an intermediate host: palm civets for SARS-CoV [5] and dromedary camels for MERS-CoV [6].IntroductionApproximately 30,000 base pairs in the coronavirus genome code for up to 11 proteins, including the surface glycoprotein Spike (S) protein binds to receptors on the host cell, which initiates virus infection.", [["cell", "ANATOMY", 339, 343], ["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 106, 110], ["infection", "DISEASE", 367, 376], ["SARS-CoV", "ORGANISM", 0, 8], ["MERS-CoV", "ORGANISM", 13, 21], ["coronaviruses", "ORGANISM", 50, 63], ["palm", "ORGANISM_SUBDIVISION", 90, 94], ["SARS-CoV", "ORGANISM", 106, 114], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 144, 152], ["coronavirus", "ORGANISM", 208, 219], ["Spike (S)", "GENE_OR_GENE_PRODUCT", 290, 299], ["host cell", "CELL", 334, 343], ["coronavirus genome", "DNA", 208, 226], ["surface glycoprotein Spike (S) protein", "PROTEIN", 269, 307], ["SARS-CoV", "SPECIES", 0, 8], ["MERS-CoV", "SPECIES", 13, 21], ["SARS-CoV", "SPECIES", 106, 114], ["MERS-CoV", "SPECIES", 144, 152], ["SARS", "PROBLEM", 0, 4], ["SARS", "PROBLEM", 106, 110], ["the surface glycoprotein Spike", "TEST", 265, 295], ["protein binds", "PROBLEM", 300, 313], ["virus infection", "PROBLEM", 361, 376], ["host cell", "OBSERVATION", 334, 343], ["virus infection", "OBSERVATION", 361, 376]]], ["Different coronaviruses can use distinct host receptors due to structural variations in the receptor binding domains of their virus S protein.", [["coronaviruses", "ORGANISM", 10, 23], ["receptor binding domains", "PROTEIN", 92, 116], ["virus S protein", "PROTEIN", 126, 141], ["Different coronaviruses", "PROBLEM", 0, 23], ["distinct host receptors", "TREATMENT", 32, 55], ["structural variations", "PROBLEM", 63, 84], ["coronaviruses", "OBSERVATION", 10, 23]]], ["SARS-CoV uses angiotensin-converting enzyme 2 (ACE2) as one of the main receptors [7] with CD209L as an alternative receptor [8], whereas MERS-CoV uses dipeptidyl peptidase 4 (DPP4, also known as CD26) as the primary receptor.", [["SARS", "DISEASE", 0, 4], ["angiotensin", "CHEMICAL", 14, 25], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 14, 45], ["ACE2", "GENE_OR_GENE_PRODUCT", 47, 51], ["CD209L", "GENE_OR_GENE_PRODUCT", 91, 97], ["MERS-CoV", "ORGANISM", 138, 146], ["dipeptidyl peptidase 4", "GENE_OR_GENE_PRODUCT", 152, 174], ["DPP4", "GENE_OR_GENE_PRODUCT", 176, 180], ["CD26", "GENE_OR_GENE_PRODUCT", 196, 200], ["angiotensin-converting enzyme 2", "PROTEIN", 14, 45], ["ACE2", "PROTEIN", 47, 51], ["CD209L", "PROTEIN", 91, 97], ["MERS", "PROTEIN", 138, 142], ["CoV", "PROTEIN", 143, 146], ["dipeptidyl peptidase 4", "PROTEIN", 152, 174], ["DPP4", "PROTEIN", 176, 180], ["CD26", "PROTEIN", 196, 200], ["primary receptor", "PROTEIN", 209, 225], ["SARS-CoV", "SPECIES", 0, 8], ["MERS-CoV", "SPECIES", 138, 146], ["SARS", "PROBLEM", 0, 4], ["angiotensin", "TREATMENT", 14, 25], ["converting enzyme", "TEST", 26, 43], ["CD209L", "TREATMENT", 91, 97], ["dipeptidyl peptidase 4 (DPP4", "TREATMENT", 152, 180]]], ["A recent study demonstrated that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming [9].IntroductionSoon after the release of the SARS-CoV-2 genome, a scientist released a full genome of a coronavirus, Bat-CoV-RaTG13, from the bat species Rhinolophus affinis, which was colonized in Yunan province, nearly 2,000 km away from Wuhan.", [["SARS", "DISEASE", 33, 37], ["SARS", "DISEASE", 186, 190], ["serine", "CHEMICAL", 94, 100], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 33, 43], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 53, 61], ["ACE2", "GENE_OR_GENE_PRODUCT", 71, 75], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 110, 117], ["S protein", "GENE_OR_GENE_PRODUCT", 122, 131], ["coronavirus", "ORGANISM", 245, 256], ["Bat-CoV-RaTG13", "GENE_OR_GENE_PRODUCT", 258, 272], ["bat species", "ORGANISM", 283, 294], ["Rhinolophus affinis", "ORGANISM", 295, 314], ["SARS-CoV receptor", "PROTEIN", 53, 70], ["ACE2", "PROTEIN", 71, 75], ["serine protease", "PROTEIN", 94, 109], ["TMPRSS2", "PROTEIN", 110, 117], ["S protein", "PROTEIN", 122, 131], ["SARS-CoV-2 genome", "DNA", 186, 203], ["RaTG13", "DNA", 266, 272], ["coronavirus", "SPECIES", 245, 256], ["Rhinolophus affinis", "SPECIES", 295, 314], ["SARS-CoV", "SPECIES", 33, 41], ["SARS-CoV", "SPECIES", 53, 61], ["SARS-CoV", "SPECIES", 186, 194], ["Rhinolophus affinis", "SPECIES", 295, 314], ["A recent study", "TEST", 0, 14], ["SARS", "PROBLEM", 33, 37], ["CoV", "TEST", 38, 41], ["the SARS", "TEST", 49, 57], ["CoV receptor ACE2", "TREATMENT", 58, 75], ["the serine protease TMPRSS2", "TREATMENT", 90, 117], ["S protein priming", "TEST", 122, 139], ["the SARS", "PROBLEM", 182, 190], ["a coronavirus", "PROBLEM", 243, 256], ["Bat-CoV", "TEST", 258, 265]]], ["Bat-CoV-RaTG13 was 96% identical at the whole genome level to the SARS-CoV-2, suggesting the SARS-CoV-2 could be of bat origin [1].", [["SARS", "DISEASE", 66, 70], ["Bat-CoV", "ORGANISM", 0, 7], ["RaTG13", "GENE_OR_GENE_PRODUCT", 8, 14], ["SARS-CoV-2", "ORGANISM", 66, 76], ["SARS-CoV-2", "ORGANISM", 93, 103], ["Bat-CoV-RaTG13", "DNA", 0, 14], ["SARS-CoV-2", "DNA", 66, 76], ["SARS-CoV-2", "DNA", 93, 103], ["SARS-CoV", "SPECIES", 66, 74], ["Bat-CoV", "TEST", 0, 7], ["RaTG13", "TEST", 8, 14], ["the SARS", "TEST", 62, 70], ["CoV", "TEST", 71, 74], ["the SARS", "PROBLEM", 89, 97], ["CoV", "TEST", 98, 101]]], ["However, because direct human-bat contact is rare, it seems to be more likely that the spillover of SARS-CoV-2 to humans from an intermediate host rather than directly from bats, as was the cases with both SARS-CoV and MERS-CoV.IntroductionThe goal of this study was to determine the genetic relationship between a coronavirus from two groups of sick pangolins and SARS-CoV-2, and to assess whether pangolins could be potential intermediate hosts of SARS-CoV-2.ResultsIn March and July of 2019, we detected Betacoronaviruses in three individuals from two sets of smuggled Malayan pangolins (Manis javanica) (n = 27) that were intercepted by Guangdong customs [10].", [["SARS", "DISEASE", 100, 104], ["SARS", "DISEASE", 206, 210], ["coronavirus", "DISEASE", 315, 326], ["pangolins", "CHEMICAL", 399, 408], ["SARS", "DISEASE", 450, 454], ["human", "ORGANISM", 24, 29], ["bat", "ORGANISM", 30, 33], ["SARS-CoV-2", "ORGANISM", 100, 110], ["humans", "ORGANISM", 114, 120], ["SARS-CoV", "ORGANISM", 206, 214], ["MERS-CoV", "ORGANISM", 219, 227], ["coronavirus", "ORGANISM", 315, 326], ["pangolins", "GENE_OR_GENE_PRODUCT", 351, 360], ["SARS-CoV-2", "ORGANISM", 365, 375], ["pangolins", "GENE_OR_GENE_PRODUCT", 399, 408], ["SARS-CoV-2", "ORGANISM", 450, 460], ["Manis javanica", "ORGANISM", 591, 605], ["human", "SPECIES", 24, 29], ["humans", "SPECIES", 114, 120], ["Manis javanica", "SPECIES", 591, 605], ["human", "SPECIES", 24, 29], ["SARS-CoV", "SPECIES", 100, 108], ["humans", "SPECIES", 114, 120], ["SARS-CoV", "SPECIES", 206, 214], ["MERS-CoV", "SPECIES", 219, 227], ["SARS-CoV", "SPECIES", 365, 373], ["SARS-CoV", "SPECIES", 450, 458], ["Malayan pangolins", "SPECIES", 572, 589], ["Manis javanica", "SPECIES", 591, 605], ["the spillover of SARS", "PROBLEM", 83, 104], ["this study", "TEST", 252, 262], ["a coronavirus", "PROBLEM", 313, 326], ["sick pangolins", "TREATMENT", 346, 360], ["CoV", "TEST", 370, 373], ["CoV", "TEST", 455, 458]]], ["All three animals suffered from serious respiratory disease and failed to be rescued by the Guangdong Wildlife Rescue Center [10] (S1 Table).", [["respiratory", "ANATOMY", 40, 51], ["respiratory disease", "DISEASE", 40, 59], ["serious respiratory disease", "PROBLEM", 32, 59], ["serious", "OBSERVATION_MODIFIER", 32, 39], ["respiratory disease", "OBSERVATION", 40, 59]]], ["Through metagenomic sequencing and de novo assembling, we recovered 38 contigs ranging from 380 to 3,377 nucleotides, and the nucleotide sequence identity among the contigs from these three samples were 99.54%.", [["samples", "ANATOMY", 190, 197], ["the nucleotide sequence identity", "TEST", 122, 154]]], ["Thus, we pooled sequences from three samples and assembled the draft genome of this pangolin origin coronavirus.", [["samples", "ANATOMY", 37, 44], ["pangolin", "GENE_OR_GENE_PRODUCT", 84, 92], ["coronavirus", "ORGANISM", 100, 111], ["three samples", "TEST", 31, 44], ["this pangolin origin coronavirus", "PROBLEM", 79, 111], ["origin coronavirus", "OBSERVATION", 93, 111]]], ["After that, gap filling with amplicon sequencing was conducted to obtain a nearly full genome sequence.", [["nearly full genome sequence", "DNA", 75, 102], ["gap filling", "PROBLEM", 12, 23], ["amplicon sequencing", "TREATMENT", 29, 48]]], ["This pangolin-CoV-2020 genome (Genbank No.: MT121216) was found to be comprised of 29,521 nucleotides.ResultsStrikingly, genomic analyses suggested the pangolin-CoV-2020 has a high identity with both SARS-CoV-2 and Bat-CoV-RaTG13, the proposed origin of SARS-CoV-2 (Fig 1A, S2 Table).", [["SARS", "DISEASE", 254, 258], ["nucleotides", "CHEMICAL", 90, 101], ["pangolin", "GENE_OR_GENE_PRODUCT", 5, 13], ["pangolin", "GENE_OR_GENE_PRODUCT", 152, 160], ["SARS-CoV-2", "ORGANISM", 200, 210], ["Bat-CoV-RaTG13", "ORGANISM", 215, 229], ["SARS-CoV-2", "ORGANISM", 254, 264], ["pangolin-CoV-2020 genome", "DNA", 5, 29], ["pangolin", "PROTEIN", 152, 160], ["RaTG13", "DNA", 223, 229], ["SARS-CoV", "SPECIES", 200, 208], ["SARS-CoV", "SPECIES", 254, 262], ["This pangolin", "TEST", 0, 13], ["genomic analyses", "TEST", 121, 137], ["CoV", "TEST", 205, 208], ["Bat-CoV", "TEST", 215, 222], ["SARS", "TEST", 254, 258], ["CoV", "TEST", 259, 262]]], ["The nucleotide sequence identity between pangolin-CoV-2020 and SARS-CoV-2 was 90.32%, whereas the protein sequence identity for individual proteins can be up to 100% (Table 1; Table 2).", [["nucleotide", "CHEMICAL", 4, 14], ["nucleotide", "CHEMICAL", 4, 14], ["pangolin-CoV", "ORGANISM", 41, 53], ["SARS-CoV-2", "ORGANISM", 63, 73], ["pangolin", "PROTEIN", 41, 49], ["SARS-CoV", "SPECIES", 63, 71], ["The nucleotide sequence identity", "TEST", 0, 32], ["pangolin", "TEST", 41, 49], ["CoV", "TEST", 50, 53], ["SARS", "TEST", 63, 67], ["CoV", "TEST", 68, 71], ["the protein sequence identity", "TEST", 94, 123], ["individual proteins", "TEST", 128, 147]]], ["The nucleotide sequence identity between pangolin-CoV-2020 and Bat-CoV-RaTG13 was 90.24%, while that for the corresponding regions between SARS-CoV-2 and Bat-CoV-RaTG13 was 96.18% (Table 1, S1 Table).ResultsThe nucleotide sequence identities among the S protein genes were 93.15% between the Bat-CoV-RaTG13 and SARS-CoV-2, 84.52% between pangolin-CoV-2020 and SARS-CoV-2, as well as 73.43% between pangolin-CoV-2020 and SARS-CoV, respectively (Table 1).", [["nucleotide", "CHEMICAL", 4, 14], ["nucleotide", "CHEMICAL", 211, 221], ["nucleotide", "CHEMICAL", 4, 14], ["nucleotide", "CHEMICAL", 211, 221], ["pangolin-CoV", "GENE_OR_GENE_PRODUCT", 41, 53], ["Bat-CoV-RaTG13", "ORGANISM", 63, 77], ["SARS-CoV-2", "ORGANISM", 139, 149], ["Bat-CoV-RaTG13", "ORGANISM", 154, 168], ["Bat-CoV-RaTG13", "ORGANISM", 292, 306], ["SARS-CoV-2", "ORGANISM", 311, 321], ["pangolin-CoV", "ORGANISM", 338, 350], ["SARS-CoV-2", "ORGANISM", 360, 370], ["pangolin-CoV", "GENE_OR_GENE_PRODUCT", 398, 410], ["SARS-CoV", "ORGANISM", 420, 428], ["pangolin", "PROTEIN", 41, 49], ["RaTG13", "DNA", 162, 168], ["S protein genes", "DNA", 252, 267], ["SARS-CoV", "SPECIES", 139, 147], ["Bat-CoV", "SPECIES", 292, 299], ["SARS-CoV", "SPECIES", 311, 319], ["SARS-CoV", "SPECIES", 360, 368], ["SARS-CoV", "SPECIES", 420, 428], ["The nucleotide sequence identity", "TEST", 0, 32], ["pangolin", "TEST", 41, 49], ["CoV", "TEST", 50, 53], ["Bat-CoV", "TEST", 63, 70], ["RaTG13", "TEST", 71, 77], ["SARS", "TEST", 139, 143], ["CoV", "TEST", 144, 147], ["Bat-CoV", "TEST", 154, 161], ["RaTG13", "TEST", 162, 168], ["The nucleotide sequence identities", "TEST", 207, 241], ["the S protein genes", "TEST", 248, 267], ["the Bat-CoV", "TEST", 288, 299], ["RaTG13", "TEST", 300, 306], ["SARS", "TEST", 311, 315], ["CoV", "TEST", 316, 319], ["pangolin", "TEST", 338, 346], ["CoV", "TEST", 347, 350], ["SARS", "TEST", 360, 364], ["CoV", "TEST", 365, 368], ["pangolin", "TEST", 398, 406], ["CoV", "TEST", 407, 410], ["SARS", "TEST", 420, 424]]], ["Further analyses suggested the S gene was relatively more genetically diverse in the S1 region than the S2 region (Fig 2A, S3 Table).", [["S gene", "DNA", 31, 37], ["S1 region", "DNA", 85, 94], ["S2 region", "DNA", 104, 113], ["Further analyses", "TEST", 0, 16], ["diverse", "OBSERVATION_MODIFIER", 70, 77], ["S1", "ANATOMY", 85, 87], ["region", "ANATOMY_MODIFIER", 88, 94], ["S2", "ANATOMY", 104, 106], ["region", "ANATOMY_MODIFIER", 107, 113]]], ["Compared with their nucleotide sequences, the S proteins of pangolin-CoV-2020 and SARS-CoV-2 were more conserved, with a sequence identity of 90.18% (Table 2).ResultsThe receptor binding domains (RBD) of the S protein were highly conserved between pangolin-CoV-2020 and SARS-CoV-2, the nucleotide and amino acid sequences identity of RBD of S gene between them was highest in comparison with those between pangolin-CoV-2020 and other SARS-like conronaviruses of 86.64% and 96.80% (Table 1, Table 2).", [["nucleotide", "CHEMICAL", 286, 296], ["amino acid", "CHEMICAL", 301, 311], ["pangolin-CoV-2020", "CHEMICAL", 406, 423], ["SARS", "DISEASE", 434, 438], ["nucleotide", "CHEMICAL", 20, 30], ["nucleotide", "CHEMICAL", 286, 296], ["amino acid", "CHEMICAL", 301, 311], ["pangolin-CoV", "GENE_OR_GENE_PRODUCT", 60, 72], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 82, 92], ["pangolin-CoV", "ORGANISM", 248, 260], ["SARS-CoV-2", "ORGANISM", 270, 280], ["amino acid", "AMINO_ACID", 301, 311], ["RBD of S gene", "GENE_OR_GENE_PRODUCT", 334, 347], ["pangolin-CoV", "ORGANISM", 406, 418], ["S proteins", "PROTEIN", 46, 56], ["pangolin", "PROTEIN", 60, 68], ["receptor binding domains", "PROTEIN", 170, 194], ["RBD", "PROTEIN", 196, 199], ["S protein", "PROTEIN", 208, 217], ["pangolin", "PROTEIN", 248, 256], ["RBD", "PROTEIN", 334, 337], ["S gene", "DNA", 341, 347], ["SARS-CoV", "SPECIES", 82, 90], ["SARS-CoV", "SPECIES", 270, 278], ["their nucleotide sequences", "TEST", 14, 40], ["the S proteins", "TEST", 42, 56], ["pangolin", "TEST", 60, 68], ["CoV", "TEST", 69, 72], ["SARS-CoV", "TEST", 82, 90], ["a sequence identity", "TEST", 119, 138], ["The receptor binding domains", "TEST", 166, 194], ["the S protein", "TEST", 204, 217], ["pangolin", "TEST", 248, 256], ["CoV", "TEST", 257, 260], ["SARS", "TEST", 270, 274], ["CoV", "TEST", 275, 278], ["the nucleotide and amino acid sequences", "TEST", 282, 321], ["pangolin", "TEST", 406, 414], ["CoV", "TEST", 415, 418], ["other SARS", "TEST", 428, 438]]], ["Pangolin-CoV-2020 and SARS-CoV-2 also shared a very conserved receptor binding motif (RBM) (98.6%), which was more conserved than in Bat-CoV-RaTG13 (76.4%) (Fig 3).", [["Pangolin-CoV-2020", "CHEMICAL", 0, 17], ["Pangolin", "GENE_OR_GENE_PRODUCT", 0, 8], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 22, 32], ["Bat-CoV", "ORGANISM", 133, 140], ["conserved receptor binding motif", "DNA", 52, 84], ["SARS-CoV", "SPECIES", 22, 30], ["Pangolin", "TEST", 0, 8], ["CoV", "TEST", 9, 12], ["SARS", "TEST", 22, 26], ["CoV", "TEST", 27, 30], ["Bat-CoV", "TEST", 133, 140], ["RaTG13", "TEST", 141, 147]]], ["These results support that pangolin-CoV-2020 and SARS-CoV-2 share the same angiotensin-converting enzyme 2 (ACE2) receptor.", [["pangolin-CoV-2020", "CHEMICAL", 27, 44], ["angiotensin", "CHEMICAL", 75, 86], ["pangolin-CoV", "GENE_OR_GENE_PRODUCT", 27, 39], ["SARS-CoV-2", "ORGANISM", 49, 59], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 75, 106], ["ACE2", "GENE_OR_GENE_PRODUCT", 108, 112], ["angiotensin-converting enzyme 2 (ACE2) receptor", "PROTEIN", 75, 122], ["SARS-CoV", "SPECIES", 49, 57], ["pangolin", "TEST", 27, 35], ["CoV", "TEST", 36, 39], ["SARS", "TEST", 49, 53], ["CoV", "TEST", 54, 57], ["converting enzyme 2 (ACE2) receptor", "TREATMENT", 87, 122]]], ["Further analyses suggested that there was one variation (Gln498) between the RBM of pangolin-CoV-2020 and that of SARS-CoV-2 but conserved in all other key residues being associated with receptor binding (Gly482, Val483, Glu484, Gly485, Phe486, Gln493, Leu455, Asn501), suggesting a potential binding affinity between pangolin-CoV-2020 and human ACE2 receptor (Fig 3).ResultsOn the other hand, unlike RBD, the nucleotide and amino acid sequence identity of NTD (N-terminal domain) were only 66.2% and 63.1% identical between pangolin-CoV-2020 and SARS-CoV-2.", [["Gln498", "CHEMICAL", 57, 63], ["RBD", "DISEASE", 401, 404], ["nucleotide", "CHEMICAL", 410, 420], ["amino acid", "CHEMICAL", 425, 435], ["Gln", "CHEMICAL", 57, 60], ["Gly482", "CHEMICAL", 205, 211], ["Val", "CHEMICAL", 213, 216], ["Glu484", "CHEMICAL", 221, 227], ["Gly485", "CHEMICAL", 229, 235], ["Phe486", "CHEMICAL", 237, 243], ["Gln493", "CHEMICAL", 245, 251], ["Leu455", "CHEMICAL", 253, 259], ["Asn501", "CHEMICAL", 261, 267], ["nucleotide", "CHEMICAL", 410, 420], ["amino acid", "CHEMICAL", 425, 435], ["N", "CHEMICAL", 462, 463], ["pangolin-CoV", "GENE_OR_GENE_PRODUCT", 84, 96], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 114, 124], ["Gly482", "GENE_OR_GENE_PRODUCT", 205, 211], ["Glu484", "GENE_OR_GENE_PRODUCT", 221, 227], ["Gly485", "GENE_OR_GENE_PRODUCT", 229, 235], ["Phe486", "GENE_OR_GENE_PRODUCT", 237, 243], ["Gln493", "GENE_OR_GENE_PRODUCT", 245, 251], ["Leu455", "GENE_OR_GENE_PRODUCT", 253, 259], ["Asn501", "GENE_OR_GENE_PRODUCT", 261, 267], ["pangolin-CoV", "GENE_OR_GENE_PRODUCT", 318, 330], ["human", "ORGANISM", 340, 345], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 346, 359], ["amino acid", "AMINO_ACID", 425, 435], ["pangolin-CoV", "GENE_OR_GENE_PRODUCT", 525, 537], ["SARS-CoV-2", "ORGANISM", 547, 557], ["pangolin", "PROTEIN", 84, 92], ["pangolin", "PROTEIN", 318, 326], ["CoV", "PROTEIN", 327, 330], ["human ACE2 receptor", "PROTEIN", 340, 359], ["Fig 3", "PROTEIN", 361, 366], ["RBD", "PROTEIN", 401, 404], ["NTD", "PROTEIN", 457, 460], ["N-terminal domain", "PROTEIN", 462, 479], ["pangolin", "PROTEIN", 525, 533], ["human", "SPECIES", 340, 345], ["SARS-CoV", "SPECIES", 114, 122], ["human", "SPECIES", 340, 345], ["SARS-CoV", "SPECIES", 547, 555], ["Further analyses", "TEST", 0, 16], ["Gln", "TEST", 57, 60], ["CoV", "TEST", 93, 96], ["SARS", "PROBLEM", 114, 118], ["CoV", "TEST", 119, 122], ["receptor binding", "TEST", 187, 203], ["Gly482", "TEST", 205, 211], ["Val", "TEST", 213, 216], ["Glu484", "TEST", 221, 227], ["Gly485", "TEST", 229, 235], ["Phe486", "TEST", 237, 243], ["Gln493", "TEST", 245, 251], ["Leu455", "TEST", 253, 259], ["a potential binding affinity", "PROBLEM", 281, 309], ["pangolin", "TEST", 318, 326], ["human ACE2 receptor", "TREATMENT", 340, 359], ["the nucleotide and amino acid sequence identity", "TEST", 406, 453], ["NTD (N-terminal domain", "TEST", 457, 479], ["pangolin", "TEST", 525, 533], ["CoV", "TEST", 534, 537], ["SARS", "TEST", 547, 551], ["CoV", "TEST", 552, 555], ["RBD", "OBSERVATION", 401, 404]]], ["However, a loci Arg408 from the RBD core of SARS-CoV-2 could form a hydrogen bond with human ACE2 was conserved in pangolin-CoV-2020 (Fig 3).", [["Arg408", "CHEMICAL", 16, 22], ["SARS", "DISEASE", 44, 48], ["Arg", "CHEMICAL", 16, 19], ["hydrogen", "CHEMICAL", 68, 76], ["Arg408", "AMINO_ACID", 16, 22], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 44, 54], ["human", "ORGANISM", 87, 92], ["ACE2", "GENE_OR_GENE_PRODUCT", 93, 97], ["pangolin-CoV", "GENE_OR_GENE_PRODUCT", 115, 127], ["RBD core", "PROTEIN", 32, 40], ["SARS-CoV-2", "DNA", 44, 54], ["human ACE2", "PROTEIN", 87, 97], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 87, 92], ["a loci Arg", "TEST", 9, 19], ["SARS", "TEST", 44, 48], ["CoV", "TEST", 49, 52], ["a hydrogen bond with human ACE2", "TREATMENT", 66, 97], ["SARS", "OBSERVATION", 44, 48], ["hydrogen bond", "OBSERVATION", 68, 81]]], ["Both pangolin-CoV-2020 and Bat-CoV-RaTG13 lack an S1/S2 cleavage site (~680\u2013690 aa) whereas SARS-CoV-2 possesses (Fig 3).ResultsGenomic analyses suggested sequence similarities were not homogeneous across the S genes of pangolin-CoV-2020, SARS-CoV-2, Bat-CoV-ZXC21 and Bat-CoV-ZC45.", [["pangolin-CoV", "GENE_OR_GENE_PRODUCT", 5, 17], ["Bat-CoV-RaTG13", "GENE_OR_GENE_PRODUCT", 27, 41], ["S2", "GENE_OR_GENE_PRODUCT", 53, 55], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 92, 102], ["pangolin-CoV", "GENE_OR_GENE_PRODUCT", 220, 232], ["SARS-CoV-2", "ORGANISM", 239, 249], ["Bat-CoV-ZXC21", "ORGANISM", 251, 264], ["Bat-CoV-ZC45", "ORGANISM", 269, 281], ["pangolin", "PROTEIN", 5, 13], ["Bat-CoV", "PROTEIN", 27, 34], ["RaTG13", "DNA", 35, 41], ["S1/S2 cleavage site", "DNA", 50, 69], ["SARS-CoV-2", "DNA", 92, 102], ["S genes", "DNA", 209, 216], ["Bat-CoV", "DNA", 251, 258], ["ZXC21", "DNA", 259, 264], ["CoV", "DNA", 273, 276], ["ZC45", "DNA", 277, 281], ["SARS-CoV", "SPECIES", 239, 247], ["CoV", "TEST", 14, 17], ["Bat-CoV", "TEST", 27, 34], ["an S1/S2 cleavage site", "PROBLEM", 47, 69], ["SARS", "TEST", 92, 96], ["CoV", "TEST", 97, 100], ["Genomic analyses", "TEST", 128, 144], ["sequence similarities", "TEST", 155, 176], ["pangolin", "TEST", 220, 228], ["CoV", "TEST", 229, 232], ["SARS", "TEST", 239, 243], ["CoV", "TEST", 244, 247], ["Bat-CoV", "TEST", 251, 258], ["ZXC21", "TEST", 259, 264], ["ZC45", "TREATMENT", 277, 281], ["CoV", "ANATOMY", 14, 17], ["S1", "ANATOMY", 50, 52], ["S2", "ANATOMY", 53, 55]]], ["For example, the first S region (i.e., nucleotides 1\u20131200) of pangolin-CoV-2020 has a higher nucleotide identity to two bat viruses (Bat-CoV-ZXC21 and Bat-CoV-ZC45) than SARS-CoV-2 and Bat-CoV-RaTG13, whereas the remaining S gene of pangolin-CoV-2020 is opposite (Fig 2A).", [["pangolin-CoV-2020", "CHEMICAL", 62, 79], ["nucleotide", "CHEMICAL", 93, 103], ["nucleotides", "CHEMICAL", 39, 50], ["nucleotide", "CHEMICAL", 93, 103], ["pangolin-CoV", "GENE_OR_GENE_PRODUCT", 62, 74], ["bat viruses", "ORGANISM", 120, 131], ["Bat-CoV-ZXC21", "ORGANISM", 133, 146], ["Bat-CoV-ZC45", "GENE_OR_GENE_PRODUCT", 151, 163], ["SARS-CoV-2", "ORGANISM", 170, 180], ["Bat-CoV-RaTG13", "ORGANISM", 185, 199], ["pangolin-CoV", "GENE_OR_GENE_PRODUCT", 233, 245], ["S region", "DNA", 23, 31], ["pangolin", "PROTEIN", 62, 70], ["ZC45", "DNA", 159, 163], ["CoV", "DNA", 189, 192], ["RaTG13", "DNA", 193, 199], ["S gene", "DNA", 223, 229], ["pangolin", "DNA", 233, 241], ["CoV", "DNA", 242, 245], ["Bat-CoV-ZC45", "SPECIES", 151, 163], ["SARS-CoV", "SPECIES", 170, 178], ["Bat-CoV-RaTG13", "SPECIES", 185, 199], ["nucleotides", "TEST", 39, 50], ["pangolin", "TEST", 62, 70], ["a higher nucleotide identity", "PROBLEM", 84, 112], ["Bat-CoV", "TEST", 133, 140], ["ZXC21", "TEST", 141, 146], ["Bat", "TEST", 151, 154], ["CoV", "TEST", 155, 158], ["SARS", "TEST", 170, 174], ["CoV", "TEST", 175, 178], ["Bat-CoV", "TEST", 185, 192], ["RaTG13", "TEST", 193, 199], ["pangolin", "TEST", 233, 241], ["viruses", "OBSERVATION", 124, 131]]], ["These results suggest that a recombination event could have occurred during the evolution of these coronaviruses.ResultsPhylogenetic analyses suggested that the S genes of pangolin-CoV-2020, SARS-CoV-2 and three bat origin coronaviruses (Bat-CoV-RaTG13, Bat-CoV-ZXC21, and Bat-CoV-ZC45) were genetically more similar to each other than other viruses in the same family (Fig 2B).", [["coronaviruses", "ORGANISM", 99, 112], ["pangolin-CoV-2020", "ORGANISM", 172, 189], ["SARS-CoV-2", "ORGANISM", 191, 201], ["bat origin coronaviruses", "ORGANISM", 212, 236], ["Bat-CoV-RaTG13", "ORGANISM", 238, 252], ["Bat-CoV", "ORGANISM", 254, 261], ["ZXC21", "GENE_OR_GENE_PRODUCT", 262, 267], ["Bat-CoV-ZC45", "GENE_OR_GENE_PRODUCT", 273, 285], ["S genes", "DNA", 161, 168], ["pangolin", "DNA", 172, 180], ["CoV", "DNA", 242, 245], ["RaTG13", "DNA", 246, 252], ["ZXC21", "DNA", 262, 267], ["Bat", "DNA", 273, 276], ["CoV", "DNA", 277, 280], ["ZC45", "DNA", 281, 285], ["SARS-CoV", "SPECIES", 191, 199], ["Bat-CoV", "SPECIES", 238, 245], ["Bat-CoV-ZC45", "SPECIES", 273, 285], ["a recombination event", "PROBLEM", 27, 48], ["these coronaviruses", "PROBLEM", 93, 112], ["Phylogenetic analyses", "TEST", 120, 141], ["the S genes", "TEST", 157, 168], ["pangolin", "TEST", 172, 180], ["CoV", "TEST", 181, 184], ["SARS", "TEST", 191, 195], ["CoV", "TEST", 196, 199], ["Bat", "TEST", 238, 241], ["CoV", "TEST", 242, 245], ["RaTG13", "TEST", 246, 252], ["Bat-", "TEST", 254, 258], ["CoV", "TEST", 258, 261], ["ZXC21", "TEST", 262, 267], ["Bat", "TEST", 273, 276], ["ZC45", "TREATMENT", 281, 285], ["coronaviruses", "OBSERVATION", 99, 112], ["viruses", "OBSERVATION", 342, 349]]], ["The S gene of Bat-CoV-RaTG13 was genetically closer to pangolin-CoV-2020 than Bat-CoV-ZXC21 and Bat-CoV-ZC45.", [["Bat-CoV-RaTG13", "GENE_OR_GENE_PRODUCT", 14, 28], ["pangolin-CoV", "GENE_OR_GENE_PRODUCT", 55, 67], ["Bat-CoV-ZXC21", "CELL", 78, 91], ["Bat-CoV-ZC45", "ORGANISM", 96, 108], ["S gene", "DNA", 4, 10], ["Bat-CoV", "DNA", 14, 21], ["RaTG13", "DNA", 22, 28], ["Bat-CoV", "DNA", 78, 85], ["ZXC21", "DNA", 86, 91], ["CoV", "DNA", 100, 103], ["ZC45", "DNA", 104, 108], ["Bat-CoV", "TEST", 14, 21], ["pangolin", "TEST", 55, 63], ["CoV", "TEST", 64, 67], ["Bat-CoV", "TEST", 78, 85], ["ZXC21", "TEST", 86, 91], ["ZC45", "TREATMENT", 104, 108]]], ["Similar tree topologies were observed for the encoding ORFs of RNA-dependent RNA polymerase (RdRp gene) and other genes (S1\u2013S3 Figs).", [["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 63, 91], ["ORFs", "DNA", 55, 59], ["RNA-dependent RNA polymerase", "PROTEIN", 63, 91], ["RdRp gene", "DNA", 93, 102], ["S1", "DNA", 121, 123], ["Similar tree topologies", "PROBLEM", 0, 23], ["the encoding ORFs of RNA", "PROBLEM", 42, 66], ["dependent RNA polymerase", "PROBLEM", 67, 91], ["tree topologies", "OBSERVATION", 8, 23]]], ["At the genomic level, SARS-CoV-2 was also genetically closer to Bat-CoV-RaTG13 than pangolin-CoV-2020 (Fig 1B).DiscussionIn this study, we assembled the genomes of coronaviruses identified in sick pangolins and our results showed that pangolin-CoV-2020 is genetically associated with both SARS-CoV-2 and a group of bat coronaviruses.", [["pangolin-CoV-2020", "CHEMICAL", 235, 252], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 22, 32], ["Bat-CoV-RaTG13", "GENE_OR_GENE_PRODUCT", 64, 78], ["pangolin-CoV", "GENE_OR_GENE_PRODUCT", 84, 96], ["coronaviruses", "ORGANISM", 164, 177], ["pangolins", "GENE_OR_GENE_PRODUCT", 197, 206], ["pangolin-CoV", "GENE_OR_GENE_PRODUCT", 235, 247], ["SARS-CoV-2", "ORGANISM", 289, 299], ["bat coronaviruses", "ORGANISM", 315, 332], ["Bat-CoV", "DNA", 64, 71], ["RaTG13", "DNA", 72, 78], ["pangolin", "DNA", 84, 92], ["CoV", "DNA", 93, 96], ["SARS-CoV", "SPECIES", 22, 30], ["SARS-CoV", "SPECIES", 289, 297], ["bat coronaviruses", "SPECIES", 315, 332], ["SARS", "TEST", 22, 26], ["CoV", "TEST", 27, 30], ["Bat-CoV", "TEST", 64, 71], ["pangolin", "TEST", 84, 92], ["CoV", "TEST", 93, 96], ["this study", "TEST", 124, 134], ["coronaviruses", "PROBLEM", 164, 177], ["pangolin", "TEST", 235, 243], ["CoV", "TEST", 294, 297], ["bat", "ANATOMY", 315, 318], ["coronaviruses", "OBSERVATION", 319, 332]]], ["There is a high sequence identity between pangolin-CoV-2020 and SARS-CoV-2.", [["pangolin-CoV", "GENE_OR_GENE_PRODUCT", 42, 54], ["SARS-CoV-2", "ORGANISM", 64, 74], ["SARS-CoV", "SPECIES", 64, 72], ["pangolin", "TEST", 42, 50], ["SARS", "TEST", 64, 68]]], ["However, phylogenetic analyses and a special amino acid sequence in the S gene of SARS-CoV-2 did not support the hypothesis of SARS-CoV-2 arising directly from the pangolin-CoV-2020.DiscussionIt is of interest that the genomic sequences of coronaviruses detected from two batches of smuggled pangolins intercepted by different customs at different dates were all be associated with bat coronaviruses.", [["amino acid", "CHEMICAL", 45, 55], ["SARS", "DISEASE", 127, 131], ["pangolins", "CHEMICAL", 292, 301], ["amino acid", "CHEMICAL", 45, 55], ["amino acid", "AMINO_ACID", 45, 55], ["SARS-CoV-2", "ORGANISM", 82, 92], ["SARS-CoV-2", "ORGANISM", 127, 137], ["pangolin-CoV", "GENE_OR_GENE_PRODUCT", 164, 176], ["coronaviruses", "ORGANISM", 240, 253], ["pangolins", "GENE_OR_GENE_PRODUCT", 292, 301], ["bat coronaviruses", "ORGANISM", 382, 399], ["S gene", "DNA", 72, 78], ["genomic sequences", "DNA", 219, 236], ["SARS-CoV", "SPECIES", 82, 90], ["SARS-CoV", "SPECIES", 127, 135], ["bat coronaviruses", "SPECIES", 382, 399], ["phylogenetic analyses", "TEST", 9, 30], ["a special amino acid sequence", "TEST", 35, 64], ["SARS", "TEST", 82, 86], ["CoV", "TEST", 87, 90], ["SARS", "PROBLEM", 127, 131], ["CoV", "TEST", 132, 135], ["coronaviruses", "PROBLEM", 240, 253], ["bat coronaviruses", "PROBLEM", 382, 399]]], ["In addition, the genetic identity of coronavirus contigs assembled in each animal was extremely high (99.54%).", [["coronavirus", "ORGANISM", 37, 48], ["coronavirus contigs", "DNA", 37, 56], ["coronavirus", "SPECIES", 37, 48], ["coronavirus contigs", "PROBLEM", 37, 56], ["coronavirus contigs", "OBSERVATION", 37, 56], ["high", "OBSERVATION_MODIFIER", 96, 100]]], ["The reads from the third pangolin acquired in July 2019 were relatively less abundant than those from the two pangolin samples acquired in March 2019.", [["pangolin", "GENE_OR_GENE_PRODUCT", 25, 33]]], ["Although it is unclear whether coronaviruses in these two batches of smuggled pangolins had the same origin, our results indicated that the pangolins can be a natural host for Betacoronaviruses, which could be enzootic in pangolins.DiscussionAll three exotic pangolins detected with Betacoronaviruses were sick with serious respiratory diseases and failed to be rescued.", [["respiratory", "ANATOMY", 324, 335], ["pangolins", "CHEMICAL", 78, 87], ["pangolins", "CHEMICAL", 140, 149], ["respiratory diseases", "DISEASE", 324, 344], ["coronaviruses", "ORGANISM", 31, 44], ["pangolins", "GENE_OR_GENE_PRODUCT", 78, 87], ["pangolins", "GENE_OR_GENE_PRODUCT", 140, 149], ["Betacoronaviruses", "GENE_OR_GENE_PRODUCT", 176, 193], ["pangolins", "SIMPLE_CHEMICAL", 222, 231], ["pangolins", "GENE_OR_GENE_PRODUCT", 259, 268], ["coronaviruses", "PROBLEM", 31, 44], ["smuggled pangolins", "PROBLEM", 69, 87], ["Betacoronaviruses", "PROBLEM", 176, 193], ["enzootic in pangolins", "PROBLEM", 210, 231], ["serious respiratory diseases", "PROBLEM", 316, 344], ["unclear whether", "UNCERTAINTY", 15, 30], ["coronaviruses", "OBSERVATION", 31, 44], ["enzootic", "OBSERVATION_MODIFIER", 210, 218]]], ["However, these pangolins were very stressful in the transportation freight when being intercepted by the customs.", [["pangolins", "GENE_OR_GENE_PRODUCT", 15, 24]]], ["It is unclear whether this coronavirus is a common virus flora in the respiratory tract of pangolins.", [["respiratory tract", "ANATOMY", 70, 87], ["coronavirus", "DISEASE", 27, 38], ["coronavirus", "ORGANISM", 27, 38], ["respiratory tract", "ORGANISM_SUBDIVISION", 70, 87], ["pangolins", "GENE_OR_GENE_PRODUCT", 91, 100], ["this coronavirus", "PROBLEM", 22, 38], ["a common virus flora", "PROBLEM", 42, 62], ["unclear whether", "UNCERTAINTY", 6, 21], ["coronavirus", "OBSERVATION", 27, 38], ["respiratory tract", "ANATOMY", 70, 87]]], ["Nevertheless, the pathogenesis of this coronavirus in pangolins remains to be elucidated.DiscussionPhylogenetic trees suggested that Bat-CoV-RaTG13 was more genetically close to SARS-CoV-2 at both individual gene and genomic sequence level compared with the genomic sequence of pangolin-CoV-2020 assembled in this study.", [["coronavirus", "DISEASE", 39, 50], ["coronavirus", "ORGANISM", 39, 50], ["pangolins", "GENE_OR_GENE_PRODUCT", 54, 63], ["Bat-CoV-RaTG13", "GENE_OR_GENE_PRODUCT", 133, 147], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 178, 188], ["pangolin-CoV", "GENE_OR_GENE_PRODUCT", 278, 290], ["Bat-CoV", "PROTEIN", 133, 140], ["RaTG13", "DNA", 141, 147], ["SARS-CoV-2", "DNA", 178, 188], ["pangolin", "DNA", 278, 286], ["CoV", "DNA", 287, 290], ["SARS-CoV", "SPECIES", 178, 186], ["this coronavirus in pangolins", "PROBLEM", 34, 63], ["Bat-CoV", "TEST", 133, 140], ["SARS", "TEST", 178, 182], ["CoV", "TEST", 183, 186], ["genomic sequence level", "TEST", 217, 239], ["the genomic sequence", "TEST", 254, 274], ["pangolin", "TEST", 278, 286], ["this study", "TEST", 309, 319], ["coronavirus", "OBSERVATION", 39, 50]]], ["Recombination analysis showed that S gene of pangolin-CoV-2020 might be constructed by fragment from Bat-CoV-ZC45 or Bat-CoV-ZXC21 and fragment from Bat-CoV-RaTG13.", [["pangolin-CoV-2020", "CHEMICAL", 45, 62], ["pangolin-CoV", "GENE_OR_GENE_PRODUCT", 45, 57], ["Bat-CoV-ZC45", "GENE_OR_GENE_PRODUCT", 101, 113], ["Bat-CoV-ZXC21", "GENE_OR_GENE_PRODUCT", 117, 130], ["Bat-CoV-RaTG13", "GENE_OR_GENE_PRODUCT", 149, 163], ["S gene", "DNA", 35, 41], ["pangolin", "DNA", 45, 53], ["Bat-CoV", "PROTEIN", 101, 108], ["ZC45", "DNA", 109, 113], ["Bat-CoV", "DNA", 117, 124], ["ZXC21", "DNA", 125, 130], ["Bat-CoV", "DNA", 149, 156], ["RaTG13", "DNA", 157, 163], ["Recombination analysis", "TEST", 0, 22], ["Bat-CoV", "TEST", 101, 108], ["ZC45", "TREATMENT", 109, 113], ["Bat-CoV", "TEST", 117, 124], ["fragment", "PROBLEM", 135, 143], ["Bat-CoV", "TEST", 149, 156]]], ["Interestingly, the cleavage site between S1 and S2 in SARS-CoV-2 had multiple insertions (i.e. PRRA), compared with those of Bat-CoV-RaTG13 and pangolin-CoV-2020, which may result from an additional recombination event.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 54, 64], ["Bat-CoV-RaTG13", "GENE_OR_GENE_PRODUCT", 125, 139], ["pangolin-CoV", "GENE_OR_GENE_PRODUCT", 144, 156], ["cleavage site", "DNA", 19, 32], ["S1", "PROTEIN", 41, 43], ["S2", "PROTEIN", 48, 50], ["SARS-CoV-2", "DNA", 54, 64], ["PRRA", "DNA", 95, 99], ["RaTG13", "DNA", 133, 139], ["pangolin", "DNA", 144, 152], ["CoV", "DNA", 153, 156], ["SARS-CoV", "SPECIES", 54, 62], ["the cleavage site", "PROBLEM", 15, 32], ["CoV", "TEST", 59, 62], ["multiple insertions", "PROBLEM", 69, 88], ["Bat-CoV", "TEST", 125, 132], ["RaTG13", "TEST", 133, 139], ["pangolin", "TEST", 144, 152], ["S1", "ANATOMY", 41, 43], ["S2", "ANATOMY", 48, 50], ["multiple", "OBSERVATION_MODIFIER", 69, 77], ["insertions", "OBSERVATION", 78, 88]]], ["A new study reported a novel bat-derived coronavirus (RmYN02) identified from a metagenomics analysis of samples from 227 bats collected from the Yunnan province in China between May and October of 2019.", [["samples", "ANATOMY", 105, 112], ["bat-derived coronavirus", "ORGANISM", 29, 52], ["RmYN02", "ORGANISM", 54, 60], ["coronavirus", "SPECIES", 41, 52], ["A new study", "TEST", 0, 11], ["a metagenomics analysis", "TEST", 78, 101]]], ["Although RmYN02 showed a relatively low nucleotide sequence identity (93.3%) to SARS-CoV-2, it had a similar manner of the insertion of multiple amino acids at the junction site of the S1 and S2 subunits of the S protein as SARS-CoV-2, providing strong evidence that such insertion events can occur in nature [11].", [["RmYN02", "CHEMICAL", 9, 15], ["nucleotide", "CHEMICAL", 40, 50], ["amino acids", "CHEMICAL", 145, 156], ["nucleotide", "CHEMICAL", 40, 50], ["amino acids", "CHEMICAL", 145, 156], ["RmYN02", "GENE_OR_GENE_PRODUCT", 9, 15], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 80, 90], ["amino acids", "AMINO_ACID", 145, 156], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 224, 234], ["RmYN02", "PROTEIN", 9, 15], ["S1 and S2 subunits", "PROTEIN", 185, 203], ["S protein", "PROTEIN", 211, 220], ["SARS-CoV-2", "PROTEIN", 224, 234], ["SARS-CoV", "SPECIES", 80, 88], ["RmYN02", "TEST", 9, 15], ["a relatively low nucleotide sequence identity", "PROBLEM", 23, 68], ["SARS", "TEST", 80, 84], ["CoV", "TEST", 85, 88], ["the insertion of multiple amino acids", "TREATMENT", 119, 156], ["SARS", "TEST", 224, 228], ["such insertion events", "PROBLEM", 267, 288], ["multiple", "OBSERVATION_MODIFIER", 136, 144], ["amino acids", "OBSERVATION", 145, 156], ["junction", "ANATOMY_MODIFIER", 164, 172], ["S1", "ANATOMY", 185, 187]]], ["Thus, these data suggest that SARS-CoV-2 originated from multiple naturally occurring recombination events among viruses present in bats and other wildlife species.DiscussionThe S protein of coronaviruses binds to host receptors via RBDs and plays an essential role in initiating viral infection and determining host tropism [2].", [["SARS", "DISEASE", 30, 34], ["viral infection", "DISEASE", 280, 295], ["SARS-CoV-2", "ORGANISM", 30, 40], ["coronaviruses", "ORGANISM", 191, 204], ["RBDs", "GENE_OR_GENE_PRODUCT", 233, 237], ["S protein", "PROTEIN", 178, 187], ["host receptors", "PROTEIN", 214, 228], ["RBDs", "PROTEIN", 233, 237], ["these data", "TEST", 6, 16], ["SARS", "PROBLEM", 30, 34], ["CoV", "TEST", 35, 38], ["coronaviruses binds", "PROBLEM", 191, 210], ["RBDs", "TREATMENT", 233, 237], ["viral infection", "PROBLEM", 280, 295], ["viral infection", "OBSERVATION", 280, 295]]], ["A prior study suggested that SARS-CoV-2 and SARS-CoV bind to the same ACE2 receptor [9].", [["SARS", "DISEASE", 29, 33], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 29, 39], ["SARS-CoV", "ORGANISM", 44, 52], ["ACE2", "GENE_OR_GENE_PRODUCT", 70, 74], ["ACE2 receptor", "PROTEIN", 70, 83], ["SARS-CoV", "SPECIES", 29, 37], ["SARS-CoV", "SPECIES", 44, 52], ["A prior study", "TEST", 0, 13], ["SARS", "TEST", 29, 33], ["CoV", "TEST", 34, 37], ["SARS", "PROBLEM", 44, 48]]], ["Our analyses showed that pangolin-CoV-2020 has a much conserved RBD to these viruses compared to MERS-CoV, suggesting that pangolin-CoV is very likely to use ACE2 as its receptor as well.", [["pangolin-CoV-2020", "CHEMICAL", 25, 42], ["pangolin-CoV", "GENE_OR_GENE_PRODUCT", 25, 37], ["RBD", "GENE_OR_GENE_PRODUCT", 64, 67], ["MERS-CoV", "ORGANISM", 97, 105], ["pangolin-CoV", "GENE_OR_GENE_PRODUCT", 123, 135], ["ACE2", "GENE_OR_GENE_PRODUCT", 158, 162], ["RBD", "PROTEIN", 64, 67], ["pangolin", "PROTEIN", 123, 131], ["ACE2", "PROTEIN", 158, 162], ["MERS-CoV", "SPECIES", 97, 105], ["pangolin-CoV", "SPECIES", 123, 135], ["Our analyses", "TEST", 0, 12], ["pangolin", "TEST", 25, 33], ["a much conserved RBD", "PROBLEM", 47, 67], ["these viruses", "PROBLEM", 71, 84], ["pangolin-CoV", "PROBLEM", 123, 135], ["ACE2", "TREATMENT", 158, 162], ["viruses", "OBSERVATION", 77, 84]]], ["A comparative analysis of the interaction of the S proteins of coronaviruses with ACE2 proteins of humans and pangolins showed that the S proteins of SARS-CoV-2 and pangolin-CoV can potentially recognize ACE2 in both humans and pangolins [12].", [["coronaviruses", "ORGANISM", 63, 76], ["ACE2", "GENE_OR_GENE_PRODUCT", 82, 86], ["humans", "ORGANISM", 99, 105], ["pangolins", "GENE_OR_GENE_PRODUCT", 110, 119], ["SARS-CoV-2", "ORGANISM", 150, 160], ["pangolin-CoV", "ORGANISM", 165, 177], ["ACE2", "GENE_OR_GENE_PRODUCT", 204, 208], ["humans", "ORGANISM", 217, 223], ["S proteins", "PROTEIN", 49, 59], ["ACE2 proteins", "PROTEIN", 82, 95], ["S proteins", "PROTEIN", 136, 146], ["pangolin", "PROTEIN", 165, 173], ["CoV", "PROTEIN", 174, 177], ["ACE2", "PROTEIN", 204, 208], ["humans", "SPECIES", 99, 105], ["humans", "SPECIES", 217, 223], ["humans", "SPECIES", 99, 105], ["SARS-CoV", "SPECIES", 150, 158], ["pangolin-CoV", "SPECIES", 165, 177], ["humans", "SPECIES", 217, 223], ["A comparative analysis", "TEST", 0, 22], ["the S proteins", "TEST", 45, 59], ["coronaviruses", "PROBLEM", 63, 76], ["ACE2 proteins", "TEST", 82, 95], ["pangolins", "TEST", 110, 119], ["the S proteins", "TEST", 132, 146], ["SARS", "TEST", 150, 154], ["CoV", "TEST", 155, 158], ["pangolin", "TREATMENT", 165, 173], ["ACE2", "TEST", 204, 208]]], ["A recent study found that a human ACE2-binding ridge in SARS-CoV-2 RBD takes a more compact conformation compared with the SARS-CoV RBD; moreover, several residue changes in SARS-CoV-2 RBD may also enhance its human ACE2-binding affinity [13].", [["human", "ORGANISM", 28, 33], ["ACE2", "GENE_OR_GENE_PRODUCT", 34, 38], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 123, 131], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 174, 184], ["human", "ORGANISM", 210, 215], ["ACE2", "GENE_OR_GENE_PRODUCT", 216, 220], ["ACE2", "PROTEIN", 34, 38], ["SARS-CoV-2 RBD", "PROTEIN", 56, 70], ["SARS-CoV RBD", "PROTEIN", 123, 135], ["SARS-CoV-2 RBD", "PROTEIN", 174, 188], ["ACE2", "PROTEIN", 216, 220], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 210, 215], ["human", "SPECIES", 28, 33], ["SARS-CoV", "SPECIES", 56, 64], ["SARS-CoV", "SPECIES", 123, 131], ["human", "SPECIES", 210, 215], ["A recent study", "TEST", 0, 14], ["a human ACE2-binding ridge", "TREATMENT", 26, 52], ["SARS", "TEST", 56, 60], ["CoV", "TEST", 61, 64], ["RBD", "PROBLEM", 67, 70], ["the SARS-CoV RBD", "PROBLEM", 119, 135], ["several residue changes in SARS", "PROBLEM", 147, 178], ["CoV-2 RBD", "PROBLEM", 179, 188]]], ["The core residues in RBM which may related to higher human ACE2-binding affinity than SARS-CoV are 100% identical between SARS-CoV-2 and CoV-Pangolin-2020.", [["RBM", "GENE_OR_GENE_PRODUCT", 21, 24], ["human", "ORGANISM", 53, 58], ["ACE2", "GENE_OR_GENE_PRODUCT", 59, 63], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 86, 94], ["CoV", "ORGANISM", 137, 140], ["RBM", "PROTEIN", 21, 24], ["ACE2", "PROTEIN", 59, 63], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 53, 58], ["SARS-CoV", "SPECIES", 86, 94], ["SARS-CoV", "SPECIES", 122, 130], ["The core residues in RBM", "PROBLEM", 0, 24], ["SARS", "TEST", 86, 90], ["CoV", "TEST", 91, 94], ["SARS", "TEST", 122, 126], ["CoV", "TEST", 127, 130], ["CoV", "TEST", 137, 140], ["core", "OBSERVATION_MODIFIER", 4, 8], ["residues", "OBSERVATION", 9, 17]]], ["Therefore, pangolin-CoV-2020 (CoV-pangolin/GD) potentially recognizes human ACE2 better than the SARS-CoV.DiscussionIn addition to RBD, NTD is also important in recognizing acetylated sialic acids on glycosylated cell-surface receptors [14].", [["cell", "ANATOMY", 213, 217], ["surface", "ANATOMY", 218, 225], ["pangolin-CoV-2020", "CHEMICAL", 11, 28], ["CoV-pangolin", "CHEMICAL", 30, 42], ["RBD", "DISEASE", 131, 134], ["sialic acids", "CHEMICAL", 184, 196], ["sialic acids", "CHEMICAL", 184, 196], ["pangolin-CoV", "SIMPLE_CHEMICAL", 11, 23], ["CoV", "ORGANISM", 30, 33], ["-pangolin", "SIMPLE_CHEMICAL", 33, 42], ["human", "ORGANISM", 70, 75], ["ACE2", "GENE_OR_GENE_PRODUCT", 76, 80], ["SARS-CoV", "ORGANISM", 97, 105], ["acetylated sialic acids", "SIMPLE_CHEMICAL", 173, 196], ["glycosylated cell-surface receptors", "GENE_OR_GENE_PRODUCT", 200, 235], ["human ACE2", "PROTEIN", 70, 80], ["RBD", "PROTEIN", 131, 134], ["NTD", "PROTEIN", 136, 139], ["glycosylated cell-surface receptors", "PROTEIN", 200, 235], ["human", "SPECIES", 70, 75], ["human", "SPECIES", 70, 75], ["SARS-CoV", "SPECIES", 97, 105], ["pangolin", "TEST", 11, 19], ["CoV", "TEST", 20, 23], ["CoV", "TEST", 30, 33], ["acetylated sialic acids", "TREATMENT", 173, 196], ["glycosylated cell-surface receptors", "TREATMENT", 200, 235]]], ["It is reported that SARS-CoV-2 can bind to human ACE2 via the viral CTD (the same as RBD), but not NTD, and that the glycan attached to Asn90 from human ACE2 forms a hydrogen bond with Arg408 from the RBD core [15].", [["Asn90", "CHEMICAL", 136, 141], ["Arg408", "CHEMICAL", 185, 191], ["Asn90", "CHEMICAL", 136, 141], ["hydrogen", "CHEMICAL", 166, 174], ["Arg", "CHEMICAL", 185, 188], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 20, 30], ["human", "ORGANISM", 43, 48], ["ACE2", "GENE_OR_GENE_PRODUCT", 49, 53], ["NTD", "GENE_OR_GENE_PRODUCT", 99, 102], ["Asn90", "GENE_OR_GENE_PRODUCT", 136, 141], ["human", "ORGANISM", 147, 152], ["ACE2", "GENE_OR_GENE_PRODUCT", 153, 157], ["Arg408", "AMINO_ACID", 185, 191], ["human ACE2", "PROTEIN", 43, 53], ["viral CTD", "PROTEIN", 62, 71], ["RBD", "PROTEIN", 85, 88], ["NTD", "PROTEIN", 99, 102], ["Asn90", "PROTEIN", 136, 141], ["human ACE2", "PROTEIN", 147, 157], ["RBD", "PROTEIN", 201, 204], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 147, 152], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 147, 152], ["SARS", "PROBLEM", 20, 24], ["human ACE2", "TEST", 43, 53], ["the viral CTD", "PROBLEM", 58, 71], ["NTD", "PROBLEM", 99, 102], ["viral CTD", "OBSERVATION", 62, 71]]], ["This glycan interacting Arginine is conserved between SARS-CoV-2 and pangolin-CoV-2.", [["Arginine", "CHEMICAL", 24, 32], ["Arginine", "CHEMICAL", 24, 32], ["Arginine", "AMINO_ACID", 24, 32], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 54, 64], ["pangolin-CoV-2", "GENE_OR_GENE_PRODUCT", 69, 83], ["SARS-CoV", "SPECIES", 54, 62], ["SARS", "TEST", 54, 58], ["CoV", "TEST", 59, 62], ["pangolin", "TREATMENT", 69, 77]]], ["Therefore, there is structural similarity in glycan binding between SARS-CoV-2 and pangolin-CoV-2020.", [["SARS-CoV-2", "ORGANISM", 68, 78], ["pangolin-CoV", "ORGANISM", 83, 95], ["structural similarity in glycan binding", "PROBLEM", 20, 59], ["SARS", "TEST", 68, 72], ["CoV", "TEST", 73, 76]]], ["On the other hand, ACE2 receptor is present in pangolins with a high sequence conservation with those in the gene homolog in humans.", [["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 19, 32], ["pangolins", "GENE_OR_GENE_PRODUCT", 47, 56], ["humans", "ORGANISM", 125, 131], ["ACE2 receptor", "PROTEIN", 19, 32], ["humans", "SPECIES", 125, 131], ["humans", "SPECIES", 125, 131], ["a high sequence conservation", "TREATMENT", 62, 90]]], ["However, the zoonosis of pangolin-CoV-2020 remains unclear.DiscussionThe coronaviruses are shown to have a wide range of hosts, and some of them can infect humans [16].", [["zoonosis", "DISEASE", 13, 21], ["pangolin-CoV-2020", "CHEMICAL", 25, 42], ["pangolin-CoV", "GENE_OR_GENE_PRODUCT", 25, 37], ["coronaviruses", "ORGANISM", 73, 86], ["humans", "ORGANISM", 156, 162], ["humans", "SPECIES", 156, 162], ["humans", "SPECIES", 156, 162], ["zoonosis", "OBSERVATION_MODIFIER", 13, 21]]], ["Thus, it is critical to determine the natural reservoir and the host tropisms of these coronaviruses, especially their potential of causing zoonosis.", [["zoonosis", "DISEASE", 140, 148], ["coronaviruses", "ORGANISM", 87, 100], ["these coronaviruses", "PROBLEM", 81, 100], ["zoonosis", "PROBLEM", 140, 148], ["zoonosis", "OBSERVATION", 140, 148]]], ["In the last two decades, apart from SARS-CoV-2, SARS and MERS have caused serious outbreaks in humans, leading to thousands of deaths [3, 4, 17, 18].", [["SARS", "DISEASE", 36, 40], ["SARS", "DISEASE", 48, 52], ["deaths", "DISEASE", 127, 133], ["SARS-CoV-2", "ORGANISM", 36, 46], ["humans", "ORGANISM", 95, 101], ["humans", "SPECIES", 95, 101], ["SARS-CoV", "SPECIES", 36, 44], ["humans", "SPECIES", 95, 101], ["SARS", "PROBLEM", 36, 40], ["CoV", "TEST", 41, 44], ["SARS", "PROBLEM", 48, 52], ["serious outbreaks in humans", "PROBLEM", 74, 101], ["serious", "OBSERVATION_MODIFIER", 74, 81], ["outbreaks", "OBSERVATION", 82, 91]]], ["Although these three zoonotic coronaviruses were shown to be of bat origin, they seemed to use different intermediate hosts.", [["zoonotic coronaviruses", "DISEASE", 21, 43], ["coronaviruses", "ORGANISM", 30, 43], ["these three zoonotic coronaviruses", "PROBLEM", 9, 43]]], ["For example, farmed palm civets were suggested to be an intermediate host for SARS-CoV, although the details of the link from bats to farmed palm civets remain unclear [19\u201321].", [["SARS", "DISEASE", 78, 82], ["palm civets", "ORGANISM", 20, 31], ["SARS-CoV", "ORGANISM", 78, 86], ["palm", "ORGANISM_SUBDIVISION", 141, 145], ["farmed palm civets", "SPECIES", 13, 31], ["SARS-CoV", "SPECIES", 78, 86], ["farmed palm civets", "TEST", 13, 31], ["SARS", "PROBLEM", 78, 82]]], ["Most recently, dromedary camels in Saudi Arabia were shown to harbor three different coronaviruses, including the dominant MERS-CoV lineage that was responsible for the outbreaks in the Middle East and South Korea during 2015 [22].", [["dromedary camels", "ORGANISM", 15, 31], ["Saudi Arabia", "ORGANISM", 35, 47], ["coronaviruses", "ORGANISM", 85, 98], ["MERS-CoV", "ORGANISM", 123, 131], ["MERS-CoV", "SPECIES", 123, 131], ["coronaviruses", "OBSERVATION", 85, 98], ["dominant", "OBSERVATION_MODIFIER", 114, 122], ["MERS", "OBSERVATION", 123, 127], ["Middle", "ANATOMY_MODIFIER", 186, 192]]], ["Although this present study does not support that pangolins would be intermediate hosts for the emergence of SARS-CoV-2, our results do not exclude the possibility that other CoVs could be circulating in pangolins.", [["pangolins", "CHEMICAL", 50, 59], ["SARS", "DISEASE", 109, 113], ["pangolins", "CHEMICAL", 50, 59], ["pangolins", "GENE_OR_GENE_PRODUCT", 50, 59], ["SARS-CoV-2", "ORGANISM", 109, 119], ["CoVs", "GENE_OR_GENE_PRODUCT", 175, 179], ["pangolins", "SIMPLE_CHEMICAL", 204, 213], ["CoVs", "DNA", 175, 179], ["SARS-CoV", "SPECIES", 109, 117], ["this present study", "TEST", 9, 27], ["other CoVs", "PROBLEM", 169, 179]]], ["Thus, surveillance of coronaviruses in pangolins could improve our understanding of the spectrum of coronaviruses in pangolins.", [["coronaviruses", "DISEASE", 100, 113], ["coronaviruses", "ORGANISM", 22, 35], ["pangolins", "GENE_OR_GENE_PRODUCT", 39, 48], ["coronaviruses", "ORGANISM", 100, 113], ["pangolins", "GENE_OR_GENE_PRODUCT", 117, 126], ["coronaviruses in pangolins", "PROBLEM", 22, 48], ["coronaviruses in pangolins", "PROBLEM", 100, 126], ["coronaviruses", "OBSERVATION", 22, 35], ["coronaviruses", "OBSERVATION", 100, 113]]], ["In addition to conservation of wildlife, minimizing the exposures of humans to wildlife will be important to reduce the spillover risks coronaviruses from wild animals to humans.DiscussionIn summary, we suggest that pangolins could be natural hosts of Betacoronaviruses with an unknown potential to infect humans.", [["pangolins", "CHEMICAL", 216, 225], ["humans", "ORGANISM", 69, 75], ["coronaviruses", "ORGANISM", 136, 149], ["humans", "ORGANISM", 171, 177], ["pangolins", "GENE_OR_GENE_PRODUCT", 216, 225], ["Betacoronaviruses", "GENE_OR_GENE_PRODUCT", 252, 269], ["humans", "ORGANISM", 306, 312], ["humans", "SPECIES", 69, 75], ["humans", "SPECIES", 171, 177], ["humans", "SPECIES", 306, 312], ["humans", "SPECIES", 69, 75], ["humans", "SPECIES", 171, 177], ["humans", "SPECIES", 306, 312], ["wildlife", "TREATMENT", 31, 39], ["the spillover risks coronaviruses", "PROBLEM", 116, 149]]], ["However, our study does not support that SARS-CoV-2 evolved directly from the pangolin-CoV.Ethics statement ::: Materials and methodsThe study design was approved by the ethics committee for animal experiments at the Guangdong Institute of Applied Biological Resources (reference number: GIABR20170720; 20 July 2017) and followed basic principles outlined by this committee.Data selection ::: Materials and methodsDuring our routine wildlife rescue efforts, one of the goals was to identify pathogens causing wildlife diseases.", [["SARS", "DISEASE", 41, 45], ["wildlife diseases", "DISEASE", 509, 526], ["SARS-CoV-2", "ORGANISM", 41, 51], ["pangolin-CoV", "GENE_OR_GENE_PRODUCT", 78, 90], ["pangolin-CoV", "DNA", 78, 90], ["pangolin-CoV", "SPECIES", 78, 90], ["our study", "TEST", 9, 18], ["SARS", "PROBLEM", 41, 45], ["CoV", "TEST", 46, 49], ["The study", "TEST", 133, 142], ["methods", "TREATMENT", 407, 414], ["pathogens", "PROBLEM", 491, 500], ["wildlife diseases", "PROBLEM", 509, 526], ["CoV", "ANATOMY", 87, 90]]], ["In 2019, we were involved in two events of pangolin rescues: one involved with 21 smuggling pangolins in March and the second with 6 smuggling pangolins in July.", [["pangolin", "CHEMICAL", 43, 51], ["pangolin", "CHEMICAL", 43, 51], ["pangolin", "GENE_OR_GENE_PRODUCT", 43, 51]]], ["Although extensive rescue efforts were made, the majority of thse pangolins were dead.", [["pangolins", "CHEMICAL", 66, 75], ["pangolins", "GENE_OR_GENE_PRODUCT", 66, 75], ["extensive", "OBSERVATION_MODIFIER", 9, 18]]], ["Most of the dead pangolins had a swollen lung, which contained a frothy liquid, and symptoms of pulmonary fibrosis.", [["swollen lung", "ANATOMY", 33, 45], ["pulmonary", "ANATOMY", 96, 105], ["pulmonary fibrosis", "DISEASE", 96, 114], ["pangolins", "CANCER", 17, 26], ["lung", "ORGAN", 41, 45], ["pulmonary", "ORGAN", 96, 105], ["a swollen lung", "PROBLEM", 31, 45], ["a frothy liquid", "PROBLEM", 63, 78], ["pulmonary fibrosis", "PROBLEM", 96, 114], ["swollen", "OBSERVATION", 33, 40], ["lung", "ANATOMY", 41, 45], ["frothy liquid", "OBSERVATION", 65, 78], ["pulmonary", "ANATOMY", 96, 105], ["fibrosis", "OBSERVATION", 106, 114]]], ["In the minority of these dead ones, we observed hepatomegaly and splenomegaly.", [["hepatomegaly", "DISEASE", 48, 60], ["splenomegaly", "DISEASE", 65, 77], ["splenomegaly", "PATHOLOGICAL_FORMATION", 65, 77], ["hepatomegaly", "PROBLEM", 48, 60], ["splenomegaly", "PROBLEM", 65, 77], ["hepatomegaly", "OBSERVATION", 48, 60], ["splenomegaly", "OBSERVATION", 65, 77]]], ["From 11 pangolins failed to be rescued, we collected samples from their lung, lymph and spleen tissues and subjected for metagenomic analyses.", [["samples", "ANATOMY", 53, 60], ["lung", "ANATOMY", 72, 76], ["lymph", "ANATOMY", 78, 83], ["spleen tissues", "ANATOMY", 88, 102], ["pangolins", "GENE_OR_GENE_PRODUCT", 8, 17], ["lung", "ORGAN", 72, 76], ["lymph", "MULTI-TISSUE_STRUCTURE", 78, 83], ["spleen tissues", "TISSUE", 88, 102], ["metagenomic analyses", "TEST", 121, 141], ["lung", "ANATOMY", 72, 76], ["lymph", "ANATOMY", 78, 83], ["spleen tissues", "ANATOMY", 88, 102]]], ["Coronaviruses were detected in three individuals by mapping clean reads without ribosomes and host sequences to an in-house virus reference dataset separated from the GenBank non-redundant nucleotide database using the Burrows-Wheeler Aligner (BWA) ver 0.7.17 [10, 23].", [["ribosomes", "ANATOMY", 80, 89], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["ribosomes", "CELLULAR_COMPONENT", 80, 89], ["Coronaviruses", "PROBLEM", 0, 13]]], ["Two of these animals were from the first batch of smuggled Malayan pangolins intercepted by Meizhou, Yangjiang, and Jiangmen customs in March, 2019, and the third one was from the second batch in a freight being transported from Qingyuan to Heyuan in July, 2019.", [["pangolins", "CHEMICAL", 67, 76], ["animals", "ORGANISM", 13, 20]]], ["The RNA samples from these three individuals were subjected to deep sequencing.Genomic assembly and sequence analyses ::: Materials and methodsClean reads from each of the three coronavirus positive animals were de novo assembled using MEGAHIT v1.2.9 [24].", [["samples", "ANATOMY", 8, 15], ["coronavirus", "ORGANISM", 178, 189], ["The RNA samples", "TEST", 0, 15]]], ["After examining the high similarity of 99.54% among the samples from three animals, to maximize the coverage of the virus genome, we pooled clean reads and de novo assembled them.", [["samples", "ANATOMY", 56, 63], ["virus genome", "DNA", 116, 128], ["the virus genome", "TREATMENT", 112, 128], ["virus genome", "OBSERVATION", 116, 128]]], ["The assembled contigs were used as references for extracting unmapped reads using Salmon v0.14.1 [25], and multiple rounds were implemented to maximize the mapping.Genomic assembly and sequence analyses ::: Materials and methodsA total of 38 contigs were identified to be highly similar to the SARS-CoV-2 genome using BLASTn and tBLASTx.", [["SARS-CoV-2 genome", "DNA", 294, 311], ["tBLASTx", "DNA", 329, 336], ["SARS-CoV", "SPECIES", 294, 302], ["the mapping", "TEST", 152, 163], ["the SARS", "PROBLEM", 290, 298], ["BLASTn and tBLASTx", "TREATMENT", 318, 336]]], ["GapFiller v1.10 and SSPACE v3.0 were used to fill gaps and draft pangolin-CoV-2020 genome was constructed with ABACAS v1.3.1 (http://abacas.sourceforge.net/) [26\u201328].Genomic assembly and sequence analyses ::: Materials and methodsGaps in the draft genomes were filled using the 2x PCR Mix (Gentech, China) by reverse transcription PCR (RT-PCR).", [["pangolin-CoV-2020 genome", "DNA", 65, 89], ["draft genomes", "DNA", 242, 255], ["GapFiller v", "TREATMENT", 0, 11], ["SSPACE", "TEST", 20, 26], ["draft pangolin", "TEST", 59, 73], ["CoV", "TEST", 74, 77], ["ABACAS v", "TEST", 111, 119], ["the 2x PCR Mix", "TREATMENT", 274, 288]]], ["Primers were designed based on the draft genome sequence of the pangolin-CoV-2020 we assembled (S4 Table).", [["draft genome sequence", "DNA", 35, 56], ["pangolin-CoV-2020", "DNA", 64, 81]]], ["After gap filling, the whole genome sequence of pangolin-CoV-2020 was submitted to GenBank databases (accession no. MT121216).Genomic assembly and sequence analyses ::: Materials and methodsMultiple sequence alignments were conducted using MUSCLE [29].", [["MT121216", "CHEMICAL", 116, 124], ["MT121216", "CHEMICAL", 116, 124], ["pangolin-CoV", "GENE_OR_GENE_PRODUCT", 48, 60], ["MT121216", "SIMPLE_CHEMICAL", 116, 124], ["whole genome sequence", "DNA", 23, 44], ["pangolin", "DNA", 48, 56], ["gap filling", "PROBLEM", 6, 17], ["Multiple sequence alignments", "TEST", 190, 218], ["filling", "OBSERVATION_MODIFIER", 10, 17]]], ["Changing patterns of sequence identity were analyzed using SimPlot v3.5.1 to determine the sequence identity among SARS-CoV-2 (MN908947.3), pangolin-CoV-2020, Bat-CoV-RaTG13 (MN996532.1), Bat-CoV-ZXC21 (MG772934.1), Bat-CoV-ZC45 (MG772933.1), SARS-CoV (AY395003.1), and MERS-CoV (NC_019843.3) at both the genomic sequence level and the individual gene level [30].", [["SARS-CoV-2", "ORGANISM", 115, 125], ["MN908947.3", "ORGANISM", 127, 137], ["pangolin-CoV", "ORGANISM", 140, 152], ["Bat-CoV-RaTG13", "ORGANISM", 159, 173], ["Bat-CoV-ZXC21", "CELL", 188, 201], ["Bat-CoV-ZC45", "ORGANISM", 216, 228], ["SARS-CoV", "ORGANISM", 243, 251], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 270, 278], ["SimPlot v3.5.1", "DNA", 59, 73], ["MERS-CoV", "DNA", 270, 278], ["NC_019843.3", "DNA", 280, 291], ["SARS-CoV-2", "SPECIES", 115, 125], ["Bat-CoV-RaTG13", "SPECIES", 159, 173], ["SARS-CoV", "SPECIES", 243, 251], ["MERS-CoV", "SPECIES", 270, 278], ["SimPlot", "TEST", 59, 66], ["the sequence identity", "TEST", 87, 108], ["SARS", "TEST", 115, 119], ["CoV", "TEST", 120, 123], ["pangolin", "TEST", 140, 148], ["CoV", "TEST", 149, 152], ["Bat-CoV", "TEST", 159, 166], ["RaTG13", "TEST", 167, 173], ["Bat-CoV", "TEST", 188, 195], ["ZXC21", "TEST", 196, 201], ["Bat-CoV", "TEST", 216, 223], ["ZC45", "TEST", 224, 228], ["SARS", "TEST", 243, 247], ["CoV", "TEST", 248, 251], ["MERS", "TEST", 270, 274], ["CoV", "TEST", 275, 278], ["NC_", "TEST", 280, 283], ["the individual gene level", "TEST", 332, 357]]], ["The sequence identity between the whole genome and different genes or regions was calculated utilizing p-distance in MEGA v10.1.7 [31].Phylogenetic analyses and recombination ::: Materials and methodsWe downloaded 44 full-length genome sequences of coronaviruses isolated from different hosts from the public database (S5 Table), with the data kindly shared by the submitters.", [["coronaviruses", "ORGANISM", 249, 262], ["whole genome", "DNA", 34, 46], ["44 full-length genome sequences", "DNA", 214, 245], ["MEGA v", "TEST", 117, 123], ["Phylogenetic analyses", "TEST", 135, 156], ["coronaviruses", "PROBLEM", 249, 262]]], ["Phylogenetic analyses were performed based on their whole genome sequences, RdRp gene, S gene, small envelope protein (E gene), as well as all other gene sequences.", [["small envelope protein", "GENE_OR_GENE_PRODUCT", 95, 117], ["E", "GENE_OR_GENE_PRODUCT", 119, 120], ["whole genome sequences", "DNA", 52, 74], ["RdRp gene", "DNA", 76, 85], ["S gene", "DNA", 87, 93], ["small envelope protein", "DNA", 95, 117], ["E gene", "DNA", 119, 125], ["Phylogenetic analyses", "TEST", 0, 21], ["their whole genome sequences", "TEST", 46, 74], ["small envelope protein (E gene)", "TREATMENT", 95, 126]]], ["We constructed multiple sequence alignments of their complete genomes and individual genes using MAFFT v7.407 [32].", [["MAFFT v", "TEST", 97, 104]]], ["Phylogenetic analyses were estimated using MrBayes [33] with 50,000,000 generations and the 25% of the generations as burnin.", [["burnin", "GENE_OR_GENE_PRODUCT", 118, 124], ["Phylogenetic analyses", "TEST", 0, 21]]], ["Then, the trees were visualized and exported as vector diagrams with FigTree v1.4.4 (http://tree.bio.ed.ac.uk/software/figtree/).", [["vector diagrams", "TEST", 48, 63], ["FigTree v", "TEST", 69, 78]]], ["Potential recombination events and the location of possible breakpoints in coronavirus genomes were detected using SimPlot v3.5.1 [30].", [["coronavirus", "ORGANISM", 75, 86], ["coronavirus genomes", "DNA", 75, 94], ["Potential recombination events", "PROBLEM", 0, 30], ["breakpoints in coronavirus genomes", "PROBLEM", 60, 94], ["coronavirus genomes", "OBSERVATION", 75, 94]]]], "05c9e683af7313183ee9d98292a77230dd15b0c2": [["IntroductionIn December 2019, patients with pneumonia of unknown cause reported to hospitals in Wuhan, Hubei, China.", [["pneumonia", "DISEASE", 44, 53], ["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38], ["pneumonia", "PROBLEM", 44, 53], ["pneumonia", "OBSERVATION", 44, 53]]], ["This unknown cause of pneumonia provoked fear, stress, and panic in China.", [["pneumonia", "DISEASE", 22, 31], ["panic", "DISEASE", 59, 64], ["pneumonia", "PROBLEM", 22, 31], ["fear", "PROBLEM", 41, 45], ["stress", "PROBLEM", 47, 53], ["panic in China", "PROBLEM", 59, 73], ["unknown cause of", "UNCERTAINTY", 5, 21], ["pneumonia", "OBSERVATION", 22, 31]]], ["Within a day, this condition spread to other provinces in China, and health authorities started immediate investigation to characterize and isolated the virus, which, by 7 January 2020, was named the Novel Coronavirus (nCoV) [1] .", [["this condition", "PROBLEM", 14, 28], ["the virus", "PROBLEM", 149, 158]]], ["On 12 January 2020, the World Health Organization (WHO) named this new virus 2019-Novel Coronavirus (2019-nCoV).", [["this new virus", "PROBLEM", 62, 76], ["Novel Coronavirus", "PROBLEM", 82, 99]]], ["The infectious disease was named COVID-19 by WHO on 11 February 2020.", [["infectious disease", "DISEASE", 4, 22], ["infectious", "OBSERVATION", 4, 14]]], ["This virus is part of a diverse family of viruses, consisting of four viral genera (alpha-, beta-, gamma-, and delta-coronaviruses) [2] .", [["alpha-, beta-", "GENE_OR_GENE_PRODUCT", 84, 97], ["gamma-", "GENE_OR_GENE_PRODUCT", 99, 105], ["This virus", "PROBLEM", 0, 10], ["viruses", "PROBLEM", 42, 49], ["four viral genera", "TEST", 65, 82], ["alpha-", "TEST", 84, 90], ["beta-, gamma-", "TREATMENT", 92, 105], ["viruses", "OBSERVATION", 42, 49]]], ["They infect different body systems of human and vertebrates like the respiratory, central nervous, hepatic, and gastrointestinal systems [3] .", [["body systems", "ANATOMY", 22, 34], ["respiratory", "ANATOMY", 69, 80], ["central nervous", "ANATOMY", 82, 97], ["hepatic", "ANATOMY", 99, 106], ["gastrointestinal systems", "ANATOMY", 112, 136], ["respiratory, central nervous, hepatic, and gastrointestinal systems", "DISEASE", 69, 136], ["body", "ORGANISM_SUBDIVISION", 22, 26], ["human", "ORGANISM", 38, 43], ["central", "ANATOMICAL_SYSTEM", 82, 89], ["nervous", "ANATOMICAL_SYSTEM", 90, 97], ["hepatic", "ANATOMICAL_SYSTEM", 99, 106], ["gastrointestinal", "ORGAN", 112, 128], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 38, 43], ["the respiratory, central nervous, hepatic, and gastrointestinal systems", "PROBLEM", 65, 136], ["respiratory", "ANATOMY_MODIFIER", 69, 80], ["central", "ANATOMY_MODIFIER", 82, 89], ["nervous", "ANATOMY", 90, 97], ["hepatic", "ANATOMY", 99, 106], ["gastrointestinal systems", "ANATOMY", 112, 136]]], ["Figure 1 shows the essential events related to the 2019-nCoV outbreak.IntroductionThe clinical features of COVID-19, as determined from 99 patients in Wuhan city, China are fever (83%), cough (82%), shortness of breath (31%), muscle pain (11%), confusion (9%), headache (8%), sore throat (5%), rhinorrhea (4%), chest pain (2%), diarrhea (2%), and nausea and vomiting (1%) [4] .", [["muscle", "ANATOMY", 226, 232], ["chest", "ANATOMY", 311, 316], ["fever", "DISEASE", 173, 178], ["cough", "DISEASE", 186, 191], ["shortness of breath", "DISEASE", 199, 218], ["muscle pain", "DISEASE", 226, 237], ["confusion", "DISEASE", 245, 254], ["headache", "DISEASE", 261, 269], ["sore throat", "DISEASE", 276, 287], ["rhinorrhea", "DISEASE", 294, 304], ["chest pain", "DISEASE", 311, 321], ["diarrhea", "DISEASE", 328, 336], ["nausea", "DISEASE", 347, 353], ["vomiting", "DISEASE", 358, 366], ["patients", "ORGANISM", 139, 147], ["muscle", "ORGAN", 226, 232], ["chest", "ORGANISM_SUBDIVISION", 311, 316], ["patients", "SPECIES", 139, 147], ["COVID", "TEST", 107, 112], ["fever", "PROBLEM", 173, 178], ["cough", "PROBLEM", 186, 191], ["shortness of breath", "PROBLEM", 199, 218], ["muscle pain", "PROBLEM", 226, 237], ["confusion", "PROBLEM", 245, 254], ["headache", "PROBLEM", 261, 269], ["sore throat", "PROBLEM", 276, 287], ["rhinorrhea", "PROBLEM", 294, 304], ["chest pain", "PROBLEM", 311, 321], ["diarrhea", "PROBLEM", 328, 336], ["nausea", "PROBLEM", 347, 353], ["vomiting", "PROBLEM", 358, 366], ["muscle", "ANATOMY", 226, 232], ["sore throat", "ANATOMY", 276, 287], ["rhinorrhea", "OBSERVATION", 294, 304], ["chest", "ANATOMY", 311, 316], ["diarrhea", "OBSERVATION", 328, 336]]], ["A study revealed that reported patients tended to be older males who had the fatal condition of acute respiratory distress syndrome (ARDS) [4] .", [["respiratory", "ANATOMY", 102, 113], ["acute respiratory distress syndrome", "DISEASE", 96, 131], ["ARDS", "DISEASE", 133, 137], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["A study", "TEST", 0, 7], ["the fatal condition", "PROBLEM", 73, 92], ["acute respiratory distress syndrome", "PROBLEM", 96, 131], ["ARDS)", "PROBLEM", 133, 138], ["acute", "OBSERVATION_MODIFIER", 96, 101], ["respiratory distress", "OBSERVATION", 102, 122]]], ["According to the WHO situation report, globally, 179,000 thousand cases have been confirmed and the number is increasing every hour.", [["increasing", "OBSERVATION_MODIFIER", 110, 120]]], ["Understanding the disease etiology, epidemics, genomics, clinical findings, and treatment options requires extensive data from sampling, laboratory work, and clinical trials [5, 6] .", [["epidemics", "PROBLEM", 36, 45], ["treatment options", "TREATMENT", 80, 97], ["laboratory work", "TEST", 137, 152]]], ["Rapid findings can help to control the disease spread as well as further outbreaks of contagious viruses.", [["the disease spread", "PROBLEM", 35, 53], ["contagious viruses", "PROBLEM", 86, 104], ["disease", "OBSERVATION", 39, 46], ["contagious viruses", "OBSERVATION", 86, 104]]], ["COVID-2019 transmission occurs person-to-person, either through direct transmission by sneeze, cough, or droplet inhalation, or contact transmission such as ocular contact or through mucous membranes of the eyes and nose and saliva [7, 8] .", [["ocular", "ANATOMY", 157, 163], ["mucous membranes", "ANATOMY", 183, 199], ["eyes", "ANATOMY", 207, 211], ["nose", "ANATOMY", 216, 220], ["sneeze", "DISEASE", 87, 93], ["cough", "DISEASE", 95, 100], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 183, 199], ["eyes", "ORGAN", 207, 211], ["nose", "ORGANISM_SUBDIVISION", 216, 220], ["saliva", "ORGANISM_SUBSTANCE", 225, 231], ["person", "SPECIES", 31, 37], ["person", "SPECIES", 41, 47], ["cough", "PROBLEM", 95, 100], ["droplet inhalation", "PROBLEM", 105, 123], ["eyes", "ANATOMY", 207, 211], ["nose", "ANATOMY", 216, 220]]], ["In this perspective, we highlight the hidden capability of saliva for the early detection of any viral, bacterial, or systemic disease [9] .", [["saliva", "ORGANISM_SUBSTANCE", 59, 65], ["any viral, bacterial", "PROBLEM", 93, 113], ["systemic disease", "PROBLEM", 118, 134], ["viral", "OBSERVATION", 97, 102], ["bacterial", "OBSERVATION_MODIFIER", 104, 113], ["systemic disease", "OBSERVATION", 118, 134]]], ["In the past, saliva was proven to be an ideal role for the isolation of proteins, peptides, and sheds of viruses via many molecular assays [10] .", [["saliva", "ORGANISM_SUBSTANCE", 13, 19], ["the isolation of proteins", "TREATMENT", 55, 80], ["peptides", "PROBLEM", 82, 90], ["viruses", "PROBLEM", 105, 112]]], ["The composition of saliva is very informative for analysis or to compare the physiology or pathology of the human body.", [["body", "ANATOMY", 114, 118], ["saliva", "ORGANISM_SUBSTANCE", 19, 25], ["human", "ORGANISM", 108, 113], ["body", "ORGANISM_SUBDIVISION", 114, 118], ["human", "SPECIES", 108, 113], ["human", "SPECIES", 108, 113], ["analysis", "TEST", 50, 58], ["the physiology", "TEST", 73, 87], ["human body", "ANATOMY", 108, 118]]], ["Currently, salivary biomarkers are helping in the detection of oral cancer, dental caries, periodontal diseases, diabetes, breast cancer, and lung cancer [9, 10] .", [["salivary", "ANATOMY", 11, 19], ["oral cancer", "ANATOMY", 63, 74], ["dental", "ANATOMY", 76, 82], ["periodontal", "ANATOMY", 91, 102], ["breast cancer", "ANATOMY", 123, 136], ["lung cancer", "ANATOMY", 142, 153], ["oral cancer", "DISEASE", 63, 74], ["dental caries", "DISEASE", 76, 89], ["periodontal diseases", "DISEASE", 91, 111], ["diabetes", "DISEASE", 113, 121], ["breast cancer", "DISEASE", 123, 136], ["lung cancer", "DISEASE", 142, 153], ["salivary", "ORGAN", 11, 19], ["oral cancer", "CANCER", 63, 74], ["breast cancer", "CANCER", 123, 136], ["lung cancer", "CANCER", 142, 153], ["salivary biomarkers", "TEST", 11, 30], ["oral cancer", "PROBLEM", 63, 74], ["dental caries", "PROBLEM", 76, 89], ["periodontal diseases", "PROBLEM", 91, 111], ["diabetes", "PROBLEM", 113, 121], ["breast cancer", "PROBLEM", 123, 136], ["lung cancer", "PROBLEM", 142, 153], ["oral", "ANATOMY", 63, 67], ["cancer", "OBSERVATION", 68, 74], ["periodontal", "ANATOMY", 91, 102], ["diseases", "OBSERVATION", 103, 111], ["diabetes", "OBSERVATION", 113, 121], ["breast", "ANATOMY", 123, 129], ["cancer", "OBSERVATION", 130, 136], ["lung", "ANATOMY", 142, 146], ["cancer", "OBSERVATION", 147, 153]]], ["The oral cavity is kept wet by salivary flow, and the normal physiological activities of the oral cavity are maintained by a saliva washout mechanism [9] .", [["oral cavity", "ANATOMY", 4, 15], ["salivary", "ANATOMY", 31, 39], ["oral cavity", "ANATOMY", 93, 104], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 4, 15], ["salivary", "ORGAN", 31, 39], ["oral cavity", "ORGANISM_SUBDIVISION", 93, 104], ["saliva", "ORGANISM_SUBSTANCE", 125, 131], ["a saliva washout mechanism", "TREATMENT", 123, 149], ["oral cavity", "ANATOMY", 4, 15], ["wet", "OBSERVATION", 24, 27], ["salivary flow", "OBSERVATION", 31, 44], ["normal", "OBSERVATION", 54, 60], ["oral cavity", "ANATOMY", 93, 104]]], ["A study revealed a large amount of RNA isolation from the saliva of a severe acute respiratory syndrome (SARS)-associated coronavirus patient in National Taiwan University Hospital [11] .", [["acute respiratory syndrome", "DISEASE", 77, 103], ["SARS", "DISEASE", 105, 109], ["coronavirus", "DISEASE", 122, 133], ["saliva", "ORGANISM_SUBSTANCE", 58, 64], ["coronavirus", "ORGANISM", 122, 133], ["patient", "ORGANISM", 134, 141], ["coronavirus", "SPECIES", 122, 133], ["patient", "SPECIES", 134, 141], ["A study", "TEST", 0, 7], ["RNA isolation", "PROBLEM", 35, 48], ["a severe acute respiratory syndrome", "PROBLEM", 68, 103], ["large", "OBSERVATION_MODIFIER", 19, 24], ["amount", "OBSERVATION_MODIFIER", 25, 31], ["RNA isolation", "OBSERVATION", 35, 48], ["severe", "OBSERVATION_MODIFIER", 70, 76], ["acute", "OBSERVATION_MODIFIER", 77, 82], ["respiratory syndrome", "OBSERVATION", 83, 103]]], ["In this study, quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) assay was used to investigate the load of SARS-CoV in the saliva samples.", [["saliva samples", "ANATOMY", 153, 167], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 137, 145], ["saliva samples", "ORGANISM_SUBSTANCE", 153, 167], ["SARS-CoV", "SPECIES", 137, 145], ["this study", "TEST", 3, 13], ["polymerase chain reaction", "PROBLEM", 60, 85], ["RT-PCR) assay", "TEST", 87, 100], ["SARS", "PROBLEM", 137, 141], ["CoV in the saliva samples", "TEST", 142, 167]]], ["Samples of saliva from 17 patients were confirmed to have lymphopenia, elevated levels of creatine kinase, and thrombocytopenia.", [["Samples", "ANATOMY", 0, 7], ["lymphopenia", "DISEASE", 58, 69], ["creatine", "CHEMICAL", 90, 98], ["thrombocytopenia", "DISEASE", 111, 127], ["creatine", "CHEMICAL", 90, 98], ["saliva", "ORGANISM_SUBSTANCE", 11, 17], ["patients", "ORGANISM", 26, 34], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 90, 105], ["creatine kinase", "PROTEIN", 90, 105], ["patients", "SPECIES", 26, 34], ["Samples of saliva", "TEST", 0, 17], ["lymphopenia", "PROBLEM", 58, 69], ["elevated levels of creatine kinase", "PROBLEM", 71, 105], ["thrombocytopenia", "PROBLEM", 111, 127], ["lymphopenia", "OBSERVATION", 58, 69], ["thrombocytopenia", "OBSERVATION", 111, 127]]], ["On 9 January 2020, WHO published guidelines for the detection of 2019-nCoV using respiratory materials (nasopharyngeal and oropharyngeal swab in ambulatory patients and sputum (if produced) and endotracheal aspirate or bronchoalveolar lavage in patients with more severe respiratory disease) and serum for serological testing (https://www.who.int/publications-detail/laboratory-testing-for-2019novel-coronavirus-in-suspected-human-cases-20200117 accessed on 28 February 2020).", [["nasopharyngeal", "ANATOMY", 104, 118], ["oropharyngeal swab", "ANATOMY", 123, 141], ["sputum", "ANATOMY", 169, 175], ["endotracheal aspirate", "ANATOMY", 194, 215], ["bronchoalveolar lavage", "ANATOMY", 219, 241], ["respiratory", "ANATOMY", 271, 282], ["serum", "ANATOMY", 296, 301], ["respiratory disease", "DISEASE", 271, 290], ["nasopharyngeal", "ORGANISM_SUBDIVISION", 104, 118], ["oropharyngeal swab", "ORGAN", 123, 141], ["patients", "ORGANISM", 156, 164], ["endotracheal aspirate", "MULTI-TISSUE_STRUCTURE", 194, 215], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 219, 241], ["patients", "ORGANISM", 245, 253], ["serum", "ORGANISM_SUBSTANCE", 296, 301], ["patients", "SPECIES", 156, 164], ["patients", "SPECIES", 245, 253], ["the detection", "TEST", 48, 61], ["respiratory materials", "TREATMENT", 81, 102], ["nasopharyngeal and oropharyngeal swab", "TEST", 104, 141], ["sputum", "TEST", 169, 175], ["endotracheal aspirate", "TEST", 194, 215], ["bronchoalveolar lavage", "TEST", 219, 241], ["more severe respiratory disease", "PROBLEM", 259, 290], ["serological testing", "TEST", 306, 325], ["nasopharyngeal", "ANATOMY", 104, 118], ["oropharyngeal", "ANATOMY", 123, 136], ["endotracheal", "ANATOMY", 194, 206], ["bronchoalveolar lavage", "OBSERVATION", 219, 241], ["respiratory disease", "OBSERVATION", 271, 290]]], ["Testing at these sites is painful, uncomfortable, and invasive for the patients, but there is strong evidence for its use in detecting the virus's presence.", [["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["painful", "PROBLEM", 26, 33], ["uncomfortable", "PROBLEM", 35, 48], ["the virus's presence", "PROBLEM", 135, 155], ["painful", "OBSERVATION", 26, 33]]], ["A recent paper reported only one case as part of a diagnostic evaluation of sputum from a 2019-nCoV patient, and it was a lower respiratory tract sample [12] .", [["sputum", "ANATOMY", 76, 82], ["lower respiratory tract sample", "ANATOMY", 122, 152], ["sputum", "ORGANISM_SUBSTANCE", 76, 82], ["patient", "ORGANISM", 100, 107], ["patient", "SPECIES", 100, 107], ["a diagnostic evaluation", "TEST", 49, 72], ["sputum", "PROBLEM", 76, 82], ["a lower respiratory tract sample", "PROBLEM", 120, 152], ["respiratory tract", "ANATOMY", 128, 145]]], ["Nasopharyngeal and oropharyngeal swabs are not suitable for monitoring the viral loads compared with saliva samples [11] .IntroductionOn 12 February 2020, a breakthrough was reported regarding the accuracy of a human saliva sample from eleven COVID-19 patients in a Hong Kong hospital [13] .", [["Nasopharyngeal", "ANATOMY", 0, 14], ["oropharyngeal swabs", "ANATOMY", 19, 38], ["Nasopharyngeal", "CANCER", 0, 14], ["oropharyngeal swabs", "PATHOLOGICAL_FORMATION", 19, 38], ["saliva", "ORGANISM_SUBSTANCE", 101, 107], ["human", "ORGANISM", 211, 216], ["saliva", "ORGANISM_SUBSTANCE", 217, 223], ["patients", "ORGANISM", 252, 260], ["human", "SPECIES", 211, 216], ["patients", "SPECIES", 252, 260], ["human", "SPECIES", 211, 216], ["Nasopharyngeal and oropharyngeal swabs", "PROBLEM", 0, 38], ["monitoring the viral loads", "TEST", 60, 86], ["saliva samples", "TEST", 101, 115], ["oropharyngeal", "ANATOMY", 19, 32]]], ["In this study, consistent detection of coronavirus was reported in the saliva of patients admitted from the first day of hospitalization.", [["coronavirus", "ORGANISM", 39, 50], ["saliva", "ORGANISM_SUBSTANCE", 71, 77], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["coronavirus", "SPECIES", 39, 50], ["this study", "TEST", 3, 13], ["coronavirus", "PROBLEM", 39, 50], ["coronavirus", "OBSERVATION", 39, 50]]], ["The sampling of saliva in this study was done by instructing the patient to cough out saliva from the throat into a sterile container, and this was transported to the laboratory for further analysis.", [["throat", "ANATOMY", 102, 108], ["cough", "DISEASE", 76, 81], ["saliva", "ORGANISM_SUBSTANCE", 16, 22], ["patient", "ORGANISM", 65, 72], ["saliva", "ORGANISM_SUBSTANCE", 86, 92], ["throat", "ORGANISM_SUBDIVISION", 102, 108], ["patient", "SPECIES", 65, 72], ["The sampling of saliva in this study", "TEST", 0, 36], ["a sterile container", "TREATMENT", 114, 133], ["further analysis", "TEST", 182, 198], ["throat", "ANATOMY", 102, 108]]], ["This study demonstrated the advantage of saliva sampling comfortability in an epidemic situation such as COVID-2019 [13] .", [["saliva", "ORGANISM_SUBSTANCE", 41, 47], ["This study", "TEST", 0, 10], ["saliva sampling comfortability", "PROBLEM", 41, 71]]], ["Further exploring the use of saliva or oral fluid will bring new treatment strategies in the prevention and early detection of COVID-19 [14] .", [["oral", "ANATOMY", 39, 43], ["COVID-19", "CHEMICAL", 127, 135], ["saliva", "ORGANISM_SUBSTANCE", 29, 35], ["oral", "ORGANISM_SUBDIVISION", 39, 43], ["saliva", "TREATMENT", 29, 35], ["oral fluid", "TREATMENT", 39, 49], ["new treatment strategies", "TREATMENT", 61, 85], ["COVID", "TEST", 127, 132]]], ["By using saliva as a form of liquid biopsy, healthcare providers, doctors, nurses, and paramedic staff will be safe from the transmission of disease.", [["saliva", "ORGANISM_SUBSTANCE", 9, 15], ["disease", "PROBLEM", 141, 148], ["disease", "OBSERVATION", 141, 148]]], ["This method of sampling is advantageous compared with the use of nasopharyngeal aspirates, oropharyngeal swabs, and nasopharyngeal swabs.", [["nasopharyngeal aspirates", "ANATOMY", 65, 89], ["oropharyngeal swabs", "ANATOMY", 91, 110], ["nasopharyngeal swabs", "ANATOMY", 116, 136], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 65, 89], ["oropharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 91, 110], ["nasopharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 116, 136], ["nasopharyngeal aspirates", "TEST", 65, 89], ["oropharyngeal swabs", "TEST", 91, 110], ["nasopharyngeal swabs", "TEST", 116, 136], ["nasopharyngeal", "ANATOMY", 65, 79], ["aspirates", "OBSERVATION", 80, 89], ["nasopharyngeal", "ANATOMY", 116, 130]]], ["Previously, it has been reported that the SARS-CoV RNA can be detected from saliva and throat wash [11] .", [["throat", "ANATOMY", 87, 93], ["SARS", "DISEASE", 42, 46], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 42, 50], ["saliva", "ORGANISM_SUBSTANCE", 76, 82], ["throat", "ORGANISM_SUBDIVISION", 87, 93], ["SARS-CoV RNA", "RNA", 42, 54], ["SARS-CoV", "SPECIES", 42, 50], ["the SARS-CoV RNA", "PROBLEM", 38, 54], ["throat", "ANATOMY", 87, 93]]], ["There are many saliva collection devices available in the market for safe and sterile collection without compromising the quality and quantity [15] .", [["saliva", "ORGANISM_SUBSTANCE", 15, 21], ["many saliva collection devices", "TREATMENT", 10, 40], ["safe and sterile collection", "TREATMENT", 69, 96], ["many", "OBSERVATION_MODIFIER", 10, 14], ["saliva", "OBSERVATION_MODIFIER", 15, 21], ["collection devices", "OBSERVATION", 22, 40]]], ["Figure 2 shows commercially available saliva sampling devices and their company names, which can be accessed by all researchers, healthcare providers, doctors, microbiologists, and virologists for the handling of samples.", [["samples", "ANATOMY", 213, 220], ["saliva", "ORGANISM_SUBSTANCE", 38, 44], ["samples", "CANCER", 213, 220], ["saliva sampling devices", "TREATMENT", 38, 61]]], ["Further investigation on salivary biomarkers related to COVID-2019 will open a corridor for optimizing cost-effective point-of-care (POC) technology [16, 17] .Conclusions and Future DirectionFurther investigation should investigate the diagnostic capability of human saliva for identifying COVID-2019, SARS-COV, MERS, ZIKV, and other viruses in the home, city, airport immigration counter or check-in, hospitals, and busy clinics in a few seconds with the cost-effective point-of-care (POC) technology.", [["salivary", "ANATOMY", 25, 33], ["SARS", "DISEASE", 302, 306], ["salivary", "ORGAN", 25, 33], ["human", "ORGANISM", 261, 266], ["saliva", "ORGANISM_SUBSTANCE", 267, 273], ["human", "SPECIES", 261, 266], ["human", "SPECIES", 261, 266], ["ZIKV", "SPECIES", 318, 322], ["Further investigation", "TEST", 0, 21], ["salivary biomarkers", "TEST", 25, 44], ["Future DirectionFurther investigation", "TEST", 175, 212], ["COVID", "TEST", 290, 295], ["ZIKV", "PROBLEM", 318, 322]]], ["Saliva collection is quite comfortable for patients as well as being easy, cheap, and non-invasive with minimal equipment required.", [["Saliva", "ORGANISM_SUBSTANCE", 0, 6], ["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["Saliva collection", "PROBLEM", 0, 17], ["minimal equipment", "TREATMENT", 104, 121]]], ["This write-up will help epidemiologists, virologists, and clinicians to understand the importance of saliva in diagnostic testing as well as the transmission of the disease.", [["saliva", "ORGANISM_SUBSTANCE", 101, 107], ["diagnostic testing", "TEST", 111, 129], ["the disease", "PROBLEM", 161, 172], ["disease", "OBSERVATION", 165, 172]]]], "164f04163f53a4fb15d74a03b6ab473b50c30989": [["ORIGIN OF M1/INHIBIT AND M2/HEAL MACROPHAGES AND THE SCOPE OF THE TOPICAs an introduction to M1 and M2 macrophages, a chronology of results (and publications) that led to their discovery is summarized below:ORIGIN OF M1/INHIBIT AND M2/HEAL MACROPHAGES AND THE SCOPE OF THE TOPIC\u2022 Macrophages have the unique ability to produce a growthinhibiting molecule (NO) or a growth-promoting molecule (ornithine), through the enzymatic conversion of l-arginine in different ways (6) (7) (8) . \u2022 Macrophages in normal tissues, healing wounds, or in growing tumors metabolize arginine primarily to ornithine via arginase (later to be named M2-type).", [["M1", "ANATOMY", 93, 95], ["M2 macrophages", "ANATOMY", 100, 114], ["Macrophages", "ANATOMY", 280, 291], ["Macrophages", "ANATOMY", 485, 496], ["tissues", "ANATOMY", 507, 514], ["wounds", "ANATOMY", 524, 530], ["tumors", "ANATOMY", 546, 552], ["NO", "CHEMICAL", 356, 358], ["ornithine", "CHEMICAL", 392, 401], ["l-arginine", "CHEMICAL", 440, 450], ["tumors", "DISEASE", 546, 552], ["arginine", "CHEMICAL", 564, 572], ["ornithine", "CHEMICAL", 586, 595], ["NO", "CHEMICAL", 356, 358], ["ornithine", "CHEMICAL", 392, 401], ["l-arginine", "CHEMICAL", 440, 450], ["arginine", "CHEMICAL", 564, 572], ["ornithine", "CHEMICAL", 586, 595], ["M1", "CELL", 93, 95], ["M2 macrophages", "CELL", 100, 114], ["Macrophages", "CELL", 280, 291], ["NO", "SIMPLE_CHEMICAL", 356, 358], ["ornithine", "SIMPLE_CHEMICAL", 392, 401], ["l-arginine", "SIMPLE_CHEMICAL", 440, 450], ["Macrophages", "CELL", 485, 496], ["normal tissues", "TISSUE", 500, 514], ["wounds", "PATHOLOGICAL_FORMATION", 524, 530], ["tumors", "CANCER", 546, 552], ["arginine", "AMINO_ACID", 564, 572], ["ornithine", "SIMPLE_CHEMICAL", 586, 595], ["arginase", "GENE_OR_GENE_PRODUCT", 600, 608], ["M1 and M2 macrophages", "CELL_LINE", 93, 114], ["Macrophages", "CELL_TYPE", 280, 291], ["growthinhibiting molecule", "PROTEIN", 329, 354], ["growth-promoting molecule", "PROTEIN", 365, 390], ["Macrophages", "CELL_TYPE", 485, 496], ["arginase", "PROTEIN", 600, 608], ["M2", "PROTEIN", 628, 630], ["M1/INHIBIT AND M2/HEAL MACROPHAGES", "TEST", 10, 44], ["a growthinhibiting molecule", "PROBLEM", 327, 354], ["the enzymatic conversion of l-arginine", "TREATMENT", 412, 450], ["healing wounds", "PROBLEM", 516, 530], ["growing tumors metabolize arginine", "PROBLEM", 538, 572], ["ornithine via arginase", "TEST", 586, 608], ["M1", "ANATOMY_MODIFIER", 10, 12], ["M2", "ANATOMY_MODIFIER", 25, 27], ["HEAL", "ANATOMY", 28, 32], ["MACROPHAGES", "OBSERVATION", 33, 44], ["M1", "ANATOMY", 217, 219], ["M2", "ANATOMY_MODIFIER", 232, 234], ["HEAL", "ANATOMY", 235, 239], ["MACROPHAGES", "OBSERVATION", 240, 251], ["normal tissues", "OBSERVATION_MODIFIER", 500, 514], ["healing", "OBSERVATION_MODIFIER", 516, 523], ["wounds", "OBSERVATION", 524, 530], ["growing", "OBSERVATION_MODIFIER", 538, 545], ["tumors", "OBSERVATION", 546, 552]]], ["Macrophages can switch to producing NO via iNOS (to be named M1-type) that is necessary to kill cancer or many pathogens.", [["Macrophages", "ANATOMY", 0, 11], ["cancer", "ANATOMY", 96, 102], ["NO", "CHEMICAL", 36, 38], ["cancer", "DISEASE", 96, 102], ["NO", "CHEMICAL", 36, 38], ["Macrophages", "CELL", 0, 11], ["NO", "GENE_OR_GENE_PRODUCT", 36, 38], ["iNOS", "GENE_OR_GENE_PRODUCT", 43, 47], ["cancer", "CANCER", 96, 102], ["Macrophages", "CELL_TYPE", 0, 11], ["iNOS", "PROTEIN", 43, 47], ["M1", "PROTEIN", 61, 63], ["Macrophages", "TREATMENT", 0, 11], ["kill cancer", "PROBLEM", 91, 102], ["many pathogens", "PROBLEM", 106, 120]]], ["Arginine is the source of both ornithine and NO (9) (10) (11) (12) . \u2022 Macrophages were specifically renamed M1 and M2 to highlight that innate immunity controls adaptive immunity.", [["Macrophages", "ANATOMY", 71, 82], ["Arginine", "CHEMICAL", 0, 8], ["ornithine", "CHEMICAL", 31, 40], ["NO", "CHEMICAL", 45, 47], ["Arginine", "CHEMICAL", 0, 8], ["ornithine", "CHEMICAL", 31, 40], ["NO (9) (10) (11)", "CHEMICAL", 45, 61], ["Arginine", "AMINO_ACID", 0, 8], ["ornithine", "SIMPLE_CHEMICAL", 31, 40], ["NO (9) (10) (11)", "SIMPLE_CHEMICAL", 45, 61], ["Macrophages", "CELL", 71, 82], ["M1", "CELL", 109, 111], ["M2", "GENE_OR_GENE_PRODUCT", 116, 118], ["Macrophages", "CELL_TYPE", 71, 82], ["M1", "PROTEIN", 109, 111], ["M2", "PROTEIN", 116, 118], ["Arginine", "TREATMENT", 0, 8], ["innate immunity controls adaptive immunity", "TREATMENT", 137, 179]]], ["M1 (NO) or M2 (ornithine)-type macrophage responses are T cell independent and they stimulate Th1-type and CTL responses, or Th2-type responses, respectively (1, (3) (4) (5) .", [["macrophage", "ANATOMY", 31, 41], ["T cell", "ANATOMY", 56, 62], ["NO", "CHEMICAL", 4, 6], ["ornithine", "CHEMICAL", 15, 24], ["NO", "CHEMICAL", 4, 6], ["ornithine", "CHEMICAL", 15, 24], ["M1", "GENE_OR_GENE_PRODUCT", 0, 2], ["NO", "GENE_OR_GENE_PRODUCT", 4, 6], ["M2", "GENE_OR_GENE_PRODUCT", 11, 13], ["ornithine", "SIMPLE_CHEMICAL", 15, 24], ["macrophage", "CELL", 31, 41], ["T cell", "CELL", 56, 62], ["CTL", "GENE_OR_GENE_PRODUCT", 107, 110], ["M2 (ornithine)", "TEST", 11, 25], ["CTL responses", "TEST", 107, 120]]], ["Thus, M1/M2 represents a sea change in our understanding of how immune responses occur.ORIGIN OF M1/INHIBIT AND M2/HEAL MACROPHAGES AND THE SCOPE OF THE TOPICThese studies have stimulated thousands of publications that have enhanced our knowledge of the importance of M1/inhibit and M2/heal functions, and other cytokines and factors that accompany these responses (1) .", [["M1/M2", "GENE_OR_GENE_PRODUCT", 6, 11], ["M1", "GENE_OR_GENE_PRODUCT", 268, 270], ["M2", "GENE_OR_GENE_PRODUCT", 283, 285], ["M1", "PROTEIN", 6, 8], ["M2", "PROTEIN", 9, 11], ["M1", "PROTEIN", 268, 270], ["M2", "PROTEIN", 283, 285], ["cytokines", "PROTEIN", 312, 321], ["a sea change", "PROBLEM", 23, 35], ["THE TOPICThese studies", "TEST", 149, 171], ["M1/inhibit", "TREATMENT", 268, 278], ["M1", "ANATOMY_MODIFIER", 6, 8], ["M2", "ANATOMY", 9, 11], ["M1", "ANATOMY_MODIFIER", 97, 99], ["M2", "ANATOMY_MODIFIER", 112, 114], ["HEAL", "ANATOMY", 115, 119], ["MACROPHAGES", "OBSERVATION", 120, 131], ["heal", "ANATOMY", 286, 290]]], ["Here, we have assembled papers by contributors that focus on basic aspects of macrophage biology, their roles in various diseases, and how they are regulated.", [["macrophage", "ANATOMY", 78, 88], ["macrophage", "CELL", 78, 88], ["various diseases", "PROBLEM", 113, 129]]], ["Macrophages evolved long before other immune cell types and are the foundation of all animal immunity (13) .", [["Macrophages", "ANATOMY", 0, 11], ["immune cell", "ANATOMY", 38, 49], ["Macrophages", "CELL", 0, 11], ["immune cell", "CELL", 38, 49], ["Macrophages", "CELL_TYPE", 0, 11], ["immune cell types", "CELL_TYPE", 38, 55], ["Macrophages", "PROBLEM", 0, 11], ["immune cell types", "OBSERVATION", 38, 55]]], ["Therefore, we begin with a series of \"introductory\" articles where readers can find basic information about macrophage biology and functions.", [["macrophage", "ANATOMY", 108, 118], ["macrophage", "CELL", 108, 118]]], ["These articles also trace the evolutionary origins of macrophages to aid in understanding their central role in immune systems.", [["macrophages", "ANATOMY", 54, 65], ["macrophages", "CELL", 54, 65], ["macrophages", "CELL_TYPE", 54, 65], ["trace", "OBSERVATION_MODIFIER", 20, 25], ["evolutionary", "OBSERVATION_MODIFIER", 30, 42], ["origins", "OBSERVATION_MODIFIER", 43, 50], ["macrophages", "OBSERVATION", 54, 65], ["immune systems", "OBSERVATION", 112, 126]]], ["Next, articles detail the roles of macrophages in protection against (or causation of) various diseases including wounds, cancer, infections, atherosclerosis, obesity, hypertension, and other conditions.", [["macrophages", "ANATOMY", 35, 46], ["wounds", "ANATOMY", 114, 120], ["cancer", "ANATOMY", 122, 128], ["wounds", "DISEASE", 114, 120], ["cancer", "DISEASE", 122, 128], ["infections", "DISEASE", 130, 140], ["atherosclerosis", "DISEASE", 142, 157], ["obesity", "DISEASE", 159, 166], ["hypertension", "DISEASE", 168, 180], ["macrophages", "CELL", 35, 46], ["wounds", "PATHOLOGICAL_FORMATION", 114, 120], ["cancer", "CANCER", 122, 128], ["macrophages", "CELL_TYPE", 35, 46], ["various diseases", "PROBLEM", 87, 103], ["wounds", "PROBLEM", 114, 120], ["cancer", "PROBLEM", 122, 128], ["infections", "PROBLEM", 130, 140], ["atherosclerosis", "PROBLEM", 142, 157], ["obesity", "PROBLEM", 159, 166], ["hypertension", "PROBLEM", 168, 180], ["other conditions", "PROBLEM", 186, 202], ["macrophages", "OBSERVATION", 35, 46], ["wounds", "OBSERVATION", 114, 120], ["cancer", "OBSERVATION", 122, 128], ["infections", "OBSERVATION", 130, 140], ["atherosclerosis", "OBSERVATION", 142, 157], ["obesity", "OBSERVATION", 159, 166], ["hypertension", "OBSERVATION", 168, 180]]], ["Finally, we look to the future with several articles detailing how macrophage M1/inhibit and M2/heal functions might be modulated for therapeutic benefits.", [["macrophage", "ANATOMY", 67, 77], ["macrophage M1", "CELL", 67, 80], ["M2", "GENE_OR_GENE_PRODUCT", 93, 95], ["M2/heal functions", "TREATMENT", 93, 110], ["heal", "ANATOMY", 96, 100]]], ["We hope that the articles enhance your knowledge of this singularly multitalented and remarkable leukocyte.INTRODUCTION TO MACROPHAGE BIOLOGY AND FUNCTIONSTo better appreciate macrophages, it is useful to known about their unique biochemistry, functions, and central role in all immune systems.", [["leukocyte", "ANATOMY", 97, 106], ["macrophages", "ANATOMY", 176, 187], ["leukocyte", "CELL", 97, 106], ["macrophages", "CELL", 176, 187], ["macrophages", "CELL_TYPE", 176, 187], ["leukocyte", "OBSERVATION", 97, 106], ["central", "ANATOMY_MODIFIER", 259, 266]]], ["Drs. Rath and Munder provide a comprehensive biochemical introduction to macrophage arginine metabolism, and how these cells can take \"the fork in the road\" to make either an arginine-based M1/inhibit or M2/heal response (14) .", [["macrophage", "ANATOMY", 73, 83], ["cells", "ANATOMY", 119, 124], ["arginine", "CHEMICAL", 84, 92], ["arginine", "CHEMICAL", 175, 183], ["arginine", "CHEMICAL", 84, 92], ["arginine", "CHEMICAL", 175, 183], ["macrophage", "CELL", 73, 83], ["arginine", "AMINO_ACID", 84, 92], ["cells", "CELL", 119, 124], ["arginine", "SIMPLE_CHEMICAL", 175, 183], ["M2", "GENE_OR_GENE_PRODUCT", 204, 206], ["M2", "PROTEIN", 204, 206]]], ["Because \"Nothing makes sense except in the light of evolution\" (Theodosius Dobzhansky), Dr. Buchmann traces the evolutionary origins of both innate and adaptive immunity, and shows when new macrophage (and other) immune functions evolved, culminating in humans (15) .", [["macrophage", "ANATOMY", 190, 200], ["macrophage", "CELL", 190, 200], ["humans", "ORGANISM", 254, 260], ["humans", "SPECIES", 254, 260], ["humans", "SPECIES", 254, 260], ["new macrophage (and other) immune functions", "PROBLEM", 186, 229]]], ["Dr. Dzik importantly reveals that the macrophage M2/heal function (arginases) preceded the M1/inhibit function in animal evolution (16) .", [["macrophage", "ANATOMY", 38, 48], ["macrophage M2", "GENE_OR_GENE_PRODUCT", 38, 51], ["arginases", "GENE_OR_GENE_PRODUCT", 67, 76], ["macrophage M2", "PROTEIN", 38, 51], ["arginases", "PROTEIN", 67, 76], ["M1", "PROTEIN", 91, 93], ["macrophage M2", "OBSERVATION", 38, 51], ["heal", "ANATOMY", 52, 56]]], ["Drs. Mills, Thomas, Lenz, and Munder describe the basic \"SHIP\" functions of macrophages [sample, heal, inhibit, and present (antigen)], and why it is important to study these functions to understand macrophage biology in vivo (17) .", [["macrophages", "ANATOMY", 76, 87], ["sample", "ANATOMY", 89, 95], ["macrophage", "ANATOMY", 199, 209], ["SHIP", "GENE_OR_GENE_PRODUCT", 57, 61], ["macrophages", "CELL", 76, 87], ["macrophage", "CELL", 199, 209], ["SHIP", "PROTEIN", 57, 61], ["macrophages", "CELL_TYPE", 76, 87]]], ["In a similar vein, Drs. Italiani and Boraschi elucidate why examining macrophages by functions versus \"phenotypes\" can be critical for understanding how they affect health (18) .", [["vein", "ANATOMY", 13, 17], ["macrophages", "ANATOMY", 70, 81], ["vein", "MULTI-TISSUE_STRUCTURE", 13, 17], ["macrophages", "CELL", 70, 81], ["macrophages", "CELL_TYPE", 70, 81], ["similar vein", "ANATOMY", 5, 17]]], ["Dr. Harris' piece colorfully describes the two-edged sword nature of macrophages as \"The Good the Bad and the Ugly\" phases of inflammation.", [["macrophages", "ANATOMY", 69, 80], ["inflammation", "DISEASE", 126, 138], ["macrophages", "CELL", 69, 80], ["macrophages", "CELL_TYPE", 69, 80], ["inflammation", "PROBLEM", 126, 138], ["macrophages", "OBSERVATION", 69, 80], ["inflammation", "OBSERVATION", 126, 138]]], ["He also illuminates that M1/inhibit or M2/heal-type macrophage activities vary enormously in different microenvironments of lungs or other sites of inflammation (19) .", [["macrophage", "ANATOMY", 52, 62], ["lungs", "ANATOMY", 124, 129], ["sites", "ANATOMY", 139, 144], ["inflammation", "DISEASE", 148, 160], ["M2", "GENE_OR_GENE_PRODUCT", 39, 41], ["macrophage", "CELL", 52, 62], ["lungs", "ORGAN", 124, 129], ["M1", "PROTEIN", 25, 27], ["M2/heal-type macrophage activities", "PROBLEM", 39, 73], ["inflammation", "PROBLEM", 148, 160], ["M1", "OBSERVATION_MODIFIER", 25, 27], ["heal", "ANATOMY", 42, 46], ["type macrophage", "OBSERVATION_MODIFIER", 47, 62], ["lungs", "ANATOMY", 124, 129], ["inflammation", "OBSERVATION", 148, 160]]], ["In turn, important local functions can be lost if one grinds up whole organs as is common.", [["organs", "ANATOMY", 70, 76], ["organs", "ORGAN", 70, 76]]], ["Drs. Thomas and Mattila provide an in-depth look at macrophage arginine metabolism in different vertebrate species (20) .", [["macrophage", "ANATOMY", 52, 62], ["arginine", "CHEMICAL", 63, 71], ["arginine", "CHEMICAL", 63, 71], ["macrophage", "CELL", 52, 62], ["arginine", "SIMPLE_CHEMICAL", 63, 71]]], ["Importantly, they show that, contrary to some reports (21, 22) , macrophages in mice and humans are quite similar, as one might expect from analyzing evolution (e.g., Drs. Buchmann and Dzik, mentioned earlier).MACROPHAGE INFLUENCES IN DIFFERENT DISEASES WOUNDS AND CANCER: STARK EXAMPLES OF THE TWO-EDGED SWORD NATURE OF MACROPHAGE RESPONSESWound healing requires M2/heal-type responses (9) .", [["macrophages", "ANATOMY", 65, 76], ["macrophages", "CELL", 65, 76], ["mice", "ORGANISM", 80, 84], ["humans", "ORGANISM", 89, 95], ["macrophages", "CELL_TYPE", 65, 76], ["M2", "PROTEIN", 364, 366], ["mice", "SPECIES", 80, 84], ["humans", "SPECIES", 89, 95], ["mice", "SPECIES", 80, 84], ["humans", "SPECIES", 89, 95], ["DIFFERENT DISEASES WOUNDS", "PROBLEM", 235, 260], ["DIFFERENT", "OBSERVATION_MODIFIER", 235, 244], ["DISEASES", "OBSERVATION", 245, 253], ["CANCER", "OBSERVATION", 265, 271], ["MACROPHAGE", "OBSERVATION_MODIFIER", 321, 331]]], ["If M1/inhibit responses occur (e.g., infected wounds) wound healing is delayed until the infection is cleared (5) .", [["wounds", "ANATOMY", 46, 52], ["wound", "ANATOMY", 54, 59], ["infection", "DISEASE", 89, 98], ["wounds", "PATHOLOGICAL_FORMATION", 46, 52], ["wound", "PATHOLOGICAL_FORMATION", 54, 59], ["M1", "PROTEIN", 3, 5], ["M1/inhibit responses", "PROBLEM", 3, 23], ["infected wounds", "PROBLEM", 37, 52], ["wound healing", "PROBLEM", 54, 67], ["the infection", "PROBLEM", 85, 98], ["infected", "OBSERVATION_MODIFIER", 37, 45], ["wounds", "OBSERVATION", 46, 52], ["healing", "OBSERVATION_MODIFIER", 60, 67], ["infection", "OBSERVATION", 89, 98]]], ["M2/heal-type macrophages also dominate inside tumors in experimental animals and humans (5, 11, 23) .", [["heal-type macrophages", "ANATOMY", 3, 24], ["tumors", "ANATOMY", 46, 52], ["tumors", "DISEASE", 46, 52], ["M2", "GENE_OR_GENE_PRODUCT", 0, 2], ["macrophages", "CELL", 13, 24], ["tumors", "CANCER", 46, 52], ["humans", "ORGANISM", 81, 87], ["M2/heal-type macrophages", "CELL_LINE", 0, 24], ["humans", "SPECIES", 81, 87], ["humans", "SPECIES", 81, 87], ["M2/heal-type macrophages", "PROBLEM", 0, 24], ["heal", "ANATOMY", 3, 7], ["type macrophages", "OBSERVATION", 8, 24], ["tumors", "OBSERVATION", 46, 52], ["experimental animals", "OBSERVATION_MODIFIER", 56, 76]]], ["In marked contrast to their beneficial effect in wounds, M2-type macrophages actively promote tumor growth [reviewed in Ref.", [["wounds", "ANATOMY", 49, 55], ["M2-type macrophages", "ANATOMY", 57, 76], ["tumor", "ANATOMY", 94, 99], ["tumor", "DISEASE", 94, 99], ["wounds", "PATHOLOGICAL_FORMATION", 49, 55], ["M2-type macrophages", "CELL", 57, 76], ["tumor", "CANCER", 94, 99], ["M2-type macrophages", "CELL_TYPE", 57, 76], ["wounds", "PROBLEM", 49, 55], ["M2-type macrophages", "TREATMENT", 57, 76], ["tumor growth", "PROBLEM", 94, 106], ["wounds", "OBSERVATION", 49, 55], ["tumor", "OBSERVATION", 94, 99]]], ["(3) ], in part, by secreting growth factors (11, 24, 25) .MACROPHAGE INFLUENCES IN DIFFERENT DISEASES WOUNDS AND CANCER: STARK EXAMPLES OF THE TWO-EDGED SWORD NATURE OF MACROPHAGE RESPONSESRegarding the relative roles of M1 or M2-type macrophages in wounds or implanted biomaterials, Drs. Brown, Sicari, and Badylak demonstrate that there is 2-3 day dominance of M1-type macrophages (26) .", [["M2-type macrophages", "ANATOMY", 227, 246], ["wounds", "ANATOMY", 250, 256], ["M1-type macrophages", "ANATOMY", 363, 382], ["M1", "CELL", 221, 223], ["M2-type macrophages", "CELL", 227, 246], ["wounds", "PATHOLOGICAL_FORMATION", 250, 256], ["M1-type macrophages", "CELL", 363, 382], ["growth factors", "PROTEIN", 29, 43], ["M1", "PROTEIN", 221, 223], ["M2-type macrophages", "CELL_TYPE", 227, 246], ["M1-type macrophages", "CELL_TYPE", 363, 382], ["DIFFERENT DISEASES WOUNDS", "PROBLEM", 83, 108], ["wounds", "PROBLEM", 250, 256], ["DIFFERENT", "OBSERVATION_MODIFIER", 83, 92], ["DISEASES", "OBSERVATION", 93, 101], ["CANCER", "OBSERVATION", 113, 119], ["MACROPHAGE", "OBSERVATION", 169, 179], ["M1", "ANATOMY", 221, 223], ["wounds", "ANATOMY", 250, 256], ["M1", "ANATOMY", 363, 365], ["type macrophages", "OBSERVATION", 366, 382]]], ["These data support that the first biologic priority of hosts following injuries is to prevent infections (5) .", [["injuries", "DISEASE", 71, 79], ["infections", "DISEASE", 94, 104], ["injuries", "PROBLEM", 71, 79], ["infections", "PROBLEM", 94, 104]]], ["However, if an injury is sterile, the priority switches to M2-type dominant macrophages that are necessary for proper healing (17) .", [["macrophages", "ANATOMY", 76, 87], ["M2", "GENE_OR_GENE_PRODUCT", 59, 61], ["macrophages", "CELL", 76, 87], ["M2-type dominant macrophages", "CELL_LINE", 59, 87], ["an injury", "PROBLEM", 12, 21], ["M2-type dominant macrophages", "TREATMENT", 59, 87], ["injury", "OBSERVATION", 15, 21], ["dominant", "OBSERVATION_MODIFIER", 67, 75], ["macrophages", "OBSERVATION", 76, 87], ["healing", "OBSERVATION_MODIFIER", 118, 125]]], ["Interestingly, they note that biomaterials with larger pore sizes have less scarring/fibrosis.", [["pore", "ANATOMY", 55, 59], ["fibrosis", "DISEASE", 85, 93], ["larger pore sizes", "PROBLEM", 48, 65], ["fibrosis", "PROBLEM", 85, 93], ["biomaterials", "OBSERVATION", 30, 42], ["larger", "OBSERVATION_MODIFIER", 48, 54], ["pore", "OBSERVATION_MODIFIER", 55, 59], ["sizes", "OBSERVATION_MODIFIER", 60, 65], ["less", "OBSERVATION_MODIFIER", 71, 75], ["scarring", "OBSERVATION", 76, 84], ["fibrosis", "OBSERVATION", 85, 93]]], ["Thus, the physical properties of implanted materials seem important in allowing functional regeneration over typical imperfect wound healing found in adult humans (27) .", [["wound", "ANATOMY", 127, 132], ["wound", "PATHOLOGICAL_FORMATION", 127, 132], ["humans", "ORGANISM", 156, 162], ["humans", "SPECIES", 156, 162], ["humans", "SPECIES", 156, 162], ["implanted materials", "TREATMENT", 33, 52], ["functional regeneration", "PROBLEM", 80, 103], ["typical imperfect wound healing", "PROBLEM", 109, 140], ["implanted", "OBSERVATION", 33, 42], ["wound", "OBSERVATION_MODIFIER", 127, 132], ["healing", "OBSERVATION_MODIFIER", 133, 140]]], ["Drs. Beljaars, Schippers, Smit, Martinez, Helming, Poelstra, and Melgert compared M1-and M2-types of macrophages inside chemically damaged livers in mice and cirrhotic livers in humans (28) .", [["macrophages", "ANATOMY", 101, 112], ["livers", "ANATOMY", 139, 145], ["livers", "ANATOMY", 168, 174], ["macrophages", "CELL", 101, 112], ["livers", "ORGAN", 139, 145], ["mice", "ORGANISM", 149, 153], ["livers", "ORGAN", 168, 174], ["humans", "ORGANISM", 178, 184], ["M2", "PROTEIN", 89, 91], ["macrophages", "CELL_TYPE", 101, 112], ["mice", "SPECIES", 149, 153], ["humans", "SPECIES", 178, 184], ["mice", "SPECIES", 149, 153], ["humans", "SPECIES", 178, 184], ["macrophages", "PROBLEM", 101, 112], ["cirrhotic livers in humans", "PROBLEM", 158, 184], ["macrophages", "OBSERVATION", 101, 112], ["livers", "ANATOMY", 139, 145], ["cirrhotic", "OBSERVATION", 158, 167], ["livers", "ANATOMY", 168, 174]]], ["The liver is one of the few organs able to regenerate (though not perfectly) (29) .", [["liver", "ANATOMY", 4, 9], ["organs", "ANATOMY", 28, 34], ["liver", "ORGAN", 4, 9], ["organs", "ORGAN", 28, 34], ["liver", "ANATOMY", 4, 9], ["one", "OBSERVATION_MODIFIER", 13, 16]]], ["So, it was interesting that they found a predominance of M1 macrophages during resolution of damage, which contrasts with M2 macrophages that dominate in wounds elsewhere, and which results in scarring/healing, as described.", [["M1 macrophages", "ANATOMY", 57, 71], ["macrophages", "ANATOMY", 125, 136], ["wounds", "ANATOMY", 154, 160], ["M1 macrophages", "CELL", 57, 71], ["M2 macrophages", "CELL", 122, 136], ["wounds", "PATHOLOGICAL_FORMATION", 154, 160], ["M1 macrophages", "CELL_TYPE", 57, 71], ["M2 macrophages", "CELL_TYPE", 122, 136], ["M1 macrophages", "PROBLEM", 57, 71], ["damage", "PROBLEM", 93, 99], ["M2 macrophages", "PROBLEM", 122, 136], ["wounds", "PROBLEM", 154, 160], ["scarring/healing", "PROBLEM", 193, 209], ["M1 macrophages", "OBSERVATION", 57, 71], ["damage", "OBSERVATION", 93, 99], ["M2 macrophages", "OBSERVATION", 122, 136], ["wounds", "OBSERVATION", 154, 160], ["scarring", "OBSERVATION", 193, 201], ["healing", "OBSERVATION", 202, 209]]], ["Also, interesting was that the authors observed distinct M1 and M2type macrophages in close proximity to each other with little overlap in markers.", [["M2type macrophages", "ANATOMY", 64, 82], ["M1", "CELL", 57, 59], ["M2type macrophages", "CELL", 64, 82], ["M1 and M2type macrophages", "CELL_LINE", 57, 82]]], ["These findings do not support the hypothesis that macrophages only resemble a \"color wheel\" with multiple overlapping characteristics (30) .MACROPHAGE INFLUENCES IN DIFFERENT DISEASES WOUNDS AND CANCER: STARK EXAMPLES OF THE TWO-EDGED SWORD NATURE OF MACROPHAGE RESPONSESIn contrast to the beneficial effects of M2-type macrophages in wounds, these same types of macrophages promote cancer growth and metastases as mentioned [reviewed in Ref.", [["macrophages", "ANATOMY", 50, 61], ["M2-type macrophages", "ANATOMY", 312, 331], ["wounds", "ANATOMY", 335, 341], ["macrophages", "ANATOMY", 363, 374], ["cancer", "ANATOMY", 383, 389], ["metastases", "ANATOMY", 401, 411], ["cancer", "DISEASE", 383, 389], ["metastases", "DISEASE", 401, 411], ["macrophages", "CELL", 50, 61], ["M2-type macrophages", "CELL", 312, 331], ["wounds", "PATHOLOGICAL_FORMATION", 335, 341], ["macrophages", "CELL", 363, 374], ["cancer", "CANCER", 383, 389], ["macrophages", "CELL_TYPE", 50, 61], ["M2-type macrophages", "CELL_TYPE", 312, 331], ["macrophages", "CELL_TYPE", 363, 374], ["DIFFERENT DISEASES WOUNDS", "PROBLEM", 165, 190], ["type macrophages in wounds", "PROBLEM", 315, 341], ["macrophages", "PROBLEM", 363, 374], ["cancer growth", "PROBLEM", 383, 396], ["metastases", "PROBLEM", 401, 411], ["macrophages", "OBSERVATION", 50, 61], ["multiple", "OBSERVATION_MODIFIER", 97, 105], ["overlapping", "OBSERVATION_MODIFIER", 106, 117], ["DIFFERENT", "OBSERVATION_MODIFIER", 165, 174], ["DISEASES", "OBSERVATION", 175, 183], ["CANCER", "OBSERVATION", 195, 201], ["wounds", "OBSERVATION", 335, 341], ["macrophages", "OBSERVATION", 363, 374], ["cancer", "OBSERVATION", 383, 389], ["metastases", "OBSERVATION", 401, 411]]], ["Why is there cancer, and why does the immune system help it grow?MACROPHAGE INFLUENCES IN DIFFERENT DISEASES WOUNDS AND CANCER: STARK EXAMPLES OF THE TWO-EDGED SWORD NATURE OF MACROPHAGE RESPONSESSpecies successfully evolve by acquiring traits that provide survival advantages, and losing undesirable traits.", [["cancer", "ANATOMY", 13, 19], ["immune system", "ANATOMY", 38, 51], ["cancer", "DISEASE", 13, 19], ["cancer", "CANCER", 13, 19], ["cancer", "PROBLEM", 13, 19], ["DIFFERENT DISEASES WOUNDS", "PROBLEM", 90, 115], ["survival advantages", "TREATMENT", 257, 276], ["cancer", "OBSERVATION", 13, 19], ["DIFFERENT", "OBSERVATION_MODIFIER", 90, 99], ["DISEASES", "OBSERVATION", 100, 108], ["CANCER", "OBSERVATION", 120, 126], ["MACROPHAGE", "OBSERVATION", 176, 186]]], ["Environmental and societal influences aside, the way animals (any species) change heritable traits is through producing progeny: breeding.", [["any species) change heritable traits", "PROBLEM", 62, 98]]], ["Cancer in humans occurs mainly after breeding age.", [["Cancer", "ANATOMY", 0, 6], ["Cancer", "DISEASE", 0, 6], ["Cancer", "CANCER", 0, 6], ["humans", "ORGANISM", 10, 16], ["humans", "SPECIES", 10, 16], ["humans", "SPECIES", 10, 16], ["Cancer in humans", "PROBLEM", 0, 16]]], ["So, there has been little evolutionary pressure (or advantage) for humans to acquire traits that prevent cancer, or that could stop it if it appears.", [["cancer", "ANATOMY", 105, 111], ["cancer", "DISEASE", 105, 111], ["humans", "ORGANISM", 67, 73], ["cancer", "CANCER", 105, 111], ["humans", "SPECIES", 67, 73], ["humans", "SPECIES", 67, 73], ["cancer", "PROBLEM", 105, 111], ["little", "OBSERVATION_MODIFIER", 19, 25], ["evolutionary", "OBSERVATION_MODIFIER", 26, 38], ["pressure", "OBSERVATION_MODIFIER", 39, 47], ["cancer", "OBSERVATION", 105, 111]]], ["The same lack of evolutionary pressure applies to atherosclerosis, or many other \"adult\" diseases that mainly occur during postbreeding (to be discussed later).", [["atherosclerosis", "DISEASE", 50, 65], ["atherosclerosis", "PROBLEM", 50, 65], ["many other \"adult\" diseases", "PROBLEM", 70, 97], ["evolutionary pressure", "OBSERVATION", 17, 38], ["atherosclerosis", "OBSERVATION", 50, 65], ["diseases", "OBSERVATION", 89, 97]]], ["Too, mate selection (important in breeding success) is mostly unaffected by knowledge of whether parents or grandparents died of cancer or other late-appearing diseases (3) .MACROPHAGE INFLUENCES IN DIFFERENT DISEASES WOUNDS AND CANCER: STARK EXAMPLES OF THE TWO-EDGED SWORD NATURE OF MACROPHAGE RESPONSESOnce it appears, cancer can be eliminated.", [["cancer", "ANATOMY", 129, 135], ["cancer", "ANATOMY", 322, 328], ["cancer", "DISEASE", 129, 135], ["cancer", "DISEASE", 322, 328], ["cancer", "CANCER", 129, 135], ["cancer", "CANCER", 322, 328], ["cancer", "PROBLEM", 129, 135], ["other late-appearing diseases", "PROBLEM", 139, 168], ["DIFFERENT DISEASES WOUNDS", "PROBLEM", 199, 224], ["cancer", "PROBLEM", 322, 328], ["cancer", "OBSERVATION", 129, 135], ["DIFFERENT", "OBSERVATION_MODIFIER", 199, 208], ["DISEASES", "OBSERVATION", 209, 217], ["CANCER", "OBSERVATION", 229, 235], ["MACROPHAGE RESPONSESOnce", "OBSERVATION", 285, 309], ["cancer", "OBSERVATION", 322, 328]]], ["Modulating macrophage functions.", [["macrophage", "ANATOMY", 11, 21], ["macrophage", "CELL", 11, 21], ["Modulating macrophage functions", "PROBLEM", 0, 31], ["macrophage functions", "OBSERVATION", 11, 31]]], ["It is now known that the majority leukocytes in tumors are macrophages: sometimes >50% of a tumor mass.", [["leukocytes", "ANATOMY", 34, 44], ["tumors", "ANATOMY", 48, 54], ["macrophages", "ANATOMY", 59, 70], ["tumor mass", "ANATOMY", 92, 102], ["tumors", "DISEASE", 48, 54], ["tumor", "DISEASE", 92, 97], ["leukocytes", "CELL", 34, 44], ["tumors", "CANCER", 48, 54], ["macrophages", "CELL", 59, 70], ["tumor", "CANCER", 92, 97], ["leukocytes", "CELL_TYPE", 34, 44], ["macrophages", "CELL_TYPE", 59, 70], ["the majority leukocytes in tumors", "PROBLEM", 21, 54], ["a tumor mass", "PROBLEM", 90, 102], ["majority", "OBSERVATION_MODIFIER", 25, 33], ["leukocytes", "OBSERVATION", 34, 44], ["tumors", "OBSERVATION", 48, 54], ["macrophages", "OBSERVATION", 59, 70], ["tumor", "OBSERVATION_MODIFIER", 92, 97], ["mass", "OBSERVATION", 98, 102]]], ["However, as mentioned, these tumor-associated macrophages (TAM) are primarily M2-type and actively promote tumor growth: Cancer is often referred to as \"a wound that doesn't heal\" (31) .", [["tumor", "ANATOMY", 29, 34], ["macrophages", "ANATOMY", 46, 57], ["TAM", "ANATOMY", 59, 62], ["tumor", "ANATOMY", 107, 112], ["Cancer", "ANATOMY", 121, 127], ["wound", "ANATOMY", 155, 160], ["tumor", "DISEASE", 29, 34], ["TAM", "CHEMICAL", 59, 62], ["tumor", "DISEASE", 107, 112], ["Cancer", "DISEASE", 121, 127], ["tumor", "CANCER", 29, 34], ["macrophages", "CELL", 46, 57], ["TAM", "CELL", 59, 62], ["tumor", "CANCER", 107, 112], ["Cancer", "CANCER", 121, 127], ["wound", "PATHOLOGICAL_FORMATION", 155, 160], ["tumor-associated macrophages", "CELL_TYPE", 29, 57], ["TAM", "CELL_TYPE", 59, 62], ["these tumor-associated macrophages", "PROBLEM", 23, 57], ["Cancer", "PROBLEM", 121, 127], ["a wound", "PROBLEM", 153, 160], ["tumor", "OBSERVATION", 29, 34], ["macrophages", "OBSERVATION", 46, 57], ["tumor", "OBSERVATION", 107, 112], ["growth", "OBSERVATION_MODIFIER", 113, 119], ["Cancer", "OBSERVATION", 121, 127]]], ["But, a wealth of recent evidence indicates that decreasing M2/heal-type and increasing M1/inhibittype macrophages can slow or reverse tumor growth (11, 32) .", [["M1/inhibittype macrophages", "ANATOMY", 87, 113], ["tumor", "ANATOMY", 134, 139], ["tumor", "DISEASE", 134, 139], ["M2", "GENE_OR_GENE_PRODUCT", 59, 61], ["inhibittype macrophages", "CELL", 90, 113], ["tumor", "CANCER", 134, 139], ["M2", "PROTEIN", 59, 61], ["M1/inhibittype macrophages", "CELL_LINE", 87, 113], ["decreasing M2/heal-type", "PROBLEM", 48, 71], ["increasing M1/inhibittype macrophages", "PROBLEM", 76, 113], ["reverse tumor growth", "PROBLEM", 126, 146], ["decreasing", "OBSERVATION_MODIFIER", 48, 58], ["M2", "OBSERVATION_MODIFIER", 59, 61], ["heal", "ANATOMY", 62, 66], ["increasing", "OBSERVATION_MODIFIER", 76, 86], ["M1", "ANATOMY", 87, 89], ["reverse", "OBSERVATION_MODIFIER", 126, 133], ["tumor", "OBSERVATION", 134, 139], ["growth", "OBSERVATION_MODIFIER", 140, 146]]], ["This is an exciting development because conventional immunologic thinking purports that tumors need to be recognized as \"foreign,\" like a pathogen.", [["tumors", "ANATOMY", 88, 94], ["tumors", "DISEASE", 88, 94], ["tumors", "CANCER", 88, 94], ["tumors", "PROBLEM", 88, 94], ["a pathogen", "PROBLEM", 136, 146], ["tumors", "OBSERVATION", 88, 94]]], ["But, most tumors are not \"foreign.\"", [["tumors", "ANATOMY", 10, 16], ["tumors", "DISEASE", 10, 16], ["tumors", "CANCER", 10, 16], ["most tumors", "PROBLEM", 5, 16], ["most", "OBSERVATION_MODIFIER", 5, 9], ["tumors", "OBSERVATION", 10, 16], ["foreign", "OBSERVATION", 26, 33]]], ["So, it falls on the shoulders of innate immunity, not adaptive immunity (T and B cells), to stop cancer.", [["B cells", "ANATOMY", 79, 86], ["cancer", "ANATOMY", 97, 103], ["cancer", "DISEASE", 97, 103], ["shoulders", "ORGANISM_SUBDIVISION", 20, 29], ["T", "CELL", 73, 74], ["B cells", "CELL", 79, 86], ["cancer", "CANCER", 97, 103], ["T and B cells", "CELL_TYPE", 73, 86], ["cancer", "PROBLEM", 97, 103], ["cancer", "OBSERVATION", 97, 103]]], ["Importantly, recent antitumor effects being observed seem primarily (or solely) mediated by macrophages/innate immunity, not T cells (32) .", [["antitumor", "ANATOMY", 20, 29], ["macrophages", "ANATOMY", 92, 103], ["T cells", "ANATOMY", 125, 132], ["antitumor", "CANCER", 20, 29], ["macrophages", "CELL", 92, 103], ["T cells", "CELL", 125, 132], ["macrophages", "CELL_TYPE", 92, 103], ["T cells", "CELL_TYPE", 125, 132], ["antitumor", "OBSERVATION", 20, 29]]], ["Even if a human cancer is recognized as \"foreign,\" it is still critical to switch M2-to M1-like macrophages.", [["cancer", "ANATOMY", 16, 22], ["M1-like macrophages", "ANATOMY", 88, 107], ["cancer", "DISEASE", 16, 22], ["human", "ORGANISM", 10, 15], ["cancer", "CANCER", 16, 22], ["M2", "GENE_OR_GENE_PRODUCT", 82, 84], ["M1-like macrophages", "CELL", 88, 107], ["M2", "PROTEIN", 82, 84], ["M1-like macrophages", "CELL_TYPE", 88, 107], ["human", "SPECIES", 10, 15], ["human", "SPECIES", 10, 15], ["a human cancer", "PROBLEM", 8, 22], ["cancer", "OBSERVATION", 16, 22], ["macrophages", "ANATOMY", 96, 107]]], ["This is so because of the new knowledge, discussed earlier, that M1-type macrophages are necessary to stimulate T cells to make tumoricidal Th1-type cellular killer responses such as CTL and further amplify M1/inhibit macrophages (1, 4) .", [["M1-type macrophages", "ANATOMY", 65, 84], ["T cells", "ANATOMY", 112, 119], ["cellular killer", "ANATOMY", 149, 164], ["CTL", "ANATOMY", 183, 186], ["macrophages", "ANATOMY", 218, 229], ["M1-type macrophages", "CELL", 65, 84], ["T cells", "CELL", 112, 119], ["cellular killer", "CELL", 149, 164], ["CTL", "CELL", 183, 186], ["macrophages", "CELL", 218, 229], ["M1-type macrophages", "CELL_LINE", 65, 84], ["T cells", "CELL_TYPE", 112, 119], ["CTL", "CELL_TYPE", 183, 186], ["M1", "PROTEIN", 207, 209], ["macrophages", "CELL_TYPE", 218, 229], ["CTL", "TEST", 183, 186], ["cellular killer", "OBSERVATION", 149, 164]]], ["In a related connection, significant prolongation of survival in human cancer has recently been observed by inhibiting immunoregulatory molecules, such as PD-1 and CTLA4 (33) .", [["cancer", "ANATOMY", 71, 77], ["cancer", "DISEASE", 71, 77], ["human", "ORGANISM", 65, 70], ["cancer", "CANCER", 71, 77], ["PD-1", "GENE_OR_GENE_PRODUCT", 155, 159], ["CTLA4", "GENE_OR_GENE_PRODUCT", 164, 169], ["immunoregulatory molecules", "PROTEIN", 119, 145], ["PD-1", "PROTEIN", 155, 159], ["CTLA4", "PROTEIN", 164, 169], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 65, 70], ["significant prolongation of survival in human cancer", "PROBLEM", 25, 77], ["immunoregulatory molecules", "PROBLEM", 119, 145], ["PD", "TEST", 155, 157], ["significant", "OBSERVATION_MODIFIER", 25, 36], ["prolongation", "OBSERVATION_MODIFIER", 37, 49], ["survival", "OBSERVATION_MODIFIER", 53, 61], ["cancer", "OBSERVATION", 71, 77]]], ["The effects observed have been postulated to involve specific anti tumor T cell activity.", [["tumor T cell", "ANATOMY", 67, 79], ["tumor", "DISEASE", 67, 72], ["tumor T cell", "CELL", 67, 79], ["specific anti tumor T cell activity", "TREATMENT", 53, 88], ["cell activity", "OBSERVATION", 75, 88]]], ["Such effects likely depend on modulating macrophage responses.", [["macrophage", "ANATOMY", 41, 51], ["macrophage", "CELL", 41, 51], ["macrophage responses", "OBSERVATION", 41, 61]]], ["Thus, increasing our knowledge of M1 and M2 polarization in cancer, and how to modulate it, is very important.Frontiers in Immunology | Molecular Innate ImmunityDrs.", [["cancer", "ANATOMY", 60, 66], ["cancer", "DISEASE", 60, 66], ["M1", "CELL", 34, 36], ["M2", "GENE_OR_GENE_PRODUCT", 41, 43], ["cancer", "CANCER", 60, 66], ["cancer", "PROBLEM", 60, 66], ["M2 polarization", "OBSERVATION_MODIFIER", 41, 56], ["cancer", "OBSERVATION", 60, 66]]], ["Laoui, Van Overmeire, Baetselier, Van Ginderachter, and Raes review the evidence that M2-type macrophages predominate in most human tumors with the notable exception of colorectal cancer (34) .", [["M2-type macrophages", "ANATOMY", 86, 105], ["tumors", "ANATOMY", 132, 138], ["colorectal cancer", "ANATOMY", 169, 186], ["tumors", "DISEASE", 132, 138], ["colorectal cancer", "DISEASE", 169, 186], ["M2-type macrophages", "CELL", 86, 105], ["human", "ORGANISM", 126, 131], ["tumors", "CANCER", 132, 138], ["colorectal cancer", "CANCER", 169, 186], ["M2-type macrophages", "CELL_TYPE", 86, 105], ["human", "SPECIES", 126, 131], ["human", "SPECIES", 126, 131], ["M2-type macrophages", "PROBLEM", 86, 105], ["most human tumors", "PROBLEM", 121, 138], ["colorectal cancer", "PROBLEM", 169, 186], ["M2", "OBSERVATION_MODIFIER", 86, 88], ["type macrophages", "OBSERVATION", 89, 105], ["most human", "OBSERVATION_MODIFIER", 121, 131], ["tumors", "OBSERVATION", 132, 138], ["notable", "OBSERVATION_MODIFIER", 148, 155], ["colorectal cancer", "OBSERVATION", 169, 186]]], ["They also describe new evidence that colonystimulating factors are important players in determining the quantity and type of macrophages that populate tumors.", [["macrophages", "ANATOMY", 125, 136], ["tumors", "ANATOMY", 151, 157], ["tumors", "DISEASE", 151, 157], ["macrophages", "CELL", 125, 136], ["tumors", "CANCER", 151, 157], ["colonystimulating factors", "PROTEIN", 37, 62], ["macrophages", "CELL_TYPE", 125, 136], ["colonystimulating factors", "PROBLEM", 37, 62], ["tumors", "OBSERVATION", 151, 157]]], ["MCSF is normally present in tissues and plasma, and is associated with M2-type macrophages.", [["tissues", "ANATOMY", 28, 35], ["plasma", "ANATOMY", 40, 46], ["M2-type macrophages", "ANATOMY", 71, 90], ["MCSF", "GENE_OR_GENE_PRODUCT", 0, 4], ["tissues", "TISSUE", 28, 35], ["plasma", "ORGANISM_SUBSTANCE", 40, 46], ["macrophages", "CELL", 79, 90], ["MCSF", "PROTEIN", 0, 4], ["M2-type macrophages", "CELL_TYPE", 71, 90], ["tissues", "ANATOMY", 28, 35], ["plasma", "OBSERVATION_MODIFIER", 40, 46], ["M2", "OBSERVATION_MODIFIER", 71, 73], ["type macrophages", "OBSERVATION", 74, 90]]], ["In contrast, GM-CSF is only present following injury or during infections, and is associated with M1-type responses.", [["GM", "CHEMICAL", 13, 15], ["infections", "DISEASE", 63, 73], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 13, 19], ["GM", "PROTEIN", 13, 15], ["CSF", "PROTEIN", 16, 19], ["GM-CSF", "TEST", 13, 19], ["injury", "PROBLEM", 46, 52], ["infections", "PROBLEM", 63, 73], ["injury", "OBSERVATION", 46, 52], ["infections", "OBSERVATION", 63, 73]]], ["Interestingly, the authors highlight findings suggesting inhibition of MCSF by various means in humans does not only simply decrease M2-type TAM but also increases the M1/M2 ratio.", [["TAM", "CHEMICAL", 141, 144], ["TAM", "CHEMICAL", 141, 144], ["MCSF", "GENE_OR_GENE_PRODUCT", 71, 75], ["humans", "ORGANISM", 96, 102], ["M2", "GENE_OR_GENE_PRODUCT", 171, 173], ["MCSF", "PROTEIN", 71, 75], ["M2", "PROTEIN", 133, 135], ["M2", "PROTEIN", 171, 173], ["humans", "SPECIES", 96, 102], ["humans", "SPECIES", 96, 102], ["inhibition of MCSF", "PROBLEM", 57, 75], ["M1", "ANATOMY_MODIFIER", 168, 170], ["M2", "ANATOMY", 171, 173]]], ["Thus, altering macrophage differentiation signals can affect macrophage polarization beneficially in clinical settings.", [["macrophage", "ANATOMY", 15, 25], ["macrophage", "ANATOMY", 61, 71], ["macrophage", "CELL", 15, 25], ["macrophage", "CELL", 61, 71], ["altering macrophage differentiation signals", "PROBLEM", 6, 49], ["macrophage differentiation", "OBSERVATION", 15, 41], ["macrophage polarization", "OBSERVATION", 61, 84]]], ["Using a different approach, Drs. Fritz, Tennis, Orlicky, Lin, Ju, Redente, Choo, Staab, Bouchard, Merrick, Malkinson, and Dwyer-Nield show that treatment of lung cancer in mice with a macrophagedepleting agent (clodronate-encapsulated liposomes) significantly decreases tumor burden (35) .", [["lung cancer", "ANATOMY", 157, 168], ["tumor", "ANATOMY", 270, 275], ["lung cancer", "DISEASE", 157, 168], ["clodronate", "CHEMICAL", 211, 221], ["tumor", "DISEASE", 270, 275], ["clodronate", "CHEMICAL", 211, 221], ["lung cancer", "CANCER", 157, 168], ["mice", "ORGANISM", 172, 176], ["clodronate", "SIMPLE_CHEMICAL", 211, 221], ["liposomes", "SIMPLE_CHEMICAL", 235, 244], ["tumor", "CANCER", 270, 275], ["mice", "SPECIES", 172, 176], ["mice", "SPECIES", 172, 176], ["a different approach", "TREATMENT", 6, 26], ["lung cancer", "PROBLEM", 157, 168], ["a macrophagedepleting agent", "TREATMENT", 182, 209], ["clodronate-encapsulated liposomes", "TREATMENT", 211, 244], ["tumor burden", "PROBLEM", 270, 282], ["Lin", "ANATOMY", 57, 60], ["lung", "ANATOMY", 157, 161], ["cancer", "OBSERVATION", 162, 168], ["decreases", "OBSERVATION_MODIFIER", 260, 269], ["tumor", "OBSERVATION", 270, 275]]], ["They also show that this treatment stimulates lung TAM that have a mixed M1-and M2-type phenotype suggesting that this depletion modality (like MCSF inhibition) may also increase the M1/M2 TAM balance.", [["lung", "ANATOMY", 46, 50], ["TAM", "CHEMICAL", 51, 54], ["TAM", "CHEMICAL", 189, 192], ["TAM", "CHEMICAL", 51, 54], ["TAM", "CHEMICAL", 189, 192], ["lung", "ORGAN", 46, 50], ["MCSF", "GENE_OR_GENE_PRODUCT", 144, 148], ["this treatment", "TREATMENT", 20, 34], ["this depletion modality", "TREATMENT", 114, 137], ["lung", "ANATOMY", 46, 50], ["TAM", "OBSERVATION", 51, 54], ["M2 TAM", "OBSERVATION", 186, 192]]], ["Together, these studies, like many others, are indicating that there are real and important clinical benefits from immunologically manipulating macrophage functions in cancer.MACROPHAGES IN INFECTIONSIn the context of animal models of bacterial infection, M1-type macrophages and NO production are often, but not exclusively (36) , associated with host protection (17) .", [["macrophage", "ANATOMY", 144, 154], ["cancer", "ANATOMY", 168, 174], ["M1-type macrophages", "ANATOMY", 256, 275], ["cancer", "DISEASE", 168, 174], ["bacterial infection", "DISEASE", 235, 254], ["NO", "CHEMICAL", 280, 282], ["NO", "CHEMICAL", 280, 282], ["macrophage", "CELL", 144, 154], ["cancer", "CANCER", 168, 174], ["M1-type macrophages", "CELL", 256, 275], ["NO", "SIMPLE_CHEMICAL", 280, 282], ["M1-type macrophages", "CELL_TYPE", 256, 275], ["these studies", "TEST", 10, 23], ["macrophage functions in cancer", "PROBLEM", 144, 174], ["bacterial infection", "PROBLEM", 235, 254], ["cancer", "OBSERVATION", 168, 174], ["animal models", "OBSERVATION_MODIFIER", 218, 231], ["bacterial", "OBSERVATION_MODIFIER", 235, 244], ["infection", "OBSERVATION", 245, 254], ["M1", "OBSERVATION_MODIFIER", 256, 258], ["type macrophages", "OBSERVATION_MODIFIER", 259, 275], ["NO", "UNCERTAINTY", 280, 282], ["production", "OBSERVATION_MODIFIER", 283, 293]]], ["Conversely, M2-type macrophages are typically associated with bacterial persistence.", [["M2-type macrophages", "ANATOMY", 12, 31], ["M2-type macrophages", "CELL", 12, 31], ["M2-type macrophages", "CELL_LINE", 12, 31], ["bacterial persistence", "PROBLEM", 62, 83], ["M2", "OBSERVATION_MODIFIER", 12, 14], ["macrophages", "OBSERVATION", 20, 31], ["typically associated with", "UNCERTAINTY", 36, 61], ["bacterial", "OBSERVATION_MODIFIER", 62, 71], ["persistence", "OBSERVATION", 72, 83]]], ["An article by Drs. Ka, Daumas, Textoris, and Mege reviews macrophage polarization in infectious diseases (37) .", [["macrophage", "ANATOMY", 58, 68], ["infectious diseases", "DISEASE", 85, 104], ["macrophage", "CELL", 58, 68], ["infectious", "OBSERVATION_MODIFIER", 85, 95]]], ["They discuss some difficulties encountered when trying to extend these concepts to bacterial infections in humans.", [["bacterial infections", "DISEASE", 83, 103], ["humans", "ORGANISM", 107, 113], ["humans", "SPECIES", 107, 113], ["humans", "SPECIES", 107, 113], ["some difficulties", "PROBLEM", 13, 30], ["bacterial infections in humans", "PROBLEM", 83, 113], ["bacterial", "OBSERVATION_MODIFIER", 83, 92], ["infections", "OBSERVATION", 93, 103]]], ["In humans suffering from leprosy or Whipple's, macrophage, M2-type polarization can be readily observed.", [["macrophage", "ANATOMY", 47, 57], ["leprosy", "DISEASE", 25, 32], ["humans", "ORGANISM", 3, 9], ["macrophage", "CELL", 47, 57], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["leprosy", "PROBLEM", 25, 32], ["Whipple's", "TREATMENT", 36, 45], ["macrophage", "PROBLEM", 47, 57], ["leprosy", "OBSERVATION", 25, 32], ["Whipple", "OBSERVATION", 36, 43]]], ["However, as mentioned earlier, analyzing whole organs can overlook microenvironmental differences in inflammation (19) .", [["whole organs", "ANATOMY", 41, 53], ["inflammation", "DISEASE", 101, 113], ["organs", "ORGAN", 47, 53], ["microenvironmental differences in inflammation", "PROBLEM", 67, 113], ["inflammation", "OBSERVATION", 101, 113]]], ["Also, studies with human patients often utilize peripheral blood monocytes that lack the polarized M1or M2-type functions associated with tissue macrophages.", [["peripheral blood monocytes", "ANATOMY", 48, 74], ["tissue macrophages", "ANATOMY", 138, 156], ["human", "ORGANISM", 19, 24], ["patients", "ORGANISM", 25, 33], ["peripheral blood monocytes", "CELL", 48, 74], ["M1or", "GENE_OR_GENE_PRODUCT", 99, 103], ["tissue macrophages", "CELL", 138, 156], ["peripheral blood monocytes", "CELL_TYPE", 48, 74], ["M2", "PROTEIN", 104, 106], ["tissue macrophages", "CELL_TYPE", 138, 156], ["human", "SPECIES", 19, 24], ["patients", "SPECIES", 25, 33], ["human", "SPECIES", 19, 24], ["peripheral blood monocytes", "TEST", 48, 74], ["tissue macrophages", "PROBLEM", 138, 156], ["tissue macrophages", "OBSERVATION", 138, 156]]], ["They also review that many pathogens, such as Leishmania, can survive or spread by blocking or subverting the process of macrophage development toward an M1/inhibit phenotype (27) .", [["macrophage", "ANATOMY", 121, 131], ["macrophage", "CELL", 121, 131], ["many pathogens", "PROBLEM", 22, 36], ["Leishmania", "PROBLEM", 46, 56], ["many", "OBSERVATION_MODIFIER", 22, 26], ["pathogens", "OBSERVATION", 27, 36], ["macrophage", "OBSERVATION", 121, 131]]], ["An article from Drs. Burrack and Morrison discusses how macrophage activation and arginine metabolism by M1-or M2-type macrophages can have diverse effects on health and disease during viral infections (38) .", [["macrophage", "ANATOMY", 56, 66], ["M2-type macrophages", "ANATOMY", 111, 130], ["arginine", "CHEMICAL", 82, 90], ["viral infections", "DISEASE", 185, 201], ["arginine", "CHEMICAL", 82, 90], ["macrophage", "CELL", 56, 66], ["arginine", "SIMPLE_CHEMICAL", 82, 90], ["M1", "GENE_OR_GENE_PRODUCT", 105, 107], ["M1-or M2-type macrophages", "CELL_LINE", 105, 130], ["macrophage activation", "PROBLEM", 56, 77], ["arginine metabolism", "PROBLEM", 82, 101], ["disease during viral infections", "PROBLEM", 170, 201]]], ["Macrophage NO production during viral infections, as in other settings, can be induced independent of lymphocytes (4).", [["Macrophage", "ANATOMY", 0, 10], ["lymphocytes", "ANATOMY", 102, 113], ["NO", "CHEMICAL", 11, 13], ["viral infections", "DISEASE", 32, 48], ["NO", "CHEMICAL", 11, 13], ["Macrophage", "CELL", 0, 10], ["NO", "GENE_OR_GENE_PRODUCT", 11, 13], ["lymphocytes", "CELL", 102, 113], ["lymphocytes", "CELL_TYPE", 102, 113], ["viral infections", "PROBLEM", 32, 48], ["NO", "UNCERTAINTY", 11, 13], ["production", "OBSERVATION_MODIFIER", 14, 24], ["viral", "OBSERVATION_MODIFIER", 32, 37], ["infections", "OBSERVATION", 38, 48]]], ["The production of NO can have direct anti-microbial effects on certain bacteria, fungi, and viruses.", [["NO", "CHEMICAL", 18, 20], ["NO", "CHEMICAL", 18, 20], ["NO", "SIMPLE_CHEMICAL", 18, 20], ["direct anti-microbial effects", "PROBLEM", 30, 59], ["certain bacteria", "PROBLEM", 63, 79], ["fungi", "PROBLEM", 81, 86], ["viruses", "PROBLEM", 92, 99], ["viruses", "OBSERVATION", 92, 99]]], ["Hence, the M1/inhibit phenotype in these settings plays an immune protective role.", [["M1", "PROTEIN", 11, 13], ["the M1/inhibit phenotype", "PROBLEM", 7, 31], ["M1", "ANATOMY", 11, 13]]], ["However, because NO kills non-specifically, it can also have immunopathologic or immune suppressive effects during infections by influenza, herpes simplex virus-1, and cytomegalovirus.", [["NO", "CHEMICAL", 17, 19], ["infections", "DISEASE", 115, 125], ["influenza", "DISEASE", 129, 138], ["herpes simplex virus", "DISEASE", 140, 160], ["cytomegalovirus", "DISEASE", 168, 183], ["NO", "CHEMICAL", 17, 19], ["NO", "SIMPLE_CHEMICAL", 17, 19], ["influenza", "ORGANISM", 129, 138], ["herpes simplex virus-1", "ORGANISM", 140, 162], ["cytomegalovirus", "ORGANISM", 168, 183], ["herpes simplex virus-1", "SPECIES", 140, 162], ["herpes simplex virus-1", "SPECIES", 140, 162], ["immunopathologic", "PROBLEM", 61, 77], ["immune suppressive effects during infections", "PROBLEM", 81, 125], ["influenza", "PROBLEM", 129, 138], ["herpes simplex virus", "PROBLEM", 140, 160], ["cytomegalovirus", "PROBLEM", 168, 183]]], ["Similarly, the two-edged sword nature of M2/heal macrophage responses can cut both ways.", [["macrophage", "ANATOMY", 49, 59], ["M2", "GENE_OR_GENE_PRODUCT", 41, 43], ["macrophage", "CELL", 49, 59], ["M2/heal macrophage responses", "TREATMENT", 41, 69], ["heal", "ANATOMY", 44, 48], ["macrophage", "OBSERVATION", 49, 59]]], ["For example, M2/heal responses (via arginase and growth-promoting ornithine) usefully promote tissue repair in some viral infection models, and via stimulating protective antibody responses.", [["tissue", "ANATOMY", 94, 100], ["ornithine", "CHEMICAL", 66, 75], ["viral infection", "DISEASE", 116, 131], ["ornithine", "CHEMICAL", 66, 75], ["M2", "GENE_OR_GENE_PRODUCT", 13, 15], ["arginase", "GENE_OR_GENE_PRODUCT", 36, 44], ["ornithine", "SIMPLE_CHEMICAL", 66, 75], ["tissue", "TISSUE", 94, 100], ["M2", "PROTEIN", 13, 15], ["arginase", "PROTEIN", 36, 44], ["M2/heal responses", "TEST", 13, 30], ["arginase", "TEST", 36, 44], ["promoting ornithine)", "TREATMENT", 56, 76], ["tissue repair", "TREATMENT", 94, 107], ["some viral infection models", "PROBLEM", 111, 138], ["heal", "ANATOMY", 16, 20], ["tissue repair", "OBSERVATION", 94, 107], ["viral infection", "OBSERVATION", 116, 131]]], ["However, M2/heal responses are also associated with viral persistence or immune pathology during many infections, such as coronavirus-induced sudden acute respiratory syndrome (SARS), hepatitis B or C viruses, Ross river virus, HIV, and influenza.", [["infections", "DISEASE", 102, 112], ["coronavirus", "DISEASE", 122, 133], ["sudden acute respiratory syndrome", "DISEASE", 142, 175], ["SARS", "DISEASE", 177, 181], ["hepatitis B", "DISEASE", 184, 195], ["influenza", "DISEASE", 237, 246], ["M2", "GENE_OR_GENE_PRODUCT", 9, 11], ["coronavirus", "ORGANISM", 122, 133], ["hepatitis B or C viruses", "ORGANISM", 184, 208], ["Ross river virus", "ORGANISM", 210, 226], ["HIV", "ORGANISM", 228, 231], ["M2", "PROTEIN", 9, 11], ["Ross river virus", "SPECIES", 210, 226], ["HIV", "SPECIES", 228, 231], ["Ross river virus", "SPECIES", 210, 226], ["HIV", "SPECIES", 228, 231], ["viral persistence", "PROBLEM", 52, 69], ["immune pathology", "PROBLEM", 73, 89], ["many infections", "PROBLEM", 97, 112], ["coronavirus", "PROBLEM", 122, 133], ["sudden acute respiratory syndrome", "PROBLEM", 142, 175], ["SARS", "PROBLEM", 177, 181], ["hepatitis B", "PROBLEM", 184, 195], ["C viruses", "PROBLEM", 199, 208], ["Ross river virus", "PROBLEM", 210, 226], ["HIV", "PROBLEM", 228, 231], ["influenza", "PROBLEM", 237, 246], ["heal", "ANATOMY", 12, 16], ["infections", "OBSERVATION", 102, 112], ["acute", "OBSERVATION_MODIFIER", 149, 154], ["respiratory syndrome", "OBSERVATION", 155, 175]]], ["These articles indicate that it is important to understand the infectious disease type, stage, and severity in order to properly modulate M1-or M2type responses to optimally eliminate pathogens and decrease untoward pathology.MACROPHAGE RESPONSES IN ATHEROSCLEROSIS AND OTHER NON-PATHOGEN-INDUCED INFLAMMATORY CONDITIONSIn contrast to the primarily protective role of M1/inhibittype responses against infection agents, described above, these killer/damaging activities are often associated with bad outcomes in chronic inflammatory conditions.MACROPHAGE RESPONSES IN ATHEROSCLEROSIS AND OTHER NON-PATHOGEN-INDUCED INFLAMMATORY CONDITIONSRegarding atherosclerosis, Drs. Thomas and Mattila show that both M1-and M2-types of macrophages are found during foam cell formation, a hallmark of atherosclerosis (20) .", [["macrophages", "ANATOMY", 722, 733], ["foam cell", "ANATOMY", 751, 760], ["infection", "DISEASE", 401, 410], ["atherosclerosis", "DISEASE", 647, 662], ["atherosclerosis", "DISEASE", 786, 801], ["M1", "CELL", 138, 140], ["M2type", "GENE_OR_GENE_PRODUCT", 144, 150], ["M1", "GENE_OR_GENE_PRODUCT", 368, 370], ["inhibittype", "GENE_OR_GENE_PRODUCT", 371, 382], ["M1", "GENE_OR_GENE_PRODUCT", 703, 705], ["M2", "GENE_OR_GENE_PRODUCT", 710, 712], ["macrophages", "CELL", 722, 733], ["foam cell", "CELL", 751, 760], ["M1", "PROTEIN", 703, 705], ["M2", "PROTEIN", 710, 712], ["macrophages", "CELL_TYPE", 722, 733], ["pathogens", "PROBLEM", 184, 193], ["decrease untoward pathology", "PROBLEM", 198, 225], ["ATHEROSCLEROSIS", "PROBLEM", 250, 265], ["M1/inhibittype responses", "TREATMENT", 368, 392], ["infection agents", "TREATMENT", 401, 417], ["chronic inflammatory conditions", "PROBLEM", 511, 542], ["ATHEROSCLEROSIS", "PROBLEM", 567, 582], ["OTHER NON-PATHOGEN-INDUCED INFLAMMATORY CONDITIONSRegarding atherosclerosis", "PROBLEM", 587, 662], ["macrophages", "PROBLEM", 722, 733], ["atherosclerosis", "PROBLEM", 786, 801], ["ATHEROSCLEROSIS", "OBSERVATION", 250, 265], ["INFLAMMATORY", "OBSERVATION_MODIFIER", 297, 309], ["M1", "ANATOMY", 368, 370], ["infection", "OBSERVATION", 401, 410], ["chronic", "OBSERVATION_MODIFIER", 511, 518], ["inflammatory", "OBSERVATION", 519, 531], ["ATHEROSCLEROSIS", "OBSERVATION", 567, 582], ["INFLAMMATORY", "OBSERVATION_MODIFIER", 614, 626], ["both", "OBSERVATION_MODIFIER", 698, 702], ["M1", "OBSERVATION_MODIFIER", 703, 705], ["M2", "ANATOMY", 710, 712], ["macrophages", "OBSERVATION", 722, 733], ["foam cell formation", "OBSERVATION", 751, 770], ["hallmark", "OBSERVATION_MODIFIER", 774, 782], ["atherosclerosis", "OBSERVATION", 786, 801]]], ["Drs. Hayes, Tsaousi, Gregoli, Jenkinson, Bond, Johnson, Bevan, Thomas, and Newby show that there is an altered expression of certain matrix metalloproteinases in atherosclerosis (39) .", [["atherosclerosis", "DISEASE", 162, 177], ["matrix metalloproteinases", "GENE_OR_GENE_PRODUCT", 133, 158], ["matrix metalloproteinases", "PROTEIN", 133, 158], ["atherosclerosis", "PROBLEM", 162, 177], ["certain matrix", "OBSERVATION_MODIFIER", 125, 139], ["atherosclerosis", "OBSERVATION", 162, 177]]], ["Interestingly, they also show that M1 and M2 macrophage polarization in atherosclerotic ApoE null mice occurs in the absence of T-and B-lymphocytes, again highlighting the independence of innate immunity from adaptive immunity discussed earlier.", [["macrophage", "ANATOMY", 45, 55], ["T-", "ANATOMY", 128, 130], ["B-lymphocytes", "ANATOMY", 134, 147], ["atherosclerotic", "DISEASE", 72, 87], ["M1", "CELL", 35, 37], ["M2 macrophage", "CELL", 42, 55], ["ApoE", "GENE_OR_GENE_PRODUCT", 88, 92], ["T", "CELL", 128, 129], ["B-lymphocytes", "CELL", 134, 147], ["T-and B-lymphocytes", "CELL_TYPE", 128, 147], ["mice", "SPECIES", 98, 102], ["T", "TEST", 128, 129], ["adaptive immunity", "TREATMENT", 209, 226], ["M1", "OBSERVATION_MODIFIER", 35, 37], ["M2", "OBSERVATION_MODIFIER", 42, 44], ["macrophage polarization", "OBSERVATION", 45, 68], ["atherosclerotic", "OBSERVATION_MODIFIER", 72, 87], ["ApoE", "OBSERVATION_MODIFIER", 88, 92], ["null mice", "OBSERVATION", 93, 102], ["lymphocytes", "ANATOMY", 136, 147]]], ["Drs. Murphy, Dragoljevic, and Tall review the recent evidence that cholesterol efflux pathways regulate myelopoiesis (40) .", [["cholesterol", "CHEMICAL", 67, 78], ["cholesterol", "CHEMICAL", 67, 78], ["cholesterol", "SIMPLE_CHEMICAL", 67, 78], ["cholesterol efflux pathways regulate myelopoiesis", "PROBLEM", 67, 116], ["cholesterol efflux", "OBSERVATION", 67, 85], ["myelopoiesis", "OBSERVATION", 104, 116]]], ["Traditionally, cholesterol efflux was considered as a safeguard against foam cell formation, but Tall's group has shown that knocking out cholesterol efflux molecules like ABCA1 and ABCG1 cause profound changes in hematopoiesis associated with more Ly6C+ inflammatory monocytes and more neutrophils.", [["foam cell", "ANATOMY", 72, 81], ["Ly6C+ inflammatory monocytes", "ANATOMY", 249, 277], ["neutrophils", "ANATOMY", 287, 298], ["cholesterol", "CHEMICAL", 15, 26], ["cholesterol", "CHEMICAL", 138, 149], ["cholesterol", "CHEMICAL", 15, 26], ["cholesterol", "CHEMICAL", 138, 149], ["cholesterol", "SIMPLE_CHEMICAL", 15, 26], ["foam cell", "CELL", 72, 81], ["cholesterol", "SIMPLE_CHEMICAL", 138, 149], ["ABCA1", "GENE_OR_GENE_PRODUCT", 172, 177], ["ABCG1", "GENE_OR_GENE_PRODUCT", 182, 187], ["Ly6C", "GENE_OR_GENE_PRODUCT", 249, 253], ["monocytes", "CELL", 268, 277], ["neutrophils", "CELL", 287, 298], ["cholesterol efflux molecules", "PROTEIN", 138, 166], ["ABCA1", "PROTEIN", 172, 177], ["ABCG1", "PROTEIN", 182, 187], ["Ly6C+ inflammatory monocytes", "CELL_TYPE", 249, 277], ["neutrophils", "CELL_TYPE", 287, 298], ["cholesterol efflux", "PROBLEM", 15, 33], ["foam cell formation", "PROBLEM", 72, 91], ["cholesterol efflux molecules", "PROBLEM", 138, 166], ["ABCA1", "PROBLEM", 172, 177], ["profound changes in hematopoiesis", "PROBLEM", 194, 227], ["inflammatory monocytes", "PROBLEM", 255, 277], ["cholesterol efflux", "OBSERVATION", 15, 33], ["profound", "OBSERVATION_MODIFIER", 194, 202], ["hematopoiesis", "OBSERVATION", 214, 227], ["inflammatory monocytes", "OBSERVATION", 255, 277]]], ["This shift could lead to altered macrophage function.", [["macrophage", "ANATOMY", 33, 43], ["macrophage", "CELL", 33, 43], ["altered macrophage function", "PROBLEM", 25, 52], ["altered", "OBSERVATION_MODIFIER", 25, 32], ["macrophage function", "OBSERVATION", 33, 52]]], ["Drs. Peled and Fisher review dynamic aspects of macrophage polarization during atherosclerosis progression and regression: progression is associated with macrophage M1 polarization and regression with M2 polarization (41) .", [["macrophage", "ANATOMY", 48, 58], ["macrophage M1", "ANATOMY", 154, 167], ["atherosclerosis", "DISEASE", 79, 94], ["macrophage", "CELL", 48, 58], ["macrophage M1", "CELL", 154, 167], ["macrophage polarization", "TREATMENT", 48, 71], ["atherosclerosis progression", "PROBLEM", 79, 106], ["macrophage polarization", "OBSERVATION", 48, 71], ["atherosclerosis", "OBSERVATION", 79, 94], ["associated with", "UNCERTAINTY", 138, 153], ["macrophage M1 polarization", "OBSERVATION", 154, 180], ["M2", "OBSERVATION_MODIFIER", 201, 203]]], ["The article by Drs. Yang and Ming looks at the less commonly studied arginase II enzyme.", [["arginase II", "GENE_OR_GENE_PRODUCT", 69, 80], ["arginase II enzyme", "PROTEIN", 69, 87]]], ["They show that, unlike arginase I, that is typically inversely related to macrophage NO production, arginase II seems under different regulation.", [["macrophage", "ANATOMY", 74, 84], ["NO", "CHEMICAL", 85, 87], ["NO", "CHEMICAL", 85, 87], ["arginase I", "GENE_OR_GENE_PRODUCT", 23, 33], ["macrophage", "CELL", 74, 84], ["NO", "SIMPLE_CHEMICAL", 85, 87], ["arginase II", "GENE_OR_GENE_PRODUCT", 100, 111], ["arginase I", "PROTEIN", 23, 33], ["arginase II", "PROTEIN", 100, 111], ["unlike arginase I", "PROBLEM", 16, 33], ["arginase II", "PROBLEM", 100, 111], ["arginase", "OBSERVATION", 23, 31], ["macrophage", "OBSERVATION", 74, 84]]], ["Also, Arg II expression in endothelial cells tends to uncouple eNOS (or NOS1) causing loss of vascular tone (42) .MACROPHAGE RESPONSES IN ATHEROSCLEROSIS AND OTHER NON-PATHOGEN-INDUCED INFLAMMATORY CONDITIONSRegarding other non-pathogen associated inflammatory conditions, Drs. Vlahos and Bozinovski review the role of alveolar macrophages in chronic obstructive pulmonary disease (COPD) (43) .", [["endothelial cells", "ANATOMY", 27, 44], ["vascular", "ANATOMY", 94, 102], ["alveolar macrophages", "ANATOMY", 319, 339], ["pulmonary", "ANATOMY", 363, 372], ["Arg II", "CHEMICAL", 6, 12], ["chronic obstructive pulmonary disease", "DISEASE", 343, 380], ["COPD", "DISEASE", 382, 386], ["Arg II", "GENE_OR_GENE_PRODUCT", 6, 12], ["endothelial cells", "CELL", 27, 44], ["eNOS", "GENE_OR_GENE_PRODUCT", 63, 67], ["NOS1", "GENE_OR_GENE_PRODUCT", 72, 76], ["vascular", "MULTI-TISSUE_STRUCTURE", 94, 102], ["alveolar macrophages", "CELL", 319, 339], ["pulmonary", "ORGAN", 363, 372], ["Arg II", "PROTEIN", 6, 12], ["endothelial cells", "CELL_TYPE", 27, 44], ["eNOS", "PROTEIN", 63, 67], ["NOS1", "PROTEIN", 72, 76], ["alveolar macrophages", "CELL_TYPE", 319, 339], ["Arg II expression in endothelial cells", "PROBLEM", 6, 44], ["loss of vascular tone", "PROBLEM", 86, 107], ["ATHEROSCLEROSIS", "PROBLEM", 138, 153], ["inflammatory conditions", "PROBLEM", 248, 271], ["alveolar macrophages", "PROBLEM", 319, 339], ["chronic obstructive pulmonary disease", "PROBLEM", 343, 380], ["COPD", "PROBLEM", 382, 386], ["endothelial cells", "OBSERVATION", 27, 44], ["vascular tone", "ANATOMY", 94, 107], ["ATHEROSCLEROSIS", "OBSERVATION", 138, 153], ["INFLAMMATORY", "OBSERVATION_MODIFIER", 185, 197], ["inflammatory", "OBSERVATION_MODIFIER", 248, 260], ["alveolar macrophages", "OBSERVATION", 319, 339], ["chronic", "OBSERVATION_MODIFIER", 343, 350], ["obstructive", "OBSERVATION_MODIFIER", 351, 362], ["pulmonary", "ANATOMY", 363, 372], ["disease", "OBSERVATION", 373, 380], ["COPD", "OBSERVATION", 382, 386]]], ["COPD is a widespread chronic inflammatory condition with immense medical and societal impact.", [["COPD", "DISEASE", 0, 4], ["COPD", "PROBLEM", 0, 4], ["a widespread chronic inflammatory condition", "PROBLEM", 8, 51], ["immense medical and societal impact", "PROBLEM", 57, 92], ["widespread", "OBSERVATION_MODIFIER", 10, 20], ["chronic", "OBSERVATION_MODIFIER", 21, 28], ["inflammatory", "OBSERVATION", 29, 41], ["immense", "OBSERVATION_MODIFIER", 57, 64]]], ["Interestingly, in COPD, there is an accumulation of airway macrophages that show a transcriptome skewed toward wound healing M2 markers suggesting defective resolution of inflammation (as occurs in wound healing).", [["airway macrophages", "ANATOMY", 52, 70], ["wound", "ANATOMY", 111, 116], ["wound", "ANATOMY", 198, 203], ["COPD", "DISEASE", 18, 22], ["inflammation", "DISEASE", 171, 183], ["airway macrophages", "CELL", 52, 70], ["wound", "PATHOLOGICAL_FORMATION", 111, 116], ["wound", "PATHOLOGICAL_FORMATION", 198, 203], ["airway macrophages", "CELL_TYPE", 52, 70], ["M2 markers", "PROTEIN", 125, 135], ["COPD", "PROBLEM", 18, 22], ["an accumulation of airway macrophages", "PROBLEM", 33, 70], ["wound healing", "PROBLEM", 111, 124], ["inflammation", "PROBLEM", 171, 183], ["wound healing", "PROBLEM", 198, 211], ["COPD", "OBSERVATION", 18, 22], ["accumulation", "OBSERVATION_MODIFIER", 36, 48], ["airway macrophages", "OBSERVATION", 52, 70], ["transcriptome", "OBSERVATION_MODIFIER", 83, 96], ["skewed", "OBSERVATION_MODIFIER", 97, 103], ["wound", "OBSERVATION_MODIFIER", 111, 116], ["healing", "OBSERVATION_MODIFIER", 117, 124], ["M2", "OBSERVATION_MODIFIER", 125, 127], ["defective", "OBSERVATION_MODIFIER", 147, 156], ["resolution", "OBSERVATION_MODIFIER", 157, 167], ["inflammation", "OBSERVATION", 171, 183], ["wound", "OBSERVATION_MODIFIER", 198, 203], ["healing", "OBSERVATION_MODIFIER", 204, 211]]], ["Drs. Kraakman, Murphy, Jandeleit-Dahm, and Kammoun review macrophage polarization in obesity and type 2 diabetes (44) .", [["macrophage", "ANATOMY", 58, 68], ["obesity", "DISEASE", 85, 92], ["type 2 diabetes", "DISEASE", 97, 112], ["Jandeleit-Dahm", "CELL", 23, 37], ["macrophage", "CELL", 58, 68], ["obesity", "PROBLEM", 85, 92], ["type 2 diabetes", "PROBLEM", 97, 112], ["Murphy", "ANATOMY", 15, 21], ["macrophage polarization", "OBSERVATION", 58, 81], ["obesity", "OBSERVATION", 85, 92]]], ["M1 \"pro-inflammatory\" macrophages are enhanced compared with M2 \"anti-inflammatory\" macrophages, www.frontiersin.org leading to chronic inflammation and the propagation of metabolic dysfunctions.", [["macrophages", "ANATOMY", 22, 33], ["macrophages", "ANATOMY", 84, 95], ["frontiersin.org", "CHEMICAL", 101, 116], ["inflammation", "DISEASE", 136, 148], ["metabolic dysfunctions", "DISEASE", 172, 194], ["macrophages", "CELL", 22, 33], ["macrophages", "CELL", 84, 95], ["pro-inflammatory\" macrophages", "CELL_TYPE", 4, 33], ["inflammatory\" macrophages", "CELL_TYPE", 70, 95], ["chronic inflammation", "PROBLEM", 128, 148], ["metabolic dysfunctions", "PROBLEM", 172, 194], ["inflammatory", "OBSERVATION_MODIFIER", 8, 20], ["macrophages", "OBSERVATION", 22, 33], ["inflammatory", "OBSERVATION_MODIFIER", 70, 82], ["chronic", "OBSERVATION_MODIFIER", 128, 135], ["inflammation", "OBSERVATION", 136, 148], ["metabolic dysfunctions", "OBSERVATION", 172, 194]]], ["The brain and spinal cord are primarily populated by macrophage-like microglial cells, which are derived from yolk sac precursors under resting conditions.", [["brain", "ANATOMY", 4, 9], ["spinal cord", "ANATOMY", 14, 25], ["macrophage-like microglial cells", "ANATOMY", 53, 85], ["yolk sac precursors", "ANATOMY", 110, 129], ["brain", "ORGAN", 4, 9], ["spinal cord", "ORGAN", 14, 25], ["macrophage-like microglial cells", "CELL", 53, 85], ["yolk sac precursors", "MULTI-TISSUE_STRUCTURE", 110, 129], ["macrophage", "CELL_TYPE", 53, 63], ["microglial cells", "CELL_TYPE", 69, 85], ["yolk sac precursors", "CELL_TYPE", 110, 129], ["microglial cells", "PROBLEM", 69, 85], ["brain", "ANATOMY", 4, 9], ["spinal cord", "ANATOMY", 14, 25], ["macrophage", "OBSERVATION", 53, 63], ["microglial cells", "OBSERVATION", 69, 85], ["sac", "OBSERVATION_MODIFIER", 115, 118], ["precursors", "OBSERVATION_MODIFIER", 119, 129]]], ["Drs. Cherry, Olschowka, and O'Banion show that these microglia are normally M2-polarized, although the microglia transcriptome is different from that of M2 macrophages in other organs (45) .", [["microglia", "ANATOMY", 53, 62], ["microglia", "ANATOMY", 103, 112], ["M2 macrophages", "ANATOMY", 153, 167], ["organs", "ANATOMY", 177, 183], ["microglia", "CELL", 53, 62], ["M2", "GENE_OR_GENE_PRODUCT", 76, 78], ["microglia", "CELL", 103, 112], ["M2 macrophages", "CELL", 153, 167], ["organs", "ORGAN", 177, 183], ["microglia", "CELL_TYPE", 53, 62], ["M2 macrophages", "CELL_TYPE", 153, 167], ["Olschowka", "ANATOMY", 13, 22], ["microglia", "ANATOMY", 53, 62], ["M2", "OBSERVATION_MODIFIER", 76, 78], ["polarized", "OBSERVATION_MODIFIER", 79, 88], ["microglia transcriptome", "OBSERVATION", 103, 126], ["different", "OBSERVATION_MODIFIER", 130, 139], ["M2 macrophages", "OBSERVATION", 153, 167]]], ["This observation fits well with an emerging concept that M1 and M2 polarization varies between organs (46) .", [["organs", "ANATOMY", 95, 101], ["M1", "CELL", 57, 59], ["M2", "GENE_OR_GENE_PRODUCT", 64, 66], ["organs", "ORGAN", 95, 101]]], ["In this connection, Drs. Brown, von Chamier, Allam, and Reyes report on M1/M2 macrophage polarity in normal and complicated pregnancies and find that the balance and location of M1-and M2-type responses show significant variation (47) .", [["M1/M2 macrophage", "ANATOMY", 72, 88], ["M1/M2 macrophage", "CELL", 72, 88], ["M1", "GENE_OR_GENE_PRODUCT", 178, 180], ["M1", "PROTEIN", 178, 180], ["M2", "PROTEIN", 185, 187], ["complicated pregnancies", "PROBLEM", 112, 135], ["M1", "TEST", 178, 180], ["significant variation", "PROBLEM", 208, 229], ["normal", "OBSERVATION", 101, 107], ["significant", "OBSERVATION_MODIFIER", 208, 219], ["variation", "OBSERVATION_MODIFIER", 220, 229]]], ["In general, over expression of M1type macrophages is associated with untoward outcomes during pregnancy.MACROPHAGE RESPONSES IN ATHEROSCLEROSIS AND OTHER NON-PATHOGEN-INDUCED INFLAMMATORY CONDITIONSFinally, this Topic focuses on macrophage polarization.", [["M1type macrophages", "ANATOMY", 31, 49], ["macrophage", "ANATOMY", 229, 239], ["M1type macrophages", "CELL", 31, 49], ["macrophage", "CELL", 229, 239], ["M1type macrophages", "CELL_TYPE", 31, 49], ["M1type macrophages", "PROBLEM", 31, 49], ["untoward outcomes during pregnancy", "PROBLEM", 69, 103], ["ATHEROSCLEROSIS", "PROBLEM", 128, 143], ["OTHER NON-PATHOGEN-INDUCED INFLAMMATORY CONDITIONSFinally", "PROBLEM", 148, 205], ["macrophage polarization", "TREATMENT", 229, 252], ["macrophages", "OBSERVATION", 38, 49], ["ATHEROSCLEROSIS", "OBSERVATION", 128, 143], ["NON-PATHOGEN-INDUCED", "OBSERVATION_MODIFIER", 154, 174], ["INFLAMMATORY", "OBSERVATION_MODIFIER", 175, 187], ["macrophage polarization", "OBSERVATION", 229, 252]]], ["Little is currently known about how the origin of macrophages in tissues (e.g., yolk sac, Ly6C-high, Ly-6C-low monocytes) influence M1/M2 polarization.", [["macrophages", "ANATOMY", 50, 61], ["tissues", "ANATOMY", 65, 72], ["yolk sac", "ANATOMY", 80, 88], ["Ly-6C-low monocytes", "ANATOMY", 101, 120], ["M1/M2", "ANATOMY", 132, 137], ["macrophages", "CELL", 50, 61], ["tissues", "TISSUE", 65, 72], ["yolk sac", "ORGAN", 80, 88], ["Ly6C", "GENE_OR_GENE_PRODUCT", 90, 94], ["Ly-6C", "GENE_OR_GENE_PRODUCT", 101, 106], ["M2", "GENE_OR_GENE_PRODUCT", 135, 137], ["macrophages", "CELL_TYPE", 50, 61], ["monocytes", "CELL_TYPE", 111, 120], ["yolk sac", "TEST", 80, 88], ["Ly6C", "TEST", 90, 94], ["Ly", "TEST", 101, 103], ["macrophages", "OBSERVATION", 50, 61], ["Ly6C", "ANATOMY", 90, 94], ["low monocytes", "OBSERVATION_MODIFIER", 107, 120]]], ["Drs. Dey, Allen, and Hankey-Giblin begin to explore how the ontogeny of monocytes and macrophage can influence M1-and M2-type responses in different tissues (48) .REGULATION OF MACROPHAGE DIFFERENTIATION AND FUNCTIONSThe importance of macrophage M1/inhibit and M2/heal imbalances in various disease or protective processes being clear, immunologists and clinicians are interested in how they might therapeutically intervene to shape macrophage differentiation or modulate various macrophage functions to restore health.", [["monocytes", "ANATOMY", 72, 81], ["macrophage", "ANATOMY", 86, 96], ["tissues", "ANATOMY", 149, 156], ["macrophage M1", "ANATOMY", 235, 248], ["macrophage", "ANATOMY", 433, 443], ["macrophage", "ANATOMY", 480, 490], ["monocytes", "CELL", 72, 81], ["macrophage", "CELL", 86, 96], ["M1", "CELL", 111, 113], ["tissues", "TISSUE", 149, 156], ["macrophage M1", "CELL", 235, 248], ["M2", "GENE_OR_GENE_PRODUCT", 261, 263], ["macrophage", "CELL", 433, 443], ["macrophage", "CELL", 480, 490], ["monocytes", "CELL_TYPE", 72, 81], ["macrophage", "CELL_TYPE", 86, 96], ["Giblin", "TREATMENT", 28, 34], ["M1", "TEST", 111, 113], ["macrophage M1/inhibit", "TREATMENT", 235, 256], ["heal imbalances", "PROBLEM", 264, 279], ["various disease", "PROBLEM", 283, 298], ["different tissues", "ANATOMY", 139, 156], ["MACROPHAGE DIFFERENTIATION", "OBSERVATION", 177, 203], ["macrophage M1", "OBSERVATION", 235, 248], ["heal", "ANATOMY", 264, 268], ["imbalances", "OBSERVATION", 269, 279]]], ["Drs. Wang, Liang, and Zen provide an overview of the various molecular mechanisms known to impact macrophage M1 and M2 polarization (49) .", [["macrophage M1", "ANATOMY", 98, 111], ["macrophage M1", "CELL", 98, 111], ["M2", "GENE_OR_GENE_PRODUCT", 116, 118], ["macrophage M1", "OBSERVATION", 98, 111]]], ["Several of these mechanisms are expanded upon in subsequent articles.", [["expanded", "OBSERVATION", 32, 40]]], ["Cytokines such as interferon gamma (IFN-\u03b3) have profound impacts on development of M1 and M2 functionality in macrophages.", [["macrophages", "ANATOMY", 110, 121], ["interferon gamma", "GENE_OR_GENE_PRODUCT", 18, 34], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 36, 41], ["M1", "CELL", 83, 85], ["M2", "CELL", 90, 92], ["macrophages", "CELL", 110, 121], ["Cytokines", "PROTEIN", 0, 9], ["interferon gamma", "PROTEIN", 18, 34], ["IFN", "PROTEIN", 36, 39], ["\u03b3", "PROTEIN", 40, 41], ["macrophages", "CELL_TYPE", 110, 121], ["Cytokines", "PROBLEM", 0, 9], ["interferon gamma", "TREATMENT", 18, 34], ["profound impacts", "PROBLEM", 48, 64], ["profound", "OBSERVATION_MODIFIER", 48, 56], ["impacts", "OBSERVATION", 57, 64], ["M1", "ANATOMY", 83, 85], ["M2 functionality", "OBSERVATION", 90, 106], ["macrophages", "ANATOMY", 110, 121]]], ["Regulators of cytokine receptor signaling can importantly impact macrophage functions.", [["macrophage", "ANATOMY", 65, 75], ["cytokine receptor", "GENE_OR_GENE_PRODUCT", 14, 31], ["macrophage", "CELL", 65, 75], ["cytokine receptor", "PROTEIN", 14, 31]]], ["Dr. Wilson details in her article evidence that various suppressor of cytokine signaling (SOCS) protein family members shape M1/M2 macrophage functions in several disease settings (50) .", [["M1/M2 macrophage", "ANATOMY", 125, 141], ["suppressor of cytokine signaling", "GENE_OR_GENE_PRODUCT", 56, 88], ["SOCS", "GENE_OR_GENE_PRODUCT", 90, 94], ["suppressor of cytokine signaling (SOCS) protein family members", "PROTEIN", 56, 118], ["macrophage functions", "TEST", 131, 151]]], ["Colony-stimulating factors (CSFs) and macrophage stimulating protein (MSP) also impact macrophage responsiveness to polarization.", [["macrophage", "ANATOMY", 87, 97], ["Colony-stimulating factors", "GENE_OR_GENE_PRODUCT", 0, 26], ["CSFs", "GENE_OR_GENE_PRODUCT", 28, 32], ["macrophage stimulating protein", "GENE_OR_GENE_PRODUCT", 38, 68], ["MSP", "GENE_OR_GENE_PRODUCT", 70, 73], ["macrophage", "CELL", 87, 97], ["Colony-stimulating factors", "PROTEIN", 0, 26], ["CSFs", "PROTEIN", 28, 32], ["macrophage stimulating protein", "PROTEIN", 38, 68], ["MSP", "PROTEIN", 70, 73], ["stimulating factors (CSFs", "TREATMENT", 7, 32], ["macrophage stimulating protein (MSP)", "TREATMENT", 38, 74], ["macrophage responsiveness", "OBSERVATION", 87, 112]]], ["Drs. Hamilton, Zhao, Pavicic, and Datta introduce the concept that the myeloid colonystimulating factors MCSF and GM-CSF act not only to promote the development and maintenance of various myeloid populations but can also shape the responsiveness of macrophages to stimuli that direct the M1 or M2 phenotype (51) .", [["myeloid", "ANATOMY", 71, 78], ["myeloid populations", "ANATOMY", 188, 207], ["macrophages", "ANATOMY", 249, 260], ["GM", "CHEMICAL", 114, 116], ["myeloid", "CELL", 71, 78], ["MCSF", "GENE_OR_GENE_PRODUCT", 105, 109], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 114, 120], ["myeloid populations", "CELL", 188, 207], ["macrophages", "CELL", 249, 260], ["M2", "GENE_OR_GENE_PRODUCT", 294, 296], ["myeloid colonystimulating factors", "PROTEIN", 71, 104], ["MCSF", "PROTEIN", 105, 109], ["GM", "PROTEIN", 114, 116], ["CSF", "PROTEIN", 117, 120], ["myeloid populations", "CELL_TYPE", 188, 207], ["macrophages", "CELL_TYPE", 249, 260], ["Pavicic", "TREATMENT", 21, 28], ["Datta", "TREATMENT", 34, 39], ["the myeloid colonystimulating factors", "PROBLEM", 67, 104], ["various myeloid populations", "PROBLEM", 180, 207], ["myeloid populations", "OBSERVATION", 188, 207]]], ["The effects of MSP and its receptor, a tyrosine kinase known as RON, on macrophage polarization are clearly presented in an article by Dr. Chaudhuri (52) .", [["macrophage", "ANATOMY", 72, 82], ["tyrosine", "CHEMICAL", 39, 47], ["tyrosine", "CHEMICAL", 39, 47], ["MSP", "GENE_OR_GENE_PRODUCT", 15, 18], ["RON", "GENE_OR_GENE_PRODUCT", 64, 67], ["macrophage", "CELL", 72, 82], ["MSP", "PROTEIN", 15, 18], ["tyrosine kinase", "PROTEIN", 39, 54], ["RON", "PROTEIN", 64, 67], ["a tyrosine kinase", "TEST", 37, 54], ["macrophage polarization", "TREATMENT", 72, 95], ["macrophage polarization", "OBSERVATION", 72, 95]]], ["Other extrinsic factors that regulate macrophage polarization include components of the complement cascade as well as extracellular nucleotides.", [["macrophage", "ANATOMY", 38, 48], ["extracellular", "ANATOMY", 118, 131], ["nucleotides", "CHEMICAL", 132, 143], ["macrophage", "CELL", 38, 48], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 118, 131], ["Other extrinsic factors", "PROBLEM", 0, 23], ["the complement cascade", "PROBLEM", 84, 106], ["extracellular nucleotides", "TREATMENT", 118, 143], ["macrophage polarization", "OBSERVATION", 38, 61], ["cascade", "OBSERVATION", 99, 106], ["extracellular nucleotides", "OBSERVATION", 118, 143]]], ["The contrasting effects of various complement components on M1 and M2 functions are described in an article by Drs. Bohlson O'Conner, Hulsebus, Ho, and Fraser (53) .", [["M1", "CELL", 60, 62], ["M2", "GENE_OR_GENE_PRODUCT", 67, 69], ["various complement components", "PROBLEM", 27, 56], ["various", "OBSERVATION_MODIFIER", 27, 34], ["complement", "OBSERVATION_MODIFIER", 35, 45], ["components", "OBSERVATION_MODIFIER", 46, 56], ["M1", "OBSERVATION_MODIFIER", 60, 62]]], ["Drs. Desai and Leitinger go on to detail how purinergic receptors for extracellular ATP and other nucleotides couple with calcium signaling to modulate macrophage activities and resolution of inflammation (54) .", [["extracellular", "ANATOMY", 70, 83], ["macrophage", "ANATOMY", 152, 162], ["ATP", "CHEMICAL", 84, 87], ["calcium", "CHEMICAL", 122, 129], ["inflammation", "DISEASE", 192, 204], ["ATP", "CHEMICAL", 84, 87], ["nucleotides", "CHEMICAL", 98, 109], ["calcium", "CHEMICAL", 122, 129], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 70, 83], ["ATP", "SIMPLE_CHEMICAL", 84, 87], ["calcium", "SIMPLE_CHEMICAL", 122, 129], ["macrophage", "CELL", 152, 162], ["purinergic receptors", "PROTEIN", 45, 65], ["extracellular ATP", "TEST", 70, 87], ["other nucleotides", "TEST", 92, 109], ["calcium signaling", "TEST", 122, 139], ["macrophage activities", "TEST", 152, 173], ["inflammation", "PROBLEM", 192, 204], ["inflammation", "OBSERVATION", 192, 204]]], ["An improved understanding of how these extrinsic factors and intrinsic signaling pathways regulate the acquisition of M1 and M2-type functions will lead to improved methods for fine-tuning of macrophage polarization to promote health.REGULATION OF MACROPHAGE DIFFERENTIATION AND FUNCTIONSAs mentioned above, a key difference between M1 and M2 macrophages is in their processing of l-arginine.", [["macrophage", "ANATOMY", 192, 202], ["M2 macrophages", "ANATOMY", 340, 354], ["l-arginine", "CHEMICAL", 381, 391], ["l-arginine", "CHEMICAL", 381, 391], ["M1", "CELL", 118, 120], ["macrophage", "CELL", 192, 202], ["M1", "CELL", 333, 335], ["M2 macrophages", "CELL", 340, 354], ["l-arginine", "SIMPLE_CHEMICAL", 381, 391], ["M2", "PROTEIN", 125, 127], ["M1 and M2 macrophages", "CELL_LINE", 333, 354], ["macrophage polarization", "TREATMENT", 192, 215], ["improved", "OBSERVATION_MODIFIER", 3, 11], ["macrophage polarization", "OBSERVATION", 192, 215], ["MACROPHAGE DIFFERENTIATION", "OBSERVATION", 248, 274]]], ["NO can not only kill susceptible microbes but also has a variety of signaling and regulatory effects on macrophages and other cell types.", [["macrophages", "ANATOMY", 104, 115], ["cell", "ANATOMY", 126, 130], ["NO", "CHEMICAL", 0, 2], ["NO", "CHEMICAL", 0, 2], ["NO", "SIMPLE_CHEMICAL", 0, 2], ["macrophages", "CELL", 104, 115], ["cell", "CELL", 126, 130], ["macrophages", "CELL_TYPE", 104, 115], ["variety", "OBSERVATION_MODIFIER", 57, 64], ["cell types", "OBSERVATION", 126, 136]]], ["NO is generated from l-arginine through the activities of three NO synthase (NOS) enzymes.", [["NO", "CHEMICAL", 0, 2], ["l-arginine", "CHEMICAL", 21, 31], ["NO", "CHEMICAL", 64, 66], ["NO", "CHEMICAL", 0, 2], ["l-arginine", "CHEMICAL", 21, 31], ["NO", "CHEMICAL", 64, 66], ["NO", "SIMPLE_CHEMICAL", 0, 2], ["l-arginine", "SIMPLE_CHEMICAL", 21, 31], ["NO synthase", "GENE_OR_GENE_PRODUCT", 64, 75], ["NOS", "GENE_OR_GENE_PRODUCT", 77, 80], ["NO synthase (NOS) enzymes", "PROTEIN", 64, 89], ["l-arginine", "TREATMENT", 21, 31], ["enzymes", "TEST", 82, 89]]], ["In contrast to canonical views, Drs. Mattila and Thomas present the perspective that \"constitutive\" enzyme activities (NOS1 and 3) can be induced, and \"inducible\" NOS2 is constitutively expressed in several tissues (55) .", [["tissues", "ANATOMY", 207, 214], ["NOS1", "GENE_OR_GENE_PRODUCT", 119, 123], ["3", "GENE_OR_GENE_PRODUCT", 128, 129], ["NOS2", "GENE_OR_GENE_PRODUCT", 163, 167], ["tissues", "TISSUE", 207, 214], ["NOS1 and 3", "PROTEIN", 119, 129], ["NOS2", "PROTEIN", 163, 167]]], ["The different functions of M1 and M2 macrophages are also associated with changes in the metabolic pathways they use to produce ATP.", [["M1", "ANATOMY", 27, 29], ["M2 macrophages", "ANATOMY", 34, 48], ["ATP", "CHEMICAL", 128, 131], ["ATP", "CHEMICAL", 128, 131], ["M1", "CELL", 27, 29], ["M2 macrophages", "CELL", 34, 48], ["ATP", "SIMPLE_CHEMICAL", 128, 131], ["M1 and M2 macrophages", "CELL_LINE", 27, 48], ["ATP", "PROBLEM", 128, 131], ["M1", "ANATOMY_MODIFIER", 27, 29], ["M2 macrophages", "OBSERVATION", 34, 48], ["metabolic pathways", "OBSERVATION", 89, 107]]], ["Drs. Galv\u00e1n-Pe\u00f1a and O'Neill discuss the differences in metabolism between M1 and M2 macrophages and how these differences impact other aspects of macrophage function (56) .", [["M1", "ANATOMY", 75, 77], ["M2 macrophages", "ANATOMY", 82, 96], ["macrophage", "ANATOMY", 147, 157], ["M1", "CELL", 75, 77], ["M2 macrophages", "CELL", 82, 96], ["macrophage", "CELL", 147, 157], ["M1 and M2 macrophages", "CELL_LINE", 75, 96], ["macrophage function", "TEST", 147, 166], ["M2", "ANATOMY", 82, 84]]], ["M1 macrophages mainly rely on glycolysis for energy, while M2 macrophages primarily use oxidative phosphorylation.", [["M1 macrophages", "ANATOMY", 0, 14], ["macrophages", "ANATOMY", 62, 73], ["M1 macrophages", "CELL", 0, 14], ["M2 macrophages", "CELL", 59, 73], ["M1 macrophages", "CELL_LINE", 0, 14], ["M2 macrophages", "CELL_TYPE", 59, 73], ["M1 macrophages", "PROBLEM", 0, 14], ["glycolysis", "TEST", 30, 40], ["oxidative phosphorylation", "TREATMENT", 88, 113]]], ["Accumulation of succinate in M1 macrophages can stimulate HIF1\u03b1 to sustain production of factors such as IL-1\u03b2 and thus can impact the ability of M1 macrophages to prolong inflammation.", [["M1 macrophages", "ANATOMY", 29, 43], ["M1 macrophages", "ANATOMY", 146, 160], ["succinate", "CHEMICAL", 16, 25], ["inflammation", "DISEASE", 172, 184], ["succinate", "CHEMICAL", 16, 25], ["succinate", "SIMPLE_CHEMICAL", 16, 25], ["M1 macrophages", "CELL", 29, 43], ["HIF1\u03b1", "GENE_OR_GENE_PRODUCT", 58, 63], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 105, 110], ["M1 macrophages", "CELL", 146, 160], ["M1 macrophages", "CELL_TYPE", 29, 43], ["HIF1\u03b1", "PROTEIN", 58, 63], ["IL-1\u03b2", "PROTEIN", 105, 110], ["M1 macrophages", "CELL_TYPE", 146, 160], ["Accumulation of succinate in M1 macrophages", "PROBLEM", 0, 43], ["M1 macrophages", "PROBLEM", 146, 160], ["prolong inflammation", "PROBLEM", 164, 184], ["succinate", "OBSERVATION_MODIFIER", 16, 25], ["M1", "ANATOMY", 29, 31], ["inflammation", "OBSERVATION", 172, 184]]], ["Manipulation of NOS enzyme expression and activities as well as the products and consequences of the different metabolic processes in M1 and M2 macrophages should further our ability to shape the outcome of infections and other diseases.SUMMARYThe \"Fork in the Road\" that macrophages take in making either M1/inhibit or M2/heal-type responses define \"immunity\" throughout the animal kingdom.", [["M1", "ANATOMY", 134, 136], ["M2 macrophages", "ANATOMY", 141, 155], ["macrophages", "ANATOMY", 272, 283], ["infections", "DISEASE", 207, 217], ["NOS enzyme", "GENE_OR_GENE_PRODUCT", 16, 26], ["M1", "CELL", 134, 136], ["M2 macrophages", "CELL", 141, 155], ["macrophages", "CELL", 272, 283], ["M2", "GENE_OR_GENE_PRODUCT", 320, 322], ["NOS enzyme", "PROTEIN", 16, 26], ["M1 and M2 macrophages", "CELL_LINE", 134, 155], ["macrophages", "CELL_TYPE", 272, 283], ["NOS enzyme expression", "TEST", 16, 37], ["infections", "PROBLEM", 207, 217], ["other diseases", "PROBLEM", 222, 236], ["NOS", "OBSERVATION", 16, 19], ["enzyme expression", "OBSERVATION", 20, 37], ["infections", "OBSERVATION", 207, 217], ["heal", "ANATOMY", 323, 327]]], ["In all animals, M1/inhibittype responses are the primary host defense, and M2/heal-type responses help repair and replace lost or effete tissue to maintain host homeostasis.", [["tissue", "ANATOMY", 137, 143], ["M1", "CELL", 16, 18], ["inhibittype", "GENE_OR_GENE_PRODUCT", 19, 30], ["M2", "GENE_OR_GENE_PRODUCT", 75, 77], ["tissue", "TISSUE", 137, 143], ["repair", "TREATMENT", 103, 109], ["effete tissue", "PROBLEM", 130, 143], ["heal", "ANATOMY", 78, 82], ["host homeostasis", "OBSERVATION", 156, 172]]], ["In humans (and other higher animals), macrophage M1/inhibit or M2/heal-type responses necessarily direct T (and B) cells/adaptive immunity to make Th1 or Th2like responses.", [["macrophage M1", "ANATOMY", 38, 51], ["T (and B) cells", "ANATOMY", 105, 120], ["humans", "ORGANISM", 3, 9], ["macrophage M1", "CELL", 38, 51], ["M2", "GENE_OR_GENE_PRODUCT", 63, 65], ["T (and B) cells", "CELL", 105, 120], ["Th1", "GENE_OR_GENE_PRODUCT", 147, 150], ["Th2like", "GENE_OR_GENE_PRODUCT", 154, 161], ["T (and B) cells", "CELL_TYPE", 105, 120], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["macrophage M1/inhibit", "PROBLEM", 38, 59], ["direct T (and B) cells/adaptive immunity", "TREATMENT", 98, 138], ["heal", "ANATOMY", 66, 70]]], ["Thus, whether acting directly or indirectly, which \"fork\" macrophages take is the central controlling element that promotes health (as in pathogen control or wound repair) or impedes health (as in atherosclerosis, autoimmunity, or cancer).", [["macrophages", "ANATOMY", 58, 69], ["wound", "ANATOMY", 158, 163], ["cancer", "ANATOMY", 231, 237], ["atherosclerosis", "DISEASE", 197, 212], ["autoimmunity", "DISEASE", 214, 226], ["cancer", "DISEASE", 231, 237], ["macrophages", "CELL", 58, 69], ["wound", "PATHOLOGICAL_FORMATION", 158, 163], ["cancer", "CANCER", 231, 237], ["macrophages", "CELL_TYPE", 58, 69], ["pathogen control", "TREATMENT", 138, 154], ["wound repair", "TREATMENT", 158, 170], ["atherosclerosis", "PROBLEM", 197, 212], ["autoimmunity", "PROBLEM", 214, 226], ["cancer", "PROBLEM", 231, 237], ["atherosclerosis", "OBSERVATION", 197, 212]]], ["By illuminating the biochemical underpinnings, evolution, diseases, and regulation of macrophage functions, the papers in this Topic advance our understanding of how to modulate this most important of all leukocytes: the chicken and the egg of immunity (1).", [["macrophage", "ANATOMY", 86, 96], ["leukocytes", "ANATOMY", 205, 215], ["egg", "ANATOMY", 237, 240], ["macrophage", "CELL", 86, 96], ["leukocytes", "CELL", 205, 215], ["chicken", "ORGANISM", 221, 228], ["leukocytes", "CELL_TYPE", 205, 215], ["chicken", "SPECIES", 221, 228], ["chicken", "SPECIES", 221, 228], ["diseases", "PROBLEM", 58, 66], ["macrophage functions", "PROBLEM", 86, 106], ["diseases", "OBSERVATION", 58, 66]]]], "b8a5c7868098ce0bd4d5fa9cd1d66510758184ad": [["IntroductionThe level of cell surface expression of class I and class II products of the major histocompatibility complex (MHC) (HLA in humans) varies widely among different cell types and it seems to be determined not only by their ontogenic lineage but to be also influenced by the direct action of several inducers and modulators.", [["cell surface", "ANATOMY", 25, 37], ["cell", "ANATOMY", 174, 178], ["cell", "CELL", 25, 29], ["class I", "GENE_OR_GENE_PRODUCT", 52, 59], ["major histocompatibility complex", "GENE_OR_GENE_PRODUCT", 89, 121], ["humans", "ORGANISM", 136, 142], ["cell", "CELL", 174, 178], ["class I and class II products", "PROTEIN", 52, 81], ["major histocompatibility complex", "PROTEIN", 89, 121], ["MHC", "PROTEIN", 123, 126], ["HLA", "PROTEIN", 129, 132], ["ontogenic lineage", "CELL_TYPE", 233, 250], ["humans", "SPECIES", 136, 142], ["humans", "SPECIES", 136, 142], ["different cell types", "OBSERVATION", 164, 184]]], ["Of the latter, the best known are lymphokines and in particular those belonging to the interferon (IFN) family (Review in Pujol-Borrell and .", [["interferon", "GENE_OR_GENE_PRODUCT", 87, 97], ["IFN", "GENE_OR_GENE_PRODUCT", 99, 102], ["lymphokines", "PROTEIN", 34, 45], ["interferon (IFN) family", "PROTEIN", 87, 110], ["lymphokines", "OBSERVATION", 34, 45]]], ["Recently, tumour necrosis factor (TNF-a) and lymphotoxin (LT or TNF-fl) , produced by macrophages and T lymphocytes respectively, have also been found to induce and/or enhance HLA molecule expression in certain systems (Collins et al., 1986; Pfizenmaier et al., 1987; .IntroductionOur previous work has clearly indicated that human endocrine cells have different sensitivities to the in vitro effect of lympho/monokines with regard to the induction of HLA class II expression.", [["macrophages", "ANATOMY", 86, 97], ["T lymphocytes", "ANATOMY", 102, 115], ["endocrine cells", "ANATOMY", 332, 347], ["tumour necrosis", "DISEASE", 10, 25], ["tumour necrosis factor", "GENE_OR_GENE_PRODUCT", 10, 32], ["TNF-a", "GENE_OR_GENE_PRODUCT", 34, 39], ["lymphotoxin", "GENE_OR_GENE_PRODUCT", 45, 56], ["LT", "GENE_OR_GENE_PRODUCT", 58, 60], ["TNF-fl", "GENE_OR_GENE_PRODUCT", 64, 70], ["macrophages", "CELL", 86, 97], ["T lymphocytes", "CELL", 102, 115], ["HLA molecule", "GENE_OR_GENE_PRODUCT", 176, 188], ["human", "ORGANISM", 326, 331], ["endocrine cells", "CELL", 332, 347], ["HLA class II", "GENE_OR_GENE_PRODUCT", 452, 464], ["tumour necrosis factor", "PROTEIN", 10, 32], ["TNF", "PROTEIN", 34, 37], ["lymphotoxin", "PROTEIN", 45, 56], ["LT", "PROTEIN", 58, 60], ["TNF", "PROTEIN", 64, 67], ["macrophages", "CELL_TYPE", 86, 97], ["T lymphocytes", "CELL_TYPE", 102, 115], ["HLA molecule", "PROTEIN", 176, 188], ["human endocrine cells", "CELL_TYPE", 326, 347], ["HLA class II", "PROTEIN", 452, 464], ["human", "SPECIES", 326, 331], ["human", "SPECIES", 326, 331], ["tumour necrosis factor", "PROBLEM", 10, 32], ["TNF", "TEST", 34, 37], ["lymphotoxin (LT or TNF", "TEST", 45, 67], ["human endocrine cells", "PROBLEM", 326, 347], ["different sensitivities", "PROBLEM", 353, 376], ["lympho/monokines", "TREATMENT", 403, 419], ["tumour", "OBSERVATION_MODIFIER", 10, 16], ["necrosis", "OBSERVATION", 17, 25], ["lymphotoxin", "ANATOMY", 45, 56], ["LT", "ANATOMY", 58, 60], ["macrophages", "ANATOMY", 86, 97]]], ["Thus viable thyrocytes are easily inducible following incubation with mitogens (Pujol-Borrell et al., 1983) or IFN-3, , but pancreatic islet cells are much more resistant to the elicitation of this phenomenon when exposed to the same or other putative modulators .", [["thyrocytes", "ANATOMY", 12, 22], ["pancreatic islet cells", "ANATOMY", 124, 146], ["thyrocytes", "CELL", 12, 22], ["IFN-3", "GENE_OR_GENE_PRODUCT", 111, 116], ["pancreatic islet cells", "CELL", 124, 146], ["thyrocytes", "CELL_TYPE", 12, 22], ["IFN", "PROTEIN", 111, 114], ["pancreatic islet cells", "CELL_TYPE", 124, 146], ["mitogens", "TEST", 70, 78], ["Pujol", "TEST", 80, 85], ["IFN", "TEST", 111, 114], ["pancreatic islet cells", "PROBLEM", 124, 146], ["this phenomenon", "PROBLEM", 193, 208], ["thyrocytes", "OBSERVATION", 12, 22], ["pancreatic", "ANATOMY", 124, 134], ["islet cells", "OBSERVATION", 135, 146]]], ["In fact, using islet cell cultures, it was only the combination of TNF or LT with IFN-'t which ultimately produced the first positive results .IntroductionThese latter studies were prompted by the interest generated by the hypothesis that endocrine cells inappropriately expressing HLA class II could present their own surface autoantigens to helper T cells and in this way generate an autoirnmune response .", [["islet cell cultures", "ANATOMY", 15, 34], ["endocrine cells", "ANATOMY", 239, 254], ["surface", "ANATOMY", 319, 326], ["T cells", "ANATOMY", 350, 357], ["islet cell cultures", "CELL", 15, 34], ["TNF", "GENE_OR_GENE_PRODUCT", 67, 70], ["LT", "GENE_OR_GENE_PRODUCT", 74, 76], ["IFN", "GENE_OR_GENE_PRODUCT", 82, 85], ["endocrine cells", "CELL", 239, 254], ["HLA class II", "GENE_OR_GENE_PRODUCT", 282, 294], ["T cells", "CELL", 350, 357], ["islet cell cultures", "CELL_LINE", 15, 34], ["TNF", "PROTEIN", 67, 70], ["LT", "PROTEIN", 74, 76], ["IFN", "PROTEIN", 82, 85], ["endocrine cells", "CELL_TYPE", 239, 254], ["HLA class II", "PROTEIN", 282, 294], ["surface autoantigens", "PROTEIN", 319, 339], ["helper T cells", "CELL_TYPE", 343, 357], ["islet cell cultures", "TEST", 15, 34], ["TNF", "PROBLEM", 67, 70], ["IFN", "TEST", 82, 85], ["These latter studies", "TEST", 155, 175]]], ["This postulation was based on the observation that thyroid cells have the capacity for de novo expression of class II molecules (Pujol-Borrell et al., 1983) , and the finding that in thyroid glands affected by autoimmune disorders, the follicular cells strongly expressed class II ).", [["thyroid cells", "ANATOMY", 51, 64], ["thyroid glands", "ANATOMY", 183, 197], ["follicular cells", "ANATOMY", 236, 252], ["thyroid glands", "DISEASE", 183, 197], ["autoimmune disorders", "DISEASE", 210, 230], ["thyroid cells", "CELL", 51, 64], ["thyroid glands", "ORGAN", 183, 197], ["follicular cells", "CELL", 236, 252], ["thyroid cells", "CELL_TYPE", 51, 64], ["class II molecules", "PROTEIN", 109, 127], ["follicular cells", "CELL_TYPE", 236, 252], ["class II", "PROTEIN", 272, 280], ["thyroid cells", "PROBLEM", 51, 64], ["thyroid glands", "PROBLEM", 183, 197], ["autoimmune disorders", "PROBLEM", 210, 230], ["the follicular cells", "PROBLEM", 232, 252], ["thyroid glands", "ANATOMY", 183, 197]]], ["Since the above hypothesis was proposed, the occurrence of inappropriate class II expression has been documented in the target organs of many organ-specific autoimmune diseases (Review in Bottazzo et al., 1986) and the ability of class II-positive thyroid cells to present antigen to T cells has been experimentally demonstrated (Londei et al., 1984 (Londei et al., , 1985 .IntroductionThe identification of class II-positive astrocytes in the active 'plaques' of patients with multiple sclerosis (MS) has attracted a great deal of interest and has led to the suggestion that astrocytes inappropriately expressing class II molecules in vivo could play a role relevant to the pathogenesis of MS (Traugott et al., 1985) , a hypothesis which is somewhat parallel to that originally proposed by us .IntroductionAs an extension of our interests, we report here the results obtained in studies on the inducibility of HLA molecules on human fetal brain cells in culture and their differential sensitivity to the action of a variety of stimuli known to be potent modulators of HLA expression in other cell types.Cell culturesTissue was obtained from 26 fetal brain specimens (provided by the Medical Research Council Tissue Bank, Royal Marsden Hospital, London, U.K.), after legal terminations carried out by aspiration between 11 and 19 weeks of gestation.", [["organs", "ANATOMY", 127, 133], ["organ", "ANATOMY", 142, 147], ["thyroid cells", "ANATOMY", 248, 261], ["T cells", "ANATOMY", 284, 291], ["astrocytes", "ANATOMY", 426, 436], ["plaques", "ANATOMY", 452, 459], ["astrocytes", "ANATOMY", 576, 586], ["fetal brain cells", "ANATOMY", 934, 951], ["cell", "ANATOMY", 1093, 1097], ["Cell cultures", "ANATOMY", 1104, 1117], ["Tissue", "ANATOMY", 1117, 1123], ["fetal brain specimens", "ANATOMY", 1145, 1166], ["autoimmune diseases", "DISEASE", 157, 176], ["multiple sclerosis", "DISEASE", 478, 496], ["MS", "DISEASE", 498, 500], ["MS", "DISEASE", 691, 693], ["inappropriate class II", "GENE_OR_GENE_PRODUCT", 59, 81], ["organs", "ORGAN", 127, 133], ["organ", "ORGAN", 142, 147], ["class II", "GENE_OR_GENE_PRODUCT", 230, 238], ["thyroid cells", "CELL", 248, 261], ["T cells", "CELL", 284, 291], ["class II", "GENE_OR_GENE_PRODUCT", 408, 416], ["plaques", "PATHOLOGICAL_FORMATION", 452, 459], ["patients", "ORGANISM", 464, 472], ["astrocytes", "CELL", 576, 586], ["class II molecules", "GENE_OR_GENE_PRODUCT", 614, 632], ["HLA", "GENE_OR_GENE_PRODUCT", 911, 914], ["human", "ORGANISM", 928, 933], ["fetal brain cells", "CELL", 934, 951], ["HLA", "GENE_OR_GENE_PRODUCT", 1069, 1072], ["cell", "CELL", 1093, 1097], ["Cell cultures", "CELL", 1104, 1117], ["Tissue", "TISSUE", 1117, 1123], ["brain specimens", "TISSUE", 1151, 1166], ["class II-positive thyroid cells", "CELL_TYPE", 230, 261], ["T cells", "CELL_TYPE", 284, 291], ["class II-positive astrocytes", "CELL_TYPE", 408, 436], ["astrocytes", "CELL_TYPE", 576, 586], ["class II molecules", "PROTEIN", 614, 632], ["HLA molecules", "PROTEIN", 911, 924], ["human fetal brain cells", "CELL_TYPE", 928, 951], ["patients", "SPECIES", 464, 472], ["human", "SPECIES", 928, 933], ["human", "SPECIES", 928, 933], ["inappropriate class II expression", "PROBLEM", 59, 92], ["specific autoimmune diseases", "PROBLEM", 148, 176], ["positive thyroid cells", "PROBLEM", 239, 261], ["class II-positive astrocytes", "PROBLEM", 408, 436], ["multiple sclerosis (MS)", "PROBLEM", 478, 501], ["a hypothesis", "PROBLEM", 720, 732], ["HLA molecules", "PROBLEM", 911, 924], ["human fetal brain cells", "PROBLEM", 928, 951], ["culture", "TEST", 955, 962], ["HLA expression in other cell types", "PROBLEM", 1069, 1103], ["Cell cultures", "TEST", 1104, 1117], ["fetal brain specimens", "TEST", 1145, 1166], ["aspiration", "PROBLEM", 1301, 1311], ["organ", "ANATOMY", 142, 147], ["autoimmune diseases", "OBSERVATION", 157, 176], ["thyroid", "ANATOMY", 248, 255], ["positive astrocytes", "OBSERVATION", 417, 436], ["active", "OBSERVATION_MODIFIER", 444, 450], ["multiple", "OBSERVATION_MODIFIER", 478, 486], ["sclerosis", "OBSERVATION", 487, 496], ["brain", "ANATOMY", 940, 945], ["cell types", "OBSERVATION", 1093, 1103], ["aspiration", "OBSERVATION", 1301, 1311]]], ["The experimental protocol described here was approved by the University College/Middlesex Hospital Ethical Committee.Cell culturesThe meninges and visible vessels were carefully removed from the brain, tissue was washed with Hanks' balanced salt solution containing 1% bovine serum albumin (BSS-BSA), minced with scissors and forceps and digested for 15 min at 37\u00b0C in a solution which contained 0.25% trypsin (Sigma, London, U.K.), and 0.04% DNAse (DNAse 25, Sigma, London, U.K.) in Dulbecco's modified Eagle's medium (DMEM, Gibco, Paisley, Scotland, U.K.).", [["Cell cultures", "ANATOMY", 117, 130], ["meninges", "ANATOMY", 134, 142], ["vessels", "ANATOMY", 155, 162], ["brain", "ANATOMY", 195, 200], ["tissue", "ANATOMY", 202, 208], ["serum", "ANATOMY", 276, 281], ["BSS-BSA", "CHEMICAL", 291, 298], ["Cell cultures", "CELL", 117, 130], ["meninges", "MULTI-TISSUE_STRUCTURE", 134, 142], ["visible vessels", "MULTI-TISSUE_STRUCTURE", 147, 162], ["brain", "ORGAN", 195, 200], ["tissue", "TISSUE", 202, 208], ["bovine", "ORGANISM", 269, 275], ["serum", "ORGANISM_SUBSTANCE", 276, 281], ["albumin", "SIMPLE_CHEMICAL", 282, 289], ["BSS-BSA", "SIMPLE_CHEMICAL", 291, 298], ["trypsin", "SIMPLE_CHEMICAL", 402, 409], ["DNAse", "SIMPLE_CHEMICAL", 443, 448], ["bovine", "SPECIES", 269, 275], ["bovine", "SPECIES", 269, 275], ["Cell cultures", "TEST", 117, 130], ["Hanks' balanced salt solution", "TREATMENT", 225, 254], ["1% bovine serum albumin", "TREATMENT", 266, 289], ["scissors and forceps", "TREATMENT", 313, 333], ["meninges", "ANATOMY", 134, 142], ["visible", "ANATOMY_MODIFIER", 147, 154], ["vessels", "ANATOMY", 155, 162], ["brain", "ANATOMY", 195, 200], ["tissue", "ANATOMY", 202, 208]]], ["Digestion was stopped by the addition of 10% fetal calf serum (FCS, Gibco).", [["fetal calf serum", "ANATOMY", 45, 61], ["fetal calf", "ORGANISM_SUBSTANCE", 45, 55], ["serum", "ORGANISM_SUBSTANCE", 56, 61], ["FCS", "ORGANISM_SUBSTANCE", 63, 66], ["Gibco", "ORGANISM_SUBSTANCE", 68, 73], ["calf", "SPECIES", 51, 55], ["10% fetal calf serum (FCS", "TREATMENT", 41, 66], ["calf", "ANATOMY", 51, 55]]], ["The undigested tissue was further disrupted by repeated pipetting.", [["tissue", "ANATOMY", 15, 21], ["tissue", "TISSUE", 15, 21], ["The undigested tissue", "PROBLEM", 0, 21], ["repeated pipetting", "TREATMENT", 47, 65], ["undigested tissue", "OBSERVATION", 4, 21]]], ["The digest was passed through a 300 #m nylon mesh to remove large fragments, pelleted by centrifugation at 800 rpm for 10 min and resuspended in 'complete medium'.", [["fragments", "ANATOMY", 66, 75], ["#m nylon mesh", "TREATMENT", 36, 49], ["large fragments", "PROBLEM", 60, 75], ["nylon mesh", "OBSERVATION", 39, 49], ["large", "OBSERVATION_MODIFIER", 60, 65], ["fragments", "OBSERVATION", 66, 75]]], ["This consisted of 45% DMEM, 45% F12 (Flow, Irvine, Scotland, U.K.), 10% FCS, glucose 500 mg/100 ml, glutamine 2 mM, gentamicin 40 gg/ml, and penicillin 50 gg/ml.", [["glucose", "CHEMICAL", 77, 84], ["glutamine", "CHEMICAL", 100, 109], ["gentamicin", "CHEMICAL", 116, 126], ["penicillin", "CHEMICAL", 141, 151], ["glucose", "CHEMICAL", 77, 84], ["glutamine", "CHEMICAL", 100, 109], ["gentamicin", "CHEMICAL", 116, 126], ["penicillin", "CHEMICAL", 141, 151], ["glucose", "SIMPLE_CHEMICAL", 77, 84], ["glutamine", "SIMPLE_CHEMICAL", 100, 109], ["gentamicin", "SIMPLE_CHEMICAL", 116, 126], ["penicillin", "SIMPLE_CHEMICAL", 141, 151], ["45% DMEM", "TREATMENT", 18, 26], ["glucose", "TEST", 77, 84], ["glutamine", "TREATMENT", 100, 109], ["gentamicin", "TREATMENT", 116, 126], ["penicillin", "TREATMENT", 141, 151]]], ["Cells were counted and viability, as assessed by differential staining with acridine orange/ethidium bromide under a UV microscope, was always close to 100%.", [["Cells", "ANATOMY", 0, 5], ["acridine orange", "CHEMICAL", 76, 91], ["ethidium bromide", "CHEMICAL", 92, 108], ["acridine orange", "CHEMICAL", 76, 91], ["ethidium bromide", "CHEMICAL", 92, 108], ["Cells", "CELL", 0, 5], ["acridine orange", "SIMPLE_CHEMICAL", 76, 91], ["ethidium bromide", "SIMPLE_CHEMICAL", 92, 108], ["Cells", "TEST", 0, 5], ["acridine orange", "TREATMENT", 76, 91], ["ethidium bromide", "TREATMENT", 92, 108], ["a UV microscope", "TEST", 115, 130]]], ["Aliquots of 105 cells were plated on glass coverslips (13 mm diameter), placed in 24-multiwell plates (Nunc, Kamstrud, Denmark) and 'complete medium' added to a final volume of 0.5 ml/well.", [["Aliquots", "ANATOMY", 0, 8], ["cells", "ANATOMY", 16, 21], ["cells", "CELL", 16, 21], ["105 cells", "CELL_LINE", 12, 21], ["Aliquots of 105 cells", "TREATMENT", 0, 21], ["glass coverslips", "TREATMENT", 37, 53], ["a final volume", "TREATMENT", 159, 173], ["105 cells", "OBSERVATION_MODIFIER", 12, 21]]], ["Cultures were kept at 37\u00b0C in a 5% CO 2 humidified incubator and left undisturbed for 4 days.", [["CO", "CHEMICAL", 35, 37], ["Cultures", "TEST", 0, 8], ["a 5% CO 2 humidified incubator", "TREATMENT", 30, 60], ["left", "ANATOMY_MODIFIER", 65, 69]]], ["In some instances small fragments of brain tissue were directly snap frozen and stored at -70\u00b0C until used for immunofluorescence studies on cryostat sections.Indirect immunofluorescence (IFL) staining of cell cultures and cryostat sectionsGiven the complexity of the architecture of the brain tissue and the heterogeneity of cell types present in primary cultures prepared from it, a two-colour IFL technique was employed throughout the study combining monoclonal antibodies (MoAbs) to HLA products with monoclonal or polyclonal antibodies to different cell markers (Review in .", [["fragments", "ANATOMY", 24, 33], ["brain tissue", "ANATOMY", 37, 49], ["sections", "ANATOMY", 150, 158], ["cell cultures", "ANATOMY", 205, 218], ["sections", "ANATOMY", 232, 240], ["brain tissue", "ANATOMY", 288, 300], ["cell", "ANATOMY", 326, 330], ["primary cultures", "ANATOMY", 348, 364], ["cell", "ANATOMY", 554, 558], ["brain tissue", "TISSUE", 37, 49], ["cell cultures", "CELL", 205, 218], ["brain tissue", "TISSUE", 288, 300], ["cell", "CELL", 326, 330], ["cell", "CELL", 554, 558], ["primary cultures", "CELL_LINE", 348, 364], ["monoclonal antibodies", "PROTEIN", 454, 475], ["MoAbs", "PROTEIN", 477, 482], ["HLA products", "PROTEIN", 487, 499], ["monoclonal or polyclonal antibodies", "PROTEIN", 505, 540], ["small fragments of brain tissue", "PROBLEM", 18, 49], ["immunofluorescence studies", "TEST", 111, 137], ["cryostat sections", "TEST", 141, 158], ["Indirect immunofluorescence", "TEST", 159, 186], ["cell cultures", "TEST", 205, 218], ["cryostat sections", "TEST", 223, 240], ["the brain tissue", "PROBLEM", 284, 300], ["cell types", "PROBLEM", 326, 336], ["primary cultures", "TEST", 348, 364], ["a two-colour IFL technique", "TREATMENT", 383, 409], ["the study", "TEST", 434, 443], ["monoclonal antibodies (MoAbs", "TREATMENT", 454, 482], ["HLA products", "TREATMENT", 487, 499], ["monoclonal or polyclonal antibodies", "TREATMENT", 505, 540], ["small", "OBSERVATION_MODIFIER", 18, 23], ["fragments", "OBSERVATION", 24, 33], ["brain tissue", "ANATOMY", 37, 49], ["brain tissue", "ANATOMY", 288, 300], ["heterogeneity", "OBSERVATION_MODIFIER", 309, 322], ["cell types", "OBSERVATION", 326, 336]]], ["This ensured the precise identification of positive and negative cells under observation.", [["cells", "ANATOMY", 65, 70], ["cells", "CELL", 65, 70], ["positive and negative cells", "CELL_TYPE", 43, 70], ["negative cells", "OBSERVATION", 56, 70]]], ["Cryostat sections and monolayer cultures were stained similarly following the same protocols.", [["Cryostat sections", "ANATOMY", 0, 17], ["monolayer cultures", "ANATOMY", 22, 40], ["monolayer cultures", "CELL", 22, 40], ["monolayer cultures", "CELL_LINE", 22, 40], ["Cryostat sections", "TEST", 0, 17], ["monolayer cultures", "TEST", 22, 40]]], ["For the identification of HLA class I and II molecules the following staining protocols were applied (for the specificity and source of the antibody used, see Table 1 ).", [["HLA class I", "GENE_OR_GENE_PRODUCT", 26, 37], ["HLA class I and II molecules", "PROTEIN", 26, 54], ["antibody", "PROTEIN", 140, 148], ["staining protocols", "TEST", 69, 87], ["the antibody", "TEST", 136, 148]]], ["HLA class L 1st layer: MoAb W6/32; 2nd layer: TRITC-conjugated goat anti-mouse IgG; 3rd layer and 4th layer: either rabbit anti-glial fibrillary acidic protein (astrocytes) or rabbit anti-factor VIII (endothelial cells) followed by FITClabelled goat anti-rabbit Ig or MoAb 04 (oligodendrocytes) followed by FITC goat anti-mouse IgM.Indirect immunofluorescence (IFL) staining of cell cultures and cryostat sectionsHLA class 11.", [["4th layer", "ANATOMY", 98, 107], ["astrocytes", "ANATOMY", 161, 171], ["endothelial cells", "ANATOMY", 201, 218], ["oligodendrocytes", "ANATOMY", 277, 293], ["cell cultures", "ANATOMY", 378, 391], ["FITC", "CHEMICAL", 307, 311], ["TRITC", "SIMPLE_CHEMICAL", 46, 51], ["rabbit", "ORGANISM", 116, 122], ["anti-glial fibrillary acidic protein", "GENE_OR_GENE_PRODUCT", 123, 159], ["astrocytes", "CELL", 161, 171], ["rabbit anti-factor VIII", "GENE_OR_GENE_PRODUCT", 176, 199], ["endothelial cells", "CELL", 201, 218], ["Ig", "GENE_OR_GENE_PRODUCT", 262, 264], ["MoAb 04", "GENE_OR_GENE_PRODUCT", 268, 275], ["oligodendrocytes", "CELL", 277, 293], ["FITC", "GENE_OR_GENE_PRODUCT", 307, 311], ["cell cultures", "CELL", 378, 391], ["MoAb", "PROTEIN", 23, 27], ["TRITC-conjugated goat anti-mouse IgG", "PROTEIN", 46, 82], ["rabbit anti-glial fibrillary acidic protein", "PROTEIN", 116, 159], ["astrocytes", "CELL_TYPE", 161, 171], ["rabbit anti-factor VIII", "PROTEIN", 176, 199], ["endothelial cells", "CELL_TYPE", 201, 218], ["FITClabelled goat anti-rabbit Ig", "PROTEIN", 232, 264], ["MoAb 04", "PROTEIN", 268, 275], ["oligodendrocytes", "CELL_TYPE", 277, 293], ["FITC goat anti-mouse IgM", "PROTEIN", 307, 331], ["goat", "SPECIES", 63, 67], ["anti-mouse", "SPECIES", 68, 78], ["rabbit", "SPECIES", 116, 122], ["rabbit", "SPECIES", 176, 182], ["goat", "SPECIES", 245, 249], ["anti-rabbit", "SPECIES", 250, 261], ["goat", "SPECIES", 312, 316], ["anti-mouse", "SPECIES", 317, 327], ["goat", "SPECIES", 63, 67], ["rabbit", "SPECIES", 116, 122], ["rabbit", "SPECIES", 176, 182], ["goat", "SPECIES", 245, 249], ["goat", "SPECIES", 312, 316], ["HLA class", "TEST", 0, 9], ["MoAb", "TEST", 23, 27], ["2nd layer", "TEST", 35, 44], ["TRITC", "TEST", 46, 51], ["conjugated goat anti-mouse IgG", "TEST", 52, 82], ["rabbit anti-glial fibrillary acidic protein (astrocytes", "PROBLEM", 116, 171], ["rabbit anti-factor VIII (endothelial cells", "TREATMENT", 176, 218], ["FITClabelled goat anti-rabbit Ig", "TREATMENT", 232, 264], ["Indirect immunofluorescence", "TEST", 332, 359], ["cell cultures", "TEST", 378, 391], ["cryostat sectionsHLA class", "TEST", 396, 422], ["cell", "OBSERVATION", 378, 382]]], ["(Using IgG MoAbs to class II) 1st layer: MoAb MID3 (class II), Tu22 (DQ specific), B7/21 (DP specific) or VIC-Y1 (class II invariant chain specific); 2nd layer: TRITC-labelled goat anti-mouse IgG; 3rd layer and 4th layer: either rabbit anti-glial fibrillary acidic protein (GFAP) followed by FITC-labelled goat anti-rabbit Ig or MoAb 04 followed by FITC-labelled goat anti-mouse IgM.Indirect immunofluorescence (IFL) staining of cell cultures and cryostat sectionsHLA class II.", [["cell cultures", "ANATOMY", 429, 442], ["FITC", "CHEMICAL", 292, 296], ["FITC", "CHEMICAL", 349, 353], ["MoAb MID3 (class II", "GENE_OR_GENE_PRODUCT", 41, 60], ["Tu22 (DQ", "GENE_OR_GENE_PRODUCT", 63, 71], ["B7/21", "GENE_OR_GENE_PRODUCT", 83, 88], ["VIC-Y1", "GENE_OR_GENE_PRODUCT", 106, 112], ["class II invariant chain", "GENE_OR_GENE_PRODUCT", 114, 138], ["TRITC", "SIMPLE_CHEMICAL", 161, 166], ["goat", "ORGANISM", 176, 180], ["rabbit", "ORGANISM", 229, 235], ["anti-glial fibrillary acidic protein", "GENE_OR_GENE_PRODUCT", 236, 272], ["GFAP", "GENE_OR_GENE_PRODUCT", 274, 278], ["FITC", "SIMPLE_CHEMICAL", 292, 296], ["goat", "ORGANISM", 306, 310], ["anti-rabbit Ig", "GENE_OR_GENE_PRODUCT", 311, 325], ["MoAb 04", "SIMPLE_CHEMICAL", 329, 336], ["FITC", "SIMPLE_CHEMICAL", 349, 353], ["goat", "ORGANISM", 363, 367], ["cell cultures", "CELL", 429, 442], ["IgG MoAbs", "PROTEIN", 7, 16], ["MoAb MID3", "PROTEIN", 41, 50], ["class II", "PROTEIN", 52, 60], ["Tu22", "PROTEIN", 63, 67], ["DQ", "PROTEIN", 69, 71], ["B7", "PROTEIN", 83, 85], ["21", "PROTEIN", 86, 88], ["DP", "PROTEIN", 90, 92], ["VIC", "PROTEIN", 106, 109], ["Y1", "PROTEIN", 110, 112], ["class II invariant chain", "PROTEIN", 114, 138], ["TRITC-labelled goat anti-mouse IgG", "PROTEIN", 161, 195], ["rabbit anti-glial fibrillary acidic protein", "PROTEIN", 229, 272], ["GFAP", "PROTEIN", 274, 278], ["FITC-labelled goat anti-rabbit Ig", "PROTEIN", 292, 325], ["MoAb 04", "PROTEIN", 329, 336], ["FITC-labelled goat anti-mouse IgM", "PROTEIN", 349, 382], ["cell cultures", "CELL_LINE", 429, 442], ["goat", "SPECIES", 176, 180], ["anti-mouse", "SPECIES", 181, 191], ["rabbit", "SPECIES", 229, 235], ["goat", "SPECIES", 306, 310], ["anti-rabbit", "SPECIES", 311, 322], ["goat", "SPECIES", 363, 367], ["anti-mouse", "SPECIES", 368, 378], ["goat", "SPECIES", 176, 180], ["rabbit", "SPECIES", 229, 235], ["goat", "SPECIES", 306, 310], ["goat", "SPECIES", 363, 367], ["B7", "TEST", 83, 85], ["DP specific", "TEST", 90, 101], ["TRITC", "TEST", 161, 166], ["labelled goat anti-mouse IgG", "TEST", 167, 195], ["GFAP", "TEST", 274, 278], ["FITC", "TEST", 292, 296], ["FITC", "TEST", 349, 353], ["Indirect immunofluorescence", "TEST", 383, 410], ["cell cultures", "TEST", 429, 442], ["cell", "OBSERVATION", 429, 433]]], ["(Using RFDR1 IgM MoAb to class II) 1st layer: MoAb RFDR1 (class II); 2nd layer: FITC goat anti-mouse IgM; 3rd layer: MoAbs GC (oligodendrocytes), 308 (astrocytes), or RT.97 (neurons); 4th layer: TRITC-labelled goat anti-mouse IgG.Indirect immunofluorescence (IFL) staining of cell cultures and cryostat sectionsMoAbs were used at a final concentration of 10 /~g/ml.", [["oligodendrocytes", "ANATOMY", 127, 143], ["astrocytes", "ANATOMY", 151, 161], ["neurons", "ANATOMY", 174, 181], ["cell cultures", "ANATOMY", 276, 289], ["sections", "ANATOMY", 303, 311], ["FITC", "CHEMICAL", 80, 84], ["FITC", "GENE_OR_GENE_PRODUCT", 80, 84], ["MoAbs GC (oligodendrocytes)", "GENE_OR_GENE_PRODUCT", 117, 144], ["astrocytes", "CELL", 151, 161], ["neurons", "CELL", 174, 181], ["TRITC", "SIMPLE_CHEMICAL", 195, 200], ["goat", "ORGANISM", 210, 214], ["cell cultures", "CELL", 276, 289], ["RFDR1 IgM MoAb", "PROTEIN", 7, 21], ["MoAb RFDR1", "PROTEIN", 46, 56], ["class II", "PROTEIN", 58, 66], ["FITC goat anti-mouse IgM", "PROTEIN", 80, 104], ["MoAbs GC", "CELL_TYPE", 117, 125], ["oligodendrocytes", "CELL_TYPE", 127, 143], ["astrocytes", "CELL_TYPE", 151, 161], ["TRITC-labelled goat anti-mouse IgG", "PROTEIN", 195, 229], ["cell cultures", "CELL_LINE", 276, 289], ["MoAbs", "PROTEIN", 311, 316], ["goat", "SPECIES", 85, 89], ["anti-mouse", "SPECIES", 90, 100], ["goat", "SPECIES", 210, 214], ["anti-mouse", "SPECIES", 215, 225], ["goat", "SPECIES", 210, 214], ["FITC goat anti-mouse IgM", "TEST", 80, 104], ["MoAbs GC", "TEST", 117, 125], ["oligodendrocytes", "TEST", 127, 143], ["astrocytes", "TEST", 151, 161], ["TRITC-labelled goat anti-mouse IgG", "TREATMENT", 195, 229], ["Indirect immunofluorescence", "TEST", 230, 257], ["cell cultures", "TEST", 276, 289], ["cryostat sectionsMoAbs", "TREATMENT", 294, 316], ["cell", "OBSERVATION", 276, 280]]], ["Unstimulated control cultures were always stained in parallel with treated cultures.", [["cultures", "ANATOMY", 21, 29], ["treated cultures", "CELL_LINE", 67, 83], ["Unstimulated control cultures", "TEST", 0, 29], ["treated cultures", "TEST", 67, 83]]], ["In addition, nonspecific binding was ruled out by staining parallel stimulated cultures with an unrelated MoAb of the same Ig class.", [["MoAb", "GENE_OR_GENE_PRODUCT", 106, 110], ["Ig", "GENE_OR_GENE_PRODUCT", 123, 125], ["stimulated cultures", "CELL_LINE", 68, 87], ["MoAb", "PROTEIN", 106, 110], ["Ig class", "PROTEIN", 123, 131], ["nonspecific binding", "PROBLEM", 13, 32], ["staining parallel stimulated cultures", "TEST", 50, 87], ["nonspecific", "OBSERVATION_MODIFIER", 13, 24]]], ["Undesirable cross-reactivities among reagents derived from different species were assessed by omitting one of the layers in turn.Indirect immunofluorescence (IFL) staining of cell cultures and cryostat sectionsTo determine HLA membrane expression, viable cultures were incubated with the corresponding MoAbs, stained by the appropriate conjugate and then, prior to counterstaining with antibodies to cell-specific cytoplasmic antigens, cultures were fixed with methane/acetone (50:50, v/v) for 10 min.", [["cell cultures", "ANATOMY", 175, 188], ["sections", "ANATOMY", 202, 210], ["HLA membrane", "ANATOMY", 223, 235], ["cultures", "ANATOMY", 255, 263], ["cell", "ANATOMY", 400, 404], ["cytoplasmic", "ANATOMY", 414, 425], ["methane/acetone", "CHEMICAL", 461, 476], ["methane", "CHEMICAL", 461, 468], ["acetone", "CHEMICAL", 469, 476], ["cell cultures", "CELL", 175, 188], ["HLA", "GENE_OR_GENE_PRODUCT", 223, 226], ["MoAbs", "GENE_OR_GENE_PRODUCT", 302, 307], ["cell", "CELL", 400, 404], ["cytoplasmic", "ORGANISM_SUBSTANCE", 414, 425], ["methane", "SIMPLE_CHEMICAL", 461, 468], ["acetone", "SIMPLE_CHEMICAL", 469, 476], ["MoAbs", "PROTEIN", 302, 307], ["antibodies", "PROTEIN", 386, 396], ["cytoplasmic antigens", "PROTEIN", 414, 434], ["Undesirable cross-reactivities", "PROBLEM", 0, 30], ["different species", "PROBLEM", 59, 76], ["Indirect immunofluorescence", "TEST", 129, 156], ["cell cultures", "TEST", 175, 188], ["cryostat sections", "TEST", 193, 210], ["HLA membrane expression", "PROBLEM", 223, 246], ["viable cultures", "TEST", 248, 263], ["the corresponding MoAbs", "TEST", 284, 307], ["antibodies", "TREATMENT", 386, 396], ["cultures", "TEST", 436, 444], ["methane/acetone", "TREATMENT", 461, 476]]], ["When the second antibody was recoLmizing membrane antigens distinct from HLA molecules, the fixation step was done at the end of the entire procedure.", [["membrane", "ANATOMY", 41, 49], ["HLA molecules", "GENE_OR_GENE_PRODUCT", 73, 86], ["recoLmizing membrane antigens", "PROTEIN", 29, 58], ["HLA molecules", "PROTEIN", 73, 86], ["the second antibody", "TEST", 5, 24], ["membrane antigens", "PROBLEM", 41, 58], ["the fixation step", "TEST", 88, 105], ["the entire procedure", "TREATMENT", 129, 149]]], ["For the detection of cytoplasmic class I, class II and class II invariant chain the cultures were fixed prior to the staining.Indirect immunofluorescence (IFL) staining of cell cultures and cryostat sectionsAll preparations were examined with a x 63 oil immersion objective using a Zeiss III UV photomicroscope equipped with epi-illumination and phase contrast.", [["cytoplasmic", "ANATOMY", 21, 32], ["cultures", "ANATOMY", 84, 92], ["cell cultures", "ANATOMY", 172, 185], ["sections", "ANATOMY", 199, 207], ["cytoplasmic", "ORGANISM_SUBSTANCE", 21, 32], ["class II", "GENE_OR_GENE_PRODUCT", 42, 50], ["class II invariant chain", "GENE_OR_GENE_PRODUCT", 55, 79], ["cell cultures", "CELL", 172, 185], ["cytoplasmic class I", "PROTEIN", 21, 40], ["class II and class II invariant chain", "PROTEIN", 42, 79], ["the cultures", "TEST", 80, 92], ["the staining", "TEST", 113, 125], ["Indirect immunofluorescence", "TEST", 126, 153], ["cell cultures", "TEST", 172, 185], ["cryostat sections", "TEST", 190, 207], ["a Zeiss III UV photomicroscope", "TREATMENT", 280, 310], ["epi-illumination and phase contrast", "TEST", 325, 360], ["chain", "OBSERVATION_MODIFIER", 74, 79]]], ["Fluorescence intensity in both membrane and cytoplasm was evaluated in 200-500 cells per culture except in the case of oligodendrocytes where, given their small number, only fewer cells (around 50) could be evaluated.", [["membrane", "ANATOMY", 31, 39], ["cytoplasm", "ANATOMY", 44, 53], ["cells", "ANATOMY", 79, 84], ["oligodendrocytes", "ANATOMY", 119, 135], ["cells", "ANATOMY", 180, 185], ["membrane", "CELLULAR_COMPONENT", 31, 39], ["cytoplasm", "ORGANISM_SUBSTANCE", 44, 53], ["cells", "CELL", 79, 84], ["oligodendrocytes", "CELL", 119, 135], ["cells", "CELL", 180, 185], ["oligodendrocytes", "CELL_TYPE", 119, 135], ["Fluorescence intensity", "TEST", 0, 22], ["culture", "TEST", 89, 96], ["oligodendrocytes", "PROBLEM", 119, 135], ["intensity", "OBSERVATION_MODIFIER", 13, 22], ["both membrane", "ANATOMY", 26, 39], ["oligodendrocytes", "OBSERVATION", 119, 135], ["small", "OBSERVATION_MODIFIER", 155, 160], ["number", "OBSERVATION_MODIFIER", 161, 167]]], ["IFL intensity was arbitrarily scored from negative to 3 +.", [["IFL", "SIMPLE_CHEMICAL", 0, 3], ["IFL", "PROTEIN", 0, 3], ["IFL intensity", "TEST", 0, 13]]], ["Table 2 lists the various biological and chemical compounds used to induce HLA product expression on human fetal brain cells in culture. \u2022 This compound was tested only for its effect on astrocyte MHC expression.Cryostat sectionsIn sections from three different human fetuses stained for neurofilaments with the MoAb RT.97, the soma of neurons was clearly visible among the complex network of fibres, while the antiserum to glial fibrillary acidic protein (anti-GFAP) produced a very intricate reticular pattern which was denser around the vessels.", [["fetal brain cells", "ANATOMY", 107, 124], ["astrocyte", "ANATOMY", 187, 196], ["sections", "ANATOMY", 221, 229], ["sections", "ANATOMY", 232, 240], ["fetuses", "ANATOMY", 268, 275], ["neurofilaments", "ANATOMY", 288, 302], ["soma", "ANATOMY", 328, 332], ["neurons", "ANATOMY", 336, 343], ["fibres", "ANATOMY", 393, 399], ["reticular", "ANATOMY", 494, 503], ["vessels", "ANATOMY", 540, 547], ["human", "ORGANISM", 101, 106], ["fetal brain cells", "CELL", 107, 124], ["astrocyte MHC", "GENE_OR_GENE_PRODUCT", 187, 200], ["sections", "MULTI-TISSUE_STRUCTURE", 232, 240], ["human", "ORGANISM", 262, 267], ["fetuses", "DEVELOPING_ANATOMICAL_STRUCTURE", 268, 275], ["neurofilaments", "GENE_OR_GENE_PRODUCT", 288, 302], ["soma", "CELLULAR_COMPONENT", 328, 332], ["neurons", "CELL", 336, 343], ["fibres", "TISSUE", 393, 399], ["antiserum", "ORGANISM_SUBSTANCE", 411, 420], ["glial fibrillary acidic protein", "GENE_OR_GENE_PRODUCT", 424, 455], ["anti-GFAP", "GENE_OR_GENE_PRODUCT", 457, 466], ["vessels", "MULTI-TISSUE_STRUCTURE", 540, 547], ["HLA product", "PROTEIN", 75, 86], ["human fetal brain cells", "CELL_TYPE", 101, 124], ["MHC", "PROTEIN", 197, 200], ["neurofilaments", "PROTEIN", 288, 302], ["MoAb", "PROTEIN", 312, 316], ["glial fibrillary acidic protein", "PROTEIN", 424, 455], ["GFAP", "PROTEIN", 462, 466], ["human", "SPECIES", 101, 106], ["human", "SPECIES", 262, 267], ["human", "SPECIES", 101, 106], ["human", "SPECIES", 262, 267], ["chemical compounds", "TREATMENT", 41, 59], ["human fetal brain cells", "PROBLEM", 101, 124], ["culture", "TEST", 128, 135], ["Cryostat sections", "TEST", 212, 229], ["neurofilaments", "TEST", 288, 302], ["the MoAb RT", "TEST", 308, 319], ["glial fibrillary acidic protein", "TEST", 424, 455], ["anti-GFAP", "TEST", 457, 466], ["a very intricate reticular pattern", "PROBLEM", 477, 511], ["brain", "ANATOMY", 113, 118], ["neurons", "ANATOMY", 336, 343], ["reticular pattern", "OBSERVATION", 494, 511], ["denser", "OBSERVATION_MODIFIER", 522, 528], ["vessels", "ANATOMY", 540, 547]]], ["In successive sections stained for class I, the only cells clearly positive were the endothelial cells lining the capillaries, these identified by antibodies to factor VIII.", [["sections", "ANATOMY", 14, 22], ["cells", "ANATOMY", 53, 58], ["endothelial cells", "ANATOMY", 85, 102], ["capillaries", "ANATOMY", 114, 125], ["cells", "CELL", 53, 58], ["endothelial cells", "CELL", 85, 102], ["capillaries", "TISSUE", 114, 125], ["antibodies to factor VIII", "GENE_OR_GENE_PRODUCT", 147, 172], ["class I", "PROTEIN", 35, 42], ["endothelial cells", "CELL_TYPE", 85, 102], ["antibodies", "PROTEIN", 147, 157], ["factor VIII", "PROTEIN", 161, 172], ["endothelial cells", "OBSERVATION", 85, 102], ["capillaries", "ANATOMY", 114, 125]]], ["In spite of careful and intensive search, no cells positive for class II products were detected in the parenchyma or in the vessels of the brain when sections were stained with the appropriate MoAbs.Monolayer cultures (a) Cell organization and identification.Cell attachment occurred as early as 24 h by the time most preparations were processed, between days 6 and 12, cultures showed a complex organization similar to that described by Dickson et at.", [["cells", "ANATOMY", 45, 50], ["parenchyma", "ANATOMY", 103, 113], ["vessels", "ANATOMY", 124, 131], ["brain", "ANATOMY", 139, 144], ["sections", "ANATOMY", 150, 158], ["Monolayer cultures", "ANATOMY", 199, 217], ["Cell", "ANATOMY", 222, 226], ["Cell", "ANATOMY", 259, 263], ["cells", "CELL", 45, 50], ["class II products", "GENE_OR_GENE_PRODUCT", 64, 81], ["parenchyma", "TISSUE", 103, 113], ["vessels", "MULTI-TISSUE_STRUCTURE", 124, 131], ["brain", "ORGAN", 139, 144], ["sections", "MULTI-TISSUE_STRUCTURE", 150, 158], ["MoAbs", "GENE_OR_GENE_PRODUCT", 193, 198], ["Monolayer cultures", "CELL", 199, 217], ["Cell", "CELL", 222, 226], ["Cell", "CELL", 259, 263], ["class II products", "PROTEIN", 64, 81], ["MoAbs", "PROTEIN", 193, 198], ["cells", "PROBLEM", 45, 50], ["class II products", "PROBLEM", 64, 81], ["Monolayer cultures", "TEST", 199, 217], ["identification", "TEST", 244, 258], ["Cell attachment", "PROBLEM", 259, 274], ["cultures", "TEST", 370, 378], ["a complex organization", "PROBLEM", 386, 408], ["parenchyma", "ANATOMY_MODIFIER", 103, 113], ["vessels", "ANATOMY", 124, 131], ["brain", "ANATOMY", 139, 144]]], ["Cells with long processes identified as neurons (RT.97 +) and oligodendrocytes (04 +) (see Fig. la-d) laid on a carpet of astrocytes (GFAP +) (Fig. 2b ) (Raft et at., 1979) .", [["Cells", "ANATOMY", 0, 5], ["neurons", "ANATOMY", 40, 47], ["oligodendrocytes", "ANATOMY", 62, 78], ["astrocytes", "ANATOMY", 122, 132], ["Cells", "CELL", 0, 5], ["neurons", "CELL", 40, 47], ["RT.97 +)", "GENE_OR_GENE_PRODUCT", 49, 57], ["oligodendrocytes", "CELL", 62, 78], ["astrocytes", "CELL", 122, 132], ["GFAP", "GENE_OR_GENE_PRODUCT", 134, 138], ["oligodendrocytes", "CELL_TYPE", 62, 78], ["astrocytes", "CELL_TYPE", 122, 132], ["GFAP", "PROTEIN", 134, 138], ["long processes", "PROBLEM", 11, 25], ["neurons", "TEST", 40, 47], ["oligodendrocytes", "TEST", 62, 78], ["GFAP", "TEST", 134, 138], ["astrocytes", "ANATOMY", 122, 132]]], ["The long processes of the neurons were arranged in dearly distinct bundles forming bridges among clusters of cells which seemed to serve as orga~i7Jng centres.", [["neurons", "ANATOMY", 26, 33], ["bundles", "ANATOMY", 67, 74], ["cells", "ANATOMY", 109, 114], ["neurons", "CELL", 26, 33], ["cells", "CELL", 109, 114], ["neurons", "ANATOMY", 26, 33]]], ["Immature ofigodendrocytes were present in smaller numbers compared to neurons and were often located in the periphery of these clusters, their intricate branching processes completing the complex three-dimensional network in which all the cells were included.", [["ofigodendrocytes", "ANATOMY", 9, 25], ["neurons", "ANATOMY", 70, 77], ["cells", "ANATOMY", 239, 244], ["ofigodendrocytes", "GENE_OR_GENE_PRODUCT", 9, 25], ["neurons", "CELL", 70, 77], ["cells", "CELL", 239, 244], ["neurons", "CELL_TYPE", 70, 77], ["Immature ofigodendrocytes", "PROBLEM", 0, 25], ["ofigodendrocytes", "OBSERVATION", 9, 25], ["smaller", "OBSERVATION_MODIFIER", 42, 49], ["numbers", "OBSERVATION_MODIFIER", 50, 57], ["periphery", "ANATOMY_MODIFIER", 108, 117], ["branching", "OBSERVATION_MODIFIER", 153, 162]]], ["The number of neurons decreased during the period of culture but even after 30 days these cells were quite numerous in the monolayers.", [["neurons", "ANATOMY", 14, 21], ["cells", "ANATOMY", 90, 95], ["monolayers", "ANATOMY", 123, 133], ["neurons", "CELL", 14, 21], ["cells", "CELL", 90, 95], ["monolayers", "CELL", 123, 133], ["culture", "TEST", 53, 60], ["these cells", "PROBLEM", 84, 95], ["number", "OBSERVATION_MODIFIER", 4, 10], ["neurons", "OBSERVATION_MODIFIER", 14, 21], ["decreased", "OBSERVATION_MODIFIER", 22, 31]]], ["Fibronectinpositive cells (fibroblasts) presumably derived from contaminating meningeal cells, were very scarce in the initial days and, although their number increased with time, they never overgrew the other cell types even after 4 weeks in culture.", [["Fibronectinpositive cells", "ANATOMY", 0, 25], ["fibroblasts", "ANATOMY", 27, 38], ["meningeal cells", "ANATOMY", 78, 93], ["cell", "ANATOMY", 210, 214], ["Fibronectinpositive cells", "CELL", 0, 25], ["fibroblasts", "CELL", 27, 38], ["meningeal cells", "CELL", 78, 93], ["cell", "CELL", 210, 214], ["Fibronectinpositive cells", "CELL_TYPE", 0, 25], ["fibroblasts", "CELL_TYPE", 27, 38], ["contaminating meningeal cells", "CELL_TYPE", 64, 93], ["Fibronectinpositive cells (fibroblasts)", "PROBLEM", 0, 39], ["contaminating meningeal cells", "PROBLEM", 64, 93], ["culture", "TEST", 243, 250], ["meningeal cells", "OBSERVATION", 78, 93], ["very", "OBSERVATION_MODIFIER", 100, 104], ["scarce", "OBSERVATION_MODIFIER", 105, 111]]], ["Attempts were not made to identify microglial cells because we lacked specific reagents to recognize them.", [["microglial cells", "ANATOMY", 35, 51], ["microglial cells", "CELL", 35, 51], ["microglial cells", "CELL_TYPE", 35, 51], ["microglial cells", "PROBLEM", 35, 51]]], ["Endothelial cells were not present in our monolayers, probably due to their inability to grow on glass surfaces (Zetter, 1981) .Monolayer cultures (a) Cell organization and identification.(b) Basal expression of HLA molecules.", [["Endothelial cells", "ANATOMY", 0, 17], ["monolayers", "ANATOMY", 42, 52], ["Monolayer cultures", "ANATOMY", 128, 146], ["Cell", "ANATOMY", 151, 155], ["Endothelial cells", "CELL", 0, 17], ["monolayers", "CELL", 42, 52], ["Monolayer cultures", "CELL", 128, 146], ["Cell", "CELL", 151, 155], ["HLA molecules", "GENE_OR_GENE_PRODUCT", 212, 225], ["Endothelial cells", "CELL_TYPE", 0, 17], ["HLA molecules", "PROTEIN", 212, 225], ["Endothelial cells", "PROBLEM", 0, 17], ["Monolayer cultures", "TEST", 128, 146], ["HLA molecules", "PROBLEM", 212, 225], ["cells", "OBSERVATION", 12, 17], ["HLA molecules", "OBSERVATION", 212, 225]]], ["Class I molecules were consistently detected throughout the culture period on astrocytes but not on oligodendrocytes or neurons ( Fig. 2a and b) .", [["astrocytes", "ANATOMY", 78, 88], ["oligodendrocytes", "ANATOMY", 100, 116], ["neurons", "ANATOMY", 120, 127], ["Class I molecules", "GENE_OR_GENE_PRODUCT", 0, 17], ["astrocytes", "CELL", 78, 88], ["oligodendrocytes", "CELL", 100, 116], ["neurons", "CELL", 120, 127], ["Class I molecules", "PROTEIN", 0, 17], ["astrocytes", "CELL_TYPE", 78, 88], ["oligodendrocytes", "CELL_TYPE", 100, 116], ["neurons", "CELL_TYPE", 120, 127], ["Class I molecules", "PROBLEM", 0, 17], ["the culture", "TEST", 56, 67], ["astrocytes", "PROBLEM", 78, 88]]], ["Class II molecules were seen in less than 1% of the cells in the culture up to day 3.", [["cells", "ANATOMY", 52, 57], ["Class II molecules", "GENE_OR_GENE_PRODUCT", 0, 18], ["cells", "CELL", 52, 57], ["Class II molecules", "PROTEIN", 0, 18], ["Class II molecules", "PROBLEM", 0, 18], ["the culture", "TEST", 61, 72]]], ["However, astrocytes (identified by GFAP-positive staining) became gradually class II positive, and by day 20, around 50% of them showed a clear and bright staining ( Fig. 2c and d, time-course in Fig. 3 ).", [["astrocytes", "ANATOMY", 9, 19], ["astrocytes", "CELL", 9, 19], ["GFAP", "GENE_OR_GENE_PRODUCT", 35, 39], ["astrocytes", "CELL_TYPE", 9, 19], ["GFAP", "PROTEIN", 35, 39], ["astrocytes", "TEST", 9, 19], ["GFAP", "TEST", 35, 39], ["positive staining", "PROBLEM", 40, 57], ["gradually class II positive", "PROBLEM", 66, 93], ["bright staining", "PROBLEM", 148, 163], ["astrocytes", "ANATOMY", 9, 19], ["clear", "OBSERVATION", 138, 143], ["bright staining", "OBSERVATION", 148, 163]]], ["This 'spontaneous' class II expression was observed in both the protoplasmic and the fibrous type of astrocytes (identified by their morphology under phase contrast and confirmed by GFAP + staining) and also in the astrocyte subtype recently defined by the 308 MoAb (Dickson et at., 1983) .", [["protoplasmic", "ANATOMY", 64, 76], ["fibrous type", "ANATOMY", 85, 97], ["astrocytes", "ANATOMY", 101, 111], ["astrocyte", "ANATOMY", 215, 224], ["class II", "GENE_OR_GENE_PRODUCT", 19, 27], ["protoplasmic", "CELLULAR_COMPONENT", 64, 76], ["astrocytes", "CELL", 101, 111], ["GFAP", "GENE_OR_GENE_PRODUCT", 182, 186], ["astrocyte", "CELL", 215, 224], ["astrocytes", "CELL_TYPE", 101, 111], ["GFAP", "PROTEIN", 182, 186], ["308 MoAb", "PROTEIN", 257, 265], ["phase contrast", "TEST", 150, 164], ["GFAP + staining", "TEST", 182, 197], ["fibrous", "OBSERVATION_MODIFIER", 85, 92], ["astrocytes", "ANATOMY", 101, 111], ["astrocyte subtype", "ANATOMY", 215, 232]]], ["Astrocyte class II expression included also HLA-DP and DQ subregion products and did not depend on the gestational age of the fetal brain.", [["fetal brain", "ANATOMY", 126, 137], ["Astrocyte class II", "GENE_OR_GENE_PRODUCT", 0, 18], ["HLA-DP", "GENE_OR_GENE_PRODUCT", 44, 50], ["fetal brain", "ORGAN", 126, 137], ["Astrocyte class II", "PROTEIN", 0, 18], ["HLA", "PROTEIN", 44, 47], ["DP", "ANATOMY", 48, 50], ["fetal brain", "ANATOMY", 126, 137]]], ["Passive absorption of class II molecules to the membrane of the astrocytes could be excluded by the concomitant detection of the non-secretory class II invariant chain in the cytoplasm of these cells when they were stained with MoAb VIC-Y1.", [["membrane", "ANATOMY", 48, 56], ["astrocytes", "ANATOMY", 64, 74], ["cytoplasm", "ANATOMY", 175, 184], ["cells", "ANATOMY", 194, 199], ["class II molecules", "GENE_OR_GENE_PRODUCT", 22, 40], ["membrane", "CELLULAR_COMPONENT", 48, 56], ["astrocytes", "CELL", 64, 74], ["cytoplasm", "ORGANISM_SUBSTANCE", 175, 184], ["cells", "CELL", 194, 199], ["VIC-Y1", "GENE_OR_GENE_PRODUCT", 233, 239], ["class II molecules", "PROTEIN", 22, 40], ["astrocytes", "CELL_TYPE", 64, 74], ["non-secretory class II invariant chain", "PROTEIN", 129, 167], ["MoAb", "PROTEIN", 228, 232], ["Passive absorption of class II molecules", "TREATMENT", 0, 40], ["membrane", "ANATOMY_MODIFIER", 48, 56], ["astrocytes", "ANATOMY", 64, 74], ["could be excluded", "UNCERTAINTY", 75, 92], ["chain", "OBSERVATION_MODIFIER", 162, 167]]], ["The other cell types (neurons and oligodendrocytes) remained negative throughout the culture period (up to 30 days).", [["cell", "ANATOMY", 10, 14], ["neurons", "ANATOMY", 22, 29], ["oligodendrocytes", "ANATOMY", 34, 50], ["cell", "CELL", 10, 14], ["neurons", "CELL", 22, 29], ["oligodendrocytes", "CELL", 34, 50], ["neurons", "CELL_TYPE", 22, 29], ["oligodendrocytes", "CELL_TYPE", 34, 50], ["cell types", "OBSERVATION", 10, 20], ["negative", "OBSERVATION", 61, 69]]], ["For the reasons mentioned above, microghal or endothelial cells could not be detected.", [["microghal", "ANATOMY", 33, 42], ["endothelial cells", "ANATOMY", 46, 63], ["microghal", "CELL", 33, 42], ["endothelial cells", "CELL", 46, 63], ["microghal or endothelial cells", "CELL_TYPE", 33, 63], ["microghal or endothelial cells", "PROBLEM", 33, 63], ["endothelial cells", "OBSERVATION", 46, 63], ["could not be detected", "UNCERTAINTY", 64, 85]]], ["Table 2 were tested during the initial 8 days of culture when the percentage of spontaneously positive astrocytes was less than 15%, as to minimize the interference of the spontaneous expression of class II in astrocytes in the reading of the preparations (see above).", [["astrocytes", "ANATOMY", 103, 113], ["astrocytes", "ANATOMY", 210, 220], ["astrocytes", "CELL", 103, 113], ["class II", "GENE_OR_GENE_PRODUCT", 198, 206], ["astrocytes", "CELL", 210, 220], ["spontaneously positive astrocytes", "CELL_TYPE", 80, 113], ["class II", "PROTEIN", 198, 206], ["astrocytes", "CELL_TYPE", 210, 220], ["culture", "TEST", 49, 56], ["spontaneously positive astrocytes", "PROBLEM", 80, 113]]], ["Among the biological and chemical compounds used (Table 2) , only IFN-a, IFN-7 and TNF-a had a clear effect on HLA expression in the different cell types and the results are summarized in Table 3 .", [["cell", "ANATOMY", 143, 147], ["IFN-a", "GENE_OR_GENE_PRODUCT", 66, 71], ["IFN-7", "GENE_OR_GENE_PRODUCT", 73, 78], ["TNF", "GENE_OR_GENE_PRODUCT", 83, 86], ["HLA", "GENE_OR_GENE_PRODUCT", 111, 114], ["cell", "CELL", 143, 147], ["IFN", "PROTEIN", 66, 69], ["IFN", "PROTEIN", 73, 76], ["TNF", "PROTEIN", 83, 86], ["IFN", "TEST", 66, 69], ["IFN", "TEST", 73, 76], ["TNF", "TEST", 83, 86], ["HLA expression", "PROBLEM", 111, 125], ["different cell", "OBSERVATION_MODIFIER", 133, 147]]], ["Neurons and oligodendrocytes both = Astrocytes did not express class II in the early stages of culture, but an increasing percentage were found spontaneously positive after 6 days in culture (see text and Fig. 4) . lacked class I expression in basal conditions but, while the former remained always negative, oligodendrocytes acquired a clear membrane staining for class I after culture with either IFN-T or TNF-a (Fig. 4) .", [["Neurons", "ANATOMY", 0, 7], ["oligodendrocytes", "ANATOMY", 12, 28], ["Astrocytes", "ANATOMY", 36, 46], ["oligodendrocytes", "ANATOMY", 309, 325], ["membrane", "ANATOMY", 343, 351], ["Neurons", "CELL", 0, 7], ["oligodendrocytes", "CELL", 12, 28], ["Astrocytes", "CELL", 36, 46], ["class I", "GENE_OR_GENE_PRODUCT", 222, 229], ["oligodendrocytes", "CELL", 309, 325], ["membrane", "CELLULAR_COMPONENT", 343, 351], ["IFN-T", "GENE_OR_GENE_PRODUCT", 399, 404], ["TNF", "GENE_OR_GENE_PRODUCT", 408, 411], ["oligodendrocytes", "CELL_TYPE", 12, 28], ["Astrocytes", "CELL_TYPE", 36, 46], ["class II", "PROTEIN", 63, 71], ["oligodendrocytes", "CELL_TYPE", 309, 325], ["class I", "PROTEIN", 365, 372], ["IFN-T", "PROTEIN", 399, 404], ["TNF", "PROTEIN", 408, 411], ["culture", "TEST", 95, 102], ["an increasing percentage", "PROBLEM", 108, 132], ["culture", "TEST", 183, 190], ["culture", "TEST", 379, 386], ["TNF", "TEST", 408, 411], ["basal", "ANATOMY_MODIFIER", 244, 249]]], ["IFN-a and IFN-T both produced an increase in class I expression in astrocytes and fibroblasts.", [["astrocytes", "ANATOMY", 67, 77], ["fibroblasts", "ANATOMY", 82, 93], ["N-T", "CHEMICAL", 12, 15], ["IFN", "GENE_OR_GENE_PRODUCT", 0, 3], ["IFN-T", "GENE_OR_GENE_PRODUCT", 10, 15], ["class I", "GENE_OR_GENE_PRODUCT", 45, 52], ["astrocytes", "CELL", 67, 77], ["fibroblasts", "CELL", 82, 93], ["IFN", "PROTEIN", 0, 3], ["astrocytes", "CELL_TYPE", 67, 77], ["fibroblasts", "CELL_TYPE", 82, 93], ["fibroblasts", "PROBLEM", 82, 93], ["increase", "OBSERVATION_MODIFIER", 33, 41], ["astrocytes", "ANATOMY", 67, 77], ["fibroblasts", "OBSERVATION", 82, 93]]], ["None of the mediators or chemicals tested were able to induce class II expression in neurons or oligodendrocytes, and this also applies to the combination of IFN-T and TNF-a.", [["neurons", "ANATOMY", 85, 92], ["oligodendrocytes", "ANATOMY", 96, 112], ["class II", "GENE_OR_GENE_PRODUCT", 62, 70], ["neurons", "CELL", 85, 92], ["oligodendrocytes", "CELL", 96, 112], ["IFN-T", "GENE_OR_GENE_PRODUCT", 158, 163], ["TNF-a.", "GENE_OR_GENE_PRODUCT", 168, 174], ["neurons", "CELL_TYPE", 85, 92], ["oligodendrocytes", "CELL_TYPE", 96, 112], ["TNF", "PROTEIN", 168, 171], ["oligodendrocytes", "PROBLEM", 96, 112]]], ["IFN-~, was able to produce a dramatic increase in the number of astrocytes positive for membrane and cytoplasmic class II and 4 days after the addition of 1000 U/ml to the cultures, all GFAP-positive cells were stained for class II.", [["astrocytes", "ANATOMY", 64, 74], ["membrane", "ANATOMY", 88, 96], ["cytoplasmic", "ANATOMY", 101, 112], ["cultures", "ANATOMY", 172, 180], ["GFAP-positive cells", "ANATOMY", 186, 205], ["IFN", "CHEMICAL", 0, 3], ["IFN", "GENE_OR_GENE_PRODUCT", 0, 3], ["astrocytes", "CELL", 64, 74], ["membrane", "CELLULAR_COMPONENT", 88, 96], ["cytoplasmic", "ORGANISM_SUBSTANCE", 101, 112], ["class II", "GENE_OR_GENE_PRODUCT", 113, 121], ["GFAP", "GENE_OR_GENE_PRODUCT", 186, 190], ["IFN", "PROTEIN", 0, 3], ["astrocytes", "CELL_TYPE", 64, 74], ["cytoplasmic class II", "PROTEIN", 101, 121], ["GFAP", "PROTEIN", 186, 190], ["class II", "PROTEIN", 223, 231], ["a dramatic increase", "PROBLEM", 27, 46], ["the cultures", "TEST", 168, 180], ["all GFAP", "TEST", 182, 190], ["positive cells", "PROBLEM", 191, 205], ["dramatic", "OBSERVATION_MODIFIER", 29, 37], ["increase", "OBSERVATION_MODIFIER", 38, 46], ["positive cells", "OBSERVATION", 191, 205]]], ["This effect was dose related (see Fig. 5 and legend) and was also detectable with the MoAb VIC-Y1 which reacts with the cytoplasmic invariant chain of class II products.", [["cytoplasmic", "ANATOMY", 120, 131], ["VIC-Y1", "GENE_OR_GENE_PRODUCT", 91, 97], ["cytoplasmic", "ORGANISM_SUBSTANCE", 120, 131], ["MoAb", "PROTEIN", 86, 90], ["cytoplasmic invariant chain", "PROTEIN", 120, 147], ["class II products", "PROTEIN", 151, 168]]], ["No apparent synergism was observed between IFN-~ and TNF-a in the induction of class II in astrocytes (Fig. 6 ).DiscussionIt has previously been reported that primary cultures of human fetal brain tissue can be a useful substrate for studying the expression of cell type-specific antigens, e.g. gangliosides, tetanus toxin receptors (Dickson et al., 1982 (Dickson et al., , 1985 , and the present data confirm that they can also be successfully employed to investigate the expression and modulation of HLA molecules.DiscussionOur findings that neurons do not express HLA class I or class II products in basal conditions are in agreement with previous reports using a similar culture system of murine origin (Wong et al., 1984; Dubois et al., 1985; Suzumura et al., 1985; Tedeschi et al., 1986) .", [["astrocytes", "ANATOMY", 91, 101], ["primary cultures", "ANATOMY", 159, 175], ["fetal brain tissue", "ANATOMY", 185, 203], ["cell", "ANATOMY", 261, 265], ["neurons", "ANATOMY", 544, 551], ["IFN-~", "GENE_OR_GENE_PRODUCT", 43, 48], ["TNF", "GENE_OR_GENE_PRODUCT", 53, 56], ["astrocytes", "CELL", 91, 101], ["human", "ORGANISM", 179, 184], ["fetal brain tissue", "TISSUE", 185, 203], ["cell", "CELL", 261, 265], ["gangliosides", "GENE_OR_GENE_PRODUCT", 295, 307], ["tetanus toxin receptors", "GENE_OR_GENE_PRODUCT", 309, 332], ["HLA molecules", "GENE_OR_GENE_PRODUCT", 502, 515], ["neurons", "CELL", 544, 551], ["HLA class I", "GENE_OR_GENE_PRODUCT", 567, 578], ["murine", "ORGANISM", 693, 699], ["IFN", "PROTEIN", 43, 46], ["TNF", "PROTEIN", 53, 56], ["class II", "PROTEIN", 79, 87], ["astrocytes", "CELL_TYPE", 91, 101], ["cell type-specific antigens", "PROTEIN", 261, 288], ["tetanus toxin receptors", "PROTEIN", 309, 332], ["HLA molecules", "PROTEIN", 502, 515], ["HLA class I", "PROTEIN", 567, 578], ["class II products", "PROTEIN", 582, 599], ["human", "SPECIES", 179, 184], ["murine", "SPECIES", 693, 699], ["human", "SPECIES", 179, 184], ["apparent synergism", "PROBLEM", 3, 21], ["IFN", "PROBLEM", 43, 46], ["TNF", "TEST", 53, 56], ["primary cultures", "TEST", 159, 175], ["human fetal brain tissue", "PROBLEM", 179, 203], ["cell type-specific antigens", "PROBLEM", 261, 288], ["apparent", "UNCERTAINTY", 3, 11], ["synergism", "OBSERVATION", 12, 21], ["brain", "ANATOMY", 191, 196]]], ["Neither IFN-7 nor TNF-a separately or in combination were able to induce class I or class II expression in human fetal neurons.", [["fetal neurons", "ANATOMY", 113, 126], ["IFN-7", "GENE_OR_GENE_PRODUCT", 8, 13], ["TNF-a", "GENE_OR_GENE_PRODUCT", 18, 23], ["class II", "GENE_OR_GENE_PRODUCT", 84, 92], ["human", "ORGANISM", 107, 112], ["fetal neurons", "CELL", 113, 126], ["IFN", "PROTEIN", 8, 11], ["TNF", "PROTEIN", 18, 21], ["human fetal neurons", "CELL_TYPE", 107, 126], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 107, 112], ["IFN", "TEST", 8, 11], ["class II expression in human fetal neurons", "PROBLEM", 84, 126], ["fetal neurons", "ANATOMY", 113, 126]]], ["With regard to class I expression our results differ from those reported by Wong et al. (1985) who showed that IFN-y can induce class I in up to 40% of mouse neurons, and from a similar report by Lampson et al. (1984 Lampson et al. ( , 1986 ) on a human neuroblastoma cell line.", [["neurons", "ANATOMY", 158, 165], ["neuroblastoma cell line", "ANATOMY", 254, 277], ["neuroblastoma", "DISEASE", 254, 267], ["class I", "GENE_OR_GENE_PRODUCT", 15, 22], ["IFN", "GENE_OR_GENE_PRODUCT", 111, 114], ["mouse", "ORGANISM", 152, 157], ["neurons", "CELL", 158, 165], ["human", "ORGANISM", 248, 253], ["neuroblastoma cell line", "CELL", 254, 277], ["IFN", "PROTEIN", 111, 114], ["class I", "PROTEIN", 128, 135], ["mouse neurons", "CELL_TYPE", 152, 165], ["human neuroblastoma cell line", "CELL_LINE", 248, 277], ["mouse", "SPECIES", 152, 157], ["human", "SPECIES", 248, 253], ["mouse", "SPECIES", 152, 157], ["human", "SPECIES", 248, 253], ["a human neuroblastoma cell line", "TREATMENT", 246, 277], ["neuroblastoma cell line", "OBSERVATION", 254, 277]]], ["Stages of development, species differences and neoplastic transformation could account for these apparent discrepancies.", [["neoplastic", "ANATOMY", 47, 57], ["species differences", "PROBLEM", 23, 42], ["neoplastic transformation", "PROBLEM", 47, 72], ["these apparent discrepancies", "PROBLEM", 91, 119], ["species", "OBSERVATION_MODIFIER", 23, 30], ["neoplastic transformation", "OBSERVATION", 47, 72], ["could account for", "UNCERTAINTY", 73, 90]]], ["Referring to class II molecules, our results agree with the generally accepted concept that cells of the neuronal lineage are refractory to the effect of available modulators, alone or in combinations, on the levels of HLA class II expression regardless of the species employed (Wong et ai., 1985) .", [["cells", "ANATOMY", 92, 97], ["neuronal lineage", "ANATOMY", 105, 121], ["cells", "CELL", 92, 97], ["neuronal lineage", "CELL", 105, 121], ["HLA class II", "GENE_OR_GENE_PRODUCT", 219, 231], ["class II molecules", "PROTEIN", 13, 31], ["neuronal lineage", "CELL_TYPE", 105, 121], ["HLA class II", "PROTEIN", 219, 231], ["available modulators", "TREATMENT", 154, 174]]], ["The inability of IFN-T to induce class I or class II in neurons contrasts with the strong positive modulation it produces on most cell types including terminally differentiated human cells such as thyrocytes and melanocytes (Houghton et al., 1984) .", [["neurons", "ANATOMY", 56, 63], ["cell", "ANATOMY", 130, 134], ["cells", "ANATOMY", 183, 188], ["thyrocytes", "ANATOMY", 197, 207], ["melanocytes", "ANATOMY", 212, 223], ["IFN-T", "GENE_OR_GENE_PRODUCT", 17, 22], ["class I", "GENE_OR_GENE_PRODUCT", 33, 40], ["class II", "GENE_OR_GENE_PRODUCT", 44, 52], ["neurons", "CELL", 56, 63], ["cell", "CELL", 130, 134], ["human", "ORGANISM", 177, 182], ["cells", "CELL", 183, 188], ["thyrocytes", "CELL", 197, 207], ["melanocytes", "CELL", 212, 223], ["IFN", "PROTEIN", 17, 20], ["class I or class II", "PROTEIN", 33, 52], ["terminally differentiated human cells", "CELL_TYPE", 151, 188], ["thyrocytes", "CELL_TYPE", 197, 207], ["melanocytes", "CELL_TYPE", 212, 223], ["human", "SPECIES", 177, 182], ["human", "SPECIES", 177, 182], ["class II in neurons contrasts", "PROBLEM", 44, 73], ["the strong positive modulation", "PROBLEM", 79, 109], ["terminally differentiated human cells", "PROBLEM", 151, 188], ["thyrocytes", "PROBLEM", 197, 207], ["most cell", "OBSERVATION_MODIFIER", 125, 134], ["terminally differentiated", "OBSERVATION_MODIFIER", 151, 176], ["human cells", "OBSERVATION", 177, 188]]], ["The biological meaning and molecular basis for this differential regulation are at present unknown.DiscussionThe potential of oligodendrocytes to express HLA products has been extensively studied, especially as these cells seem to be the target of the postulated autoimmune response in MS and experimental allergic encephalomyelitis (EAE).", [["oligodendrocytes", "ANATOMY", 126, 142], ["cells", "ANATOMY", 217, 222], ["MS", "DISEASE", 286, 288], ["allergic encephalomyelitis", "DISEASE", 306, 332], ["EAE", "DISEASE", 334, 337], ["oligodendrocytes", "CELL", 126, 142], ["HLA", "GENE_OR_GENE_PRODUCT", 154, 157], ["cells", "CELL", 217, 222], ["oligodendrocytes", "CELL_TYPE", 126, 142], ["HLA products", "PROTEIN", 154, 166], ["this differential regulation", "TEST", 47, 75], ["oligodendrocytes", "PROBLEM", 126, 142], ["HLA products", "TREATMENT", 154, 166], ["the postulated autoimmune response", "PROBLEM", 248, 282], ["MS", "PROBLEM", 286, 288], ["experimental allergic encephalomyelitis", "PROBLEM", 293, 332], ["allergic encephalomyelitis", "OBSERVATION", 306, 332]]], ["Our finding that human oligodendrocytes are constitutively negative for both class I and class II molecules but express class I after incubation with IFN-T is in agreement with numerous previous studies on cultures of murine brain cells and suggests the presence of receptors for IFN-T on the surface of these cells (Wong et al., 1984; Suzumura et al., 1985; Tedeschi et al., 1986) .", [["oligodendrocytes", "ANATOMY", 23, 39], ["cultures", "ANATOMY", 206, 214], ["brain cells", "ANATOMY", 225, 236], ["surface", "ANATOMY", 293, 300], ["cells", "ANATOMY", 310, 315], ["human", "ORGANISM", 17, 22], ["oligodendrocytes", "CELL", 23, 39], ["IFN-T", "GENE_OR_GENE_PRODUCT", 150, 155], ["murine", "ORGANISM", 218, 224], ["brain cells", "CELL", 225, 236], ["IFN-T", "GENE_OR_GENE_PRODUCT", 280, 285], ["surface", "CELLULAR_COMPONENT", 293, 300], ["cells", "CELL", 310, 315], ["human oligodendrocytes", "CELL_TYPE", 17, 39], ["class I and class II molecules", "PROTEIN", 77, 107], ["class I", "PROTEIN", 120, 127], ["IFN", "PROTEIN", 150, 153], ["murine brain cells", "CELL_TYPE", 218, 236], ["IFN", "PROTEIN", 280, 283], ["human", "SPECIES", 17, 22], ["murine", "SPECIES", 218, 224], ["human", "SPECIES", 17, 22], ["numerous previous studies", "TEST", 177, 202], ["cultures", "TEST", 206, 214], ["murine brain cells", "PROBLEM", 218, 236], ["IFN", "PROBLEM", 280, 283]]], ["More interesting is the observation that TNF-a can also induce class I expression in oligodendrocytes from human fetal brain.", [["oligodendrocytes", "ANATOMY", 85, 101], ["fetal brain", "ANATOMY", 113, 124], ["TNF", "GENE_OR_GENE_PRODUCT", 41, 44], ["class I", "GENE_OR_GENE_PRODUCT", 63, 70], ["oligodendrocytes", "CELL", 85, 101], ["human", "ORGANISM", 107, 112], ["fetal", "ORGAN", 113, 118], ["brain", "ORGAN", 119, 124], ["TNF", "PROTEIN", 41, 44], ["oligodendrocytes", "CELL_TYPE", 85, 101], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 107, 112], ["oligodendrocytes from human fetal brain", "PROBLEM", 85, 124], ["brain", "ANATOMY", 119, 124]]], ["Reports of a similar action of TNF-a on other cell types (Collins et al., 1986) have suggested that this may be one of the mechanisms through which this mediator exerts its anti-tumour action in vivo (Pfizenmaier et ai., 1987) .", [["cell", "ANATOMY", 46, 50], ["anti-tumour", "ANATOMY", 173, 184], ["TNF", "GENE_OR_GENE_PRODUCT", 31, 34], ["cell", "CELL", 46, 50], ["anti-tumour", "CANCER", 173, 184], ["TNF", "PROTEIN", 31, 34], ["TNF", "PROBLEM", 31, 34]]], ["Neither IFN-T or TNF-a alone or the combination of the two were able, however, to induce class II expression in oligodendrocytes in our system.", [["oligodendrocytes", "ANATOMY", 112, 128], ["IFN-T", "CHEMICAL", 8, 13], ["IFN-T", "GENE_OR_GENE_PRODUCT", 8, 13], ["TNF-a", "GENE_OR_GENE_PRODUCT", 17, 22], ["class II", "GENE_OR_GENE_PRODUCT", 89, 97], ["oligodendrocytes", "CELL", 112, 128], ["IFN", "PROTEIN", 8, 11], ["TNF", "PROTEIN", 17, 20], ["oligodendrocytes", "CELL_TYPE", 112, 128]]], ["This is in contrast with our recent findings which showed that human pancreatic islet cells, another cell type unresponsive to IFN-T alone, could be induced to express class II products by the synergistic action of IFN-T and TNF-a or -fl .", [["pancreatic islet cells", "ANATOMY", 69, 91], ["cell", "ANATOMY", 101, 105], ["IFN-T", "CHEMICAL", 127, 132], ["IFN-T", "CHEMICAL", 215, 220], ["human", "ORGANISM", 63, 68], ["pancreatic islet cells", "CELL", 69, 91], ["cell type", "CELL", 101, 110], ["IFN-T", "GENE_OR_GENE_PRODUCT", 127, 132], ["IFN-T", "GENE_OR_GENE_PRODUCT", 215, 220], ["TNF", "GENE_OR_GENE_PRODUCT", 225, 228], ["human pancreatic islet cells", "CELL_TYPE", 63, 91], ["IFN", "PROTEIN", 127, 130], ["class II products", "PROTEIN", 168, 185], ["IFN-T", "PROTEIN", 215, 220], ["TNF", "PROTEIN", 225, 228], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 63, 68], ["our recent findings", "TEST", 25, 44], ["human pancreatic islet cells", "PROBLEM", 63, 91], ["TNF", "TEST", 225, 228], ["pancreatic", "ANATOMY", 69, 79], ["islet cells", "OBSERVATION", 80, 91]]], ["There is no consensus in the literature on whether adult human oligodendrocytes can express class II molecules following incubation with IFN-T.", [["oligodendrocytes", "ANATOMY", 63, 79], ["human", "ORGANISM", 57, 62], ["oligodendrocytes", "CELL", 63, 79], ["IFN-T.", "GENE_OR_GENE_PRODUCT", 137, 143], ["adult human oligodendrocytes", "CELL_TYPE", 51, 79], ["class II molecules", "PROTEIN", 92, 110], ["IFN", "PROTEIN", 137, 140], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 57, 62], ["IFN", "TREATMENT", 137, 140], ["no", "UNCERTAINTY", 9, 11]]], ["Lysak et al. (1983) , like us, did not find class II expression in stimulated primary cultures while Kim (1985) and Kim et al. (1985) reported 4-16% of class II-positive oligodendrocytes (although only in half of the culture preparations); the reason for these differences remains at present unclear.DiscussionRegulation of HLA expression in astrocytes has also been extensively studied both in rodent (Hirsch et al., 1983; Wong et al., 1984; Dubois et al., 1985; Massa et al., 1986) and in human systems (Shen et al., 1985; Takiguchi et al., 1985) , again due to its potential importance in the pathogenesis of MS. Astrocytes expressing class II are present in the 'active' plaques in the brain of MS patients (Traugott et al., 1985) and, most importantly, it has been shown that they can present antigens to T cell clones in vitro (Fierz et al., 1985) .", [["primary cultures", "ANATOMY", 78, 94], ["oligodendrocytes", "ANATOMY", 170, 186], ["astrocytes", "ANATOMY", 342, 352], ["Astrocytes", "ANATOMY", 616, 626], ["plaques", "ANATOMY", 675, 682], ["brain", "ANATOMY", 690, 695], ["T cell clones", "ANATOMY", 810, 823], ["MS", "DISEASE", 612, 614], ["MS", "DISEASE", 699, 701], ["class II", "GENE_OR_GENE_PRODUCT", 152, 160], ["HLA", "GENE_OR_GENE_PRODUCT", 324, 327], ["astrocytes", "CELL", 342, 352], ["human", "ORGANISM", 491, 496], ["Astrocytes", "CELL", 616, 626], ["class II", "GENE_OR_GENE_PRODUCT", 638, 646], ["brain", "ORGAN", 690, 695], ["patients", "ORGANISM", 702, 710], ["T cell clones", "CELL", 810, 823], ["stimulated primary cultures", "CELL_LINE", 67, 94], ["class II-positive oligodendrocytes", "CELL_TYPE", 152, 186], ["astrocytes", "CELL_TYPE", 342, 352], ["Astrocytes", "CELL_TYPE", 616, 626], ["class II", "PROTEIN", 638, 646], ["T cell clones", "CELL_LINE", 810, 823], ["human", "SPECIES", 491, 496], ["patients", "SPECIES", 702, 710], ["human", "SPECIES", 491, 496], ["Kim et al.", "TEST", 116, 126], ["class II-positive oligodendrocytes", "PROBLEM", 152, 186], ["the culture preparations", "TEST", 213, 237], ["the 'active' plaques", "PROBLEM", 662, 682], ["positive oligodendrocytes", "OBSERVATION", 161, 186], ["HLA expression", "OBSERVATION", 324, 338], ["active", "OBSERVATION_MODIFIER", 667, 673], ["plaques", "OBSERVATION", 675, 682], ["brain", "ANATOMY", 690, 695]]], ["The postulate has accordingly been made that by presenting myelin basic protein (MBP) or related antigens to autoreactive T lymphocytes, class II-positive astrocytes may initiate and possibly perpetuate an autoimmune recognition to MBP which subsequently leads to the demyelination process in active MS (Fontana, 1984; Sun and Wekerle, 1986; Takiguchi et al., 1986) .", [["T lymphocytes", "ANATOMY", 122, 135], ["astrocytes", "ANATOMY", 155, 165], ["demyelination", "DISEASE", 268, 281], ["MS", "DISEASE", 300, 302], ["myelin basic protein", "GENE_OR_GENE_PRODUCT", 59, 79], ["MBP", "GENE_OR_GENE_PRODUCT", 81, 84], ["T lymphocytes", "CELL", 122, 135], ["class II", "GENE_OR_GENE_PRODUCT", 137, 145], ["MBP", "GENE_OR_GENE_PRODUCT", 232, 235], ["myelin basic protein", "PROTEIN", 59, 79], ["MBP", "PROTEIN", 81, 84], ["autoreactive T lymphocytes", "CELL_TYPE", 109, 135], ["class II-positive astrocytes", "CELL_TYPE", 137, 165], ["MBP", "PROTEIN", 232, 235], ["myelin basic protein", "TEST", 59, 79], ["MBP", "TEST", 81, 84], ["autoreactive T lymphocytes", "PROBLEM", 109, 135], ["class II-positive astrocytes", "PROBLEM", 137, 165], ["an autoimmune recognition", "PROBLEM", 203, 228], ["MBP", "TEST", 232, 235], ["the demyelination process", "PROBLEM", 264, 289], ["autoimmune", "OBSERVATION", 206, 216], ["demyelination", "OBSERVATION", 268, 281]]], ["In short-term cultures we found that astrocytes express class I but not class II molecules and this is in accordance with previous work (Fierz et al., 1985) .", [["astrocytes", "ANATOMY", 37, 47], ["astrocytes", "CELL", 37, 47], ["astrocytes", "CELL_TYPE", 37, 47], ["class I but not class II molecules", "PROTEIN", 56, 90], ["short-term cultures", "TEST", 3, 22]]], ["However, we were surprised by the arousal of a population of astrocytes positive for class II after 5-6 days while these cells were growing in culture.", [["astrocytes", "ANATOMY", 61, 71], ["cells", "ANATOMY", 121, 126], ["astrocytes", "CELL", 61, 71], ["cells", "CELL", 121, 126], ["astrocytes", "CELL_TYPE", 61, 71], ["class II", "PROTEIN", 85, 93], ["these cells", "PROBLEM", 115, 126], ["culture", "TEST", 143, 150]]], ["These results may substantiate the report by Kim (1985) which showed that in cultures of human adult brain 9-27% of the astrocytes were class II positive at day 10.", [["adult brain", "ANATOMY", 95, 106], ["astrocytes", "ANATOMY", 120, 130], ["human", "ORGANISM", 89, 94], ["brain", "ORGAN", 101, 106], ["astrocytes", "CELL", 120, 130], ["astrocytes", "CELL_TYPE", 120, 130], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 89, 94], ["cultures", "TEST", 77, 85], ["human adult brain", "TEST", 89, 106], ["astrocytes", "ANATOMY", 120, 130]]], ["Similar findings were described on a human fetal astrocyte cell line, but the spontaneous class II expression disappeared after subsequent passages (Pulver et al., 1987) .", [["fetal astrocyte cell line", "ANATOMY", 43, 68], ["human", "ORGANISM", 37, 42], ["fetal astrocyte cell line", "CELL", 43, 68], ["human fetal astrocyte cell line", "CELL_LINE", 37, 68], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 37, 42], ["a human fetal astrocyte cell line", "TREATMENT", 35, 68], ["astrocyte cell line", "OBSERVATION", 49, 68]]], ["This phenomenon seems to be a unique characteristic of the astrocytes since fibroblasts and other cell types present in our cultures remained negative, thus arguing against the possibility that it is mediated by IFNs or other non-specific soluble factors generated during the culture period or by the medium employed, as previously suggested (Pulver et al., 1987) .", [["astrocytes", "ANATOMY", 59, 69], ["fibroblasts", "ANATOMY", 76, 87], ["cell", "ANATOMY", 98, 102], ["cultures", "ANATOMY", 124, 132], ["astrocytes", "CELL", 59, 69], ["fibroblasts", "CELL", 76, 87], ["cell", "CELL", 98, 102], ["IFNs", "GENE_OR_GENE_PRODUCT", 212, 216], ["astrocytes", "CELL_TYPE", 59, 69], ["fibroblasts", "CELL_TYPE", 76, 87], ["IFNs", "PROTEIN", 212, 216], ["non-specific soluble factors", "PROTEIN", 226, 254], ["the astrocytes", "PROBLEM", 55, 69], ["fibroblasts", "PROBLEM", 76, 87], ["other cell types", "PROBLEM", 92, 108], ["our cultures", "TEST", 120, 132], ["other non-specific soluble factors", "PROBLEM", 220, 254], ["seems to be", "UNCERTAINTY", 16, 27], ["astrocytes", "OBSERVATION", 59, 69], ["cell types", "OBSERVATION", 98, 108]]], ["This spontaneous induction of class II expression indicates that in vivo the expression of class II by astrocytes should be constantly suppressed by still unidentified humoral or locally produced mediators.", [["astrocytes", "ANATOMY", 103, 113], ["class II", "GENE_OR_GENE_PRODUCT", 30, 38], ["class II", "GENE_OR_GENE_PRODUCT", 91, 99], ["astrocytes", "CELL", 103, 113], ["class II", "PROTEIN", 91, 99], ["astrocytes", "CELL_TYPE", 103, 113]]], ["Alternatively, it is also possible that the abundant debris which our cultures initially contained could have stimulated phagocytosis by the astrocytes and this then triggered the expression of class II, as part of the general activation process undergoing in these cells.", [["cultures", "ANATOMY", 70, 78], ["astrocytes", "ANATOMY", 141, 151], ["cells", "ANATOMY", 266, 271], ["astrocytes", "CELL", 141, 151], ["class II", "GENE_OR_GENE_PRODUCT", 194, 202], ["cells", "CELL", 266, 271], ["astrocytes", "CELL_TYPE", 141, 151], ["class II", "PROTEIN", 194, 202], ["the abundant debris", "PROBLEM", 40, 59], ["our cultures", "TEST", 66, 78], ["stimulated phagocytosis", "PROBLEM", 110, 133], ["the astrocytes", "PROBLEM", 137, 151], ["the general activation process", "PROBLEM", 215, 245], ["is also possible", "UNCERTAINTY", 18, 34], ["abundant", "OBSERVATION_MODIFIER", 44, 52], ["debris", "OBSERVATION", 53, 59]]], ["In this context, it is of interest to recall that it has recently been shown that the phagocytosis of coronavirus particles induced class II expression in rat astrocytes (Massa et al., 1986) .DiscussionAs expected, IFN-a and IFN-3, both produced an increase in class I expression in astrocytes.", [["astrocytes", "ANATOMY", 159, 169], ["astrocytes", "ANATOMY", 283, 293], ["coronavirus", "ORGANISM", 102, 113], ["class II", "GENE_OR_GENE_PRODUCT", 132, 140], ["rat", "ORGANISM", 155, 158], ["astrocytes", "CELL", 159, 169], ["IFN-a", "GENE_OR_GENE_PRODUCT", 215, 220], ["IFN-3", "GENE_OR_GENE_PRODUCT", 225, 230], ["class I", "GENE_OR_GENE_PRODUCT", 261, 268], ["astrocytes", "CELL", 283, 293], ["rat astrocytes", "CELL_TYPE", 155, 169], ["IFN", "PROTEIN", 215, 218], ["IFN", "PROTEIN", 225, 228], ["astrocytes", "CELL_TYPE", 283, 293], ["rat", "SPECIES", 155, 158], ["rat", "SPECIES", 155, 158], ["the phagocytosis of coronavirus particles", "PROBLEM", 82, 123], ["IFN", "TEST", 215, 218], ["increase", "OBSERVATION_MODIFIER", 249, 257], ["astrocytes", "ANATOMY", 283, 293]]], ["The studies of class II modulation on astrocytes were carried out at the beginning of the culture period while the level of spontaneous expression was still low and in this way we were able to reproduce previous work which has shown that IFN-7 is indeed able to induce a rapid increase in the percentage of class II-positive human fetal astrocytes (Pulver et al., 1987) as well as enhance the intensity of the staining (Fig. 5) .", [["astrocytes", "ANATOMY", 38, 48], ["fetal astrocytes", "ANATOMY", 331, 347], ["class II", "GENE_OR_GENE_PRODUCT", 15, 23], ["astrocytes", "CELL", 38, 48], ["IFN-7", "GENE_OR_GENE_PRODUCT", 238, 243], ["class II", "GENE_OR_GENE_PRODUCT", 307, 315], ["human", "ORGANISM", 325, 330], ["fetal astrocytes", "CELL", 331, 347], ["astrocytes", "CELL_TYPE", 38, 48], ["IFN", "PROTEIN", 238, 241], ["class II-positive human fetal astrocytes", "CELL_TYPE", 307, 347], ["human", "SPECIES", 325, 330], ["human", "SPECIES", 325, 330], ["The studies", "TEST", 0, 11], ["astrocytes", "TEST", 38, 48], ["the culture", "TEST", 86, 97], ["IFN", "TEST", 238, 241], ["a rapid increase", "PROBLEM", 269, 285], ["positive human fetal astrocytes", "PROBLEM", 316, 347], ["rapid", "OBSERVATION_MODIFIER", 271, 276], ["increase", "OBSERVATION_MODIFIER", 277, 285], ["fetal astrocytes", "ANATOMY", 331, 347]]], ["Microglial cells were not easy to identify in our monolayers and this was most probably due to the early gestational age of the fetal tissue.", [["Microglial cells", "ANATOMY", 0, 16], ["monolayers", "ANATOMY", 50, 60], ["fetal tissue", "ANATOMY", 128, 140], ["Microglial cells", "CELL", 0, 16], ["monolayers", "CELL", 50, 60], ["fetal tissue", "TISSUE", 128, 140], ["Microglial cells", "CELL_TYPE", 0, 16], ["Microglial cells", "TEST", 0, 16], ["most probably due to", "UNCERTAINTY", 74, 94], ["fetal tissue", "ANATOMY", 128, 140]]], ["However, even if these cells were present in small amounts, our lack of any specific marker made their identification, solely on morphological ground, very difficult.DiscussionIn summary, we have presented for the first time data on a large number of human fetal brains both in sections and in primary cultures indicating that the regulation of the expression of HLA products in human fetal brain cells varies widely among the different cell types.", [["cells", "ANATOMY", 23, 28], ["fetal brains", "ANATOMY", 257, 269], ["sections", "ANATOMY", 278, 286], ["primary cultures", "ANATOMY", 294, 310], ["fetal brain cells", "ANATOMY", 385, 402], ["cell", "ANATOMY", 437, 441], ["cells", "CELL", 23, 28], ["human", "ORGANISM", 251, 256], ["fetal brains", "MULTI-TISSUE_STRUCTURE", 257, 269], ["HLA", "GENE_OR_GENE_PRODUCT", 363, 366], ["human", "ORGANISM", 379, 384], ["fetal brain cells", "CELL", 385, 402], ["cell", "CELL", 437, 441], ["HLA products", "PROTEIN", 363, 375], ["human fetal brain cells", "CELL_TYPE", 379, 402], ["human", "SPECIES", 251, 256], ["human", "SPECIES", 379, 384], ["human", "SPECIES", 251, 256], ["human", "SPECIES", 379, 384], ["these cells", "PROBLEM", 17, 28], ["primary cultures", "TEST", 294, 310], ["HLA products in human fetal brain cells", "PROBLEM", 363, 402], ["small amounts", "OBSERVATION_MODIFIER", 45, 58], ["fetal brains", "ANATOMY", 257, 269], ["brain cells", "OBSERVATION", 391, 402], ["different cell types", "OBSERVATION", 427, 447]]], ["There is a gradation in both constitutive expression and inducibility which ranges from neurons, which lack HLA products completely and are refractory to all inducers and modulators tested so far, to astrocytes which in culture become spontaneously positive for class II and are highly responsive to IFN-y.", [["neurons", "ANATOMY", 88, 95], ["astrocytes", "ANATOMY", 200, 210], ["neurons", "CELL", 88, 95], ["astrocytes", "CELL", 200, 210], ["IFN-y", "GENE_OR_GENE_PRODUCT", 300, 305], ["HLA products", "PROTEIN", 108, 120], ["astrocytes", "CELL_TYPE", 200, 210], ["class II", "PROTEIN", 262, 270], ["IFN", "PROTEIN", 300, 303], ["astrocytes", "TEST", 200, 210], ["culture", "TEST", 220, 227], ["gradation", "OBSERVATION_MODIFIER", 11, 20], ["both", "OBSERVATION_MODIFIER", 24, 28], ["constitutive expression", "OBSERVATION", 29, 52]]], ["This heterogeneity of HLA regulation among the brain cells is reminiscent of that observed for class II in the human pancreas where ductal/exocrine cells are easily induced to express class II while islet endocrine cells require a two-med~tor signal .", [["brain cells", "ANATOMY", 47, 58], ["pancreas", "ANATOMY", 117, 125], ["ductal", "ANATOMY", 132, 138], ["exocrine cells", "ANATOMY", 139, 153], ["islet endocrine cells", "ANATOMY", 199, 220], ["HLA", "GENE_OR_GENE_PRODUCT", 22, 25], ["brain cells", "CELL", 47, 58], ["human", "ORGANISM", 111, 116], ["pancreas", "ORGAN", 117, 125], ["ductal", "CELL", 132, 138], ["exocrine cells", "CELL", 139, 153], ["islet endocrine cells", "CELL", 199, 220], ["brain cells", "CELL_TYPE", 47, 58], ["ductal/exocrine cells", "CELL_TYPE", 132, 153], ["islet endocrine cells", "CELL_TYPE", 199, 220], ["human", "SPECIES", 111, 116], ["human", "SPECIES", 111, 116], ["HLA regulation", "PROBLEM", 22, 36], ["class II in the human pancreas", "PROBLEM", 95, 125], ["ductal/exocrine cells", "PROBLEM", 132, 153], ["HLA", "OBSERVATION", 22, 25], ["brain cells", "OBSERVATION", 47, 58], ["human", "ANATOMY_MODIFIER", 111, 116], ["pancreas", "ANATOMY", 117, 125], ["ductal", "ANATOMY", 132, 138], ["exocrine cells", "ANATOMY", 139, 153]]], ["Considering the analogies between the different cell populations which form these two complex organs it seems that the cells with a high or intermediate turnover (ductal cells, astrocytes) are more easily induced to express HLA molecules than those with a low turnover (e.g. islet cells) or no turnover (e.g. neurons).", [["cell", "ANATOMY", 48, 52], ["organs", "ANATOMY", 94, 100], ["cells", "ANATOMY", 119, 124], ["ductal cells", "ANATOMY", 163, 175], ["astrocytes", "ANATOMY", 177, 187], ["islet cells", "ANATOMY", 275, 286], ["neurons", "ANATOMY", 309, 316], ["cell populations", "CELL", 48, 64], ["organs", "ORGAN", 94, 100], ["cells", "CELL", 119, 124], ["ductal cells", "CELL", 163, 175], ["astrocytes", "CELL", 177, 187], ["islet cells", "CELL", 275, 286], ["neurons", "CELL", 309, 316], ["ductal cells", "CELL_TYPE", 163, 175], ["astrocytes", "CELL_TYPE", 177, 187], ["HLA molecules", "PROTEIN", 224, 237], ["islet cells", "CELL_TYPE", 275, 286], ["the different cell populations", "TREATMENT", 34, 64], ["the cells", "PROBLEM", 115, 124], ["a high or intermediate turnover (ductal cells", "PROBLEM", 130, 175], ["HLA molecules", "PROBLEM", 224, 237], ["a low turnover (e.g. islet cells", "PROBLEM", 254, 286], ["different cell populations", "OBSERVATION", 38, 64], ["ductal cells", "OBSERVATION", 163, 175]]], ["One possibility is that the lack of inducibility of class II expression may constitute one of the mechanisms which maintain tolerance to autoantigens present in highly specialized cells Cowing, 1985) .", [["cells", "ANATOMY", 180, 185], ["class II", "GENE_OR_GENE_PRODUCT", 52, 60], ["cells", "CELL", 180, 185], ["autoantigens", "PROTEIN", 137, 149]]], ["On the other hand, absence of class I and inability to express it, may represent a more extreme way of excluding irreplaceable cells from the interaction with the immune system and in particular from the attack by cytotoxic T lymphocytes.", [["cells", "ANATOMY", 127, 132], ["immune system", "ANATOMY", 163, 176], ["cytotoxic T lymphocytes", "ANATOMY", 214, 237], ["cells", "CELL", 127, 132], ["immune system", "ANATOMICAL_SYSTEM", 163, 176], ["cytotoxic T lymphocytes", "CELL", 214, 237], ["cytotoxic T lymphocytes", "CELL_TYPE", 214, 237], ["irreplaceable cells", "PROBLEM", 113, 132], ["cytotoxic T lymphocytes", "PROBLEM", 214, 237], ["irreplaceable cells", "OBSERVATION", 113, 132]]], ["This may help to explain the inability of the cellular immune mechanisms to eradicate certain neuronal viral infections, such as herpes simplex.", [["cellular", "ANATOMY", 46, 54], ["neuronal", "ANATOMY", 94, 102], ["neuronal viral infections", "DISEASE", 94, 119], ["herpes simplex", "DISEASE", 129, 143], ["cellular", "CELL", 46, 54], ["neuronal", "CELL", 94, 102], ["herpes simplex", "ORGANISM", 129, 143], ["herpes simplex", "SPECIES", 129, 143], ["the cellular immune mechanisms", "PROBLEM", 42, 72], ["neuronal viral infections", "PROBLEM", 94, 119], ["herpes simplex", "PROBLEM", 129, 143], ["viral infections", "OBSERVATION", 103, 119]]], ["It may well be that it is more advantageous for the organism to have some neurons latently infected than not to have them at all, with the consequence of an irreversible disability.", [["neurons", "ANATOMY", 74, 81], ["neurons", "CELL", 74, 81], ["the organism", "PROBLEM", 48, 60], ["an irreversible disability", "PROBLEM", 154, 180], ["irreversible", "OBSERVATION_MODIFIER", 157, 169], ["disability", "OBSERVATION", 170, 180]]], ["If these postulates are correct, it follows that a better knowledge of the differential regulation of HLA protein expression in the central nervous system may contribute to our understanding of the autoimmune processes and latent viral infections occurring in this organ.", [["central nervous system", "ANATOMY", 132, 154], ["organ", "ANATOMY", 265, 270], ["viral infections", "DISEASE", 230, 246], ["HLA", "GENE_OR_GENE_PRODUCT", 102, 105], ["central nervous system", "ANATOMICAL_SYSTEM", 132, 154], ["organ", "ORGAN", 265, 270], ["HLA protein", "PROTEIN", 102, 113], ["HLA protein expression", "PROBLEM", 102, 124], ["the autoimmune processes", "PROBLEM", 194, 218], ["latent viral infections", "PROBLEM", 223, 246], ["central", "ANATOMY_MODIFIER", 132, 139], ["nervous", "ANATOMY", 140, 147], ["autoimmune", "OBSERVATION", 198, 208], ["latent", "OBSERVATION_MODIFIER", 223, 229], ["viral", "OBSERVATION_MODIFIER", 230, 235], ["infections", "OBSERVATION", 236, 246]]]], "75d2afecf04685d6c9910737d852b53d8ab9be78": [["IntroductionModern societies require abundant quantities of energy to perform normal daily activities, such as cooking or transportation, to ensure human comfort and wellness, and to provide the products and services used by people and companies.", [["human", "ORGANISM", 148, 153], ["people", "ORGANISM", 225, 231], ["human", "SPECIES", 148, 153], ["people", "SPECIES", 225, 231], ["human", "SPECIES", 148, 153]]], ["As the standards of living are improving, in particular in the developing world, the energy consumption is increasing and will continue to rise in the near future (BP, 2019).", [["BP", "TEST", 164, 166], ["increasing", "OBSERVATION_MODIFIER", 107, 117]]], ["Currently, most of the energy needs is generated from fossil sources, in particular oil, coal, and natural gas, a state of affairs that is clearly unsustainable and has resulted in significant environmental problems, in particular climate change due to increasing emissions of greenhouse gases, and in economic and even social impacts due to price variability and supply security.", [["oil", "ANATOMY", 84, 87], ["coal", "CHEMICAL", 89, 93], ["oil", "ORGANISM_SUBSTANCE", 84, 87], ["significant environmental problems", "PROBLEM", 181, 215], ["increasing emissions of greenhouse gases", "PROBLEM", 253, 293], ["coal", "OBSERVATION", 89, 93], ["significant", "OBSERVATION_MODIFIER", 181, 192], ["environmental problems", "OBSERVATION", 193, 215], ["greenhouse gases", "OBSERVATION", 277, 293]]], ["Hence, governments and international organizations are developing and implementing policies and/ or strategies to promote the generation of more renewable energy, contributing to reduce the dependence on fossil fuels and to decarbonize the economy, thus also contributing to fulfil the goals of the Paris Agreement (UNCC, 2016) .IntroductionIn particular, the United Nations (UN) Sustainable Development Goals (UN, 2014) explicitly consider energy in its goal 7 -Affordable and clean energy, which states that people should have access to affordable, reliable, sustainable and modern energy.", [["people", "ORGANISM", 510, 516], ["people", "SPECIES", 510, 516]]], ["Also, any policy and https://doi.org/10.1016/j.tej.2020.106822 \u204e Corresponding author.IntroductionE-mail address: aamartins@fe.up.pt (A.A. Martins) .IntroductionThe Electricity Journal 33 (2020) 106822 1040-6190/ \u00a9 2020 Elsevier Inc. All rights reserved.IntroductionT strategy aimed at promoting RES must also consider explicitly all other UN goals, in particular goal 9 -Industry, innovation and infrastructure; goal 10 -Reduces inequalities; goal 11 -Sustainable cities and communities; goal 12 -Responsible consumption and production; and goal 13 -Climate action; as these UN goals are the most related to energy generation and consumption.IntroductionThe European Union (EU) defined specific strategies, in particular the recent directive on renewable energy (EC, 2018a) , that determines a goal of a least 32 % on the overall energy mix until 2030, with the possibility of upwards revision in 2023.", [["RES", "CHEMICAL", 296, 299], ["IntroductionT strategy", "TREATMENT", 254, 276], ["upwards revision", "TREATMENT", 878, 894]]], ["To address the specific questions of different activities, several directives and regulations were approved, currently under implementation, each one defining particular goals and activities, that collectively are combined in the \"Clean Energy for all Europeans\" (EC, 2019c), a key part of the \"European Green Deal\" recently proposed to tackle the sustainability issues affecting all members of EU (EC, 2019a, b) .", [["EC", "CELL", 399, 401]]], ["An important part is the \"Energy Performance of Buildings\" directive that deals with the reduction and a more efficient utilization of energy in buildings, either households or commercial/industrial (EC, 2018b) .", [["the reduction", "TREATMENT", 85, 98]]], ["This sector accounts for around a third of the primary energy consumption in the EU, and includes specific measures and goals to be achieved, as for example the objective of all new buildings to be Net Zero Energy Buildings (NZEB) from 2021 onwards.IntroductionIn 2019 the Portuguese government has launched several documents and strategic plans, especially the \"National Roadmap for Carbon Neutrality\" (RCM, 2019) and the \"2030 National Energy and Climate Plan\" (PNEC, 2019).", [["Carbon", "CHEMICAL", 384, 390]]], ["The main goal is to make Portugal a carbon neutral country in 2050 in terms of energy generation and consumption, taking into consideration the goals and main development strategies/policies defined by the EU strategic plans, as described above.", [["carbon", "CHEMICAL", 36, 42], ["a carbon neutral country", "TREATMENT", 34, 58], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["This naturally implies a significant investment in the renewable energy capacity, and most of the increase will come from photovoltaic (PV) electricity, in particular a 10 fold increase in installed capacity between 2020 and 2030, with more modest increases planned for hydro and wind.IntroductionAlthough energy generation from renewable sources is increasing rapidly (BP, 2019), and various renewable energy systems (RES) are being developed and implemented for different settings, the impact of RES on the energy mix is still small.", [["RES", "CHEMICAL", 498, 501], ["RES", "CHEMICAL", 498, 501], ["RES", "SIMPLE_CHEMICAL", 498, 501], ["photovoltaic (PV) electricity", "TREATMENT", 122, 151], ["hydro and wind", "PROBLEM", 270, 284], ["BP", "TEST", 370, 372], ["significant", "OBSERVATION_MODIFIER", 25, 36], ["investment", "OBSERVATION", 37, 47], ["renewable energy capacity", "OBSERVATION", 55, 80], ["increasing", "OBSERVATION_MODIFIER", 350, 360], ["small", "OBSERVATION_MODIFIER", 529, 534]]], ["Some reasons behind this situation include limitations on their scope, type of energy generated, production strongly dependents on factors outside the producer's control, in particular climatic factors, imbalances in supply and demand, availability of key raw materials, high production costs, among others (IEA, 2013).", [["their scope", "TEST", 58, 69]]], ["Demand and supply imbalances are important in RES that provide electricity, in particular wind and PV systems, that represents today most of the renewable energy produced (IEA, 2011) .IntroductionEnergy storage is currently seen as an adequate form to mitigate those issues.", [["RES", "CHEMICAL", 46, 49], ["RES", "SIMPLE_CHEMICAL", 46, 49], ["IntroductionEnergy storage", "TREATMENT", 184, 210], ["supply imbalances", "OBSERVATION", 11, 28]]], ["The incorporation of energy storage systems (ESS) can also increase existing or future RES efficiency, resilience, and ultimately their competiveness, as it allows a reduction of the energy production costs (IRENA, 2015; Frankel and Wagner, 2017) .", [["RES", "CHEMICAL", 87, 90]]], ["Various energy storage technologies based on various physical or chemical phenomena were proposed in literature, each one with its specific range of applications, scale, advantages and weaknesses (Huggins, 2016; IRENA, 2017) .", [["Various energy storage technologies", "TREATMENT", 0, 35], ["various physical or chemical phenomena", "PROBLEM", 45, 83], ["energy storage", "OBSERVATION", 8, 22], ["chemical phenomena", "OBSERVATION", 65, 83]]], ["Moreover, the most adequate options may depend on the local and regional conditions, in particular climatic conditions, and/or already existing infrastructures (IRENA, 2015 (IRENA, , 2017 .", [["the local and regional conditions", "PROBLEM", 50, 83]]], ["Whereas large scale ESS are valuable to balance the supply and demand imbalances in a regional and national scale, distributed energy storage (DES) may be valuable in smaller scales.", [["DES", "CHEMICAL", 143, 146], ["large scale ESS", "PROBLEM", 8, 23], ["demand imbalances", "PROBLEM", 63, 80]]], ["In particular, DES could be used in small communities, sparsely populated regions or in islands, in which investment in the electricity distribution network may be too expensive considering the benefits.", [["DES", "CHEMICAL", 15, 18], ["DES", "CHEMICAL", 15, 18], ["DES", "TREATMENT", 15, 18], ["small", "OBSERVATION_MODIFIER", 36, 41], ["communities", "OBSERVATION_MODIFIER", 42, 53], ["sparsely", "OBSERVATION_MODIFIER", 55, 63], ["populated", "OBSERVATION", 64, 73], ["islands", "OBSERVATION_MODIFIER", 88, 95]]], ["Also, for a household or building to be a NZEB it is necessary to generate renewable energy locally, and the inclusion of energy storage can help achieve this goal.IntroductionThe EU has recognized the importance of combining ESS in existing and future RES, and has published several strategic and guidance documents on the subjet, as well as supporting various research and development programs and stakeholders (companies, researchers, end user, among others) consortia in specific ESS, such as batteries, hydrogen, and others energy storage technologies (https://ec.europa.eu/ energy/topics/technology-and-innovation/energy-storage_en).", [["NZEB", "CHEMICAL", 42, 46], ["hydrogen", "CHEMICAL", 508, 516], ["RES", "CHEMICAL", 253, 256], ["hydrogen", "CHEMICAL", 508, 516], ["hydrogen", "SIMPLE_CHEMICAL", 508, 516], ["a NZEB", "TREATMENT", 40, 46], ["energy storage", "TREATMENT", 122, 136], ["combining ESS", "TREATMENT", 216, 229]]], ["Two relevant examples include the Batteries Europe initiative (https://ec. europa.eu/energy/topics/technology-and-innovation/energy-storage/ batteries-europe_en), and the EERA -European Energy Research Alliance (https://eera-es.eu/), in which the various scientific, technologic, practical/implementation and commercial aspects of ESS are taken into account, with the goals of contributing to fulfill the EU goals concerning the increase in the generation and consumption of renewable energy.", [["europa.eu", "CHEMICAL", 75, 84], ["practical/implementation", "TREATMENT", 280, 304], ["increase", "OBSERVATION_MODIFIER", 429, 437]]], ["In a Portuguese context, the two strategic plans referred above (RCM, 2019; PNEC, 2019) also consider large scale energy storage, focusing in two forms: batteries and hydrogen.", [["hydrogen", "CHEMICAL", 167, 175], ["hydrogen", "CHEMICAL", 167, 175], ["hydrogen", "SIMPLE_CHEMICAL", 167, 175], ["PNEC", "TEST", 76, 80], ["large scale energy storage", "PROBLEM", 102, 128], ["large", "OBSERVATION_MODIFIER", 102, 107]]], ["Similar capacities are planned for both forms, and the main focus will be in the storage of excess electricity produced in large scale PV solar farms.", [["Similar capacities", "PROBLEM", 0, 18], ["excess electricity", "PROBLEM", 92, 110], ["capacities", "OBSERVATION", 8, 18], ["main", "OBSERVATION_MODIFIER", 55, 59], ["excess electricity", "OBSERVATION", 92, 110], ["large", "OBSERVATION_MODIFIER", 123, 128], ["scale", "OBSERVATION_MODIFIER", 129, 134], ["PV", "OBSERVATION", 135, 137], ["solar farms", "OBSERVATION", 138, 149]]], ["It is planned that hydrogen will be used by industry, either as raw material or as energy carrier, or by households and other consumers, after mixing it with biogas and injecting it in the existing gas distribution network.IntroductionDespite the ongoing strong investment in research and development of ESS coupled to RES, many key issues still need to be adequately analysed.", [["hydrogen", "CHEMICAL", 19, 27], ["hydrogen", "CHEMICAL", 19, 27], ["RES", "CHEMICAL", 319, 322], ["hydrogen", "SIMPLE_CHEMICAL", 19, 27], ["hydrogen", "TREATMENT", 19, 27], ["biogas", "TREATMENT", 158, 164], ["ESS", "PROBLEM", 304, 307], ["many key issues", "PROBLEM", 324, 339], ["gas distribution", "OBSERVATION", 198, 214], ["strong", "OBSERVATION_MODIFIER", 255, 261], ["investment", "OBSERVATION", 262, 272]]], ["One of the most relevant involves the definition of objective criteria to define what are the most adequate technology options for ESS depending on the specific application conditions.", [["ESS", "TREATMENT", 131, 134]]], ["Thus, in this work we look to the current Portuguese situation and expected evolution, in particular fostered by the development strategies referred above (RCM, 2019; PNEC, 2019) , in order to identify which are the best energy storage options in a Portuguese context, considering the already existing technologies.", [["PNEC", "TEST", 167, 171]]], ["The main criteria for technology selection will be identified, taking into account key aspects such as regional geographic and climate conditions, main sources of renewable energy, infrastructure, population distribution, economic and social aspects, energy storage characteristics, among others; and analysed to identify the currently more viable technology for DES in a Portuguese context.", [["DES", "CHEMICAL", 363, 366], ["technology selection", "TREATMENT", 22, 42], ["renewable energy", "PROBLEM", 163, 179], ["main", "OBSERVATION_MODIFIER", 4, 8], ["renewable energy", "OBSERVATION", 163, 179]]], ["Also, the strategies and plans defined at the national scale (RCM, 2019; PNEC, 2019) will be critically analysed, especially how they consider energy storage and DES.Electricity generation in PortugalPortugal does not possess significant fossil energy resources to fulfil the needs of citizens and companies.", [["DES", "CHEMICAL", 162, 165], ["DES", "TREATMENT", 162, 165]]], ["This state of affairs has resulted in significant dependence on imported energy (Pordata, 2017) , especially in the transportation sector, where the dependence on fossil fuels is almost complete.", [["significant", "OBSERVATION_MODIFIER", 38, 49], ["dependence", "OBSERVATION_MODIFIER", 50, 60]]], ["Thus, it is imperative to counteract this dependence that has significant economic and supply security impacts.", [["this dependence", "PROBLEM", 37, 52], ["significant", "OBSERVATION_MODIFIER", 62, 73], ["economic", "OBSERVATION_MODIFIER", 74, 82]]], ["To generate the energy needed to support the economic development and the expansion of electrical network to supply the electricity necessary to increase the standards of living, there is an ongoing strategy to develop the internal energy resources, focusing in electricity generation since the second half of the twentieth century (Martins et al., 2018) .", [["electrical network", "MULTI-TISSUE_STRUCTURE", 87, 105]]], ["Due to its climate conditions and topography, there is significant potential in hydroelectricity and wind power in the Northern Portugal, and PV power nationwide (DGEG, 2019).Electricity generation in PortugalOn an initial phase, a focus was given to explore hydro power resources (Nunes, 2018) .", [["PortugalOn", "CHEMICAL", 201, 211], ["significant potential in hydroelectricity", "PROBLEM", 55, 96], ["significant", "OBSERVATION_MODIFIER", 55, 66], ["hydroelectricity", "OBSERVATION", 80, 96]]], ["But, by the beginning of the 21st century most of the hydro resources were exploited, as almost all the sites and rivers adequate to construct and implement large hydro are already used.", [["the hydro resources", "TREATMENT", 50, 69], ["large hydro", "PROBLEM", 157, 168], ["large", "OBSERVATION_MODIFIER", 157, 162], ["hydro", "OBSERVATION", 163, 168]]], ["Although retrofitting existing hydroelectric power plants is being implemented and considered to increase the generation of hydroelectricity, the overall increase in the renewable energy capacity is limited and not enough to fulfil the increasing energy needs.Electricity generation in PortugalIn the last two decades most business investments were directed to wind power farms, with a 10 fold increase in the first decade of 21st century (IRENA, 2013), as shown in Fig. 1 (APREN , 2020) .", [["hydroelectricity", "DISEASE", 124, 140], ["hydroelectric power plants", "TREATMENT", 31, 57], ["the generation of hydroelectricity", "PROBLEM", 106, 140], ["the renewable energy capacity", "PROBLEM", 166, 195], ["a 10 fold increase", "PROBLEM", 384, 402], ["hydroelectric", "OBSERVATION_MODIFIER", 31, 44], ["power plants", "OBSERVATION", 45, 57], ["overall", "OBSERVATION_MODIFIER", 146, 153], ["increase", "OBSERVATION_MODIFIER", 154, 162], ["energy capacity", "OBSERVATION", 180, 195], ["10 fold", "OBSERVATION_MODIFIER", 386, 393], ["increase", "OBSERVATION_MODIFIER", 394, 402]]], ["Only recently there was a significant increase in the large-scale generation from PV and biomass based power plants (Nunes, 2018) .", [["PV", "SPECIES", 82, 84], ["a significant increase", "PROBLEM", 24, 46], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["increase", "OBSERVATION_MODIFIER", 38, 46], ["large", "OBSERVATION_MODIFIER", 54, 59], ["-scale", "OBSERVATION_MODIFIER", 59, 65], ["PV", "ANATOMY", 82, 84]]], ["Currently most investments in RES are forecasted to be done in PV capacity (RCM, 2019; PNEC, 2019), even though solar is still not very significant in the overall electricity mix (Fig. 1) .", [["RES", "CHEMICAL", 30, 33], ["RES", "SIMPLE_CHEMICAL", 30, 33], ["PNEC", "TEST", 87, 91]]], ["Currently, the electricity mix consists of roughly 50 % renewables, with large variations between the years, as shown in Fig. 1 (APREN , 2020) .", [["the electricity mix", "TEST", 11, 30], ["large", "OBSERVATION_MODIFIER", 73, 78], ["variations", "OBSERVATION", 79, 89]]], ["The variations are due to different dominant climatic conditions, especially the occurrence or not of droughts, as the availability of water and proper wind conditions are interrelated and depend on the passage of weather systems from the Atlantic Ocean.", [["different dominant climatic conditions", "PROBLEM", 26, 64], ["dominant", "OBSERVATION_MODIFIER", 36, 44], ["climatic conditions", "OBSERVATION", 45, 64]]], ["Depending on the particular conditions, in some periods the existing RES can generate enough electricity to supply the needs for several days (The Guardian, 2016) , excluding the Azores and Madeira archipelagos that have independent electricity generation and supply networks.", [["RES", "CHEMICAL", 69, 72], ["RES", "SIMPLE_CHEMICAL", 69, 72]]], ["This situation also explains why in Fig. 1 for some years the total energy generated is larger than consumption, as the periods when electricity is exported cover the periods when imports are required.", [["larger", "OBSERVATION_MODIFIER", 88, 94]]], ["Yet, as fossil is still very relevant, currently between 20 to 30 %, this means that in practice Portugal is a net energy importer.Electricity generation in PortugalAlthough Portugal has made impressive investments in large-scale renewable energy technologies during the last 20 years, the participation of small-scale decentralized generation systems has assumed a growing role in electricity generation, as shown in Table 1 .Electricity generation in PortugalThe weight of decentralized generation on total electricity produced from renewable sources has steadily increased since 2012, especially after the publication of the national diploma (DL 153, 2014) that establishes the legal regime for self-consumption and small production units.", [["small-scale decentralized generation systems", "TREATMENT", 307, 351], ["total electricity", "TREATMENT", 503, 520], ["the legal regime", "TREATMENT", 677, 693], ["small production units", "TREATMENT", 719, 741], ["large", "OBSERVATION_MODIFIER", 218, 223], ["steadily", "OBSERVATION_MODIFIER", 557, 565], ["increased", "OBSERVATION_MODIFIER", 566, 575]]], ["This piece of legislation has brought greater certainty for private and small-scale investors, and it boosted the UPAC/UPP generation.", [["the UPAC/UPP generation", "TREATMENT", 110, 133], ["UPP generation", "OBSERVATION", 119, 133]]], ["On the other hand, national and local regulations are mandatory for the installation of RES in new buildings, public buildings, infrastructures and on existing buildings subject to deep rehabilitation, following also the goals defined by the Energy Performance of Buildings Directive (EC, 2018b).", [["RES", "CHEMICAL", 88, 91], ["RES", "CHEMICAL", 88, 91], ["RES", "SIMPLE_CHEMICAL", 88, 91], ["deep rehabilitation", "TREATMENT", 181, 200]]], ["All the previous factors are pressing and creating room for an increasing presence of decentralized generation on national energy scenario.", [["decentralized generation", "OBSERVATION", 86, 110]]], ["However, to increase its efficiency and relevance to the electricity mix proper ESS must be employed.Electricity generation in PortugalConcerning the current status of energy storage in Portugal, there is still a renewable energy surplus in the range of 800-1200 GW h (Miguel et al., 2018) that is lost, mainly in Winter and Spring.", [["the electricity mix", "TREATMENT", 53, 72]]], ["Pumped hydro, based on reverse pumping systems installed in the large hydro plants is currently the dominant form of energy storage.", [["Pumped hydro", "PROBLEM", 0, 12], ["reverse pumping systems", "TREATMENT", 23, 46], ["the large hydro plants", "PROBLEM", 60, 82], ["hydro", "OBSERVATION", 7, 12], ["large", "OBSERVATION_MODIFIER", 64, 69], ["hydro plants", "OBSERVATION", 70, 82], ["dominant", "OBSERVATION_MODIFIER", 100, 108], ["energy storage", "OBSERVATION", 117, 131]]], ["However, given the variability of the rainfall and the tendency for more frequent drought periods, as well as the sharing of major international rivers with neighbouring Spain with the consequent pressure on the various uses of the water, this solution may not fulfill the country future needs.", [["the rainfall", "PROBLEM", 34, 46], ["this solution", "TREATMENT", 239, 252], ["pressure", "OBSERVATION_MODIFIER", 196, 204]]], ["Paradoxically, the plans that embody the strategies defined for Portugal, place a great emphasis on large scale ESS (RCM, 2019; PNEC, 2019), while DES are not considered at all.", [["DES", "CHEMICAL", 147, 150], ["DES", "CHEMICAL", 147, 150], ["PNEC", "TEST", 128, 132], ["DES", "TREATMENT", 147, 150]]], ["For large scale ESS an auction in 2020 in which PV capacity coupled with storage was planned, but due to the COVID-19 pandemic the auction was postponed, and at the time of writing this work there is no date to proceed with the auction.Evaluation of decentralized energy storage optionsAs stated before, to increase the efficiency of existing and future RES it is necessary to store the renewable energy produced in excess using proper energy storage technologies.", [["RES", "CHEMICAL", 354, 357], ["RES", "SIMPLE_CHEMICAL", 354, 357], ["PV", "SPECIES", 48, 50], ["large scale ESS", "TREATMENT", 4, 19], ["the COVID", "TEST", 105, 114], ["Evaluation", "TEST", 236, 246], ["decentralized energy storage options", "TREATMENT", 250, 286], ["proper energy storage technologies", "TREATMENT", 429, 463]]], ["Many possibilities exist based on different physical and/or chemical phenomena or methods (Huggin, 2010; IRENA, 2017), including: mechanic (pumped hydroelectric currently dominant in Portugal); electric (super capacitors), electrochemical (batteries of different types, including Li-ion, flow batteries, and lead acid), thermal energy (PCM -phase change materials), Chemical (hydrogen, power to gas, biofuels), among others.", [["hydrogen", "CHEMICAL", 376, 384], ["Li-ion", "SIMPLE_CHEMICAL", 280, 286], ["hydrogen", "SIMPLE_CHEMICAL", 376, 384], ["electric (super capacitors", "TREATMENT", 194, 220], ["electrochemical (batteries of different types", "TREATMENT", 223, 268], ["Li-ion, flow batteries", "TREATMENT", 280, 302], ["lead acid", "TREATMENT", 308, 317], ["thermal energy (PCM -phase change materials", "TREATMENT", 320, 363], ["Chemical (hydrogen", "TREATMENT", 366, 384]]], ["A full description of the available energy storage technologies, costs and optimal utilization conditions, among other factors, is outside the scope of this work and can be found in the literature (Ferreira et al., 2013; IRENA, 2017; Mostert et al., 2018; Mongird et al., 2019) .Evaluation of decentralized energy storage optionsThe different technologies vary in their range of applications, requirements and suitability to various renewable energy generation systems or energy applications.", [["Evaluation", "TEST", 279, 289], ["decentralized energy storage options", "TREATMENT", 293, 329], ["renewable energy generation systems", "TREATMENT", 433, 468], ["energy applications", "TREATMENT", 472, 491]]], ["This also must be taken into account when considering policy definition and implementation, not only at international or national, but also at company or even household levels.Evaluation of decentralized energy storage optionsThus, the selection process is akin to a multi-criteria decision procedure, that should meet questions such as energy resources available, and political and/or strategic issues at national or international levels, especially when directly related to renewable energy generation and use.", [["Evaluation", "TEST", 176, 186], ["decentralized energy storage options", "TREATMENT", 190, 226], ["a multi-criteria decision procedure", "TREATMENT", 265, 300]]], ["Other considerations include: the characteristics of the systems in which energy storage will be implemented; technical viability, costs and return of investment; easiness and safety of operation; storage efficiency, including resilience and eventual storage and overall capacity losses in time; ability to recycle or not different parts of a ESS; among other issues.Evaluation of decentralized energy storage optionsBefore evaluating the potential options for decentralized energy storage (DES), to identity which option(s) may be more suitable in the Portuguese context, it is important to define what represent a DES.", [["DES", "CHEMICAL", 491, 494], ["DES", "CHEMICAL", 616, 619], ["DES", "CHEMICAL", 616, 619], ["operation", "TREATMENT", 186, 195], ["storage efficiency", "PROBLEM", 197, 215], ["overall capacity losses", "PROBLEM", 263, 286], ["Evaluation", "TEST", 367, 377], ["decentralized energy storage options", "TREATMENT", 381, 417], ["decentralized energy storage (DES", "TREATMENT", 461, 494], ["a DES", "PROBLEM", 614, 619], ["DES", "OBSERVATION", 616, 619]]], ["The authors didn't found in the literature or in the legislation/regulation any practical definition of what is a DES.", [["DES", "CHEMICAL", 114, 117], ["DES", "CHEMICAL", 114, 117]]], ["Thus, in this work it is considered that DES represent small to medium size ESS, implemented throughout the electricity distribution system closer to the energy consumers, which can be eitheir domestic, industrial, or other type of users, normally associated with a RES with a small electricity generation capacity within a decentralized energy system framework.", [["DES", "CHEMICAL", 41, 44], ["DES", "CHEMICAL", 41, 44], ["RES", "CHEMICAL", 266, 269], ["small to medium size ESS", "PROBLEM", 55, 79], ["a small electricity generation capacity", "PROBLEM", 275, 314], ["small", "OBSERVATION_MODIFIER", 55, 60], ["medium", "OBSERVATION_MODIFIER", 64, 70], ["size", "OBSERVATION_MODIFIER", 71, 75], ["ESS", "OBSERVATION", 76, 79], ["small", "OBSERVATION_MODIFIER", 277, 282]]], ["A good example is a family residence, where a PV system may generate the electricity needed for heating purposes and to operate all the electrical appliances.", [["a PV system", "TREATMENT", 44, 55], ["heating purposes", "TREATMENT", 96, 112], ["the electrical appliances", "TREATMENT", 132, 157], ["good", "OBSERVATION_MODIFIER", 2, 6]]], ["Under those circumstances the incorporation of a ESS will increase the RES efficiency and its cost effectiveness, by supplying electricity produced in site when the conditions do not allow electricity generation (for example at night).", [["RES", "CHEMICAL", 71, 74], ["a ESS", "TREATMENT", 47, 52], ["the RES efficiency", "TREATMENT", 67, 85]]], ["Furthermore, EES may contribute to reduce losses in energy transmission, and thus to increase the overall resilience of the global energy system, helping fulfil legislative goals (EC, 2018b).Criteria identification and evaluationA literature review is essential to identify the available technologies for decentralized energy storage and to systematize their main features.", [["EES", "CHEMICAL", 13, 16], ["EC", "CELL", 180, 182], ["EC", "CELL_TYPE", 180, 182], ["reduce losses in energy transmission", "PROBLEM", 35, 71], ["Criteria identification", "TEST", 191, 214], ["decentralized energy storage", "TREATMENT", 305, 333], ["main", "OBSERVATION_MODIFIER", 359, 363]]], ["After that, a comparative analysis among the identified technologies must be performed, considering the various possibilities identified and taking into account several factors, such as: costs, storage capacity, safety of operation, sustainability, among other issues.", [["a comparative analysis", "TEST", 12, 34], ["operation", "TREATMENT", 222, 231]]], ["Hence, a full multidimensional analysis is necessary, involving the environmental, technical, economic and social aspects, in order to select the most adequate technology option.", [["a full multidimensional analysis", "TEST", 7, 39]]], ["Specific indicators are then proposed, as for example the levelized cost of energy (LCOE) and levelized cost of storage (LCOS), available in the literature for the various technologies, that will support the decision making process according to the particular application conditions.", [["storage (LCOS", "TREATMENT", 112, 125]]], ["Market and regulatory barriers to electricity storage have been widely studied, but we intend to identify those that apply to a specific region within a restricted set of technologies.", [["electricity storage", "TREATMENT", 34, 53]]], ["Fig. 2 presents the main types of criteria involved in the selection of an ESS, including economic, technical and environmental/sustainability aspects.", [["an ESS", "TEST", 72, 78], ["ESS", "OBSERVATION", 75, 78]]], ["They cover all the main aspects/criteria that should be taken into account, and may be classified according to the main dimension of sustainability to which they are more related.Criteria identification and evaluationThe aspects presented in Fig. 2 are also applicable to the selection of energy storage technologies for DES, taking into account the local or regional specificities.", [["DES", "CHEMICAL", 321, 324], ["Criteria identification", "TEST", 179, 202], ["evaluation", "TEST", 207, 217], ["energy storage technologies", "TREATMENT", 289, 316], ["DES", "TREATMENT", 321, 324], ["main", "OBSERVATION_MODIFIER", 115, 119], ["Fig", "OBSERVATION_MODIFIER", 242, 245]]], ["Although a general analysis can be done, valid in a qualitative way regardless of the geographic conditions, in this work each criteria/aspect will be analysed considering the Portuguese specific conditions.", [["a general analysis", "TEST", 9, 27]]], ["From a technical point of view, DES should be robust, easy to operate, control and maintain, as most distributed RES are operated by non-specialists or people with limited knowledge of the inner workings of the RES and/or DES under their responsibility.", [["DES", "CHEMICAL", 32, 35], ["DES", "CHEMICAL", 222, 225], ["RES", "CHEMICAL", 113, 116], ["RES", "CHEMICAL", 211, 214], ["people", "ORGANISM", 152, 158], ["people", "SPECIES", 152, 158], ["DES", "TREATMENT", 32, 35]]], ["It is also desirable that the DES will be implemented and operated as a turn-key project.", [["DES", "CHEMICAL", 30, 33], ["the DES", "TREATMENT", 26, 33]]], ["Thus, ESS that involve the combination of various processes, in particular chemical-based, such as Power-to-Gas or biofuels that require specific raw materials and comples, are not suitable for DES.", [["DES", "CHEMICAL", 194, 197], ["DES", "CHEMICAL", 194, 197], ["ESS", "TEST", 6, 9], ["various processes", "PROBLEM", 42, 59], ["DES", "PROBLEM", 194, 197]]], ["Likewise, ESS that require very specific conditions, in particular pumped hydroelectric that requires buildings dams and water reservoirs, or very specialized equipment such as cryogenic storage or CAES, are not adequate for DES.", [["DES", "CHEMICAL", 225, 228], ["very specific conditions", "PROBLEM", 27, 51], ["water reservoirs", "TREATMENT", 121, 137], ["DES", "PROBLEM", 225, 228]]], ["Also, as space to install the DES is normally an issue, compact technologies that do not have moving or separated parts are more suitable, among which batteries are currently seen as a good option.Criteria identification and evaluationA key issue is the integration or the coupling of ESS with existing or future RES.", [["DES", "CHEMICAL", 30, 33], ["RES", "CHEMICAL", 313, 316], ["Criteria identification", "TEST", 197, 220]]], ["While it may be reasonable in some cases to use non-renewable resources to generate the energy supplied to a ESS, for example when the ESS will operate off-grid in an emergency situation, the ESS should be used only with renewable electricity or integrated directly with a RES.", [["RES", "CHEMICAL", 273, 276], ["non-renewable resources", "TREATMENT", 48, 71], ["the ESS", "TEST", 131, 138], ["the ESS", "TREATMENT", 188, 195]]], ["The same arguments also apply naturally to DES, and as the storage capacities of DES are limited, the most adequate RES in which they will be integrated are PV systems in particular households, small hydroelectric power plants or wind turbines.", [["DES", "CHEMICAL", 43, 46], ["DES", "CHEMICAL", 81, 84], ["DES", "CHEMICAL", 43, 46], ["DES", "CHEMICAL", 81, 84], ["RES", "CHEMICAL", 116, 119], ["RES", "SIMPLE_CHEMICAL", 116, 119], ["small", "OBSERVATION_MODIFIER", 194, 199], ["wind turbines", "OBSERVATION", 230, 243]]], ["This also impacts the distribution network that should allow the two-way movement of electricity, and be smart to account for the various fluxes within the network.Criteria identification and evaluationThe flexibility and adjustment to the final user's needs are other key issues to consider.", [["the various fluxes within the network", "PROBLEM", 126, 163], ["Criteria identification", "TEST", 164, 187], ["evaluation", "TEST", 192, 202]]], ["In particular, the DES should be flexible enough to account for the variability of the user's needs and intended uses of the energy.", [["DES", "CHEMICAL", 19, 22], ["the DES", "TREATMENT", 15, 22]]], ["Thus, DES based on thermal energy storage, such as PCM storage, have limited use, as they are not easy to control and the energy uses are very limited.", [["DES", "CHEMICAL", 6, 9], ["DES", "CHEMICAL", 6, 9], ["DES", "TREATMENT", 6, 9], ["thermal energy storage", "TREATMENT", 19, 41], ["PCM storage", "TREATMENT", 51, 62]]], ["Moreover, as in most cases DES will be used in households, buildings and small to medium size companies, that consume mostly electricity, the most viable options for DES will be technologies that store and generate directly electricity, among which the various batteries technologies are good options.", [["DES", "CHEMICAL", 27, 30], ["DES", "CHEMICAL", 166, 169], ["DES", "CHEMICAL", 27, 30], ["DES", "TREATMENT", 166, 169], ["small", "OBSERVATION_MODIFIER", 73, 78], ["medium size", "OBSERVATION_MODIFIER", 82, 93]]], ["Also relevant is the ability to change the storage capacity according to the users need or the characteristics of the RES in which the DES change.", [["DES", "CHEMICAL", 135, 138], ["RES", "CHEMICAL", 118, 121], ["DES", "CHEMICAL", 135, 138], ["the storage capacity", "TREATMENT", 39, 59], ["the DES change", "TREATMENT", 131, 145]]], ["Once again, electrochemical storage is the most adequate option, in particular those in which energy storage and power generation are separated, as for example flow batteries (Soloveichik, 2015) .Criteria identification and evaluationHealth and safety issues are also important aspects to be taken into account.", [["Criteria identification", "TEST", 196, 219], ["evaluation", "TEST", 224, 234]]], ["As DES will be mostly operated by non-specialists and in environments where the vigilance and ability to mitigate will be limited, the technologies used for DES should be intrinsically secure, in particular with minimal or non-existent fire and toxic risks.", [["DES", "CHEMICAL", 3, 6], ["DES", "CHEMICAL", 157, 160], ["DES", "CHEMICAL", 3, 6], ["DES", "TREATMENT", 157, 160], ["toxic risks", "OBSERVATION", 245, 256]]], ["Based on this criterion, DES based on chemical compounds, such as hydrogen, are not desirable options, as they are highly flammable and require special containment equipment.Criteria identification and evaluationEnvironmental and sustainability issues are increasingly more relevant, as recent decades have witnessed an increased attention to environmental and sustainability issues, to the point that currently any decision making process should consider them explicitly within a life cycle thinking approach.", [["DES", "CHEMICAL", 25, 28], ["hydrogen", "CHEMICAL", 66, 74], ["DES", "CHEMICAL", 25, 28], ["hydrogen", "CHEMICAL", 66, 74], ["hydrogen", "SIMPLE_CHEMICAL", 66, 74], ["this criterion", "TEST", 9, 23], ["DES", "TREATMENT", 25, 28], ["chemical compounds", "TREATMENT", 38, 56], ["special containment equipment", "TREATMENT", 144, 173], ["Criteria identification", "TEST", 174, 197], ["evaluation", "TEST", 202, 212], ["a life cycle thinking approach", "TREATMENT", 479, 509], ["flammable", "OBSERVATION", 122, 131], ["increased", "OBSERVATION_MODIFIER", 320, 329]]], ["A DES installation should have a minimal impact on the surrounding environment, if possible not involving potential irreversible changes in ecosystems and other natural systems.", [["DES", "CHEMICAL", 2, 5], ["DES", "CHEMICAL", 2, 5], ["A DES installation", "TREATMENT", 0, 18], ["potential irreversible changes in ecosystems and other natural systems", "PROBLEM", 106, 176], ["minimal", "OBSERVATION_MODIFIER", 33, 40], ["irreversible", "OBSERVATION_MODIFIER", 116, 128]]], ["Also, the DES construction should not involve as much as possible nonrenewable resources, especially of materials with limited supply, as for example lithium.", [["DES", "CHEMICAL", 10, 13], ["lithium", "CHEMICAL", 150, 157], ["DES", "CHEMICAL", 10, 13], ["lithium", "CHEMICAL", 150, 157], ["lithium", "SIMPLE_CHEMICAL", 150, 157], ["the DES construction", "TREATMENT", 6, 26], ["lithium", "TREATMENT", 150, 157]]], ["After decommission, the materials should be easily recyclable and/or reusable.Criteria identification and evaluationLegislative and policy issues should also be considered.", [["Criteria identification", "TEST", 78, 101]]], ["Currently, the Portuguese national strategy focuses mainly in large scale storage and hydrogen to store the excess electricity generated by the existing and future RES, for the later mainly based on PV power (RCM, 2019; PNEC, 2019) .", [["hydrogen", "CHEMICAL", 86, 94], ["hydrogen", "CHEMICAL", 86, 94], ["RES", "CHEMICAL", 164, 167], ["hydrogen", "SIMPLE_CHEMICAL", 86, 94], ["PNEC", "TEST", 220, 224]]], ["Also, no specific support for DES is available, in particular in form of fixed prices for electricity injection in the supply network or subsidies/fiscal support.", [["DES", "CHEMICAL", 30, 33], ["DES", "CHEMICAL", 30, 33], ["DES", "PROBLEM", 30, 33], ["fixed prices", "TREATMENT", 73, 85], ["electricity injection", "TREATMENT", 90, 111], ["fiscal support", "TREATMENT", 147, 161], ["fiscal support", "OBSERVATION", 147, 161]]], ["Yet, some current policies and strategic goals implicitly promote the deployment of DES.", [["DES", "CHEMICAL", 84, 87], ["DES", "CHEMICAL", 84, 87], ["the deployment of DES", "TREATMENT", 66, 87]]], ["Key examples are the imposition of all new buildings to be NZEB (EC, 2018b) , and the efficiency measures imposed in industry, that will be much easier to reach if DES are implemented, in particular combined with RES such as PV (Gouveia et al., 2019) .Criteria identification and evaluationEnergy density and duration of storage are also important issues.", [["DES", "CHEMICAL", 164, 167], ["DES", "CHEMICAL", 164, 167], ["RES", "CHEMICAL", 213, 216], ["EC", "CELL", 65, 67], ["PV", "SPECIES", 225, 227], ["Criteria identification", "TEST", 252, 275], ["evaluation", "TEST", 280, 290]]], ["Similar to the distributed RES in which they are incorporated, DES will also have variable operating conditions, depending on the availability of renewable energy for storage, and the users energy needs.", [["DES", "CHEMICAL", 63, 66], ["RES", "CHEMICAL", 27, 30], ["DES", "CHEMICAL", 63, 66]]], ["Thus, it is imperative that the energy is not lost during periods of non-operation, as it will represent an economic loss and lower the DES overall efficiency.", [["DES", "CHEMICAL", 136, 139], ["an economic loss", "PROBLEM", 105, 121], ["lower the DES overall efficiency", "PROBLEM", 126, 158], ["economic", "OBSERVATION_MODIFIER", 108, 116], ["loss", "OBSERVATION", 117, 121], ["lower", "OBSERVATION_MODIFIER", 126, 131]]], ["Energy density, normally defined as quantity of energy per unit volume, is also relevant, as the higher its value the smaller and lower deployment impacts are expected.Criteria identification and evaluationThe local resources should also be taken into account.", [["Energy density", "PROBLEM", 0, 14], ["Criteria identification", "TEST", 168, 191], ["evaluation", "TEST", 196, 206], ["density", "OBSERVATION", 7, 14], ["normally defined", "OBSERVATION_MODIFIER", 16, 32], ["quantity", "OBSERVATION_MODIFIER", 36, 44], ["unit volume", "OBSERVATION_MODIFIER", 59, 70], ["higher", "OBSERVATION_MODIFIER", 97, 103], ["smaller", "OBSERVATION_MODIFIER", 118, 125], ["lower", "OBSERVATION_MODIFIER", 130, 135], ["deployment", "OBSERVATION", 136, 146]]], ["Although under Portuguese conditions PV is valuable nationwide, in certain regions other forms of renewable energy may be significant, as for example wind power in the north, and geothermal energy in the Azores archipelago.", [["PV", "SPECIES", 37, 39], ["geothermal energy", "OBSERVATION", 179, 196]]], ["Also, the local or regional capabilities of the electricity distribution network may limit the ability of DES to interchange electricity with it, reducing their overall efficiency.Criteria identification and evaluationSeveral aspects have to be considered in the economic issues.", [["DES", "CHEMICAL", 106, 109], ["DES", "CHEMICAL", 106, 109], ["Criteria identification", "TEST", 180, 203], ["local", "OBSERVATION_MODIFIER", 10, 15], ["regional", "OBSERVATION_MODIFIER", 19, 27], ["capabilities", "OBSERVATION_MODIFIER", 28, 40], ["overall efficiency", "OBSERVATION", 161, 179]]], ["First, the initial investment costs and the cost of the capital are important issues, and a suitable indicator for these is the Energy Investment Costs (IRENA, 2017) .", [["the initial investment costs", "TREATMENT", 7, 35]]], ["As DES will be mostly implemented by individuals and small/medium companies, ESS that involve large initial investments are not adequate, as they normally do not have the necessary funds or access to credit.", [["DES", "CHEMICAL", 3, 6], ["small/medium companies", "PROBLEM", 53, 75], ["small", "OBSERVATION_MODIFIER", 53, 58]]], ["This sub criterion limits the potential technologies for DES to those that do not require large initial investments, as for example batteries.", [["DES", "CHEMICAL", 57, 60], ["DES", "TREATMENT", 57, 60], ["large initial investments", "TREATMENT", 90, 115]]], ["Second, a comparison between different ESS should also consider the operation and investment costs and the capital depreciation.", [["the operation", "TREATMENT", 64, 77], ["investment costs", "TREATMENT", 82, 98], ["the capital depreciation", "PROBLEM", 103, 127], ["capital depreciation", "OBSERVATION", 107, 127]]], ["Although a normal project evaluation analysis is suitable, an indicator that is becoming increasingly more consensual to assess the viability of a given ESS or to compare different ESS is the Levelized Cost of Storage, LCOS (Lazard, 2018; Schmidt et al., 2019; Julch, 2016; Zakeri and Syri, 2015) .", [["a normal project evaluation analysis", "TEST", 9, 45], ["normal", "OBSERVATION", 11, 17]]], ["LCOS can be calculated from data obtained from suppliers and/or the literature.", [["LCOS", "TEST", 0, 4]]], ["LCOS estimation depends on the assumptions made for the investment, technology and operation and on the specificities of the installation conditions.", [["LCOS estimation", "TEST", 0, 15], ["operation", "TREATMENT", 83, 92]]], ["The indicator may present large differences between ranges (Lazard, 2018) .", [["large", "OBSERVATION_MODIFIER", 26, 31]]], ["For example, considering residential PV and storage, LCOS (US$/MWh) varies between 476 and 735 for lithium batteries, between 512 and 707 for lead batteries, and between 498 and 675 for advanced lead.", [["lithium", "CHEMICAL", 99, 106], ["lithium", "CHEMICAL", 99, 106], ["lithium batteries", "TEST", 99, 116], ["lead batteries", "TEST", 142, 156]]], ["It is expected that estimated LCOS values for batteries would reduce largely over the next few years as a result of technology development and reduction of production costs (Lazard, 2018) .", [["estimated LCOS values", "PROBLEM", 20, 41], ["reduction", "OBSERVATION_MODIFIER", 143, 152]]], ["Moreover, the support policies may play a role in terms of subsidies or fiscal abatements, reducing the investment and operational costs of DES.", [["DES", "CHEMICAL", 140, 143], ["DES", "CHEMICAL", 140, 143], ["fiscal abatements", "TREATMENT", 72, 89], ["operational costs of DES", "TREATMENT", 119, 143]]], ["This is important in poor and sparsely populated regions, as it is the case of some Portuguese regions, where households and companies may lack the capital needed to invest in ESS or DES.Criteria identification and evaluationTaking into account the various criteria and the current state of the art, electrochemical-based storage, in particular batteries, are seen as the best option for DES.", [["DES", "CHEMICAL", 183, 186], ["DES", "CHEMICAL", 388, 391], ["Criteria identification", "TEST", 187, 210], ["evaluation", "TEST", 215, 225], ["DES", "PROBLEM", 388, 391], ["poor", "OBSERVATION_MODIFIER", 21, 25], ["sparsely", "OBSERVATION_MODIFIER", 30, 38], ["populated", "OBSERVATION", 39, 48]]], ["Some of the key reasons are the robustness of existing technologies, easiness of operation and natural integration in the currently dominant RES that are currently dominant.", [["RES", "CHEMICAL", 141, 144], ["RES", "CANCER", 141, 144], ["operation", "TREATMENT", 81, 90], ["natural integration", "TREATMENT", 95, 114], ["dominant", "OBSERVATION", 164, 172]]], ["Thus, while the solutions already available in the market are adequate for many situations, the present strong investments in R& D, focusing for example in reducing costs and increasing the energy storage density, ensures that batteries will be increasingly seen as the most adequate choice for DES.", [["DES", "CHEMICAL", 295, 298], ["DES", "CHEMICAL", 295, 298], ["R& D", "SIMPLE_CHEMICAL", 126, 130], ["increasing the energy storage density", "PROBLEM", 175, 212], ["DES", "PROBLEM", 295, 298]]], ["Hence, policies to stimulate energy storage should promote as much as possible electrochemical energy storage, especially batteries.Conclusions and policy implicationsBetter ESS can improve the overall efficiency of existing RES, providing energy/electricity when it is not possible to generate energy, mainly due to climatic conditions.", [["RES", "CHEMICAL", 225, 228], ["RES", "SIMPLE_CHEMICAL", 225, 228], ["energy storage", "TREATMENT", 29, 43], ["electrochemical energy storage", "PROBLEM", 79, 109], ["energy/electricity", "TREATMENT", 240, 258]]], ["ESS contribute to stabilize the energy distribution network, and to reduce the uncertainty in grid management, helping flatten the electricity price and providing energy storage in lower demand hours.", [["grid management", "TREATMENT", 94, 109], ["energy storage", "TREATMENT", 163, 177]]], ["Storage systems may allow that the renewable energy generation fixed costs are distributed for a larger marketed production, inducing the price per kWh to fall.", [["Storage systems", "TREATMENT", 0, 15], ["the renewable energy generation fixed costs", "TREATMENT", 31, 74]]], ["Thus, there is a strategic interest in promoting ESS, as their development and implementation contributes to accelerate the transition to a fully renewable and decarbonized energy generation system.Conclusions and policy implicationsDespite the advantages, the selection of the proper ESS for a given system is a complex process that depends on many factors, not only the economic issues, but also technical, safety and environmental ones.", [["a complex process", "PROBLEM", 311, 328]]], ["This work identified the criteria and guidelines that are most suitable to select an adequate energy storage technology for DES, with a focus in the Portuguese context.", [["DES", "CHEMICAL", 124, 127], ["DES", "TREATMENT", 124, 127]]], ["The analysis performed showed that for DES electrochemical based ESS, in particular batteries, are the most adequate options.", [["DES", "CHEMICAL", 39, 42], ["DES", "CHEMICAL", 39, 42], ["The analysis", "TEST", 0, 12], ["DES electrochemical based ESS", "PROBLEM", 39, 68]]], ["Batteries are expected to have an increasing presence in the near future, as the costs are falling and the energy density is increasing due to the strong investment in R&D. Although, it is still not clear which is the most adequate battery technology, as many technologies have similar performance and costs.", [["the energy density", "PROBLEM", 103, 121], ["increasing", "OBSERVATION_MODIFIER", 34, 44], ["energy", "OBSERVATION_MODIFIER", 107, 113], ["density", "OBSERVATION", 114, 121], ["strong", "OBSERVATION_MODIFIER", 147, 153], ["investment", "OBSERVATION", 154, 164], ["clear", "OBSERVATION", 199, 204]]], ["The results support the idea that policies that promote DES should be put in place.Conclusions and policy implicationsAlthough decentralized generation presently represents a low weight in national generation, storage systems can contribute to limit the fluctuating availability to solar and wind energy, promoting the development of local grids, and increasing the resilience and flexibility of the energy system.", [["DES", "CHEMICAL", 56, 59], ["DES", "CHEMICAL", 56, 59], ["DES", "TREATMENT", 56, 59], ["a low weight", "PROBLEM", 173, 185], ["local grids", "TREATMENT", 334, 345]]], ["The European Union regulatory framework encourages the use of small-scale decentralized electricity storage systems; however support for its local implementation is still vague or nonexistent, as it is the case of Portugal that supports large scale storage in its strategic plans (RCM, 2019; PNEC, 2019).", [["small-scale decentralized electricity storage systems", "TREATMENT", 62, 115]]], ["There is room to improve recent national strategic plans relating to decentralized small-scale storage, to capture the opportunities and advantages that can arise from the ongoing technical developments.", [["decentralized small-scale storage", "TREATMENT", 69, 102], ["small", "OBSERVATION_MODIFIER", 83, 88]]], ["Yet, the incentives for promoting storage technologies in Portugal, mainly those at decentralised level, are unclear.", [["promoting storage technologies", "TREATMENT", 24, 54]]], ["Our research also indicated that mechanisms for payment of flexibility services inherent to the use of energy storage devices are still missing.", [["payment of flexibility services", "TREATMENT", 48, 79], ["energy storage devices", "TREATMENT", 103, 125]]], ["The capacity market is lacking further studies in the economic and social perspectives that ground the institutional support for its promotion and development.", [["the institutional support", "TREATMENT", 99, 124], ["capacity", "OBSERVATION_MODIFIER", 4, 12]]], ["Our results integrate a preliminary study of the use of batteries on decentralized generation.", [["a preliminary study", "TEST", 22, 41], ["decentralized generation", "TREATMENT", 69, 93]]], ["The next steps for the present research are a quantitative and a hierarchical analysis that could treat and structure the data collected in the literature and in the market place, so it can be used to help support decision making.Declaration of Competing InterestNone.", [["a hierarchical analysis", "TEST", 63, 86], ["the data", "TEST", 118, 126]]]]}